



European
Crohn's and Colitis
Organisation

Amsterdam
The Netherlands

Inflammatory Bowel Diseases

Final Programme



11th Congress of ECCO
RAI Amsterdam
March 16-19, 2016

www.ecco-ibd.eu



European
Crohn's and Colitis
Organisation

Amsterdam
The Netherlands

e-CCO Learning

Open access
preview @ the
ECCO Booth



Congress special: Open access preview

Become a part of e-CCO Learning

e-Courses

- Interactive case-based & topic-based e-Courses
- Integrated tests
- Talking Heads

e-Library

- Abstracts
- Documents
- Images
- Podcasts & Webcasts
- Literature reviews

Latest e-Courses

- Malignancies
- Extra-intestinal Manifestations
- Structuring Crohn's Disease
- Surgery in UC
- Endoscopic Assessment of UC Activity with UCEIS
- Maintenance of Remission in CD
- Opportunistic Infections
- Ultrasound

Upcoming e-Courses

- N-ECCO Perspective on existing Anaemia e-Course
- N-ECCO Perspective on existing UC e-Course
- P-ECCO e-Course

Scan and visit

www.e-learning.ecco-ibd.eu



Word of welcome

Dear Colleagues,

I am delighted to welcome you to ECCO 2016 here in the beautiful city of Amsterdam!

This is already the 11th Congress of the European Crohn's and Colitis Organisation. The ECCO Congress is still growing and over 5,000 delegates bring challenges to the available destinations. It is nevertheless a vision to continue visiting different cities in Europe. For now, I hope that Amsterdam is a much welcomed alternative to our previous destinations!

Amsterdam, the city of one million bicycles, but also city of Rembrandt, city of as many as 165 canals and city of Heineken Beer and this week the city of ECCO 2016!

The Organising Committee has painted again a colourful programme for you. Our aims remain to advance the understanding of the causes of Crohn's Disease and Ulcerative Colitis, to share and discuss top-line results of therapeutic agents and algorithms, to stimulate and promote the implementation of guidelines, to ultimately further improve patient care.

The theme of this congress is "IBD innovations driving clinical decisions". Indeed, cell therapies and genetic testing are increasingly being implemented, and a wider variety of drugs leads to personalised medicine being a necessity. Patient safety remains the main focus in our sessions on bugs and drugs, viruses and perioperative management of patients. Amsterdam is the cradle of liberalism which invites us to challenge dogmas and look critically at our current management.

The whole picture is made even more colourful by the many original oral and poster presentations. This year, we are again very proud to present top-line results from large randomised controlled trials for the first time!

Besides the core programme, we always offer education for everybody: Our IBD specialists of the future, our IBD nurses and our colleagues from industry.

We hope you enjoy Amsterdam and I personally hope to see and greet you to foster friendship. On behalf of the whole ECCO Team I therefore extend a warm and colourful welcome to all of you!

Yours sincerely,

A handwritten signature in black ink, appearing to read 'Séverine Vermeire', written over a vertical line.

Séverine Vermeire

ECCO President & Chair of Organising Committee




Séverine Vermeire

Table of contents

Word of welcome.....	3
ECCO Structure	5
Scientific Information: A-Z	11
Scientific programme day by day.....	18
Abstract presentation format	35
Poster exhibition	38
Digital oral presentations.....	41
Poster presentation	68
Educational programme	155
14 th IBD Intensive Advanced Course	155
1 st School for Clinical Trialists.....	158
7 th N-ECCO School.....	159
3 rd Basic ECCO: EduCational COurse for Industry.....	162
3 rd N-ECCO Research Forum.....	164
1 st ECCO Endoscopy Workshop.....	165
2 nd Advanced ECCO: EduCational COurse for Industry	166
EU Project Forum.....	167
9 th Y-ECCO Career Workshop.....	169
5 th S-ECCO IBD Masterclass in collaboration with ESCP...	170
3 rd ECCO-ESGAR Ultrasound Workshop.....	173
3 rd EpiCom Workshop	174
5 th ClinCom Workshop.....	175
Molecular aetiology of IBD.....	176
10 th N-ECCO Network Meeting	177
3 rd P-ECCO Educational Course	179
1 st H-ECCO IBD Masterclass.....	181
1 st D-ECCO Workshop.....	183
2 nd Y-ECCO Basic Science Workshop	185
Industry sponsored satellite symposia	188
Congress information.....	198
ECCO Business meetings	206
ECCO Interaction: Hearts and Minds	207
Industry exhibition.....	209
Corporate sponsors.....	213
Floor plans.....	214
Index of authors	217

ECCO Structure



Governing Board

President
 President-Elect
 Past-President and Liaison Officer
 Secretary
 Treasurer
 Education Officer
 Scientific Officer

Séverine Vermeire (Belgium)
 Julián Panés (Spain)
 Simon Travis (United Kingdom)
 Laurent Peyrin-Biroulet (France)
 Tibor Hlavaty (Slovakia)
 Gerassimos Mantzaris (Greece)
 Filip Baert (Belgium)

ClinCom

Chair	Alessandro Armuzzi (Italy)
Members	Marc Ferrante (Belgium) Vipul Jairath (United Kingdom) Fernando Magro (Portugal) Edyta Zagorowicz (Poland)

EduCom

Chair	James Lindsay (United Kingdom)
Members	Peter Irving (United Kingdom) Konstantinos Katsanos (Greece) Torsten Kucharzik (Germany) Peter Lakatos (Hungary) Antonio López-Sanromán (Spain)

EpiCom

Chair	Tine Jess (Denmark)
Members	Vito Annese (Italy) Dana Duricova (Czech Republic) Corinne Gower-Rousseau (France) Ebbe Langholz (Denmark)

GuiCom

Chair	Marcus Harbord (United Kingdom)
Members	Gionata Fiorino (Italy) Paolo Gionchetti (Italy) Christian Maaser (Germany) Andreas Sturm (Germany)

N-ECCO

Chair	Janette Gaarenstroom (The Netherlands)
Members	Palle Bager (Denmark) Usha Chauhan (Canada) Kay Greveson (United Kingdom) Karen Kemp (United Kingdom)

P-ECCO

Chair	Arie Levine (Israel)
Members	Salvatore Cucchiara (Italy) Richard Russell (United Kingdom) Dan Turner (Israel) Patrick van Rheenen (The Netherlands)

SciCom

Chair	Gerhard Rogler (Switzerland)
Members	Iris Dotan (Israel) Charlie Lees (United Kingdom) Britta Siegmund (Germany) Gijs van den Brink (The Netherlands)

S-ECCO

Chair	Willem Bemelman (The Netherlands)
Members	Paulo Kotze (Brazil) Gianluca Sampietro (Italy) Janindra Warusavitarne (United Kingdom) Oded Zmora (Israel)

Y-ECCO

Chair	Timothy Raine (United Kingdom)
Members	Isabelle Cleynen (Belgium) Nuha Yassin (United Kingdom) Sebastian Zeissig (Germany)

D-ECCO Working Group

Chair	Rotem Sigall-Boneh (Israel)
Members	Konstantinos Gerasimidis (United Kingdom) Miranda Lomer (United Kingdom) Nicolette Wierdsma (The Netherlands)

H-ECCO Working Group

Chair	Cord Langner (Austria)
Members	Paula Borralho Nunes (Portugal) Roger Feakins (United Kingdom) Magali Svrcek (France) Vincenzo Villanacci (Italy)

Organising Committee - 11th Congress of ECCO

Chair	Séverine Vermeire (Belgium)
Members	Peter Irving (United Kingdom) Julián Panés (Spain) Laurent Peyrin-Biroulet (France) Britta Siegmund (Germany)

National Representatives



Christoph Högenauer
Gottfried Novacek



Peter Lakatos
Tamás Molnar



Peter Bossuyt
Cathérine Reenaers



Glen Doherty
Jane McCarthy



Emil Babić
Ante Bogut



Shomron Ben-Horin
Matti Waterman



Iskren Kotzev
Zoya Spassova



Paolo Gionchetti
Anna Kohn



Zeljko Krznaric
Brankica Mijandrušić-Sinčić



Jelena Derova
Aleksejs Derovs



Theodora Demetriou
Ioannis Kaimakliotis



Gediminas Kiudelis
Limas Kupcinskis



Martin Bortlík
Tomas Douda



Pierre Ellul



Jørn Brynskov
Torben Knudsen



Vlada Dumbrava
Svetlana Turcan



Karin Kull
Benno Margus



Marte Lie Høivik
Kristin Kaasen Jørgensen



Clas-Göran af Björkesten
Pauliina Molander



Jaroslav Kierkus
Edyta Zagorowicz



Arnaud Boueille
Xavier Roblin



Paula Ministro
Ana Isabel Vieira



Britta Siegmund
Torsten Kucharzik



Mihai Mircea Diculescu
Adrian Goldis



Giorgos Bamias
Ioannis Koutroubakis



Elena Belousova
Alexander Potapov



Marijana Protic
Dino Tarabar



Pierre Michetti
Frank Seibold



Martin Huorka
Mária Zakuciová



Dirk de Jong
Marieke Pierik



David Drobne
Ivan Ferkolj



Aykut Ferhat Celik
Yusuf Erzin



Eugeni Domènech
Javier Gisbert



Juriy Vinnyk
Mykhailo Zakharash



Hans Strid
Leif Törkvist



Barney Hawthorne
Peter Irving

Honorary Members

Renzo Caprilli (Italy)

Yehuda Chowers (Israel)

Jean-Frédéric Colombel (United States)

Geert D'Haens (The Netherlands)

Axel Dignass (Germany)

Daniel Hommes (United States)

Miquel Gassull (Spain)

Pierre Michetti (Switzerland)

Pia Munkholm (Denmark)

Walter Reinisch (Austria/Canada)

Herbert Tilg (Austria)

Boris Vucelić (Croatia)

Corporate Members

AbbVie

Biogen

Bühlmann Laboratories

Celgene

Celltrion

Cosmo Pharmaceuticals

Dr. Falk Pharma

J&J Ethicon

Ferring

Hospira, A Pfizer Company

Janssen

MSD

Mundipharma

Nestlé Health Science

Nographarma

Otsuka Pharmaceuticals

Pfizer

Roche

Shield Therapeutics

Shire

Takeda Pharmaceuticals Europe

Tigenix

Tillotts Pharma

Vifor Pharma



European
Crohn's and Colitis
Organisation

Announcement
2017

Inflammatory Bowel Diseases



12th Congress of ECCO
February 15-18, 2017

- CCIB Barcelona, Spain
- EACCME applied
- Register at the 11th Congress of ECCO in Amsterdam

Scan and contact the ECCO Office
www.ecco-ibd.eu



Scientific Information: A-Z

Awards – ECCO Fellowships & Grants

On Friday, March 18, 2016, 15:34-15:40 ECCO officially announces the following prizes:

- ECCO Fellowships 2016
- ECCO-IOIBD Fellowship 2016
- ECCO-Nestlé Health Science Nutrition Fellowship 2016
- ECCO Grants 2016
- ECCO Travel Awards 2016

The awarded candidates will officially be handed over their prize by naming the title of their fellowship/grant research project.

A major part of this session is dedicated to the presentation of the research projects of Carla Felice and Cristina Mascaraque who were awarded with ECCO Fellowships in 2015.

For further information and guidelines for these awards please refer to www.ecco-ibd.eu.

Business meetings

Attendance of business meetings is upon invitation only (please refer to page 206).

Compliance

Based on the EFPIA HCP Code and the Dutch Medicines Act, ECCO has adopted measures that allow compliance with applicable regulations regarding publicity and promotion of medicines at the ECCO Congress 2016.

- Exhibitors have been asked to respect the Code of Practice in the context of the ECCO'16 Exhibitor & Sponsor Prospectus.
- Exhibitors have been alerted to the regulations about the promotion of prescription-only medicine, explaining that non-prescribing congress delegates can be identified with the NP sign on the congress badge.
- In the course of the online and onsite registration, the congress delegates will also be informed about the regulations regarding publicity and promotion of medicine and are asked to indicate their prescriber/non-prescriber status accordingly.

Disclosure policy

ECCO has diligently maintained a disclosure policy of potential conflicts of interests (CoI) and its aim is to foster transparency and to ensure scientific rigour and objectivity in all of its scientific and educational activities. Therefore, all presenters, including invited faculty members and abstract presenters, are required to disclose any relevant financial support or relationship that may lead to a potential conflict. Please note that the responsibility for the content of each presentation lies with the presenting author.

All presenters are required to complete a Conflict of Interest form to disclose any financial support as well as advisory and consultancy roles in the biomedical industry. All submitted forms are open to public scrutiny on the ECCO Website (www.ecco-ibd.eu/about-ecco/ecco-disclosures) providing a comprehensive overview of potential conflicts of interest of presenters. As soon as the CoI Forms are online, the IBD Community is also notified by the eNewsletter about the online access to the up-to

date disclosure information. In addition, these conflicts are requested to be shown at the beginning of each presentation on a PowerPoint slide.

In order to facilitate the process and reinforce the 2nd slide policy, faculty speakers are reminded to disclose their potential conflicts of interest in their ppt in line with UEMS regulations.

Based on the submitted Col form of each speaker, a draft Col slide has been prepared and is made available in the Speakers' centre with a reminder that if the respective presentation does not yet include a disclosure form, the slide draft should be checked/amended and included in the ppt.

Conflicts of interest may include financial relationships or when the individual has the opportunity to influence the content of a presentation, and can comprise grants, honoraria, shares, paid positions on advisory boards etc. ECCO expects many presenters to have some conflicts of interest, which do not prevent them from presenting their work given that the conflict is disclosed.

EACCME – Continuing Medical Education

The 11th Congress of ECCO in Amsterdam is accredited by the European Accreditation Council for Continuing Medical Education (EACCME) to provide the following CME activity for medical specialists. The EACCME is an institution of the European Union of Medical Specialists (UEMS), www.uems.net. The **11th Congress of ECCO** in Amsterdam is designated for European external CME credits. Full congress days count 6 credits, half congress days for 3 credits. Thus, a maximum of **12 CME credits** can be obtained for the scientific sessions of the core programme.



For the **14th IBD Intensive Advanced Course** for Junior Gastroenterologists (upon invitation only) **8 CME credits** will be accredited. Please refer to page 155.

For the **1st School for Clinical Trialists** for Regular Members of ECCO (pre-registered participants only) **3 CME credits** will be accredited. Please refer to page 158.

For the **1st ECCO Endoscopy Workshop** for Regular Members of ECCO (pre-registered participants only) **3 CME credits** will be accredited. Please refer to page 165.

For the **EU Project Forum** for pre-registered participants **3 CME credits** will be accredited. Please refer to page 167.

For the **9th Y-ECCO Career Workshop** for Regular Members of ECCO (pre-registered participants only) **2 CME credits** will be accredited. Please refer to page 169.

For the **5th S-ECCO IBD Masterclass** for Regular Members of ECCO (pre-registered participants only) **6 CME credits** will be accredited. Please refer to page 170.

For the **3rd ECCO-ESGAR Ultrasound Workshop** for Regular Members of ECCO (pre-registered participants only) **3 CME credits** will be accredited. Please refer to page 173.

For the **3rd EpiCom Workshop** for Regular Members of ECCO (pre-registered participants only) **3 CME credits** will be accredited. Please refer to page 174.

For the **5th ClinCom Workshop** for Regular Members of ECCO (pre-registered participants only) **3 CME credits** will be accredited. Please refer to page 175.

For the **Molecular aetiology of IBD Workshop** for Regular Members of ECCO (pre-registered participants only) **3 CME credits** will be accredited. Please refer to page 176.

For the **3rd P-ECCO Educational Course** for Regular Members of ECCO (pre-registered participants only) **2 CME credits** will be accredited. Please refer to page 179.

For the **1st H-ECCO IBD Masterclass** for Regular Members of ECCO (pre-registered participants only) **6 CME credits** will be accredited. Please refer to page 181.

For the **2nd Y-ECCO Basic Science Workshop** for Regular Members of ECCO (pre-registered participants only) **3 CME credits** will be accredited. Please refer to page 185.

In order to obtain CME credits ECCO requires feedback on its educational activities. Therefore, we kindly ask delegates to complete the congress evaluation form included in the congress bag and/or the evaluation forms handed out at the end of the respective courses/workshops and return it to the registration desk on the last day of attendance. **The certificate with the CME credits** for the 11th Congress of ECCO and/or the respective courses/workshops **will be sent to delegates by e-mail after the congress.**

Plenary session

The plenary session is held from Thursday, March 17 to Saturday, March 19, 2016 and starts off with the official welcome & opening of the core scientific programme. The programme includes all official speeches, with a mixture of invited speakers and oral presentations of the best submitted abstracts. No parallel sessions are scheduled.

Oral presentations – Best abstracts

Out of 1183 submitted abstracts the 30 best submitted abstracts have carefully been chosen by a panel of referees and selected for oral presentation during the scientific programme. For the presentation schedule please refer to the scientific programme (page 18).

Digital oral presentations

Abstracts have been selected from the ranking by taking 90 abstracts after those 30 selected for presentation in the scientific programme. These abstracts will be presented as digital oral presentations, with a 5 minute oral presentation in several rooms on Level 1 of the RAI Amsterdam on Thursday, March 17, 2016 from 17:15-18:15 or on Friday, March 18, 2016 from 18:05-19:05. Please find the schedule and selected abstracts for each digital oral presentation room on page 41.

Poster exhibition

The remaining accepted abstracts will be displayed as hard copy posters throughout the congress in the exhibition hall (Hall 9). For further details on all posters included in the poster exhibition please refer to page 68.

Scientific congress theme

This year's congress theme is "IBD innovations driving clinical decisions".

Top tips for chairs

All chairs are kindly asked to attend the closed session on "Top tips for chairs" which takes place on Thursday, March 17, 2016 at 10:45-11:15 in the Plenary hall (Hall 11) on Level 1 of the RAI Amsterdam. During this session, Laurence Egan will give essential information on how to chair scientific sessions in a highly humorous manner – do not miss out on it!



European
Crohn's and Colitis
Organisation

ECCO Pioneer Award



For the first time in 2017

The ECCO Pioneer Award aims to enhance visionary, collaborative, and interdisciplinary scientific research in IBD centres.

Theme 2017: Functional Impact of Environment in IBD

- EUR 200.000 prize
- 1 exceptional award per year
- Fund up to 24 months of basic/clinical research in IBD
- For innovative and collaborative research projects between at least 3 participating institutions

To find out more,
Contact the ECCO Office and visit
www.ecco-ibd.eu






European
Crohn's and Colitis
Organisation

Amsterdam
The Netherlands

Abstracts 2016



Look out for your voucher in your congress bag!

Option 1: Otsuka logo

- Bicycle shaped USB drive
- Pick up at Otsuka booth Nr. 024
- Limited number

Option 2: ECCO Logo

- ECCO Key USB drive
- Pick up at ECCO Booth

Scan and contact the ECCO Office
www.ecco-ibd.eu



Educational programme

		08:00-08:30	08:30-10:30	10:30-11:30	11:30-11:45	11:45-12:45	12:45-13:00	13:00-14:00	14:00-15:00	15:00-15:30	15:30-16:00	16:00-16:15	16:15-17:00	17:00-18:00	18:00-18:15
WED Mar 16, 2016	Room														
	E104-105 (Level 1)	14 th IBD Intensive Advanced Course p. 155										9 th Y-ECCO Career Workshop p. 169			
	E102 (Level 1)	1 st School for Clinical Trialists p. 158							3 rd N-ECCO Research Forum p. 164						
	G104 (Level 1)	7 th N-ECCO School p. 159													
	G106-107 (Level 1)	3 rd Basic ECCO: EduCational COurse for Industry p. 162													
	G103 (Level 1)				Endoscopy Workshop ISSS p. 196		1 st ECCO Endoscopy Workshop p. 165								
	Forum (Ground Level)	2 nd Advanced ECCO: EduCational COurse for Industry p. 166													
G102 (Level 1)	EU Project Forum p. 167														
THU Mar 17, 2016	Room	07:30-08:00	08:00-08:30	08:30-09:00	09:00-10:00	10:00-11:30	11:30-12:00	12:00-12:15	12:15-12:30	12:30-12:45	12:45-13:30	13:30-13:45	13:45-14:00	14:00-17:00	
	G103 (Level 1)	3 rd ECCO-ESGAR Ultrasound Workshop p. 173													
	Forum (Ground level)	5 th S-ECCO IBD Masterclass p. 170													
	E104-105 (Level 1)	14 th IBD Intensive Advanced Course p. 155													
	E103 (Level 1)	3 rd EpiCom Workshop p. 174													
	E102 (Level 1)	5 th ClinCom Workshop p. 175													
	Elicium 1 (Level 1)	10 th N-ECCO Network Meeting p. 177										N-ECCO Network Meeting ISSS p. 196	10 th N-ECCO Network Meeting p. 177		
	G104-105 (Level 1)	Molecular aetiology of IBD p. 176													
	G106-107 (Level 1)	3 rd P-ECCO Educational Course p. 179													
Emerald Room (Level 1)	1 st H-ECCO IBD Masterclass p. 181														
FRI Mar 18, 2016	Room	08:00-08:30		08:30-12:15			12:15-12:30			12:30-15:00		15:00-18:00			
	Emerald Room (Level 1)	1 st H-ECCO IBD Masterclass p. 181													
	E102 (Level 1)						1 st D-ECCO Workshop p. 183								
E103 (Level 1)												2 nd Y-ECCO Basic Science Workshop p. 185			

Programme overview Congress theme: “IBD innovations driving clinical decisions”

Scientific programme

THU Mar 17, 2016	Room	10:45-11:15	11:15-11:30	11:30-12:00	12:00-12:30	12:30-12:45	12:45-13:00	13:00-14:30	14:30-15:00	15:00-17:00	17:00-17:15	17:15-18:00	18:00-18:15
	Plenary hall (Hall 11, Level 1)	Top tips for chairs p. 18		ISSS 1a p. 188		Welcome and opening p. 18	SS 1: Cell therapy: Ready for clinical practice? p. 18		SS 2: Application of genetic testing in understanding and managing IBD p. 20				ISSS 2a p. 189
	Elicium 2 (Level 1)			ISSS 1b p. 189									ISSS 2b p. 190
	Exhibition hall (Hall 9 + 10, Level 1)			Exhibition p. 209				Coffee break	Exhibition p. 209				
E104-106, E102, G102-103, G104-105, G106-107 (Level 1)											DOP Sessions 1-5 p. 42-54		

FRI Mar 18, 2016	Room	07:15-08:15	08:15-08:30	08:30-09:30	09:30-10:30	10:30-11:00	11:00-12:20	12:20-12:30	12:30-13:10	13:10-13:20	13:20-14:50	14:50-15:20	15:20-16:00	16:00-17:00	17:00-17:50	17:50-18:05	18:05-19:05	
	Plenary hall (Hall 11, Level 1)	ISSS 3a p. 190		SS 3: Resolution of inflammation p. 23	SS 4: Viruses and IBD p. 24	SS 5: Challenging dogmas – from clinical trials to clinical practice p. 25			ISELSS LS 1 p. 191		SS 6: Bugs and drugs in IBD p. 26		SS 7: ECCO Fellowships & Grants p. 27	SS 8: Challenging cases p. 28	SS 9: What's new on the Guidelines front? p. 28			ISSS 4a p. 193
	Elicium 2 (Level 1)	ISSS 3b p. 191							ISELSS LS 4 p. 192									ISSS 4b p. 193
	Exhibition hall (Hall 9 + 10, Level 1)			Exhibition p. 209	Coffee break	Exhibition p. 209	Lunch break and guided poster session p. 38	Exhibition p. 209	Coffee break	Exhibition p. 209								
	Forum (Ground level)								ISELSS LS 2 p. 191									
	Elicium 1 (Level 1)								ISELSS LS 3 p. 192									
E104-106, E102, G102-103, G104-105, G106-107 (Level 1)																	DOP Sessions 6-10 p. 56-66	

SAT Mar 19, 2016	Room	07:15-08:15	08:15-08:30	08:30-09:30	09:30-10:20	10:20-10:50	10:50-12:20	12:20-12:50	12:50-12:55	12:55-13:00	
	Plenary hall (Hall 11, Level 1)	ISSS 5a p. 194		SS 10: Surgical and endoscopic FAQs in IBD p. 30			SS 11: Right time, right drug, right strategy p. 32	SS 12: ECCO Lecture p. 33	Awards and closing remarks p. 33	The ECCO Film 2015 p. 33	
	Elicium 2 (Level 1)	ISSS 5b p. 194									
Exhibition hall (Hall 9 + 10, Level 1)				Exhibition p. 209	Coffee break	Exhibition p. 209					



European
Crohn's and Colitis
Organisation

Become a member!

3-year membership:
Regular & Y-ECCO
Members save up to 20%



Be a bee in our hive to experience the ECCO Spirit

To reach our objectives, our members can access the following ECCO Initiatives:

- Reduced Congress fee
- JCC – Journal of Crohn's and Colitis (12 online issues/year)*
- e-CCO Learning Platform incl. e-Courses & e-Library
- Monthly eNewsletter
- Access to online members' area
- Quarterly ECCO News – The society's magazine
- Educational and networking activities
- Guidelines, ECCO Fellowships, Grants and Travel Awards
- Access to ECCO Scientific Platform – Who does What?

Scan and contact the ECCO Office
www.ecco-ibd.eu



*For Regular Members (incl. Y-ECCO) only; online access only

“IBD innovations driving clinical decisions”

Thursday, March 17, 2016

Scientific programme day by day (as of February 15, 2016)
Plenary Hall (Hall 11), Level 1, RAI Amsterdam

10:45 - 11:15	Top tips for chairs (closed session) Laurence Egan, Galway, Ireland
11:30 - 12:30	Industry sponsored satellite symposia 1a & 1b Please refer to pages 188-189
12:45 - 12:50	1: Welcome Janneke van der Woude, Rotterdam, The Netherlands Bas Oldenburg, Utrecht, The Netherlands
12:50 - 13:00	2: Opening Séverine Vermeire, Leuven, Belgium
13:00 - 14:30	Scientific session 1: Cell therapy: Ready for clinical practice? Pierre Desreumaux, Lille, France Dominik Bettenworth, Munster, Germany
13:00 - 13:20	3: Haematopoietic stem cell transplantation Azucena Salas, Barcelona, Spain Elena Ricart, Barcelona, Spain
13:20 - 13:30	4: Best abstract: A phase III randomised controlled trial of Cx601, expanded allogeneic adipose-derived mesenchymal stem cells (eASC), for complex perianal fistulae in Crohn's Disease J. Panés ¹ , D. García-Olmo ² , G. van Assche ³ , J.F. Colombel ⁴ , W. Reinisch ⁵ , D.C. Baumgart ⁶ , M. Nachury ⁷ , M. Ferrante ³ , L. Kazemi-Shirazi ⁸ , J.C. Grimaud ⁸ , F. de la Portilla ⁹ , E. Goldin ¹⁰ , A. Leselbaum ¹¹ , M.C. Diez ¹¹ , S. Danese ¹² ¹ Hospital Clínic Barcelona, Barcelona, Spain, ² Hospital U. Fundación Jiménez-Díaz, Madrid, Spain, ³ University Hospitals Leuven, KU Leuven, Leuven, Belgium, ⁴ Icahn School of Medicine at Mount Sinai, New York, United States, ⁵ Medical University of Vienna, Vienna, Austria, ⁶ Charité Medical School - Humboldt-University of Berlin, Berlin, Germany, ⁷ CHU Lille, Lille, France, ⁸ Hôpital Nord, Marseille, France, ⁹ Hospital Virgen del Rocío, Sevilla, Spain, ¹⁰ Sharee Zedek MC, Jerusalem, Israel, ¹¹ TiGenix, Madrid, Spain, ¹² Istituto Clinico Humanitas, Milano, Italy
13:30 - 13:50	5: Immune cell manipulation Graham Lord, London, United Kingdom Matthieu Allez, Paris, France
13:50 - 14:00	6: Best abstract: Histopathological response and remission after dual topical application of the toll-like-receptor 9 agonist DIMS0150 in patients with moderate to severe Ulcerative Colitis R. Atreya ¹ , A. Öst ² , C. Admyre ³ , A. Karlsson ³ , T. Knittel ³ , J. Kowalski ³ , F. Scaldaferrì ⁴ , M. Neurath ¹ , C. Hawkey ⁵ ¹ University of Erlangen-Nuernberg, Department of Medicine 1, Erlangen, Germany, ² Aleris Medilab, Department of Pathology and Cytology, Täby, Sweden, ³ Index Pharmaceuticals, Stockholm, Sweden, ⁴ Catholic University of Rome, Internal Medicine Department, Gastroenterology Division, Rome, Italy, ⁵ Nottingham University Hospitals, Department of Gastroenterology, Nottingham, United Kingdom

Thursday, March 17, 2016, cont.

Scientific programme day by day (as of February 15, 2016)

Plenary Hall (Hall 11), Level 1, RAI Amsterdam

14:00 - 14:20	<p>7: Mesenchymal stem cells Tandem talk: Stefania Vetrano, Milan, Italy Laurence Egan, Galway, Ireland</p>
14:20 - 14:30	<p>8: Best abstract: Predicting short and medium-term efficacy of the biosimilar infliximab: Trough levels/ADAs or clinical/biochemical markers play a more important role? P.A. Golovics¹, Z. Vegh¹, M. Rutka², K. Gecse¹, A. Balint², K. Farkas², J. Banai³, L. Bene⁴, B. Gasztonyi⁵, T. Kristof⁶, L. Lakatos⁷, P. Miheller⁸, K. Palatka⁹, A. Patai¹⁰, A. Salamon¹¹, T. Szamosi³, Z. Szepes¹², G.T. Toth¹³, A. Vincze¹⁴, E. Biro¹⁵, B. Lovasz¹, Z. Kurti¹, F. Nagy¹², T. Molnar², P. Lakatos¹ ¹Semmelweis University, 1st Department of Medicine, Budapest, Hungary, ²University of Szeged, 1st Department of Medicine, Szeged, Hungary, ³Military Hospital, State Health Centre, Department of Gastroenterology, Budapest, Hungary, ⁴Peterfy Hospital, 1st Department of Medicine, Budapest, Hungary, ⁵Zala County Hospital, 2nd Department of Medicine, Zalaegerszeg, Hungary, ⁶B-A-Z County and University Teaching Hospital, 2nd Department of Medicine, Miskolc, Hungary, ⁷Csolnoky F. Province Hospital, Department of Medicine, Veszprem, Hungary, ⁸Semmelweis University, 2nd Department of Medicine, Budapest, Hungary, ⁹University of Debrecen, Institute of Medicine, Department of Gastroenterology, Debrecen, Hungary, ¹⁰Markusovszky Hospital, 1st Department of Medicine and Gastroenterology, Szombathely, Hungary, ¹¹Tolna County Teaching Hospital, 1st Department of Gastroenterology, Szekszard, Hungary, ¹²University of Szeged, First Department of Internal Medicine, Szeged, Hungary, ¹³Janos Hospital, Department of Gastroenterology, Budapest, Hungary, ¹⁴University of Pecs, 1st Department of Medicine, Pecs, Hungary, ¹⁵Semmelweis University, Department of Laboratory Medicine, Budapest, Hungary</p>
<p>14:30 - 15:00 Coffee break</p>	

Thursday, March 17, 2016, cont.

Scientific programme day by day (as of February 15, 2016)

Plenary Hall (Hall 11), Level 1, RAI Amsterdam

15:00 - 17:00	Scientific session 2: Application of genetic testing in understanding and managing IBD Andre Franke, Kiel, Germany Thomas Billiet, Heverlee, Belgium	
	15:00 - 15:20	9: Very early onset IBD – from research to bedside Holm Uhlig, Oxford, United Kingdom
15:20 - 15:30	10: Best abstract: Gene expression profiling indicates similar molecular pathways are active in adult and paediatric Crohn's Disease A. Stojmirovic , R. Dobrin, R. Strauss, D. Chan, K. Li, J. Friedman Janssen R & D, LLC, Spring House, United States	
15:30 - 15:50	11: Genetics in predicting drug response Tariq Ahmad, Exeter, United Kingdom	
15:50 - 16:00	12: Best abstract: A variable number of tandem repeat polymorphism in the promotor region of the neonatal Fc receptor affects anti-TNF serum levels in IBD T. Billiet¹ , I. Cleyen ¹ , M. Ferrante ² , G. van Assche ² , A. Gils ³ , S. Vermeire ²	
	¹ Department of Clinical and Experimental Medicine, KU Leuven, Translational Research in Gastrointestinal Disorders (TARGID), Leuven, Belgium, ² University Hospitals Leuven, Gastroenterology - Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium, ³ KU Leuven, Laboratory for Therapeutic and Diagnostic Antibodies, Leuven, Belgium	
16:00 - 16:10	13: Best abstract: Autophagy regulates dendritic cell migration through Rac1 – implications for thiopurine therapy M. Wildenberg¹ , P. Koelink ² , K. Diederens ² , A. te Velde ² , V. Nuij ³ , M. Peppelenbosch ³ , M. Nobis ⁴ , O. Sansom ⁴ , C.J. van der Woude ³ , G. D'Haens ¹ , G. van den Brink ¹	
	¹ Academic Medical Center, Gastroenterology and Hepatology, Amsterdam, Netherlands, ² Academic Medical Center, Tytgat Institute, Amsterdam, Netherlands, ³ Erasmus Medical Center, Department of Gastroenterology and Hepatology, Rotterdam, Netherlands, ⁴ Beatson Institute for Cancer Research, Glasgow, United Kingdom	
16:10 - 16:30	14: The future of genetics in clinical medicine Rinse Weersma, Groningen, The Netherlands	
16:30 - 16:40	15: Best abstract: Comprehensive epigenome-wide DNA methylation profiling in Inflammatory Bowel Disease N. Ventham¹ , N. Kennedy ¹ , A. Adams ¹ , R. Kalla ¹ , S. Heath ² , K. O'Leary ¹ , H. Drummond ¹ , D. Wilson ³ , on behalf of the IBD-BIOM Consortium ¹ , on behalf of the IBD-CHARACTER Consortium ¹ , I. Gut ² , E.R. Nimmo ¹ , J. Satsangi ¹	
	¹ University of Edinburgh, CGEM, Edinburgh, United Kingdom, ² Centro Nacional de Análisis Genómico, Barcelona, Spain, ³ University Of Edinburgh, Department of Child Life and Health, Edinburgh, United Kingdom	



Y-ECCO
Abstract Award



Y-ECCO
Abstract Award

Thursday, March 17, 2016, cont.

Scientific programme day by day (as of February 15, 2016)

Plenary Hall (Hall 11), Level 1, RAI Amsterdam

16:40 - 16:50

16: Best abstract: Genotype-phenotype analysis across 130,422 genetic variants identifies RSPO3 as the first genome-wide significant modifier gene in primary sclerosing cholangitis

R. Alberts¹, E.M. de Vries², G. Alexander³, D. Alvaro⁴, A. Bergquist⁵, U. Beuers², E. Björnsson⁶, K.M. Boberg⁷, C.L. Bowlus⁸, R.W. Chapman⁹, O. Chazouillères¹⁰, A. Cheung¹¹, G. Dalekos¹², B. Eksteen¹³, D. Ellinghaus¹⁴, M. Färkkilä¹⁵, E.A. Festen¹, A. Floreani¹⁶, T. Folseraas⁷, E. Goode¹⁷, D.N. Gotthardt¹⁸, G.M. Hirschfield¹⁹, B. van Hoek²⁰, K. Holm⁷, S. Hohenester²¹, J.R. Hov⁷, F. Imhann¹, P. Invernizzi²², X. Jiang⁷, J. Eaton²³, B.D. Juran²⁴, K.N. Lazaridis²⁴, V. Leppa²⁵, J.Z. Liu²⁶, J. Löfberg²⁷, M.P. Manns²⁸, H.-U. Marschall²⁹, M. Marzioni³⁰, A.L. Mason³¹, E. Melum⁷, P. Milkiewicz³², T. Müller³³, A. Pares³⁴, C. Rupp³⁵, S.M. Rushbrook³⁶, C. Rust³⁷, F. Sampaziotis³⁸, R.N. Sandford³⁹, C. Schramm⁴⁰, S. Schreiber¹⁴, E. Schrupp⁷, M. Silverberg⁴¹, B. Srivastava³⁹, M. Sterneck⁴², A. Teufel⁴³, L. Tittmann⁴⁴, L. Vallier³⁸, A.V. Vila¹, B. de Vries¹, T.J. Weismüller²⁸, C. Wijmenga⁴⁵, K. Zachou⁴⁶, A. Franke¹⁴, C.A. Anderson²⁶, T.H. Karlsen⁷, C.Y. Ponsioen², R.K. Weersma¹

¹University of Groningen and University Medical Centre Groningen, Department of Gastroenterology and Hepatology, Groningen, Netherlands, ²Academic Medical Center, Department of Gastroenterology and Hepatology, Amsterdam, Netherlands, ³University of Cambridge, Department of Medicine, Division of Hepatology, Cambridge, United Kingdom, ⁴Sapienza University of Rome, Department of Clinical Medicine, Division of Gastroenterology, Rome, Italy, ⁵Karolinska University Hospital Huddinge, Karolinska Institutet, Department of Gastroenterology and Hepatology, Stockholm, Sweden, ⁶Landspítali University Hospital, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Reykjavik, Iceland, ⁷Oslo University Hospital, Rikshospitalet, Norwegian PSC Research Center, Division of Cancer Medicine, Surgery and Transplantation, Oslo, Norway, ⁸University of California Davis, Division of Gastroenterology and Hepatology, Davis, United States, ⁹John Radcliffe University Hospitals NHS Trust, Department of Hepatology, Oxford, United Kingdom, ¹⁰Hôpital Saint Antoine and U.P.M.C. Univ Paris 06, AP-HP and Department of Hepatology, Paris, France, ¹¹University Health Network - Toronto General Hospital, Gen. Internal Medicine, Toronto, Canada, ¹²Medical School, University of Thessaly, Department of Medicine and Research Laboratory of Internal Medicine, Larissa, Greece, ¹³University of Calgary, Snyder Institute of Chronic Diseases, Department of Medicine, Calgary, Canada, ¹⁴Christian-Albrechts-University of Kiel, Institute of Clinical Molecular Biology, Kiel, Germany, ¹⁵Helsinki University Hospital, Division of Gastroenterology, Department of Medicine, Helsinki, Finland, ¹⁶University of Padova, Department of Surgical, Oncological and Gastroenterological Sciences, Padova, Italy, ¹⁷Norfolk and Norwich University Hospital, Department of Gastroenterology, Norwich, United Kingdom, ¹⁸University Hospital of Heidelberg, Department of Medicine, Heidelberg, Germany, ¹⁹University of Toronto, Division of Gastroenterology, Department of Medicine, Toronto, Canada, ²⁰Leiden University Medical Centre, Department of Gastroenterology and Hepatology, Leiden, Netherlands, ²¹University of Munich, Department of Medicine II, Munich, Germany, ²²Humanitas Clinical and Research Center, Center for Autoimmune Liver Diseases, Rozzano, Italy, ²³Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, United States, ²⁴Mayo Clinic, College of Medicine, Center for Basic Research in Digestive Diseases, Division of Gastroenterology and Hepatology, Rochester, United States,

Thursday, March 17, 2016, cont.

Scientific programme day by day (as of February 15, 2016)

Plenary Hall (Hall 11), Level 1, RAI Amsterdam

<p>16:40 - 16:50 cont.</p>	<p>²⁵Institute for Molecular Medicine Finland F.I.M.M., University of Helsinki and National Institute for Health and Welfare, Public Health Genomics Unit, Helsinki, Finland, ²⁶Wellcome Trust Sanger Institute, Wellcome Trust Genome Campus, Hinxton, Cambridge, United Kingdom, ²⁷Karolinska Institute, Stockholm, Sweden, ²⁸Hannover Medical School, Department of Gastroenterology, Hepatology and Endocrinology, Hannover, Germany, ²⁹Institute of Medicine, Sahlgrenska Academy and University Hospital, Department of Internal Medicine, Gothenburg, Sweden, ³⁰Università Politecnica delle Marche, Ospedali Riuniti University Hospital, Department of Gastroenterology, Ancona, Italy, ³¹University of Alberta, Division of Gastroenterology and Hepatology, Edmonton, Canada, ³²Medical University of Warsaw, Liver and Internal Medicine Unit, Warsaw, Poland, ³³Charité Universitätsmedizin Berlin, Department of Internal Medicine, Hepatology and Gastroenterology, Berlin, Germany, ³⁴University of Barcelona, Liver Unit, Hospital Clínic, I.D.I.B.A.P.S., C.I.B.E.R.ehd, Barcelona, Spain, ³⁵University Hospital of Heidelberg, Department of Internal Medicine IV, Heidelberg, Germany, ³⁶University Hospitals NHS Trust, Department of Gastroenterology and Hepatology, Norfolk and Norwich, Norwich, United Kingdom, ³⁷University of Munich, Department of Medicine 2, Grosshadern, Munich, Germany, ³⁸Wellcome Trust-Medical Research Council Stem Cell Institute, Anne McLaren Laboratory, Cambridge, United Kingdom, ³⁹University of Cambridge, Academic Department of Medical Genetics, Cambridge, United Kingdom, ⁴⁰University Medical Center Hamburg-Eppendorf, ¹st Department of Medicine, Hamburg, Germany, ⁴¹Mount Sinai Hospital Toronto, Inflammatory Bowel Disease (IBD) Group, Zane Cohen Centre for Digestive Diseases, Toronto, Canada, ⁴²University Medical Center Hamburg-Eppendorf, Department of Hepatobiliary Surgery and Transplantation, Hamburg, Germany, ⁴³University of Mainz, ¹st Department of Medicine, Mainz, Germany, ⁴⁴Christian-Albrechts-University of Kiel, Institute for Epidemiology, Kiel, Germany, ⁴⁵University of Groningen and University Medical Centre Groningen, Department of Genetics, Groningen, Netherlands, ⁴⁶University of Thessaly, Department of Internal Medicine, Larissa, Greece</p>
<p>16:50 - 17:00</p>	<p>17: Best abstract: Gene-microbiome interactions underlying the onset and the clinical phenotypes of Inflammatory Bowel Disease F. Imhann¹, A. Vich Vila¹, M.J. Bonder², D. Gevers³, J. Fu², M.C. Visschedijk¹, L.M. Spekhorst¹, L. Franke², H. van Dullemen¹, R.W.F. Ter Steege¹, C. Huttenhower⁴, G. Dijkstra¹, R.J. Xavier³, C. Wijmenga², E.A.M. Festen¹, A. Zhernakova², R.K. Weersma¹ ¹University of Groningen and University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, Netherlands, ²University of Groningen and University Medical Center Groningen, Department of Genetics, Groningen, Netherlands, ³The Broad Institute of MIT and Harvard, Cambridge, United States, ⁴Harvard School of Public Health, Biostatistics Department, Boston, United States</p>
<p>17:15 - 18:15</p>	<p>Digital oral presentations (Sessions 1-5) Please refer to pages 42-54</p>
<p>17:15 - 18:15</p>	<p>Industry sponsored satellite symposia 2a & 2b Please refer to pages 189-190</p>

Friday, March 18, 2016

Scientific programme day by day (as of February 15, 2016)



Plenary Hall (Hall 11), Level 1, RAI Amsterdam

07:15 - 08:15	Industry sponsored satellite symposia 3a & 3b Please refer to pages 190-191
08:30 - 09:30	Scientific session 3: Resolution of inflammation Javier Gisbert, Madrid, Spain Giovanni Monteleone, Rome, Italy
08:30 - 08:50	18: Mechanisms by which inflammation resolves Silvio Danese, Milan, Italy
08:50 - 09:10	19: Stopping drugs Charlie Lees, Edinburgh, United Kingdom
09:10 - 09:20	20: Best abstract: Azathioprine dose reduction in Inflammatory Bowel Disease patients on combination therapy: A prospective study E. Del Tedesco ¹ , S. Paul ² , H. Marotte ³ , C. Jarlot ¹ , N. Williet ⁴ , J.M. Phelip ⁴ , L. Peyrin-Biroulet ⁵ , J.F. Colombel ⁶ , X. Roblin⁴ ¹ University Hospital, Gastroenterology, Saint Etienne, France, ² University of Saint Etienne, Immunology, Saint Etienne, France, ³ University Hospital, Rheumatology, Saint Etienne, France, ⁴ CHU Saint Etienne, Saint Etienne, France, ⁵ CHU de Nancy, Department of Gastroenterology, Vandoeuvre-Lès-Nancy, France, ⁶ Mount Sinai Hospital, New York, United States
09:20 - 09:30	21: Best abstract: Comparison of adalimumab monotherapy and a combination with azathioprine for patients with Crohn's Disease: A prospective, multicentre, open-labeled clinical trial (DIAMOND study) T. Matsumoto¹ , S. Motoya ² , K. Watanabe ³ , T. Hisamatsu ⁴ , H. Nakase ⁵ , N. Yoshimura ⁶ , T. Ishida ⁷ , S. Kato ⁸ , T. Nakagawa ⁹ , M. Esaki ¹⁰ , M. Nagahori ¹¹ , T. Matsui ¹² , Y. Naito ¹³ , T. Kanai ¹⁴ , Y. Suzuki ¹⁵ , M. Nojima ¹⁶ , M. Watanabe ¹¹ , T. Hibi ¹⁷ ¹ Iwate Medical University, Division of Gastroenterology, Department of Medicine, Morioka, Japan, ² Sapporo Kosei General Hospital, Inflammatory Bowel Disease Center, Sapporo, Japan, ³ Osaka City General Hospital, Division of Gastroenterology, Osaka, Japan, ⁴ Kyorin University School of Medicine, The Third Department of Internal Medicine, Tokyo, Japan, ⁵ Kyoto University, Department of Gastroenterology and Hepatology, Endoscopic Medicine, Kyoto, Japan, ⁶ Tokyo Yamate Medical Center, Department of Medicine, Division of Gastroenterology, Tokyo, Japan, ⁷ Oita Red Cross Hospital, Department of Gastroenterology, Oita, Japan, ⁸ Saitama Medical Center, Saitama Medical University, Department of Gastroenterology and Hepatology, Kawagoe, Japan, ⁹ Chiba University, Department of Gastroenterology and Nephrology (K1), Graduate School of Medicine, Chiba, Japan, ¹⁰ Kyushu University, Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Fukuoka, Japan, ¹¹ Tokyo Medical and Dental University, Department of Gastroenterology and Hepatology, Tokyo, Japan, ¹² Fukuoka University Chikushi Hospital, Department of Gastroenterology, Chikushino, Japan, ¹³ Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Department of Molecular Gastroenterology and Hepatology, Kyoto, Japan, ¹⁴ Keio University, Department of Internal Medicine, School of Medicine, Tokyo, Japan, ¹⁵ Toho University Sakura Medical Center, Department of Internal Medicine, Sakura, Japan, ¹⁶ The Institute of Medical Science Hospital, The University of Tokyo, Center for Translational Research, Tokyo, Japan, ¹⁷ Kitasato University Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan

Friday, March 18, 2016, cont.

Scientific programme day by day (as of February 15, 2016)

Plenary Hall (Hall 11), Level 1, RAI Amsterdam

Scientific session 4: Viruses and IBD		
09:30 - 10:30 Laurent Beaugerie, Paris, France Marina Shapina, Moscow, Russia		
	09:30 - 09:50	22: Should we treat CMV in patients with UC? Britta Siegmund, Berlin, Germany
 Y-ECCO Abstract Award	09:50 - 10:00	23: Best abstract: Risk factors for colorectal neoplasia in Ulcerative Colitis: Results from the largest and longest-running colonoscopic surveillance programme C.H.R. Choi ^{1,2} , I. Al Bakir ^{1,2} , N.S.J. Ding ¹ , M. Moorghen ¹ , S. Thomas-Gibson ¹ , J. Warusavitarne ¹ , B. Saunders ¹ , M. Rutter ³ , T. Graham ² , A. Hart ¹ ¹ St. Mark's Hospital, London, United Kingdom, ² Barts Cancer Institute, Tumour Biology, London, United Kingdom, ³ University Hospital of North Tees, Department of Gastroenterology, Stockton-on-Tees, Teesside, United Kingdom
 Y-ECCO Abstract Award	10:00 - 10:10	24: Best abstract: Evolution of corticosteroid use in Crohn's Disease patients between 1991 and 2014: Results from the Dutch population-based IBDSL cohort S. Jeuring ^{1,2} , V. Biemans ¹ , L. Liu ¹ , T. van den Heuvel ^{1,2} , M. Zeegers ^{3,4} , W. Hameeteman ¹ , M. Romberg-Camps ⁵ , L. Oostenbrug ⁵ , A. Masclee ^{1,2} , D. Jonkers ^{1,2} , M. Pierik ^{1,2} ¹ Maastricht University Medical Centre, Internal Medicine - Division of Gastroenterology and Hepatology, Maastricht, Netherlands, ² Maastricht University Medical Centre, NUTRIM - School for Nutrition and Translational Research in Metabolism, Maastricht, Netherlands, ³ Maastricht University Medical Centre, Complex Genetics - School for Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht, Netherlands, ⁴ Maastricht University Medical Centre, CAPHRI - School for Public Health and Primary Care, Maastricht, Netherlands, ⁵ Zuyderland Medical Centre, Internal Medicine and Gastroenterology-Hepatology, Sittard-Geleen, Netherlands, ⁶ Zuyderland Medical Centre, Internal Medicine and Gastroenterology-Hepatology, Heerlen, Netherlands
	10:10 - 10:30	25: Other viral complications in clinical practice Jonas Halfvarsson, Örebro, Sweden
10:30 - 11:00 Coffee break		

Friday, March 18, 2016, cont.

Scientific programme day by day (as of February 15, 2016)

Plenary Hall (Hall 11), Level 1, RAI Amsterdam

11:00 - 12:20		Scientific session 5: Challenging dogmas – from clinical trials to clinical practice Torsten Kucharzik, Lüneburg, Germany Maria Chaparro, Madrid, Spain
	11:00 - 11:20	26: Mucosal healing – Is it the holy grail? Geert D'Haens, Amsterdam, The Netherlands
	11:20 - 11:30	27: Best abstract: A multicentre, double-blind, placebo-controlled phase3 study of ustekinumab, a human interleukins-12/23p40 mab, in moderate-severe Crohn's Disease refractory to anti-TNFα: UNITI-1 P. Rutgeerts ¹ , C. Gasink ² , M. Blank ³ , Y. Lang ² , J. Johanss ² , L.-L. Gao ² , B. Sands ² , S. Hanauer ² , B. Feagan ⁶ , S. Targan ⁷ , S. Ghosh ⁸ , W. de Villiers ⁹ , J.-F. Colombel ¹⁰ , S. Lee ¹¹ , P. Desreumaux ¹² , E.V. Loftus Jr ¹³ , S. Vermeire ¹⁴ , W.J. Sandborn ¹⁵ ¹ University Hospital Gasthuisberg, Department of Haematology, Leuven, Netherlands, ² Janssen R & D, LLC, Spring House, United States, ³ Janssen Scientific Affairs, LLC., Horsham, United States, ⁴ Mount Sinai Medical Center, New York, United States, ⁵ Northwestern University Feinberg School of Medicine, Chicago, United States, ⁶ Robarts Clinical Trials, Robarts Research Institute, Western University, London, Canada, ⁷ Cedars-Sinai Medical Center, Division of Gastroenterology, Los Angeles, United States, ⁸ University of Calgary, Department of Gastroenterology, Calgary, Canada, ⁹ Universiteit Stellenbosch University, Stellenbosch, South Africa, ¹⁰ Mount Sinai, Icahn School of Medicine, New York, United States, ¹¹ University of Washington, Seattle, United States, ¹² University of Lille, Lille, France, ¹³ Mayo Clinic Rochester, Department of Gastroenterology, Rochester, United States, ¹⁴ University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium, ¹⁵ University of California San Diego, Division of Gastroenterology, La Jolla, United States
	11:30 - 11:40	28: Best abstract: Results of ANDANTE, a randomised clinical study with an anti-IL6 antibody (PF-04236921) in subjects with Crohn's Disease who are anti-TNF inadequate responders S. Danese ¹ , S. Vermeire ² , P. Hellstern ³ , R. Panaccione ⁴ , G. Rogler ⁵ , G. Fraser ⁶ , A. Kohn ⁷ , P. Desreumaux ⁸ , R.W. Leong ⁹ , G.M. Comer ¹⁰ , F. Cataldi ¹⁰ , A. Banerjee ¹⁰ , M.K. Maguire ¹¹ , C. Li ¹⁰ , N. Rath ¹¹ , J. Beebe ¹⁰ , S. Schreiber ¹² ¹ Humanitas University Clinical and Research Hospital, Rozzano, Milan, Italy, ² University Hospitals Leuven, Leuven, Belgium, ³ Nature Coast Clinical Research, Inverness, United States, ⁴ University of Calgary, Calgary, Canada, ⁵ University of Zürich, Zürich, Switzerland, ⁶ Rabin Medical Centre and University of Tel-Aviv, Petah Tikva, Israel, ⁷ AO San Camillo Forlanini, Rome, Italy, ⁸ University of Lille, Inserm U995, Lille, France, ⁹ Concord Hospital, Sydney, New South Wales, Australia, ¹⁰ Pfizer Inc, Cambridge, United States, ¹¹ Pfizer Inc, Collegeville, United States, ¹² Christian-Albrechts University, Kiel, Germany
	11:40 - 12:00	29: Patient-reported outcomes William Sandborn, San Diego, United States
	12:00 - 12:20	30: Should clinical trials in children be different? Dan Turner, Jerusalem, Israel
12:20 - 13:20		Lunch break and guided poster session in the exhibition hall Please refer to pages 38-39
12:30 - 13:10		Industry sponsored educational lunchtime satellite symposia LS1-4 Please refer to pages 191-192

Friday, March 18, 2016, cont.

Scientific programme day by day (as of February 15, 2016)

Plenary Hall (Hall 11), Level 1, RAI Amsterdam

13:20 - 14:50	Scientific session 6: Bugs and drugs in IBD Philippe Seksik, Paris, France Barry Hall, Dublin, Ireland	
13:20 - 13:40		31: The microbiome and geographical spread of IBD Philip Rosenstiel, Kiel, Germany
13:40 - 13:50		32: Best abstract: Development and validation of diagnostic criteria for IBD-Unclassified (IBDU) in children: A multicentre longitudinal study from the Paediatric IBD Porto group of ESPGHAN L. Birimberg Schwartz ¹ , D. Zucker ² , A. Akriv ² , C. Salvatore ³ , F. Cameron ⁴ , I. Lazowska ⁵ , L. Yianni ⁶ , P. Siba ⁷ , S. Kolacek ⁸ , C. Romano ⁹ , S. Buderus ¹⁰ , A. Pærregaard ¹¹ , J. C. Escher ¹² , D. Turner ¹³ ¹ Shaare Zedek Medical Center, Paediatrics, Jerusalem, Israel, ² The Hebrew University, Jerusalem, Israel, ³ Sapienza University of Rome, Rome, Italy, ⁴ Yorkhill Children's Hospital, Glasgow, United Kingdom, ⁵ Medical University of Warsaw, Warsaw, Poland, ⁶ University Hospital Southampton, Hampshire, United Kingdom, ⁷ University of Dundee, Scotland, United Kingdom, ⁸ Zagreb University Medical School, Zagreb, Croatia, ⁹ University of Messina, Messina, Italy, ¹⁰ St. Marien Hospital, Bonn, Germany, ¹¹ Hvidovre University Hospital, Copenhagen, Denmark, ¹² Erasmus Medical Center, Netherlands, ¹³ Shaare Zedek Medical Center, Jerusalem, Israel
13:50 - 14:10		33: Manipulating the microbiota in everyday practice Francisco Guarner, Barcelona, Spain
14:10 - 14:20		34: Best abstract: Multi donor intense faecal microbiota transplantation is an effective treatment for resistant Ulcerative Colitis: A randomised placebo-controlled trial S. Paramsothy ¹ , M. Kamm ^{2,3} , A. Walsh ⁴ , J. van den Bogaerde ⁵ , D. Samuel ⁶ , R. Leong ⁶ , S. Connor ⁷ , W. Ng ⁷ , R. Paramsothy ⁷ , N. Kaakoush ⁸ , H. Mitchell ⁹ , W. Xuan ⁹ , E. Lin ¹⁰ , T. Borody ¹⁰ ¹ University of New South Wales, St Vincent's Clinical School, Sydney, Australia, ² St Vincent's Hospital, Melbourne, Australia, ³ Imperial College London, London, United Kingdom, ⁴ St Vincent's Hospital, Sydney, Australia, ⁵ Nambour General Hospital, Nambour, Australia, ⁶ Bankstown-Lidcombe Hospital, Sydney, Australia, ⁷ Liverpool Hospital, Sydney, Australia, ⁸ University of New South Wales, School of Biotechnology & Biomolecular Sciences, Sydney, Australia, ⁹ Ingham Institute, Sydney, Australia, ¹⁰ Centre for Digestive Diseases, Sydney, Australia
14:20 - 14:30		35: Best abstract: The impact of "Crohn's Disease-Treatment-with-EATing" diet (CD-TREAT diet) and exclusive enteral nutrition on healthy gut bacteria metabolism V. Svols ¹ , R. Hansen ² , K. Hughes ¹ , U.Z. Ijaz ³ , C. Quince ⁴ , D. Gaya ⁵ , R. Russell ¹ , K. Gerasimidis ¹ ¹ Human Nutrition, School of Medicine, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow Royal Infirmary, Glasgow, United Kingdom, ² Department of Paediatric Gastroenterology, Hepatology and Nutrition, Royal Hospital for Children, Glasgow, United Kingdom, ³ School of Engineering, University of Glasgow, Glasgow, United Kingdom, ⁴ Warwick Medical School, University of Warwick, Warwick, United Kingdom, ⁵ Department of Gastroenterology, Glasgow Royal Infirmary, Glasgow, United Kingdom
14:30 - 14:50		36: Future strategies to change the flora Harry Sokol, Paris, France
14:50 - 15:20	Coffee break	



IIS Abstract Award

Friday, March 18, 2016, cont.

Scientific programme day by day (as of February 15, 2016)

Plenary Hall (Hall 11), Level 1, RAI Amsterdam

15:20 - 16:00		Scientific session 7: ECCO Fellowships & Grants Gerhard Rogler, Zürich, Switzerland Noortje Festen, Groningen, The Netherlands
15:20 - 15:27	37: Outcomes from the 2015 Fellowships – Part 1 Selective histone deacetylase inhibitors: A potential new treatment of Inflammatory Bowel Diseases Carla Felice, Rome, Italy	
15:27 - 15:34	38: Outcomes from the 2015 Fellowships – Part 2 Sphingosine 1-phosphate (S1P)/S1PR3 axis a novel therapeutic target for intestinal fibrosis in Crohn's Disease Cristina Mascaraque, Granada, Spain	
15:34 - 15:40	39: Announcement of ECCO Fellowships & Grants 2016 Gerhard Rogler, Zürich, Switzerland	
15:40 - 15:50	40: Best abstract: Efficacy and safety of oral tofacitinib as induction therapy in patients with moderate to severe Ulcerative Colitis: Results from two phase 3 randomised controlled trials W.J. Sandborn ¹ , B.E. Sands ² , G. D'Haens ³ , S. Vermeire ⁴ , S. Schreiber ⁵ , S. Danese ⁶ , J. Panés ⁷ , B.G. Feagan ⁸ , W. Reinisch ⁹ , W. Niezychowski ¹⁰ , G. Friedman ¹⁰ , N. Lawendy ¹⁰ , D. Yu ¹⁰ , D. Woodworth ¹⁰ , A. Mukherjee ¹¹ , P. Healey ¹¹ , H. Zhang ¹⁰ , C. Su ¹⁰ ¹ Division of Gastroenterology, University of California, San Diego, United States, ² Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, United States, ³ Academic Medical Centre, University of Amsterdam, Amsterdam, Netherlands, ⁴ Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium, ⁵ Klinik für Innere Medizin I, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany, ⁶ IBD Center, Department of Gastroenterology, Humanitas Research Hospital, Milan, Italy, ⁷ Hospital Clinicas de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain, ⁸ Robarts Research Institute, London, Canada, ⁹ McMaster University, Hamilton, Canada, ¹⁰ Pfizer Inc, Collegeville, United States, ¹¹ Pfizer Inc, Groton, United States	
15:50 - 16:00	41: Best abstract: Filgotinib, a selective JAK1 inhibitor, induces clinical remission in patients with moderate-to-severe Crohn's Disease: Interim analysis from the phase 2 FITZROY study S. Vermeire ¹ , S. Schreiber ² , R. Petryka ³ , T. Kuehbachner ⁴ , X. Hebuterne ⁵ , X. Roblin ⁶ , M. Klopocka ⁷ , E. Goldis ⁸ , M. Wisniewska-Jarosinska ⁹ , A. Baranovsky ¹⁰ , R. Sike ¹¹ , C. Tasset ¹² , A. van der Aa ¹² , P. Harrison ¹² ¹ UZ Leuven, Campus Gasthuisberg, Leuven, Belgium, ² University Medical Center Schleswig-Holstein Kiel, Department of Internal Medicine I, Kiel, Germany, ³ Vivamed, Warsaw, Poland, ⁴ Asklepios Hospital West Hamburg, Department of Internal Medicine, Gastroenterology, Hamburg, Germany, ⁵ Archet 2 Hospital, Department of Gastroenterology, Nice, France, ⁶ Saint Etienne Hospital, Department of Gastroenterology, Saint Priest en Jarez, France, ⁷ University Hospital Nr. 2 im. Bizuela, Department of Gastroenterology, Bydgoszcz, Poland, ⁸ Policlinica Algomed, Department of Gastroenterology, Timisoara, Romania, ⁹ Saint Family Hospital Medical Center, Department of Gastroenterology and Endoscopy, Lodz, Poland, ¹⁰ City Clinical Hospital #31, St Petersburg, Russian Federation, ¹¹ Szent Margit Hospital, Department of Internal Medicine and Gastroenterology III, Budapest, Hungary, ¹² Galapagos NV, Department of Development, Mechelen, Belgium	

Friday, March 18, 2016, cont.

Scientific programme day by day (as of February 15, 2016)

Plenary Hall (Hall 11), Level 1, RAI Amsterdam

16:00 - 17:00	Scientific session 8: Challenging Cases Peter Irving, London, United Kingdom Laurent Peyrin-Biroulet, Vandœuvre-lès-Nancy, France	
	16:00 - 16:20	42: Case 1: Challenges during pregnancy: Anti-TNF treatment during pregnancy Shannon Kanis, Rotterdam, The Netherlands
	16:20 - 16:40	43: Case 2: Refractory upper gut Crohn's Disease: Refractory upper gut Crohn's Disease with fatal outcome Miquel Cusachs, Barcelona, Spain
	16:40 - 17:00	44: Case 3: When extra-intestinal symptoms dominate: Severe arthralgia in Crohn's Disease – disease or drug-related? Donata Lissner, Berlin, Germany
17:00 - 17:50	Scientific session 9: What's new on the Guidelines front? Oded Zmora, Tel Aviv, Israel Loris Lopetuso, Rome, Italy	
	17:00 - 17:10	45: ECCO Guidelines: Surgical CD Willem Bemelman, Amsterdam, The Netherlands
	17:10 - 17:20	46: Best abstract: Efficacy and safety of oral tofacitinib for maintenance therapy in patients with moderate to severe Crohn's Disease: Results of a Phase 2b randomised placebo-controlled trial G. D'Haens ¹ , R. Pannaccione ² , P.D.R. Higgins ³ , J.-F. Colombel ³ , B.G. Feagan ⁴ , M. Moscariello ⁵ , G. Chan ⁵ , P. Healey ⁶ , W. Niezychowski ⁵ , W. Wang ⁵ , A. Marren ⁵ , E. Maller ⁵ ¹ Academic Medical Centre, University of Amsterdam, Amsterdam, Netherlands, ² University of Calgary, Calgary, Canada, ³ University of Michigan, Ann Arbor, United States, ⁴ Robarts Research Institute, London, Canada, ⁵ Pfizer Inc, Collegeville, United States, ⁶ Pfizer Inc, Groton, United States
	17:20 - 17:30	47: Best abstract: Efficacy and safety of oral tofacitinib for induction therapy in patients with moderate to severe Crohn's Disease: Results of a Phase 2b randomised placebo-controlled trial J. Panés ¹ , W.J. Sandborn ² , S. Schreiber ³ , B.E. Sands ⁴ , S. Vermeire ⁵ , G. Chan ⁶ , M. Moscariello ⁶ , W. Wang ⁶ , W. Niezychowski ⁶ , A. Marren ⁶ , P. Healey ⁷ , E. Maller ⁶ ¹ Hospital Clinicas de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain, ² Division of Gastroenterology, University of California, San Diego, United States, ³ Klinik für Innere Medizin I, Universitätsklinikum Schleswig-Holstein, Campus Kiel, Kiel, Germany, ⁴ Janowitz Division of Gastroenterology, Icahn School of Medicine at Mount Sinai, New York, United States, ⁵ Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium, ⁶ Pfizer Inc, Collegeville, United States, ⁷ Pfizer Inc, Groton, United States
	17:30 - 17:40	48: ECCO Guidelines: UC Update Rami Eliakim, Tel Hashomer, Israel Marcus Harbord, London, United Kingdom
	17:40 - 17:45	49: ECCO Topical Review: Fibrosis Florian Rieder, Cleveland, United States
	17:45 - 17:50	50: ECCO Topical Review: Elderly in IBD Paolo Gionchetti, Bologna, Italy
18:05 - 19:05	Digital oral presentations (Sessions 6-10) Please refer to pages 56-66	
18:05 - 19:05	Industry sponsored satellite symposia 4a & 4b Please refer to page 193	
20:00	ECCO Interaction: Hearts & Minds Beurs van Berlage, Damrak 243, 1012 ZJ Amsterdam (Please refer to page 207)	



European
Crohn's and Colitis
Organisation

Amsterdam
The Netherlands

ECCO UR-CARE

Learn
more @ the
ECCO Booth

United Registries for Clinical
Assessment and REsearch



Launch in 2016

What to expect

- Comprehensive registry capturing demographics, environmental factors, clinical characteristics, examinations and therapeutic interventions in IBD
- Ground-breaking cross-project cooperation and comparison of results
- Independent data management software offered to National Societies
- Quality of care assessment
- High mobility & continuity of care for patients
- Retro- & pro-spective data collection/evaluation
- Sophisticated/user friendly data export and report function
- Precise data ownership rules

Launch at Strategic Council:

Thursday, March 17, 2016 from 19:30 to 20:00 @ Elicium 1 (First floor), RAI Amsterdam

Scan and contact the ECCO Office
www.ecco-ibd.eu



Saturday, March 19, 2016

Scientific programme day by day (as of February 15, 2016)

Plenary Hall (Hall 11), Level 1, RAI Amsterdam

07:15 - 08:15

Industry sponsored satellite symposia 5a & 5b

Please refer to page 194

08:30 - 10:20

Scientific session 10: Surgical and endoscopic FAQs in IBD

André D'Hoore, Leuven, Belgium

Zuzana Serclova, Prague, Czech Republic

08:30 - 08:50

51: Case 1 – Preparing your patient for optimal surgery

Richard Fedorak, Edmonton, Canada

08:50 - 09:00

52: Best abstract: Comparison between newly-developed NBI and panchromoendoscopy for surveillance colonoscopy in patients with Ulcerative Colitis: A prospective multicentre randomised controlled trial, Navigator Study

K. Watanabe¹, M. Nishishita², F. Shimamoto³, T. Fukuchi⁴, M. Esaki⁵, Y. Okamoto⁵, Y. Maehata⁵, S. Oka⁶, S. Nishiyama⁶, S. Fujii⁷, F. Hirai⁸, T. Inoue⁹, N. Hida¹⁰, R. Nozaki¹¹, T. Sakurai¹², K. Takeuchi¹³, M. Saruta¹⁴, S. Saito¹⁵, Y. Saito¹⁶, N. Ohmiya¹⁷, H. Hashida¹², S. Tanaka⁶, T. Matsui⁸, Y. Suzuki¹³, Y. Ajioka¹⁸, H. Tajiri¹⁹

¹Osaka City General Hospital, Gastroenterology, Osaka, Japan, ²Nishishita Gastrointestinal Hospital, Osaka, Japan, ³Faculty of Human Culture and Science Prefectural University of Hiroshima, Hiroshima, Japan, ⁴Osakafu Saiseikai Nakatsu Hospital, Gastroenterology and Hepatology, Osaka, Japan, ⁵Graduate School of Medical Sciences, Kyushu University, Department of Medicine and Clinical Science, Fukuoka, Japan, ⁶Hiroshima University Hospital, Department of Endoscopy, Hiroshima, Japan, ⁷Kyoto Katsura Hospital, Digestive Disease Centre, Department of Gastroenterology, Kyoto, Japan, ⁸Fukuoka University Chikushi Hospital, Department of Gastroenterology, Fukuoka, Japan, ⁹Osaka Medical College, Second Department of Internal Medicine, Osaka, Japan, ¹⁰Hyogo College of Medicine, Department of Inflammatory Bowel Disease, Hyogo, Japan, ¹¹Takano Hospital, Division of Gastroenterology, Coloproctology Center, Kumamoto, Japan, ¹²Kinki University, Department of Gastroenterology, Osaka, Japan, ¹³Toho University Sakura Medical Center, Department of Internal Medicine, Chiba, Japan, ¹⁴The Jikei University School of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Tokyo, Japan, ¹⁵The Jikei University School of Medicine, Department of Endoscopy, Tokyo, Japan, ¹⁶National Cancer Center Hospital, Endoscopy Division, Tokyo, Japan, ¹⁷School of Medicine, Fujita Health University, Department of Gastroenterology, Aichi, Japan, ¹⁸Graduate School of Medical and Dental Sciences, Niigata University, Division of Molecular and Diagnostic Pathology, Niigata, Japan, ¹⁹The Jikei University School of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Department of Endoscopy, Tokyo, Japan

09:00 - 09:10

53: Best abstract: Mucosal healing and dysplasia surveillance in a large referral centre cohort of patients with Crohn's Disease and Ulcerative Colitis treated with vedolizumab

M. Noman¹, M. Ferrante¹, R. Bisschops¹, G. De Hertogh², K. van den Broeck¹, K. Rans¹, P. Rutgeerts¹, S. Vermeire¹, **G. van Assche¹**
¹UZ Leuven, Gastroenterology, Leuven, Belgium, ²UZ Leuven, Campus Gasthuisberg, Pathology, Leuven, Belgium



IIS
Abstract Award

Saturday, March 19, 2016, cont.

Scientific programme day by day (as of February 15, 2016)

Plenary Hall (Hall 11), Level 1, RAI Amsterdam

09:10 - 09:20	<p>54: Best abstract: Escalation of medical therapy decreases need for repeat dilatation in Crohn's anastomatic strictures N.S. Ding^{1,2}, W. Yip¹, R. Choi¹, B. Saunders³, S. Thomas-Gibson³, N. Arebi¹, A. Humphries³, A. Hart¹ ¹St Mark's Hospital, IBD, London, United Kingdom, ²Imperial College London, Department of Surgery and Cancer, London, United Kingdom, ³St Mark's Hospital, Wolfson Unit For Endoscopy, Department of Gastroenterology, Harrow, United Kingdom</p>
09:20 - 09:40	<p>55: Case 2 – Post-surgery prevention Marc Ferrante, Leuven, Belgium</p>
09:40 - 09:50	<p>56: Best abstract: The TOPPIC trial: A randomised, double-blind parallel group trial of mercaptopurine vs placebo to prevent recurrence of Crohn's Disease following surgical resection in 240 patients I. Arnott¹, C. Mowat², H. Ennis³, C. Keerie³, S. Lewis³, N. Kennedy⁴, A. Cahill⁵, A. Morris⁵, M. Dunlop⁶, S. Bloom⁷, J. Lindsay⁸, S. Subramanian⁹, J. Satsangi¹, on behalf of the Toppic Trial Study Group¹⁰ ¹NHS Lothian, Gastroenterology, Edinburgh, United Kingdom, ²NHS Tayside, Gastroenterology, Dundee, United Kingdom, ³University of Edinburgh, Edinburgh Clinical Trials Unit, Edinburgh, United Kingdom, ⁴University of Edinburgh, Gastroenterology, Edinburgh, United Kingdom, ⁵NHS Greater Glasgow and Clyde, Gastroenterology, Glasgow, United Kingdom, ⁶University of Edinburgh, Institute of Genetics and Molecular Medicine, Edinburgh, United Kingdom, ⁷University College Hospital, Department of Gastroenterology, London, United Kingdom, ⁸Bart's Health NHS Trust, Newham University Hospital, Department of Gastroenterology, London, United Kingdom, ⁹Royal Liverpool University Hospital, Gastroenterology, Liverpool, United Kingdom, ¹⁰Toppic Trial Study Group, UK, United Kingdom</p>
09:50 - 10:00	<p>57: Best abstract: Anti-TNF therapy is associated with increased risk of postoperative morbidity after surgery for ileocolonic Crohn's Disease: Outcome analysis in a prospective nationwide cohort of 592 patients conducted by the GETAID chirurgie group A. Brouquet¹, L. Maggiori², P. Zerbib³, J. Lefèvre⁴, Q. Denost⁵, A. Germain⁶, E. Cotte⁷, L. Beyer-Berjot⁸, N. Munoz-Bongrand⁹, V. Desfourneaux¹⁰, A. Rahili¹¹, J.-P. Duffas¹², K. Pautrat¹³, C. Denet¹⁴, V. Bridoux¹⁵, G. Meurette¹⁶, J.-L. Faucheron¹⁷, J. Loriau¹⁸, F. Guillon¹⁹, E. Vicaut²⁰, S. Benoist¹, Y. Panis² ¹Bicêtre Hospital - Université Paris Sud, Oncologic and Digestive Surgery, Le Kremlin Bicêtre, France, ²Beaumont Hospital, Colorectal Surgery, Clichy, France, ³CHU Lille, Digestive Surgery, Lille, France, ⁴Saint Antoine Hospital, Digestive Surgery, Paris, France, ⁵CHU Bordeaux, Digestive Surgery, Bordeaux, France, ⁶CHU Nancy, Digestive Surgery, Nancy, France, ⁷CHU Lyon-Sud, Digestive Surgery, Lyon, France, ⁸CHU Marseille, Digestive Surgery, Marseille, France, ⁹Saint Louis Hospital, Digestive Surgery, Paris, France, ¹⁰CHU Rennes, Digestive Surgery, Rennes, France, ¹¹CHU Nice, Digestive Surgery, Nice, France, ¹²CHU Toulouse, Digestive Surgery, Toulouse, France, ¹³Lariboisière Hospital, Digestive Surgery, Paris, France, ¹⁴Montsouris Institute, Digestive Surgery, Paris, France, ¹⁵CHU Rouen, Digestive Surgery, Rouen, France, ¹⁶CHU Nantes, Digestive Surgery, Nantes, France, ¹⁷CHU Grenoble, Digestive Surgery, Grenoble, France, ¹⁸Saint-Joseph Hospital, Digestive Surgery, Paris, France, ¹⁹CHU Montpellier, Digestive Surgery, Montpellier, France, ²⁰Fernand Widal Hospital, Clinical Research, Paris, France</p>

Saturday, March 19, 2016, cont.

Scientific programme day by day (as of February 15, 2016)

Plenary Hall (Hall 11), Level 1, RAI Amsterdam

10:00 - 10:20	58: Case 3 – Dealing with a problematic pouch Michael Kamm, Melbourne, Australia
10:20 - 10:50	Coffee break
10:50 - 12:20	Scientific session 11: Right time, right drug, right strategy Marieke Pierik, Maastricht, The Netherlands Nik Ding, London, United Kingdom
10:50 - 11:10	59: Molecular stratification of the patient Miles Parkes, Cambridge, United Kingdom
11:10 - 11:20	60: Best abstract: Pharmacokinetics and exposure-response relationships of intravenously administered ustekinumab during induction treatment in patients with Crohn's Disease: Results from the UNITI-1 and UNITI-2 studies O.J. Adedokun¹ , Z. Xu ¹ , C. Gasink ¹ , J. Friedman ¹ , P. Szapary ¹ , Y. Lang ¹ , J. Johans ¹ , L.-L. Gao ¹ , Y. Miao ¹ , H. Davis ¹ , S. Hanauer ² , B. Feagan ³ , W. Sandborn ⁴ ¹ Janssen R & D, LLC, Spring House, United States, ² Northwestern University Feinberg School of Medicine, Chicago, United States, ³ Robarts Clinical Trials Inc., Robarts Research Institute, University of Western Ontario, London, Canada, ⁴ UCSD, Medicine, La Jolla, United States
11:20 - 11:40	61: Choosing the right drug Iris Dotan, Tel Aviv, Israel
11:40 - 11:50	62: Best abstract: Drug-concentration versus symptom-driven dose adaptation of infliximab in patients with active Crohn's Disease: A prospective, randomised, multicentre trial (Tailorix) G. D'Haens¹ , S. Vermeire ² , G. Lambrecht ³ , F. Baert ⁴ , P. Bossuyt ⁵ , M. Nachury ⁶ , A. Buisson ⁷ , Y. Bouhnik ⁸ , J. Filippi ⁹ , J. van der Woude ¹⁰ , P. van Hooetegem ¹¹ , J. Moreau ¹² , E. Louis ¹³ , D. Franchimont ¹⁴ , M. De Vos ¹⁵ , F. Mana ¹⁶ , L. Peyrin-Biroulet ¹⁷ , H. Brix ¹⁸ , M. Allez ¹⁹ , P. Caenepeel ²⁰ , A. Aubourg ²¹ , B. Oldenburg ²² , M. Pierik ²³ , A. Gils ²⁴ , S. Chevret ²⁵ , D. Laharie ²⁶ ¹ Academic Medical Centre, Gastroenterology, Amsterdam, Netherlands, ² University Hospitals Gasthuisberg, Gastroenterology, Leuven, Belgium, ³ AZ Damiaan, Oostende, Belgium, ⁴ AZ Delta, Roeselare, Belgium, ⁵ Imelda GI Clinical Research Centre, Bonheiden, Belgium, ⁶ Hopital Claude Hurriez, Lille, France, ⁷ Hopital Estaing, Clermont-Ferrand, France, ⁸ Hopital Beaujon, Clichy, France, ⁹ Hopital Archet, Nice, France, ¹⁰ Erasmus Medical Centre, Rotterdam, Netherlands, ¹¹ St Lukas Hospital, Bruges, Belgium, ¹² Hopital Rangueil, Toulouse, France, ¹³ Hopital Sart Tilman, Liège, Belgium, ¹⁴ Hopital Erasme, Brussels, Belgium, ¹⁵ University of Ghent, Ghent, Belgium, ¹⁶ Free University of Brussels, Brussels, Belgium, ¹⁷ Hopital Brabois, Nancy, France, ¹⁸ Hopital Robert Debre, Reims, France, ¹⁹ Hopital St Louis, Paris, France, ²⁰ Ziekenhuis Oost Limburg, Genk, Belgium, ²¹ Hopital Trousseau, Tours, France, ²² University of Utrecht, Utrecht, Netherlands, ²³ University Hospital Maastricht, Maastricht, Netherlands, ²⁴ University of Leuven, Leuven, Belgium, ²⁵ Department Biostatistique St Louis, Paris, France, ²⁶ Haut-Leveque, Pessac, France

Saturday, March 19, 2016, cont.

Scientific programme day by day (as of February 15, 2016)

Plenary Hall (Hall 11), Level 1, RAI Amsterdam

11:50 - 12:00	<p>63: Best abstract: Factors associated with the first trough level of infliximab at week 2 that predicts short- and long-term outcomes in Ulcerative Colitis T. Kobayashi¹, Y. Suzuki², S. Motoya³, F. Hirai⁴, H. Ogata⁵, H. Ito⁶, N. Sato⁷, K. Ozaki⁷, M. Watanabe⁸, T. Hibi¹ ¹Kitasato University Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan, ²Toho University Sakura Medical Center, Department of Internal Medicine, Sakura, Japan, ³Sapporo-kosei General Hospital, Inflammatory Bowel Diseases Center, Sapporo, Japan, ⁴Fukuoka University Chikushi Hospital, Department of Gastroenterology, Chikushino, Japan, ⁵Keio University School of Medicine, Center for Diagnostic and Therapeutic Endoscopy, Tokyo, Japan, ⁶Kitano Hospital The Tazuke Kofukai Medical Research Institute, Digestive Disease Center, Osaka, Japan, ⁷Mitsubishi Tanabe Pharma Corporation, Osaka, Japan, ⁸Tokyo Medical and Dental University, Department of Gastroenterology and Hepatology, Tokyo, Japan</p>
12:00 - 12:20	<p>64: Care or action plans for patients Jane Andrews, Adelaide, Australia Karen Kemp, Manchester, United Kingdom</p>
<p>12:20 - 12:50 Scientific session 12: ECCO Lecture Séverine Vermeire, Leuven, Belgium Julián Panés, Barcelona, Spain</p>	
12:20 - 12:50	<p>65: Future of IBD healthcare in Europe Daniel Hommes, Los Angeles, United States</p>
12:50 - 12:55	<p>66: Awards and closing remarks Julián Panés, Barcelona, Spain on behalf of the Organising Committee</p>
12:55 - 13:00	<p>The ECCO Film 2016</p>



Abstract presentation format

Oral presentations

Out of 904 accepted abstracts the 30 best submitted abstracts have been chosen for oral presentation by a panel of referees and will be presented during the scientific programme of the ECCO Congress. For the presentation title and schedule please refer to the scientific congress programme per day.

Note: Oral poster presentations will not be displayed as hard copy posters.

Digital oral presentations (DOP)

Abstracts have been selected from the ranking by taking 90 abstracts after those 30 selected for presentation in the scientific programme. These abstracts will be presented as digital oral presentations, with a 5 minute oral presentation in several rooms on Level 1 of the RAI Amsterdam on Thursday, March 17, 2016 from 17:15-18:15, or on Friday, March 18, 2016 from 18:05-19:05.

The schedule and selected abstracts for each digital oral presentation room can be found on pages 42-66.

Note: Digital oral presentations will not be displayed as hard copy posters.

Hard copy poster presentations

All remaining accepted abstracts are selected for "hard copy poster presentation" and are listed on pages 68-155. Hard copy posters will be installed on poster walls in the poster exhibition area in the exhibition hall on the ground level and will be available for viewing throughout the Congress.

Poster award ceremony:

On Saturday, March 19, 2016, from 12:50 to 12:55 the poster prizes will be awarded for the ten 'Best Posters'. One abstract of each digital oral presentation room has been nominated by the chairs of the respective session.

Please note that this year for the seventh time the ECCO Congress hosts a separate nurses poster section in the exhibition hall (Hall 9) on Level 1 at the RAI Amsterdam. Please find the list of nurses' posters on pages 154-155.

Poster award ceremony is chaired by:

Séverine Vermeire (Belgium)
 Peter Irving (United Kingdom)
 Julián Panés (Spain)
 Laurent Peyrin-Biroulet (France)
 Britta Siegmund (Germany)

Reviewers

ECCO gratefully thanks the following reviewers for their valuable time and efforts in reviewing abstracts:

(i) Basic Science:

Maria Teresa Abreu (United States), Giorgio Bamias (Greece), Dominik Bettenworth (Germany), Yehuda Chowers (Israel), Vincenza Di Leo (Italy), Gerard Dijkstra (The Netherlands), Roger Feakins (United Kingdom), Ailsa Hart (United Kingdom), Satish Keshav (United Kingdom), James Lindsay (United Kingdom), Giovanni Monteleone (Italy), Maria Papp (Hungary), Theresa Pizarro (United States), Gerhard Rogler (Switzerland), Michael Schumann (Germany), Murat Törüner (Turkey), Gijs van den Brink (The Netherlands), Sebastian Zeissig (Germany)

(ii) Clinical: Diagnosis & outcome:

Ayesha Akbar (United Kingdom), Laith Alrubaiy (United Kingdom), Raja Atreya (Germany), Oliver Bachmann (Germany), Marko Banic (Croatia), Shomron Ben-Horin (Israel), Marko Brinar (Croatia), Fabiana Castiglione (Italy), Jacques Cosnes (France), Marco Daperno (Italy), Axel Dignass (Germany), Iris Dotan (Israel), Hankje Escher (The Netherlands), Gionata Fiorino (Italy), Paolo Gionchetti (Italy), Corinne Gower-Rousseau (France), Guru lyngkaran (Australia), Njegica Jojic (Serbia), Ioannis Karagiannis (Greece), Anna Kohn (Italy), Torsten Kucharzik (Germany), Ian Lawrance (Australia), Jimmy Limdi (United Kingdom), Christian Maaser (Germany), Philippe Marteau (France), Paula Ministro (Portugal), Bjorn Moum (Norway), Stephan Nancey (France), Bas Oldenburg (The Netherlands), Konstantinos Papadakis (Greece), Harald Peeters (Belgium), Valérie Pittet (Switzerland), Catherine Reenaers (Belgium), Florian Rieder (United States), Richard Russell (United Kingdom), Shaji Sebastian (United Kingdom), Simon Travis (United Kingdom), Janneke van der Woude (The Netherlands), Janindra Warusavitarné (United Kingdom), Zuzana Zelinkova (The Netherlands)

(iii) Clinical: Therapy & observation:

Xavier Aldeguer (Spain), Matthieu Allez (France), Jorge Amil Dias (Portugal), Nathalie G. Aoun (Lebanon), Filip Baert (Belgium), Manuel Barreiro de Acosta (Spain), Laurent Beaugerie (France), Bernd Bokemeyer (Germany), Natalia Borrueal (Spain), Martin Bortlik (Czech Republic), Daniel Burger (United Kingdom), Francesco Casellas (Spain), Andrea Cassinotti (Italy), Cristina Cijevschi (Romania), Francesco Colombo (Italy), Mario Cottone (Italy), Silvio Danese (Italy), Martine De Vos (Belgium), Antonio Di Sabatino (Italy), Mircea Diculescu (Romania), Eugeni Domènech (Spain), Tomas Douda (Czech Republic), David Drobne (Slovenia), Dana Duricová (Czech Republic), Laurence Egan (Ireland), Rami Eliakim (Israel), Aykut Ferhat Celik (Turkey), Richard Geary (New Zealand), Kristina Gecse (Hungary), Daniel Ginard Vicens (Spain), Javier Perez Gisbert (Spain), Adrian Goldis (Romania), Fernando Gomollón García (Spain), Marcus Harbord (United Kingdom), Tibor Hlavaty (Slovakia), Daniel Hommes (United States), Peter Irving (United Kingdom), Konstantinos Karmiris (Greece), Konstantinos Katsanos (Greece), Sanja Kolacek (Croatia), Iskren Kotzev (Bulgaria), Ioannis Koutroubakis (Greece), David Laharie (France), Ebbe Langholz (Denmark), Arie Levine (Israel), Antonio López-Sánroman (Spain), Edouard Louis (Belgium), Milan Lukas (Czech Republic), Fernando Magro (Portugal), Gerassimos Mantzaris (Greece), Ignacio Marin-Jimenez (Spain), Pierre Michetti (Switzerland), Tamas Molnar (Hungary), Siew Ng (Hong Kong), Tom Oresland (Norway), Remo Panaccione (Canada), Julián Panés (Spain),

Natalia Pedersen (Denmark), Guillaume Pineton de Chambrun (France), Francisco Portela (Portugal), Walter Reinisch (Canada), Elena Ricart (Spain), Xavier Roblin (France), Iago Rodríguez Lago (Spain), Zuzana Serclova (Czech Republic), Dino Tarabar (Serbia), John Triantafyllidis (Greece), Niels Vande Casteele (Belgium), Séverine Vermeire (Belgium)

(iv) Epidemiology:

Tim Card (United Kingdom), Katrine Carlsen (Denmark), Renata D’Inca (Italy), Peter Lakatos (Hungary), Tom Moreels (Belgium), Selwyn Odes (Israel), Laurent Peyrin-Biroulet (France), Gianluca Sampietro (Italy), Antje Timmer (Germany), Gábor Veres (Hungary), Ida Vind (Denmark)

(v) Genetics:

Vito Annese (Italy), Alessandro Armuzzi (Italy), Shay Ben-Shachar (Israel), Mathias Chamillard (France), Jack Satsangi (United Kingdom)

(vi) Microbiology:

Dirk Haller (Germany), Arthur Kaser (United Kingdom), Colm O’Morain (Ireland), Richard Pollok (United Kingdom), Philippe Seksik (France)

(vii) Nurses abstracts:

Palle Bager (Denmark), Lesley Dibley (United Kingdom), Janette Gaarenstroom (The Netherlands), Petra Hartmann (Germany), Matteo Martinato (Italy), Lisa Younge (United Kingdom)

Poster exhibition

Opening hours

<i>Industry and Poster exhibition</i>	
Thursday, March 17, 2016	12:00 – 18:00
Friday, March 18, 2016	09:30 – 18:00
Saturday, March 19, 2016	09:30 – 13:00

Guided poster session

The guided poster session is scheduled on Friday, March 18, 2016 from 12:20 to 13:20 in the exhibition hall (Hall 9) on Level 1 at the RAI Amsterdam.

At least one of the authors of the abstracts will be present in order to give a 1-2 minute summary of the major findings described in the poster. Poster session chairs will guide through the poster exhibition in pairs. Congress delegates being present during that time will enjoy the possibility to engage in poster discussions.

Please choose one of the below listed poster groups and follow the respective poster chairs (they will carry a button with the words "ECCO Poster Chair" as well as a sign indicating the poster group number and the topic). The starting poster of each group is indicated below – please make sure to be there at 12:20.

Guided poster sessions are chaired by:

(i) **Basic Science:**

- Group 1** (starts at **P001**): Matthieu Allez, Paris, France
Giovanni Monteleone, Rome, Italy
- Group 2** (starts at **P029**): Raja Atreya, Erlangen, Germany
Torsten Kucharzik, Lüneburg, Germany
- Group 3** (starts at **P057**): Oliver Bachman, Hamburg, Germany
Florian Rieder, Cleveland, United States
- Group 4** (starts at **P084**): Yehuda Chowers, Haifa, Israel
Laurence Egan, Galway, Ireland

(ii) **Clinical: Diagnosis & outcome:**

- Group 5** (starts at **P111**): Vito Annese, Florence, Italy
Laurent Beaugerie, Paris, France
- Group 6** (starts at **P139**): Shomron Ben-Horin, Ramat Gan, Israel
Marc Ferrante, Leuven, Belgium
- Group 7** (starts at **P167**): Gionata Fiorino, Milan, Italy
Paolo Gionchetti, Bologna, Italy
- Group 8** (starts at **P195**): Marcus Harbord, London, United Kingdom
Konstantinos Katsanos, Ioannina, Greece
- Group 9** (starts at **P223**): Ebbe Langholz, Hellerup, Denmark
Arie Levine, Tel Aviv, Israel

Group 10 (starts at **P251**): Christian Maaser, Lüneburg, Germany
Fernando Magro, Porto, Portugal

Group 11 (starts at **P278**): Gerassimos Mantzaris, Athens, Greece
Pierre Michetti, Lausanne, Switzerland

(iii) Clinical: Therapy and observation:

Group 12 (starts at **P305**): Daniel Burger, Oxford, United Kingdom
Harald Peeters, Ghent, Belgium

Group 13 (starts at **P422**): Martin Bortlik, Prague, Czech Republic
Gianluca Sampietro, Milan, Italy

Group 14 (starts at **P452**): Laurent Peyrin-Biroulet, Vandoeuvre-lès-Nancy, France
Walter Reinisch, Vienna, Austria / Hamilton, Canada

Group 15 (starts at **P482**): David Drobne, Ljubljana, Slovenia
James Lindsay, London, United Kingdom

Group 16 (starts at **P512**): Konstantinos Karmiris, Heraklion, Greece
Peter Lakatos, Budapest, Hungary

Group 17 (starts at **P542**): Tibor Hlavaty, Bratislava, Slovakia
Daniel Hommes, Los Angeles, United States

Group 18 (starts at **P572**): Dana Duricová, Prague, Czech Republic
Sebastian Shaji, Hull, United Kingdom

Group 19 (starts at **P602**): Rami Eliakim, Tel Hashomer, Israel
Javier Perez Gisbert, Madrid, Spain

Group 20 (starts at **P631**): Ailsa Hart, London, United Kingdom
Ian Lawrance, Fremantle, Australia

Group 21 (starts at **P554**): Zuzana Serclova, Prague, Czech Republic
Dino Tarabar, Belgrade, Serbia

Group 22 (starts at **P335**): Xavier Aldeguer, Girona, Spain
Tom Oresland, Lorenskog, Norway

Group 23 (starts at **P364**): Anna Kohn, Rome, Italy
Ioannis Koutroubakis, Heraklion, Greece

(iv) Epidemiology:

Group 24 (starts at **P660**): Iskren Kotzev, Varna, Bulgaria
Jimmy Limdy, Manchester, United Kingdom

Group 25 (starts at **P690**): Paula Ministro, Viseu, Portugal
Colm O' Morain, Dublin, Ireland

(v) Genetics:

Group 26 (starts at **P719**): Alessandro Armuzzi, Rome, Italy
Richard Russell, Glasgow, United Kingdom

(vi) Microbiology:

Group 27 (starts at **P735**): Natalia Borruel, Barcelona, Spain
Philippe Seksik, Paris, France



European
Crohn's and Colitis
Organisation

Why submit your research to JCC?



Prompt and professional peer review

JCC publishes scholarship that has undergone rigorous peer review, including an initial screening by one of the Editors and recommendation by independent reviewers. The average time from submission to first decision is three weeks.

Fast publication speeds

- Fast Advance Access publication of the author manuscript version within one week of acceptance making your work discoverable faster.

Increased Impact Factor

- JCC's latest Impact Factor increased by 75% to 6.234, now ranked eighth in Gastroenterology & Hepatology.

Wide dissemination


- Publishing in JCC will ensure that your article will be seen, read and cited by your research community.

Scan and visit
www.ecco-jcc.oxfordjournals.org



RAI Amsterdam, Level 1

- Digital oral presentations



Digital oral presentation

For details please refer to p. 35.

Please find below an overview of all DOP sessions. The schedule and selected abstracts for each digital oral presentation room can be found on pages 42-66. Please make sure to be there on time.

Digital Oral Presentation Session 1 (please refer to pages 42-43)	Pathogenesis of IBD Isabelle Cleynen, Leuven, Belgium Pierre Desreumaux, Lille, France
Digital Oral Presentation Session 2 (please refer to pages 44-46)	Altering disease outcome in IBD Laurence Egan, Galway, Ireland Rami Eliakim, Tel Hashomer, Israel
Digital Oral Presentation Session 3 (please refer to pages 46-48)	Novel therapies in IBD Vito Annese, Florence, Italy Javier Perez Gisbert, Madrid, Spain
Digital Oral Presentation Session 4 (please refer to pages 49-51)	IFX & IFX biosimilars Alessandro Armuzzi, Rome, Italy Iris Dotan, Tel Aviv, Israel
Digital Oral Presentation Session 5 (please refer to pages 52-54)	Improving the care and outcome of IBD patients Maria Chaparro, Madrid, Spain Nanne de Boer, Amsterdam, The Netherlands
Digital Oral Presentation Session 6 (please refer to pages 56-58)	Short & long term efficacy of biologics James Lindsay, London, United Kingdom Britta Siegmund, Berlin, Germany
Digital Oral Presentation Session 7 (please refer to pages 58-61)	Managing children and adolescents with IBD Salvatore Cucchiara, Rome, Italy Dan Turner, Jerusalem, Israel
Digital Oral Presentation Session 8 (please refer to pages 61-62)	Pharmacokinetics of IBD therapies Shomron Ben-Horin, Ramat Gan, Israel Yehuda Chowers, Haifa, Israel
Digital Oral Presentation Session 9 (please refer to pages 63-65)	Predicting IBD and IBD-related neoplasia Laurent Beaugerie, Paris, France Dana Duricová, Prague, Czech Republic
Digital Oral Presentation Session 10 (please refer to pages 65-66)	Biomarker discovery in IBD Jonas Halfvarson, Orebro, Sweden Charlie Lees, Edinburgh, United Kingdom

Please find the detailed schedule for each session on the following pages:

Thursday, March 17, 2016

<p>Digital Oral Presentation Session 1 - Pathogenesis of IBD</p> <p>Room E104-E106, Level 1 Isabelle Cleynen, Leuven, Belgium Pierre Desreumaux, Lille, France</p>	
17:15 - 18:15	
17:15 - 17:22	<p>DOP001: Genetic and environmental risk model to predict intestinal inflammation in asymptomatic first-degree relatives of Crohn's Disease patients K.M. Taylor^{1,2}, N.S. Taylor³, S.H. Anderson¹, P.M. Irving¹, N.J. Prescott², C.M. Lewis², C.G. Mathew², J.D. Sanderson¹ ¹Guy's & St Thomas' NHS Foundation Trust, Department of Gastroenterology, London, United Kingdom, ²King's College London, Department of Medical & Molecular Genetics, London, United Kingdom, ³University Hospital Southampton NHS Foundation Trust, Department of Gastroenterology, Southampton, United Kingdom</p>
17:22 - 17:29	<p>DOP002: Molecular response to ustekinumab in moderate-to-severe Crohn's Disease by serum protein analysis: Results from the UNITI-1 and UNITI-2 phase 3 induction studies K. Li, K. Hayden, E. Wadman, S. Bhagat, S. Emrich, J.R. Friedman, C. Gasink, C. Brodmerkel Janssen R & D, LLC, Spring House, United States</p>
17:29 - 17:36	<p>DOP003: Gene expression profiling indicates similar molecular pathways are active in adult and paediatric Ulcerative Colitis K. Li¹, J. Ouahed², J. Friedman¹, R. Strauss¹, D. Chan¹, S. Telesco¹, D. Shouval², J. Canavan³, C. Brodmerkel¹, S. Snapper^{2,3} ¹Janssen R & D, LLC, Spring House, United States, ²Boston Children's Hospital, Harvard Medical School, Boston, United States, ³Harvard Medical School, Brigham & Women's Hospital, Boston, United States</p>
17:36 - 17:43	<p>DOP004: Epigenetic control of colonic epithelial antigen processing, barrier function, and the microbiome via methyl-CpG binding domain protein 2 G.-R. Jones¹, A. MacDonald², P. Cook² ¹University of Edinburgh, Gastroenterology, Edinburgh, United Kingdom, ²University of Manchester, Department of Immunology, Manchester, United Kingdom</p>
17:43 - 17:50	<p>DOP005: A role for IL1 in mediating intestinal inflammation in IL10 receptor deficiency in mice and humans D. Shouval^{1,2}, A. Biswas², Y.-H. Kang², A. Griffith², B. Horwitz², A. Bousvaros², S. Snapper² ¹Safra Children's Hospital, Paediatric Gastroenterology, Tel Hashomer, Israel, ²Boston Children's Hospital, Boston, United States</p>
17:50 - 17:57	<p>DOP006: Gut homing adipose tissue T-cells might influence intestinal barrier function in Crohn's Disease and obesity L.J. Jödicke¹, L.I. Kredel¹, A.A. Kuehl¹, I. Freise¹, J. Gröne², J. Ordemann³, B. Siegmund¹ ¹Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Gastroenterology, Infectiology and Rheumatology, Berlin, Germany, ²Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, General, Vascular and Thoracic Surgery, Berlin, Germany, ³Charité, Campus Mitte, Centre for Obesity and Metabolic Surgery, Berlin, Germany</p>

Thursday, March 17, 2016, cont.

17:57 - 18:04	<p>DOP007: Interleukin-10 inhibits human IFNγ and IL-17-producing T helper cells indirectly by controlling antigen-presenting cell function S. Veenbergen¹, P. Li², H. Raatgeep¹, D. Lindenbergh-Kortleve¹, L. de Ruiter¹, M. van Leeuwen¹, D. Winter³, Y. Simons-Oosterhuis¹, L. van Berkel¹, S. Nugteren¹, J. Arnold¹, Y. Wakabayashi⁴, J. Zhu⁴, L. de Ridder³, G. Driessen⁵, J. Escher³, W. Leonard², J. Samsom¹</p> <p>¹Erasmus University Medical Center, Laboratory of Paediatrics, Division Gastroenterology and Nutrition, Rotterdam, Netherlands, ²National Heart, Lung and Blood Institute, National Institutes of Health, Laboratory of Molecular Immunology, Bethesda, United States, ³Sophia Children's Hospital-Erasmus Medical Center, Department of Paediatric Gastroenterology, Rotterdam, Netherlands, ⁴National Heart, Lung and Blood Institute, National Institutes of Health, DNA Sequencing and Genomics Core, Bethesda, United States, ⁵Erasmus University Medical Center, Department of Paediatric Infectious Disease and Immunology, Rotterdam, Netherlands</p>
18:04 - 18:11	<p>DOP008: Human intestinal Vδ2+ T-cells acquire antigen-presenting potency upon exposure to microbial phosphoantigen: Modulation by mucosal inflammation and vedolizumab therapy C. Tyler¹, N. McCarthy², B. Moser¹, A. Stagg², M. Eberl¹, J. Lindsay^{2,3}</p> <p>¹Cardiff University, Cardiff Institute of Infection & Immunity, School of Medicine, Cardiff, United Kingdom, ²Barts and The London School of Medicine and Dentistry, Queen Mary University of London, The Blizard Institute, Centre for Immunobiology, London, United Kingdom, ³Barts Health NHS Trust, Department of Gastroenterology, Barts and The London Hospitals, London, United Kingdom</p>
18:11 - 18:18	<p>DOP009: An autoimmunity-associated variant in PTPN22 protects from disease onset in mouse models of colitis M. Spalinger¹, S. Kasper¹, C. Gottier¹, S. Lang¹, M. Fried^{1,2}, G. Rogler^{1,2}, M. Scharl^{1,2}</p> <p>¹University Hospital Zurich, Division of Gastroenterology and Hepatology, Zürich, Switzerland, ²University of Zurich, Zurich Center for Integrative Human Physiology, Zürich, Switzerland</p>

Thursday, March 17, 2016, cont.

Digital Oral Presentation Session 2 - Altering disease outcome in IBD

Room E102, Level 1

Laurence Egan, Galway, Ireland

Rami Eliakim, Tel Hashomer, Israel

17:15 - 18:15

DOP010: Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in Inflammatory Bowel Diseases: Results from Central European nationwide cohort

A. Bálint¹, K. Farkas¹, M. Rutka¹, Z. Végh², Z. Kürti³, J. Banai⁴, L. Bene⁵, B. Gasztonyi⁶, T. Kristóf⁷, L. Lakatos⁸, P. Miheller⁹, K. Palatka¹⁰, A. Patai¹¹, A. Salamon¹², T. Szamosi⁴, Z. Szepes¹, G.T. Tóth¹³, A. Vincze¹⁴, R. Bor¹, A. Milassin¹, F. Nagy¹, M. Kolar^{15,16}, M. Bortlik^{15,17}, D. Duricova^{15,18}, V. Hrubá¹⁵, M. Lukas¹⁵, K. Mitrova^{15,19}, K. Malickova²⁰, M. Lukas^{15,20}, P.L. Lakatos², T. Molnár¹

¹University of Szeged, 1st Department of Medicine, Szeged, Hungary, ²Semmelweis University, 1st Department of Medicine, Budapest, Hungary, ³Semmelweis University, First Department of Internal Medicine, Budapest, Hungary, ⁴Military Hospital – State Health Centre, Budapest, Hungary, ⁵Peterfy Hospital, 1st Department of Medicine, Budapest, Hungary, ⁶Zala County Hospital, 2nd Department of Medicine, Zalaegerszeg, Hungary, ⁷B-A-Z County and University Teaching Hospital, 2nd Department of Medicine, Miskolc, Hungary, ⁸Csolnoky Ferenc Regional Hospital, Department of Internal Medicine, Veszprém, Hungary, ⁹Semmelweis University, Second Department of Internal Medicine, Budapest, Hungary, ¹⁰University of Debrecen, 2nd Department of Medicine, Debrecen, Hungary, ¹¹Markusovszky Hospital, Department of Medicine and Gastroenterology, Szombathely, Hungary, ¹²Tolna County Teaching Hospital, Department of Gastroenterology, Szekszárd, Hungary, ¹³Janos Hospital, Department of Gastroenterology, Budapest, Hungary, ¹⁴University of Pécs, 1st Department of Medicine, Pécs, Hungary, ¹⁵IBD Clinical and Research Centre, Iscare a.s, Prague, Czech Republic, ¹⁶Charles University, 1st Medical Faculty, Prague, Czech Republic, ¹⁷Military Hospital, Charles University, Department of Internal Medicine, Prague, Czech Republic, ¹⁸1st Medical Faculty, Charles University, Institute of Pharmacology, Prague, Czech Republic, ¹⁹Faculty Hospital Motol, 2nd Medical Faculty, Charles University, Department of Paediatrics, Prague, Czech Republic, ²⁰1st Medical Faculty and General Teaching Hospital, Charles University, Institute of Medical Biochemistry and Laboratory Diagnostics, Prague, Czech Republic

17:15 - 17:22

DOP011: Early immunomodulator exposure and the long-term outcome of Crohn's Disease: Target for changing the natural history?

S. Jeuring^{1,2}, D. Wintjens¹, A. Wesselius³, T. van den Heuvel^{1,2}, M. Zeegers^{3,4}, W. Hameeteman¹, M. Romberg-Camps⁵, L. Oostenbrug⁶, A. Masclee^{1,2}, D. Jonkers^{1,2}, M. Pierik^{1,2}

¹Maastricht University Medical Centre, Internal Medicine - Division of Gastroenterology and Hepatology, Maastricht, Netherlands, ²Maastricht University Medical Centre, NUTRIM - School for Nutrition and Translational Research in Metabolism, Maastricht, Netherlands, ³Maastricht University Medical Centre, Complex Genetics - School for Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht, Netherlands, ⁴Maastricht University Medical Centre, CAPHRI - School for Public Health and Primary Care, Maastricht, Netherlands, ⁵Zuyderland Medical Centre, Internal Medicine and Gastroenterology-Hepatology, Sittard-Geleen, Netherlands, ⁶Zuyderland Medical Centre, Internal Medicine and Gastroenterology-Hepatology, Heerlen, Netherlands

17:22 - 17:29


Thursday, March 17, 2016, cont.

17:29 - 17:36	<p>DOP102: Do Ulcerative Colitis patients treated with corticosteroids at diagnosis really have a more aggressive disease course? L. Bertani¹, N. de Bortoli¹, G. Bodini², G. Mumolo³, L. Ceccarelli⁴, M.C. Plaz Torres², G. Laino¹, M. Bellini³, A. Ricchiuti³, V. Savarino², S. Marchi¹, F. Costa³</p> <p>¹University of Pisa, Department of Gastroenterology, Pisa, Italy, ²University of Genoa, Department of Gastroenterology, Genoa, Italy, ³Pisa University Hospital, Department of Gastroenterology, Pisa, Italy, ⁴SSD Endoscopy ASL 1, Massa, Italy</p>
17:36 - 17:43	<p>DOP103: A 104 week mucosal healing assessment of symptomatic small bowel Crohn's Disease B. Hall¹, G. Holleran¹, L. Chapman¹, B. Ryan¹, N. Mahmud², D. McNamara¹</p> <p>¹Adelaide & Meath Hospital, Dublin, Incorporating The National Children's Hospital, Department of Gastroenterology, Dublin, Ireland, ²Trinity College Dublin, St James Hospital, Department of Gastroenterology, Dublin, Ireland</p>
17:43 - 17:50	<p>DOP104: Nutritional optimisation of pre-surgical Crohn's Disease patients with enteral nutrition significantly decreases length of stay and need for a stoma K.V. Patel¹, A.M. Sandall², D.V. O'Hanlon³, A.A. Darakhshan⁴, A.B. Williams⁴, S.H. Anderson¹, P.M. Irving¹, M.C. Lomer², J.D. Sanderson¹</p> <p>¹Guy's and St Thomas' NHS Foundation Trust, Gastroenterology, London, United Kingdom, ²King's College London, Diabetes and Nutritional Sciences Division, London, United Kingdom, ³Guy's and St Thomas' NHS Foundation Trust, Dietetics, London, United Kingdom, ⁴Guy's and St Thomas' NHS Foundation Trust, Colorectal Surgery, London, United Kingdom</p>
17:50 - 17:57	<p>DOP105: Myenteric plexitis is a risk factor for endoscopic and clinical postoperative recurrence after ileocolonic resection in Crohn's Disease S. Decousus¹, A.-L. Boucher², J. Joubert¹, M. Goutte^{2,3}, F. Goutorbe², A. Dubois⁴, B. Pereira², P. Dechelotte¹, G. Bommelaer^{2,3}, A. Buisson^{2,3}</p> <p>¹University Hospital Estaing, Pathology Department, Clermont-Ferrand, France, ²University Hospital Estaing, Gastroenterology Department, Clermont-Ferrand, France, ³UMR 1071 Inserm/ Université d'Auvergne, USC-INRA 2018, Microbes, Intestine, Inflammation and Susceptibility of the host, Clermont-Ferrand, France, ⁴CHU Estaing, Department of Digestive Surgery, Clermont-Ferrand, France, ⁵GM – Clermont-Ferrand University and Medical Center, Biostatistics Unit, Clermont-Ferrand, France</p>
17:57 - 18:04	<p>DOP106: Postoperative clinical recurrence is not different in Crohn's Disease patients classified as i2 on the Rutgeerts score with lesions confined to the ileocolonic anastomosis than in those with lesions of the neo-terminal ileum P. Bayart¹, N. Duveau¹, M. Nachury¹, P. Zerbib¹, R. Gerard¹, J. Branche¹, V. Maunoury¹, A. Boruchowicz², M. Boualit², J.-E. Laberanne³, O. Manolache³, G. Pineton de Chambrun⁴, B. Pariente¹</p> <p>¹CHRU de Lille, Lille, France, ²CH Valenciennes, Valenciennes, France, ³CH Seclin, Seclin, France, ⁴CHU Montpellier, Montpellier, France</p>
18:04 - 18:11	<p>DOP107: Colectomy free survival is independent of initial infliximab dosing strategy in hospitalised Ulcerative Colitis patients S. Shah¹, S. Naymagon, B. Sands, B. Cohen, M. Dubinsky</p> <p>Mount Sinai Hospital, Gastroenterology, New York, United States</p>

Thursday, March 17, 2016, cont.

18:11 - 18:18	<p>DOP018: Long-term follow-up after ileorectal anastomosis in Ulcerative Colitis (UC) identified factors associated with rectal outcome: A multicentre retrospective cohort of 343 patients from the GETAID/GETAID Surgery</p> <p>M. Uzzan¹, J. Cosnes², N. Oubaya³, A. Amiot⁴, N. Gault⁵, J.-M. Gornet⁵, P. Seksik², S. Nancey⁶, E. Cotte⁷, M. Allez⁸, D. Laharie⁸, N. De Angelis⁴, M. Nachury⁹, A.-L. Pelletier¹⁰, V. Abitbol¹¹, M. Fumery¹², A. Brouquet¹³, A. Buisson¹⁴, R. Altwegg¹⁵, Y. Panis¹⁶, X. Treton¹</p> <p>¹APHP Beaujon, Department of Gastroenterology, Clichy, France, ²APHP St. Antoine Hospital, Department of Gastroenterology, Paris, France, ³APHP Beaujon, Epidémiologie et Recherche Clinique, Clichy, France, ⁴CHU Henri Mondor, Digestive Surgery, Creteil, France, ⁵Hospital Saint Louis, Department of Gastroenterology, Paris, France, ⁶Centre Hospitalier Lyon-Sud, Department of Gastroenterology, Pierre-Benite, France, ⁷Lyon-Sud Hospital, Department of Digestive Surgery, Pierre-Bénite, France, ⁸Hospital Haut-Leveque, Department of Gastroenterology and Hepatology, Pessac, France, ⁹CHRU Lille, Department of Gastroenterology, Lille, France, ¹⁰Hospital Bichat Claude Bernard, Department of Gastroenterology, Paris, France, ¹¹Cochin Hospital, Department of Gastroenterology, Paris, France, ¹²Amiens University Hospital, Department of Gastroenterology, Amiens, France, ¹³CHU Bicêtre, Digestive Surgery, Le Kremlin-Bicêtre, France, ¹⁴CHU Estaing, Department of Gastroenterology, Clermont-Ferrand, France, ¹⁵CHU Montpellier Saint Eloi Hospital, Department of Gastroenterology, Montpellier, France, ¹⁶APHP Beaujon, Department of Colorectal Surgery, Clichy, France</p>
---------------	--

17:15 - 18:15	<p>Digital Oral Presentation Session 3 - Novel therapies in IBD Room G102-G103, Level 1 Vito Annese, Florence, Italy Javier Perez Gisbert, Madrid, Spain</p>
---------------	---

 Y-ECCO Abstract Award	17:15 - 17:22	<p>DOP019: Efficacy of autologous haematopoietic stem cell transplantation for refractory Crohn's Disease</p> <p>A. López García¹, M. Rovira², A. Jauregui Amezcaga¹, P. Marin³, A. Salas¹, S. Pinó Donnay¹, R. Barastegui¹, F. Feu¹, J. Elizalde¹, F. Fernández-Avilés², C. Martínez⁴, G. Gutierrez², L. Rosiñol², E. Carreras², A. Urbano², M. Lozano³, J. Cid³, M. Suárez-Lledó², J. Mensa⁵, J. Rimola⁶, S. Rodriguez⁶, M.C. Masamunt¹, D. Comas¹, A. Ramirez Morros¹, M. Gallego¹, I. Ordás¹, J. Panés¹, E. Ricart¹</p> <p>¹Hospital Clinic Barcelona, Gastroenterology, Barcelona, Spain, ²Hospital Clinic Barcelona, Hematology, Barcelona, Spain, ³Hospital Clinic Barcelona, Biomedic Diagnostic Center, Barcelona, Spain, ⁴Hospital Clinic Barcelona, Gynaecology, Barcelona, Spain, ⁵Hospital Clinic Barcelona, Internal Medicine, Barcelona, Spain, ⁶Hospital Clinic Barcelona, Radiology, Barcelona, Spain</p>
---	---------------	--

Thursday, March 17, 2016, cont.

17:22 - 17:29	<p>DOP20: Prediction of clinical and endoscopic remission after autologous stem cell transplantation in treatment refractory Crohn's Disease: Pooled results from the ASTIC trial J. Lindsay¹, M. Allez², M. Clark³, M. Labopin⁴, E. Ricart⁵, G. Rogler⁶, M. Rovira⁷, J. Satsangi⁸, D. Farge⁹, C. Hawkey³</p> <p>¹Blizard Institute, Barts and the London School of Medicine, Centre for Immunobiology, London, United Kingdom, ²APHP St. Antoine Hospital, Department of Gastroenterology, Paris, France, ³Nottingham Digestive Diseases Centre, Department of Digestive Diseases, Biomedical Research Unit, Nottingham, United Kingdom, ⁴European Group for Blood and Marrow Transplantation (EBMT), Paris, France, ⁵Hospital Clinic Barcelona, Gastroenterology, Barcelona, Spain, ⁶University Hospital Zurich, Department of Gastroenterology and Hepatology, Zurich, Switzerland, ⁷Hospital Clinic de Barcelona, Department of Hematology, Barcelona, Spain, ⁸Western General Hospital, Gastrointestinal Unit, Edinburgh, United Kingdom, ⁹Hospital Saint-Louis, Department of Internal Medicine and Vascular Pathology, Inserm U 976, Paris, France</p>
17:29 - 17:36	<p>DOP21: Long term efficacy of autologous haematopoietic stem cells transplantation for refractory Crohn's Disease: Ten years of Milan experience without CD34+ cell selection A. Cassinotti¹, F. Onida², C. Annaloro³, G. Saporiti², M. Fichera¹, M. Daperno³, B. Motta², P. Fociani⁴, E. Tagliaferri², G. Sampietro⁵, D. Vincenti², A. Gregorini², G. Maconi¹, M. Nebuloni², A. Cortelezzi², S. Ardizzone¹</p> <p>¹Gastroenterology Unit, Luigi Sacco University Hospital, Milan, Italy, ²Bone Marrow Transplantation Centre, Fondazione Ospedale Maggiore Policlinico, Mangiagalli e Regina Elena, University of Milan, Milan, Italy, ³Gastroenterology Unit, AO Ordine Mauriziano, Turin, Italy, ⁴Luigi Sacco University Hospital, Pathology Unit, Milan, Italy, ⁵2nd Division of Surgery, Luigi Sacco University Hospital, Milan, Italy</p>
17:36 - 17:43	<p>DOP22: Targeting immune cell metabolism: LYC-30937, a novel therapeutic approach for Inflammatory Bowel Disease L. Carter¹, R. Morgan¹, C. Lesch¹, M. Spahr¹, L. Franchi², I. Monteleone³, G. Monteleone³, G. Glick², H.J. Wilkins¹, P. Higgins²</p> <p>¹Lycera, Ann Arbor, United States, ²University of Michigan, Ann Arbor, United States, ³Tor Vergata, Rome, Italy</p>
17:43 - 17:50	<p>DOP23: Safety and efficacy of a novel i.v. targeted pegylated liposomal prednisolone product (Nanocort): Results from a phase 2a study in patients with active Ulcerative Colitis G. van Assche¹, P. Rutgeerts¹, M. Ferrante¹, M. Noman¹, H. Fidder², B. Oldenburg², J. Metselaer^{3,4}, S. Vermeire¹</p> <p>¹University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium, ²University Medical Center Utrecht, Department of Gastroenterology and Hepatology, Utrecht, Netherlands, ³Enceladus Pharmaceuticals, Naarden, Netherlands, ⁴University Clinic RWTH, Experimental Molecular Imaging, Aachen, Germany</p>
17:50 - 17:57	<p>DOP24: Electrical vagus nerve stimulation as an innovative treatment in Inflammatory Bowel Diseases V. Sinniger^{1,2,3}, S. Pellissier^{3,4}, D. Hoffmann⁵, C. Trocmé⁶, L. Vercueil^{3,7}, D. Clarençon^{3,8}, B. Bonaz^{3,9}</p> <p>¹Hospital University Center, Hepatogastroenterology, Grenoble Cx9, France, ²Hospital University Center, Gastroenterology, Grenoble Cx⁹, France, ³Inserm U836, Grenoble, France, ⁴University of Savoie Mont Blanc, Psychology Department, Chambéry, France, ⁵Hospital University Center, Neurosurgery, Grenoble, France, ⁶Hospital University Center, Biology, Grenoble, France, ⁷Hospital University Center, Neurology, Grenoble Cx⁹, France, ⁸Research Institute of the French Army, Brétigny sur Orge, France, ⁹Hospital University Center, Gastroenterology, Grenoble, France</p>

Thursday, March 17, 2016, cont.

17:57 - 18:04	<p>DOP025: Clinical response to anti-MMP9 antibody (GS-5745) is accompanied by histologic improvement in Ulcerative Colitis W. Sandborn^{1,2}, B. Bhandari³, R. Fogel⁴, J. Onken⁵, E. Yen⁶, E. Huntzicker⁶, Y. Xin⁶, D. French⁶, J. Silverman⁶, B. Kanwar⁶, M. Subramanian⁶, J. McHutchison⁶, S. Lee⁷, L. Shackelton⁸, L. Stitt⁸, R. Pai⁹, B. Levesque², G. D'Haens^{10,11}, B. Feagan^{8,12}</p> <p>¹University of California, San Diego, Canada, ²Robarts Clinical Trials, San Diego, United States, ³Delta Research Partners, Monroe, United States, ⁴Clinical Research Institute of Michigan, LLC, Chesterfield, United States, ⁵Duke University Medical Center, Durham, United States, ⁶Gilead Sciences Inc, Foster City, United States, ⁷University of Washington, Seattle, United States, ⁸Robarts Clinical Trials, London, Canada, ⁹Mayo Clinic Arizona, Scottsdale, United States, ¹⁰Academic Medical Center, Amsterdam, Canada, ¹¹Robarts Clinical Trials, Amsterdam, Netherlands, ¹²University of Western Ontario, London, Canada</p>
18:04 - 18:11	<p>DOP026: The Toll-like-receptor 9 agonist DIMS0150 demonstrates therapeutic efficacy for the patient reported outcome measures PRO-2 and CLINPRO in moderate to severe active Ulcerative Colitis R. Atreya¹, S. Bloom², F. Scalfaferrì³, V. Gerardi⁴, C. Admyre⁵, A. Karlsson⁵, T. Knittel⁵, J. Kowalski⁵, M. Lukas⁶, R. Löfberg⁷, R. Petryka⁸, R. Schnabel⁹, U. Seidler¹⁰, S. Nancey¹¹, M. Neurath¹, C. Hawkey¹²</p> <p>¹University of Erlangen-Nuernberg, Department of Medicine 1, Erlangen, Germany, ²University College London Hospital, Department of Gastroenterology, London, United Kingdom, ³Catholic University of Rome, Internal Medicine Department, Gastroenterology Division, Rome, Italy, ⁴Catholic University of Rome, Rome, Italy, ⁵Index Pharmaceuticals, Stockholm, Sweden, ⁶IBD Clinical and Research Centre, Clinical Centre Iscare Lighthouse, Prague, Czech Republic, ⁷Karolinska Institute and Sophiahemmet, Stockholm, Sweden, ⁸NZOZ Vivamed, Warsaw, Poland, ⁹Pannonia Maganorvosi Centrum, Budapest, Hungary, ¹⁰MHH, Department of Gastroenterology, Hepatology and Endocrinology, Hannover, Germany, ¹¹Lyon-Sud Hospital, Department of Gastroenterology, Lyon, France, ¹²Nottingham University Hospitals, Department of Gastroenterology, Nottingham, United Kingdom</p>
18:11 - 18:18	<p>DOP027: Large scale drug screen reveals benzimidazole anti-helminthics as potential anti-TNF co-therapy M. Wildenberg¹, A. Levin², A. Ceroni³, Z. Guo², F. Bloemendaal², D. Ebner², G. van den Brink¹</p> <p>¹Academic Medical Center, Gastroenterology and Hepatology, Amsterdam, Netherlands, ²Academic Medical Center, Tytgat Institute, Amsterdam, Netherlands, ³Oxford University, Target Discovery Institute, Oxford, United Kingdom</p>

Thursday, March 17, 2016, cont.

Digital Oral Presentation Session 4 - IFX & IFX biosimilars

17:15 - 18:15

 Room G104-G105, Level 1
 Alessandro Armuzzi, Rome, Italy
 Iris Dotan, Tel Aviv, Israel

17:15 - 17:22

DOP028: Efficacy and safety of biosimilar infliximab after one-year: Results from a prospective nationwide cohort
K. Gecse¹, Z. Vegh¹, Z. Kurti¹, M. Rutka², K. Farkas², J. Banai³, L. Bene⁴, B. Gasztonyi⁵, P.A. Golovics¹, T. Kristof⁶, L. Lakatos⁷, P. Miheller⁸, F. Nagy⁹, K. Palatka¹⁰, M. Papp¹¹, L. Lakner¹², A. Patai¹³, A. Salamon¹⁴, T. Szamosi³, Z. Szepes³, B. Szalay¹⁵, G.T. Toth¹⁶, A. Vincze¹⁷, T. Molnar², P. Lakatos¹
¹Semmelweis University, ^{1st} Department of Medicine, Budapest, Hungary, ²University of Szeged, ^{1st} Department of Medicine, Szeged, Hungary, ³Military Hospital, State Health Centre, Department of Gastroenterology, Budapest, Hungary, ⁴Peterfy Hospital, ^{1st} Department of Medicine, Budapest, Hungary, ⁵Zala County Hospital, ^{2nd} Department of Medicine, Zalaegerszeg, Hungary, ⁶B-A-Z County and University Teaching Hospital, ^{2nd} Department of Medicine, Miskolc, Hungary, ⁷Csolnoky F. Province Hospital, Department of Medicine, Veszprem, Hungary, ⁸Semmelweis University, ^{2nd} Department of Medicine, Budapest, Hungary, ⁹University of Szeged, ^{1st} Department of Internal Medicine, Szeged, Hungary, ¹⁰University of Debrecen, Institute of Medicine, Department of Gastroenterology, Debrecen, Hungary, ¹¹University of Debrecen, Institute of Internal Medicine, Department of Gastroenterology, Debrecen, Hungary, ¹²Markusovszky Hospital, Department of Medicine and Gastroenterology, Szombathely, Hungary, ¹³Markusovszky Hospital, ^{1st} Department of Medicine and Gastroenterology, Szombathely, Iceland, ¹⁴Tolna County Teaching Hospital, ^{1st} Department of Gastroenterology, Szekszard, Hungary, ¹⁵Semmelweis University, Department of Laboratory Medicine, Budapest, Hungary, ¹⁶Janos Hospital, Department of Gastroenterology, Budapest, Hungary, ¹⁷University of Pecs, ^{1st} Department of Medicine, Pecs, Hungary

17:22 - 17:29

DOP029: Outcomes of a managed switching programme changing IBD patients established on originator infliximab to biosimilar infliximab
 M. Bettey¹, L. Downey¹, C. Underhill¹, J. Callaghan¹, M. Rush², I. Ahmed¹, **F. Cummings¹**
¹University Hospital Southampton NHS Trust, Department of Gastroenterology, Southampton, United Kingdom, ²University of Southampton, Department of Gastroenterology, Southampton, United Kingdom

17:29 - 17:36

DOP030: Elective switching from Remicade® to biosimilar CT-P13 in Inflammatory Bowel Disease patients: A prospective observational cohort study
L. Smits¹, L. Derix¹, J. Drenth¹, D. de Jong¹, A. van Esch¹, F. Hoentjen
 Radboud University Medical Centre, Inflammatory Bowel Disease Centre, Department of Gastroenterology and Hepatology, Nijmegen, Netherlands

Thursday, March 17, 2016, cont.

17:36 - 17:43	<p>DOP031: Efficacy of infliximab biosimilar CT-P13 therapy on mucosal healing in Ulcerative Colitis – data from two Central European countries K. Farkas¹, M. Rutka¹, P.A. Golovics², Z. Végh², B.D. Lovász², T. Nyári³, K.B. Gece², M. Kolar^{4,5}, M. Bortlik^{4,6}, D. Duricova^{4,7}, N. Machkova⁴, V. Hruba⁴, M. Lukas⁴, K. Mitrova^{4,8}, K. Malickova⁹, A. Bálint¹, F. Nagy¹, R. Bor¹, A. Milassin¹, Z. Szepes¹, K. Palatka¹⁰, P.L. Lakatos², M. Lukas^{4,9}, T. Molnár¹</p> <p>¹University of Szeged, ^{1st} Department of Medicine, Szeged, Hungary, ²Semmelweis University, ^{1st} Department of Medicine, Budapest, Hungary, ³University of Szeged, Department of Medical Physics and Informatics, Szeged, Hungary, ⁴IBD Clinical and Research Centre, Iscare a.s, Prague, Czech Republic, ⁵Charles University, ^{1st} Medical Faculty, Prague, Czech Republic, ⁶Military Hospital, Charles University, Department of Internal Medicine, Prague, Czech Republic, ⁷^{1st} Medical Faculty, Charles University, Institute of Pharmacology, Prague, Czech Republic, ⁸Faculty Hospital Motol, ^{2nd} Medical Faculty, Charles University, Department of Paediatrics, Prague, Czech Republic, ⁹^{1st} Medical Faculty and General Teaching Hospital, Charles University, Institute of Medical Biochemistry and Laboratory Diagnostics, Prague, Czech Republic, ¹⁰University of Debrecen, ^{2nd} Department of Medicine, Debrecen, Hungary</p>
17:43 - 17:50	<p>DOP032: Switching of patients with Inflammatory Bowel Disease from original infliximab (Remicade®) to biosimilar infliximab (Remsima™) is effective and safe M. Kolar¹, D. Duricová¹, M. Brotlik¹, V. Hruba¹, N. Machkova¹, K. Mitrova¹, K. Malickova², M. Lukas¹, M. Lukas¹</p> <p>¹Charles University, IBD Clinical and Research Centre, ISCARE, Prague, Czech Republic, ²^{1st} Medical Faculty and General Teaching Hospital, Charles University, Institute of Medical Biochemistry and Laboratory Diagnostics, Prague, Czech Republic</p>
17:50 - 17:57	<p>DOP033: Immunogenicity profile and predictors of T_Ls and ADA development of biosimilar infliximab during the first 6 months of the therapy: Results from a prospective nationwide cohort B. Lovasz¹, Z. Kurti¹, M. Rutka², Z. Vegh¹, K. Gece¹, K. Farkas³, J. Banai³, L. Bene⁴, B. Gasztonyi⁵, T. Kristof⁶, L. Lakatos⁷, P. Miheller⁸, K. Palatka⁹, A. Patai¹⁰, A. Salamon¹¹, T. Szamosi³, Z. Szepes¹², E. Biro¹³, G.T. Toth¹⁴, A. Vincze¹⁵, T. Molnar², P. Lakatos¹</p> <p>¹Semmelweis University, ^{1st} Department of Medicine, Budapest, Hungary, ²University of Szeged, ^{1st} Department of Medicine, Szeged, Hungary, ³Military Hospital, State Health Centre, Department of Gastroenterology, Budapest, Hungary, ⁴Peterfy Hospital, ^{1st} Department of Medicine, Budapest, Hungary, ⁵Zala County Hospital, ^{2nd} Department of Medicine, Zalaegerszeg, Hungary, ⁶B-A-Z County and University Teaching Hospital, ^{2nd} Department of Medicine, Miskolc, Hungary, ⁷Csolnok F. Province Hospital, Department of Medicine, Veszprem, Hungary, ⁸Semmelweis University, ^{2nd} Department of Medicine, Budapest, Hungary, ⁹University of Debrecen, Institute of Medicine, Department of Gastroenterology, Debrecen, Hungary, ¹⁰Markusovszky Hospital, ^{1st} Department of Medicine and Gastroenterology, Szombathely, Iceland, ¹¹Tolna County Teaching Hospital, ^{1st} Department of Gastroenterology, Szekszard, Hungary, ¹²University of Szeged, First Department of Internal Medicine, Szeged, Hungary, ¹³Semmelweis University, Department of Laboratory Medicine, Budapest, Hungary, ¹⁴Janos Hospital, Department of Gastroenterology, Budapest, Hungary, ¹⁵University of Pecs, ^{1st} Department of Medicine, Pecs, Hungary</p>

Thursday, March 17, 2016, cont.

17:57 - 18:04	<p>DOP034: Comparative effectiveness of infliximab and adalimumab in Crohn's Disease: Results from a real-life population-based cohort S. Jeuring^{1,2}, D. Wintjens¹, T. van den Heuvel^{1,2}, M. Zeegers^{3,4}, W. Hameeteman¹, M. Romberg-Camps⁵, L. Oostenbrug⁶, A. Masclee^{1,2}, D. Jonkers^{1,2}, M. Pierik^{1,2}</p> <p>¹Maastricht University Medical Centre, Internal Medicine - Division of Gastroenterology and Hepatology, Maastricht, Netherlands, ²Maastricht University Medical Centre, NUTRIM - School for Nutrition and Translational Research in Metabolism, Maastricht, Netherlands, ³Maastricht University Medical Centre, Complex Genetics - School for Nutrition and Translational Research in Metabolism (NUTRIM), Maastricht, Netherlands, ⁴Maastricht University Medical Centre, CAPHRI - School for Public Health and Primary Care, Maastricht, Netherlands, ⁵Zuyderland Medical Centre, Internal Medicine and Gastroenterology-Hepatology, Sittard-Geleen, Netherlands, ⁶Zuyderland Medical Centre, Internal Medicine and Gastroenterology-Hepatology, Heerlen, Netherlands</p>
18:04 - 18:11	<p>DOP035: Long-term outcome of Inflammatory Bowel Disease patients with deep remission after discontinuation of TNFa - blocking agents P. Molander^{1,2}, M. Färkkilä^{2,3}, H. Kempainen⁴, T. Blomster⁵, A. Jussila⁶, H. Mustonen⁷, T. Sipponen^{2,3}</p> <p>¹Helsinki University Central Hospital, Peijas Hospital, Gastroenterology, Vantaa, Finland, ²University of Helsinki, Helsinki, Finland, ³Helsinki University Central Hospital, Abdominal Center, Clinic of Gastroenterology, Helsinki, Finland, ⁴Turku University Central Hospital, Department of Gastroenterology, Turku, Finland, ⁵Oulu University Hospital, Department of Gastroenterology, Oulu, Finland, ⁶Tampere University Hospital, Department of Gastroenterology and Alimentary Tract Surgery, Tampere, Finland, ⁷Helsinki University Central Hospital, Department of Surgery, Helsinki, Finland</p>
18:11 - 18:18	<p>DOP036: Infliximab discontinuation is associated with a higher risk for relapse in patients with Ulcerative Colitis in remission: A multinational collaborative retrospective study G. Fiorino¹, P. Ellul², M. Muscat², P. Karatzas³, M. Silva⁴, A. Peixoto⁴, C. Felice⁵, F. Bossa⁶, P.L. Lakatos⁷, S. Sebastian⁸, B. Ungar⁹, F. Furfaro¹, K. Karmiris¹⁰, K.H. Katsanos¹¹, P. Navarro Cortes¹², M.M. Boscà Watts¹², D.K. Christodoulou¹¹, G. Maconi¹³, U. Kopylov⁹, A. Armuzzi⁵, F. Magro⁴, G. Mantzaris³, S. Ben-Horin⁹, S. Danese^{1,14}</p> <p>¹Humanitas Research Hospital, IBD Center, Gastroenterology, Rozzano, Milan, Italy, ²Mater Dei Hospital, Department of Gastroenterology, Msida, Malta, ³Evangelismos Hospital, Department of Gastroenterology, Athens, Greece, ⁴Centro Hospitalar São João, Oporto, Portugal, Gastroenterology, Oporto, Portugal, ⁵Complexo Integrato Columbus, Gemelli Hospital Catholic University Foundation, IBD Unit, Rome, Italy, ⁶Casa Sollievo della Sofferenza Hospital, Division of Gastroenterology, San Giovanni Rotondo, Italy, ⁷Semmelweis University, ^{1st} Department of Medicine, Budapest, Hungary, ⁸Hull & East Yorkshire NHS Trust, Hull & York Medical School, Hull, United Kingdom, ⁹Sheba Medical Center, Gastroenterology, Tel Hashomer, Tel Aviv, Israel, ¹⁰Venizelion General Hospital, Department of Gastroenterology, Heraklion, Greece, ¹¹University Hospital of Ioannina - Greece, Department of Gastroenterology, Ioannina, Greece, ¹²University Clinic Hospital of Valencia, Department of Gastroenterology, Valencia, Spain, ¹³Luigi Sacco University Hospital, Department of Gastroenterology, Milan, Italy, ¹⁴Humanitas University, Department of Biomedical Sciences, Rozzano, Italy</p>

Thursday, March 17, 2016, cont.

Digital Oral Presentation Session 5 - Improving the care and outcome of IBD patients

17:15 - 18:15

Room G106-G107, Level 1
Maria Chaparro, Madrid, Spain
Nanne de Boer, Amsterdam, The Netherlands

17:15 - 17:22	<p>DOP037: Excess steroid use in IBD: Too much, how much and why? Results from a UK nationwide audit</p> <p>T. Raine¹, A. Bassi², E. Fogden³, B. Hayee⁴, J.K. Limdi⁵, H. Ludlow⁶, S. McLaughlin⁷, G.C. Parkes⁸, P. Patel⁹, M. Smith¹⁰, C. Selinger¹¹</p> <p>¹Addenbrooke's Hospital, Cambridge University Hospitals NHS Foundation Trust, Department of Gastroenterology Research, Cambridge, United Kingdom, ²Whiston Hospital, Department of Gastroenterology, Prescot, United Kingdom, ³Sandwell District General Hospital, Department of Gastroenterology, West Bromwich, United Kingdom, ⁴King's College Hospital, Department of Gastroenterology, London, United Kingdom, ⁵Pennine Acute Hospitals NHS Trust, Department of Gastroenterology, Manchester, United Kingdom, ⁶University Hospital Llandough, Department of Gastroenterology, Penarth, Cardiff, United Kingdom, ⁷Royal Bournemouth Hospital, Department of Gastroenterology, Bournemouth, United Kingdom, ⁸Barts and The London, Queen Mary's School of Medicine and Dentistry, Department of Gastroenterology, London, United Kingdom, ⁹Epsom General Hospital, Department of Gastroenterology, Epsom, United Kingdom, ¹⁰Brighton and Sussex University Hospitals Trust, Digestive Diseases, Hove, East Sussex, United Kingdom, ¹¹St James University Hospital, Gastroenterology, Leeds, United Kingdom</p>
17:22 - 17:29	<p>DOP038: Analytical and clinical validation of a rapid point-of-care assay for infliximab quantification in patients with Ulcerative Colitis</p> <p>T. van Stappen¹, L. Bollen¹, N. Vande Castele¹, K. Papamichail¹, ², N. Geukens¹, C. Barthel³, Y. Kölmel³, N. Zali³, S. Rameil³, G. van Assche², M. Ferrante², S. Vermeire², A. Gils¹</p> <p>¹KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium, ²UZ Leuven, Department of Clinical and Experimental Medicine, Leuven, Belgium, ³R-Biopharm AG, Darmstadt, Germany</p>
17:29 - 17:36	<p>DOP039: Point-of-care monitoring of infliximab trough levels in capillary fingerstick blood of patients with Inflammatory Bowel Disease (IBD)</p> <p>J. Maljaars¹, C. de Dood², S. van der Burg¹, A. van der Meulen¹, H. Tanke², P. Corstjens²</p> <p>¹LUMC, Gastroenterology-Hepatology, Leiden, Netherlands, ²Leiden University Medical Center, Department of Molecular Cell Biology Geb. 1, Leiden, Netherlands</p>
17:36 - 17:43	<p>DOP040: Effects of education and information on vaccination behaviour in IBD patients</p> <p>S. Coenen¹, E. Weyts¹, C. Jorissen², P. de Munter³, M. Noman¹, V. Ballet¹, S. Vermeire¹, G. van Assche¹, M. Ferrante¹</p> <p>¹UZ Leuven, Gastroenterology, Leuven, Belgium, ²KU Leuven, Leuven, Belgium, ³UZ Leuven, Leuven, Belgium</p>

Thursday, March 17, 2016, cont.

17:43 - 17:50	<p>DOP041: Impact of an education programme on IBD patient's skills: One year results of the ECiPE randomised, controlled multicentre study</p> <p>J. Moreau¹, L. Marthey², C. Trang³, M. Nachury⁴, R. Altwegg⁵, J.-C. Grimaud⁶, S. Orempuller¹, J. Filippi⁷, A. Aubourg⁸, C. Baudry⁹, P. Seksik¹⁰, X. Roblin¹¹, S. Nahon¹², G. Savoye¹³, B. Mesnard¹⁴, C. Stefanescu¹⁵, M. Simon¹⁶, B. Coffin¹⁷, J.-L. Dupas¹⁸, S. Chevret¹⁹, M. Allez²⁰</p> <p>¹Rangueil Hospital, Department of Gastroenterology, Toulouse, France, ²Bicêtre Hospital, Department of Gastroenterology, Le Kremlin Bicêtre, France, ³CHU Hotel Dieu, Department of Gastroenterology, Nantes, France, ⁴Huriez Hospital, Department of Gastroenterology, Lille, France, ⁵Saint Eloi Hospital, Department of Hepatology and Gastroenterology, Montpellier, France, ⁶Nord Hospital, Department of Gastroenterology, Marseille, France, ⁷Archet Hospital, Department of Gastroenterology and Nutrition, Nice, France, ⁸Trousseau University Hospital, Department of Gastroenterology, Tours, France, ⁹Saint-Louis Hospital, Department of Gastroenterology and Hepatology, Paris, France, ¹⁰St. Antoine Hospital, Department of Gastroenterology, Paris, France, ¹¹CHU St Etienne, Department of Gastroenterology, Saint-Etienne, France, ¹²Montfermeil Hospital, Department of Gastroenterology, Montfermeil, France, ¹³Charles Nicolle Hospital, Department of Gastroenterology, Rouen, France, ¹⁴CH Dron, Department of Gastroenterology, Tourcoing, France, ¹⁵Beaujon Hospital, Department of Gastroenterology, Paris, France, ¹⁶Montsouris Mutualist Institute, Department of Gastroenterology, Paris, France, ¹⁷Louis Mourier Hospital AHP, Department of Gastroenterology and Hepatology, Colombes, France, ¹⁸Nord Hospital, Department of Gastroenterology, Amiens, France, ¹⁹Saint-Louis Hospital, Department of Biostatistics, Paris, France, ²⁰Saint-Louis Hospital, Department of Gastroenterology, Paris, France</p>
17:50 - 17:57	<p>DOP042: Most anti-TNF injectors are stored under suboptimal conditions at home</p> <p>M. de Jong^{1,2}, M. Pierik^{1,2}, A. Peters³, M. Roemers⁴, F. van der Heijden⁵, V. Hilhorst⁶, A. van Tubergen^{7,8}</p> <p>¹Maastricht University Medical Centre+, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Maastricht, Netherlands, ²Maastricht University Medical Centre+, NUTRIM – School for Nutrition and Translational Research in Metabolism, Maastricht, Netherlands, ³Maastricht University Medical Centre+, Department of Internal Medicine, Maastricht, Netherlands, ⁴AntTail, Utrecht, Netherlands, ⁵MSD, Haarlem, Netherlands, ⁶Maastricht University Medical Centre+, Department of Clinical Pharmacy & Toxicology, Maastricht, Netherlands, ⁷Maastricht University Medical Centre+, Department of Internal Medicine, Division of Rheumatology, Maastricht, Netherlands, ⁸Maastricht University Medical Centre+, CAPHRI - School for Public Health and Primary Care, Maastricht, Netherlands</p>

Thursday, March 17, 2016, cont.

17:57 - 18:04	<p><i>DOP043: Non-adherence to anti-TNF therapy predicts clinical outcomes in outpatients with Inflammatory Bowel Disease: Results from a prospective multicentre study</i> <i>M. van der Have</i>¹, B. Oldenburg¹, A.A. Kaptein², J.M. Jansen³, R.C. Scheffer⁴, S.A. van Tuyl⁵, A.E. van der Meulen - de Jong⁶, M. Pierik⁷, P.D. Siersema¹, M.G. van Oijen^{1,8}, H.H. Fidder¹</p> <p>¹University Medical Centre Utrecht, Department of Gastroenterology and Hepatology, Utrecht, Netherlands, ²Leiden University Medical Centre, Section Medical Psychology, Leiden, Netherlands, ³Onze Lieve Vrouwe Gasthuis, Department of Gastroenterology and Hepatology, Amsterdam, Netherlands, ⁴Jeroen Bosch Hospital, Department of Gastroenterology and Hepatology, s Hertogenbosch, Netherlands, ⁵Diakonessenhuis, Department of Gastroenterology and Hepatology, Utrecht, Netherlands, ⁶Leiden University Medical Centre, Department of Gastroenterology and Hepatology, Leiden, Netherlands, ⁷Maastricht University Medical Centre, Department of Gastroenterology and Hepatology, Maastricht, Netherlands, ⁸Academic Medical Centre, Department of Medical Oncology, Amsterdam, Netherlands</p>
18:04 - 18:11	<p><i>DOP044: Self-administered telemedicine reduces number of outpatient visits and days of absence from school in paediatric and adolescent patients with Inflammatory Bowel Disease</i> <i>K. Carlsen</i>^{1,2}, C. Jakobsen², L.F. Hansen², A. Paerregaard², L.B. Riis³, P.S. Munkholm⁴, V. Wewer²</p> <p>¹Hvidovre Hospital, Paediatric, Hvidovre, Denmark, ²Hvidovre Hospital, Department of Paediatrics, Hvidovre, Denmark, ³Herlev Hospital, Department of Pathology, Herlev, Denmark, ⁴North Zealand Hospital, Department of Gastroenterology, Frederikssund, Denmark</p>
18:11 - 18:18	<p><i>DOP045: Self-administered telemedicine empowers paediatric and adolescent patients with Inflammatory Bowel Disease</i> <i>K. Carlsen</i>^{1,2}, C. Jakobsen², L.F. Hansen², A. Paerregaard², T. Kallemose³, G. Houen⁴, L.B. Riis³, P.S. Munkholm⁶, V. Wewer²</p> <p>¹Hvidovre Hospital, Paediatric, Hvidovre, Denmark, ²Hvidovre Hospital, Department of Paediatrics, Hvidovre, Denmark, ³Hvidovre Hospital, Clinical Research Centre and Department of Orthopaedic, Hvidovre, Denmark, ⁴Statens Serum Institute, Department of Autoimmunology and Biomarkers, Copenhagen, Denmark, ⁵Herlev Hospital, Department of Pathology, Herlev, Denmark, ⁶North Zealand Hospital, Department of Gastroenterology, Frederikssund, Denmark</p>



European
Crohn's and Colitis
Organisation

Amsterdam
The Netherlands

ECCO EU Project Forum

**First Edition:
Ask for further
details @ the
ECCO Booth**



Exchange your experience about EU Projects and IBD

The EU Project Forum aims to facilitate exchange of knowledge and sharing of project experience and to identify potential new synergies in European projects.

Featuring:

- EU funding for the research on gastrointestinal disorders Presentation by a European Commissioner
- SADEL: Scaffolds for Alternative DELivery
- IBD-BIOM
- BIOCYCLE: BIOlogical therapy CYCLEs towards tailored, needs-driven, safer and cost-effective management of Crohn's Disease
- IBD-Character

Want to learn more about these projects? Read the JCC Viewpoint Article on How to apply for and secure EU funding for collaborative IBD research projects
J. Satsangi, O.Kitten, M. Chavez, R. Kalla, N. Prel, M-A. Meuwis, S.Scott, I.Bonetti, N. Ventham, E. Loui
Journal of Crohn's and Colitis Jan 2016 DOI: 10.1093/ecco-jcc/jjv237

Scan and visit
www.ecco-jcc.oxfordjournals.org



Friday, March 18, 2016

<p>Digital Oral Presentation Session 6 - Short & long term efficacy of biologics Room E104-E106, Level 1 James Lindsay, London, United Kingdom Britta Siegmund, Berlin, Germany</p>	
<p>18:05 - 19:05</p>	<p>DOP046: Mid- to long-term stability and associated prognostic factors of adalimumab treatment for 1189 patients with Crohn's Disease: A multicentre cohort study H. Tanaka¹, N. Kamata², A. Yamada³, K. Endo⁴, T. Fujii⁵, T. Yoshino⁶, 7. T. Sugaya⁸, Y. Yokoyama⁹, S. Bamba¹⁰, J. Umeno¹¹, Y. Yanai¹², M. Ishii¹³, T. Kawaguchi¹⁴, S. Shinzaki¹⁵, Y. Toya¹⁶, T. Kobayashi¹⁷, M. Nojima¹⁸, T. Hibi¹⁷ ¹Sapporo Kosei General Hospital, IBD Center, Sapporo, Japan, ²Osaka City University Graduate School of Medicine, Department of Gastroenterology, Osaka, Japan, ³Sakura Medical Center, Toho University, Department of Internal Medicine, Chiba, Japan, ⁴Tohoku University Graduate School of Medicine, Division of Gastroenterology, Sendai, Japan, ⁵Tokyo Medical and Dental University, Department of Gastroenterology and Hepatology, Tokyo, Japan, ⁶Graduate School of Medicine, Kyoto University, Department of Gastroenterology and Hepatology, Kyoto, Japan, ⁷Tazuke Kofukai Medical Research Institute, Kitano Hospital, IBD Center, Osaka, Japan, ⁸Dokkyo Medical University, Department of Gastroenterology, Tochigi, Japan, ⁹Hyogo College of Medicine, Division of Internal Medicine, Department of Inflammatory Bowel Disease, Hyogo, Japan, ¹⁰Shiga University of Medical Science, Division of Gastroenterology, Shiga, Japan, ¹¹Kyushu University, Department of Medicine and Clinical Science, Graduate School of Medical Sciences, Fukuoka, Japan, ¹²Oita Red Cross Hospital, Department of Gastroenterology, Oita, Japan, ¹³Kawasaki Medical School, Department of Internal Medicine, Division of Gastroenterology, Kurashiki, Japan, ¹⁴Tokyo Yamate Medical Center, Department of Internal Medicine, Division of IBD, Tokyo, Japan, ¹⁵Osaka University Graduate School of Medicine, Department of Gastroenterology and Hepatology, Osaka, Japan, ¹⁶School of Medicine, Iwate Medical University, Division of Gastroenterology, Iwate, Japan, ¹⁷Kitasato University Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan, ¹⁸The Institute of Medical Science, The University of Tokyo, Center for Translational Research, Tokyo, Japan</p>
<p>18:05 - 18:12</p>	<p>DOP047: PYRAMID registry: An observational study of adalimumab in Crohn's Disease: Results at year 7 G. D'Haens¹, W. Reinisch², J. Satsangi³, E. Loftus Jr⁴, R. Panaccione⁵, H. Read⁶, M. Heinrich⁷, J. Pettersson⁶, A.M. Robinson⁶ ¹Academic Medical Centre, Department of Gastroenterology, Amsterdam, Netherlands, ²Medical University of Vienna, Vienna, Austria, ³Western General Hospital, Gastrointestinal Unit, Edinburgh, United Kingdom, ⁴Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, United States, ⁵University of Calgary, Department of Medicine, Calgary, Canada, ⁶AbbVie Inc., North Chicago, United States, ⁷AbbVie Deutschland, Ludwigshafen, Germany</p>
<p>18:12 - 18:19</p>	<p>DOP047: PYRAMID registry: An observational study of adalimumab in Crohn's Disease: Results at year 7 G. D'Haens¹, W. Reinisch², J. Satsangi³, E. Loftus Jr⁴, R. Panaccione⁵, H. Read⁶, M. Heinrich⁷, J. Pettersson⁶, A.M. Robinson⁶ ¹Academic Medical Centre, Department of Gastroenterology, Amsterdam, Netherlands, ²Medical University of Vienna, Vienna, Austria, ³Western General Hospital, Gastrointestinal Unit, Edinburgh, United Kingdom, ⁴Mayo Clinic, Division of Gastroenterology and Hepatology, Rochester, United States, ⁵University of Calgary, Department of Medicine, Calgary, Canada, ⁶AbbVie Inc., North Chicago, United States, ⁷AbbVie Deutschland, Ludwigshafen, Germany</p>

Friday, March 18, 2016, cont.

18:19 - 18:26	<p>DOP048: Delayed response to golimumab therapy: UC patient characteristics and long-term clinical outcome: Post-hoc analyses from the PURSUIT programme J.-F. Colombel¹, W. Reinisch², P. Gibson³, W.J. Sandborn⁴, B. Feagan⁵, S. Xu⁶, R. Strauss⁶, H. Zhang⁶, D. Tarabar⁷, Z. Hebzda⁸, P. Rutgeerts⁹, C. Marano⁶</p> <p>¹Mount Sinai, Icahn School of Medicine, New York, United States, ²Universitätsklinik für Innere Medizin III and McMaster University, Vienna and Hamilton, Austria, ³Alfred Hospital, Melbourne, Australia, ⁴University of California San Diego, Division of Gastroenterology, La Jolla, United States, ⁵Robarts Clinical Trials Inc., Robarts Research Institute, University of Western Ontario, London, Ontario, Canada, ⁶Janssen R & D, LLC, Spring House, United States, ⁷Military Medical Academy, Department of Gastroenterology and Hepatology, Belgrade, Serbia, ⁸Military Hospital, Krakow, Poland, ⁹University Hospital Gasthuisberg, Department of Haematology, Leuven, Netherlands</p>
18:26 - 18:33	<p>DOP049: Efficacy and safety of golimumab induction for moderate to severe Ulcerative Colitis in the United Kingdom: Results from the GO-COLITIS study C. Probert¹, D.R. Gaya², P.J. Hamlin³, P. Irving⁴, S. Sebastian⁵, G. Gillespie⁶, H. Tate⁶, C. Wheeler⁶</p> <p>¹University of Liverpool, Liverpool, United Kingdom, ²Glasgow Royal Infirmary, Glasgow, United Kingdom, ³Leeds Teaching Hospitals Trust, Leeds, United Kingdom, ⁴Guy's and St. Thomas' Hospitals, London, United Kingdom, ⁵Hull & East Yorkshire NHS Trust, Hull, United Kingdom, ⁶MSD UK, Hoddesdon, United Kingdom</p>
18:33 - 18:40	<p>DOP050: The efficacy of vedolizumab by disease activity and prior tumour necrosis factor alpha antagonist failure in patients with ulcerative colitis or Crohn's disease: Post hoc analyses from the GEMINI 1 and GEMINI 2 studies G. D'Haens¹, J.-F. Colombel², M. Dubinsky², B. Abhyankar³, A. James³, K. Lasch⁴</p> <p>¹Academic Medical Center, Amsterdam, Netherlands, ²Icahn School of Medicine at Mount Sinai Hospital, New York, New York, United States, ³Takeda Development Centre Europe Ltd, London, United Kingdom, ⁴Takeda Pharmaceuticals U.S.A., Inc, Deerfield, United States</p>
18:40 - 18:47	<p>DOP051: Response and remission rates with up to 3 years of vedolizumab treatment in patients with Ulcerative Colitis E.V. Loftus Jr¹, J.-F. Colombel², A. Previtali³, M. Smyth³</p> <p>¹Mayo Clinic, Rochester, Minnesota, United States, ²Icahn School of Medicine at Mount Sinai Hospital, New York, New York, United States, ³Takeda Development Centre Europe Ltd, London, United Kingdom</p>
18:47 - 18:54	<p>DOP052: Ozanimod induces histological response and remission: Results from the TOUCHSTONE study, a randomised, double-blind, placebo-controlled trial of ozanimod, an oral S1P receptor modulator, in moderate to severe Ulcerative Colitis W. Sandborn¹, B. Feagan², G. D'Haens³, B. Levesque⁴, R. Pai⁴, S. Hanauer⁵, D. Wolf⁶, S. Vermeire⁷, S. Ghosh⁸, H. Smith⁹, M. Cravets⁹, P. Frohna⁹, S. Gujrathi⁹, R. Aranda⁹, A. Olson⁹</p> <p>¹University of California San Diego, Division of Gastroenterology, La Jolla, United States, ²Western University/Robarts Research Institute, Robarts Clinical Trials Inc., London, Canada, ³Academic Medical Center (AMC), Amsterdam, Netherlands, ⁴Mayo Clinic, Scottsdale, United States, ⁵Northwestern University Feinberg School of Medicine, Chicago, United States, ⁶Atlanta Gastroenterology Associates, Atlanta, United States, ⁷University of Leuven, Leuven, Belgium, ⁸University of Calgary, Calgary, Canada, ⁹Receptos, Inc., San Diego, United States</p>

Friday, March 18, 2016, cont.

18:54 - 19:01	<p>DOP053: Effects of oral tofacitinib on patient-reported outcomes in patients with moderate to severe Crohn's Disease: Results of two Phase 2b randomised placebo-controlled trials J. Panés¹, M. Mosciariello², E. Maller², G. Chan², W. Wang², P. Healey³ ¹Hospital Clinicas de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain, ²Pfizer Inc, Collegetown, United States, ³Pfizer Inc, Groton, United States</p>
19:01 - 19:08	<p>DOP054: Discrepancies between patient-reported outcomes, endoscopic and histologic appearance in Ulcerative Colitis J.-F. Colombel¹, M. Keir², A. Scherl², R. Zhao², G. de Hertogh³, W. Faubion⁴, T. Lu² ¹Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, NY, United States, ²Genentech, South San Francisco, United States, ³Department of Imaging and Pathology, Catholic University of Leuven, Leuven, Belgium, ⁴Mayo Clinic Rochester, Department of Gastroenterology, Rochester, United States</p>

18:05 - 19:05 **Digital Oral Presentation Session 7 - Managing children and adolescents with IBD**
 Room E102, Level 1
 Salvatore Cucchiara, Rome, Italy
 Dan Turner, Jerusalem, Israel

18:05 - 18:12	<p>DOP055: Azithromycin based therapy for induction of remission in mild to moderate active paediatric Crohns Disease: The multicentre azithromycin for Crohn's Disease AZCRO trial A. Levine^{1,2}, J. Kierkus³, M. Kori⁴, M. Sladek⁵, R. Sigall Boneh¹, J. Escher⁶, E. Wine⁷, B. Yerushalmi⁸, J. Amil Dias⁹, R. Shaul¹⁰, A. Akvri¹¹, D. Zucker¹¹, D. Turner^{11,12} ¹Wolfson Medical Center, Paediatric Gastroenterology and Nutrition Unit, Tel Aviv, Israel, ²Tel Aviv University, Tel Aviv, Israel, ³The Children's Memorial Health Institute, Gastroenterology, Hepatology, Feeding Disorders and Paediatrics, Warsaw, Poland, ⁴Kaplan Medical Center, Paediatric Day Care Unit, Rehovot, Israel, ⁵Jagiellonian University Medical College, Department of Paediatrics, Gastroenterology and Nutrition, Cracow, Poland, ⁶Erasmus MC-Sophia Children's Hospital, Department of Paediatric Gastroenterology, Rotterdam, Netherlands, ⁷University of Alberta, Division of Paediatric Gastroenterology, Department of Paediatrics, Edmonton, Canada, ⁸Soroka Medical Center, Ben Gurion University of the Negev, Paediatric Gastroenterology, Beer-Sheva, Israel, ⁹Hospital, S. Joao, Department of Paediatrics, Porto, Portugal, ¹⁰Meyer Children's Hospital, Gastroenterology Unit, Haifa, Israel, ¹¹The Hebrew University of Jerusalem, Jerusalem, Israel, ¹²Shaare Zedek Medical Center, The Juliet Keidan Institute of Paediatric Gastroenterology & Nutrition, Jerusalem, Israel</p>
18:12 - 18:19	<p>DOP056: Pharmacokinetics and exposure-response relationships of golimumab in paediatric patients with moderate to severe Ulcerative Colitis: Results from a multicentre open label study O.J. Adedokun¹, D. Chan¹, L. Padgett¹, Y. Xu¹, J. Hyams², D. Turner³, Z. Xu¹, H. Davis¹, R. Strauss¹ ¹Janssen R & D, LLC, Spring House, United States, ²Connecticut Children's Medical Center, Hartford, United States, ³The Juliet Keidan Institute of Paediatric Gastroenterology and Nutrition, Shaare Zedek Medical Center, Jerusalem, Israel</p>

Friday, March 18, 2016, cont.

18:19 - 18:26	<p><i>DOP057: Tailored step-up approach results in beneficial long-term disease outcome in the prospective Belgian registry of paediatric Crohn's Disease (BELCRO)</i> L. Wauters¹, F. Smets², E. de Greef³, I. Hoffman⁴, P. Bontems⁵, S. van Biervliet⁶, I. Paquot⁷, P. Alliet⁸, W. Arts⁹, M. de Vos¹⁰, P. Bossuyt¹¹, J.-F. Rahier¹², O. Dewit¹³, T. Moreels¹³, D. Franchimont¹⁴, V. Muls¹⁴, F. Fontaine¹⁵, E. Louis¹⁵, J.-C. Coche¹⁶, B. Hauser³, H. Peeters¹⁷, E. van de Vijver¹⁸, F. Baert¹⁹, S. Vermeire¹, G. Veereman³</p> <p>¹UZ Leuven, Gastroenterology and Hepatology, Leuven, Belgium, ²UCL St Luc, Paediatric Gastroenterology, Brussels, Belgium, ³UZ Brussel, Paediatric Gastroenterology, Brussels, Belgium, ⁴UZ Leuven, Paediatric Gastroenterology, Leuven, Belgium, ⁵HUDERF, Paediatric Gastroenterology, Brussels, Belgium, ⁶UZ Gent, Paediatric Gastroenterology, Ghent, Belgium, ⁷CHC Liège, Paediatric Gastroenterology, Liège, Belgium, ⁸Jessa Ziekenhuis, Paediatric Gastroenterology, Hasselt, Belgium, ⁹ZOL Genk, Paediatric Gastroenterology, Genk, Belgium, ¹⁰UZ Gent, Gastroenterology, Ghent, Belgium, ¹¹Imelda Ziekenhuis, Gastroenterology, Bonheiden, Belgium, ¹²UCL Mont Godinne, Gastroenterology, Mont Godinne, Belgium, ¹³UCL St Luc, Gastroenterology, Brussels, Belgium, ¹⁴ULB Erasme, Gastroenterology, Brussels, Belgium, ¹⁵CHU Liège, Gastroenterology, Liège, Belgium, ¹⁶St Pierre, Gastroenterology, Ottignies, Belgium, ¹⁷St Lucas, Gastroenterology, Ghent, Belgium, ¹⁸UZ Antwerpen, Paediatric Gastroenterology, Antwerp, Belgium, ¹⁹Heilig Hart Ziekenhuis, Gastroenterology, Roeselaere, Belgium</p>
18:26 - 18:33	<p><i>DOP058: Long term avoidance of steroids associated with exclusive enteral nutrition as induction therapy in paediatric Crohn's Disease does not increase surgery, hospitalisations or biologics use: Results of a propensity score-matched cohort analysis</i> S. Basseri¹, J. Connors², A. Grant², B. MacIntyre², N. Giffin¹, G. Mahdi², A. Noble², M. Rashid², A.R. Otley², J. van Limbergen²</p> <p>¹Dalhousie University, Halifax, Canada, ²IWK Health Centre, Halifax, Canada</p>
18:33 - 18:40	<p><i>DOP059: Efficacy of exclusive enteral nutrition in adult active Crohn's Disease with complications or failure of medical treatment</i> Q. Yang, X. Gao, M. Zhi, H. Chen, N. Ding, S. Hu, J. Guo, P. Hu The Sixth Affiliated Hospital, Sun Yan-sen University, Department of Gastroenterology, Guangzhou, China</p>
18:40 - 18:47	<p><i>DOP060: Anti-TNF cord levels are significantly higher after IFX exposure during pregnancy compared to ADA exposure</i> S. Kanis¹, A. de Lima¹, C. van der Ent², C. van der Woude¹</p> <p>¹Erasmus Medical Center, Gastroenterology and Hepatology, Rotterdam, Netherlands, ²Erasmus Medical Center, Rotterdam, Netherlands</p>
18:47 - 18:54	<p><i>DOP061: Intrauterine exposure to thiopurine: Assessing health outcome of children born to patients with an Inflammatory Bowel Disease</i> S. Kanis, A. de Lima, C. van der Woude Erasmus Medical Center, Gastroenterology and Hepatology, Rotterdam, Netherlands</p>

Friday, March 18, 2016, cont.

18:54 - 19:01	<p>DOP062: Malignancy and mortality in paediatric onset Inflammatory Bowel Disease</p> <p>L. de Ridder¹, M. Joosse², D. Turner³, D. Wilson⁴, S. Koletzko⁵, J. Martin-de-Carpi⁶, U. Fagerberg⁷, C. Spray⁸, M. Sladek⁹, R. Shaoul¹⁰, E. Roma-Giannikou¹¹, J. Bronsky¹², D. Serban¹³, S. Cucchiara¹⁴, G. Veres¹⁵, F. Ruemmele¹⁶, I. Hojsak¹⁷, K. Kolho¹⁸, I. Davies¹⁹, M. Aloï¹⁴, P. Lionetti²⁰, G. Veereman-Wauters²¹, C. Braegger²², E. Trindade²³, A.V. Wewer²⁴, A. Hauer²⁵, A. Levine²⁶</p> <p>¹Erasmus MC Sophia Children's Hospital, Department of Paediatric Gastroenterology, Rotterdam, Netherlands, ²Erasmus MC, Laboratory of Paediatrics, Division Gastroenterology and Nutrition, Rotterdam, Netherlands, ³Shaare Zedek Medical Center in Jerusalem, Department of Paediatric Gastroenterology, Jerusalem, Israel, ⁴University of Edinburgh, Department of Paediatric Gastroenterology, Child Life and Health, Edinburgh, United Kingdom, ⁵University of Munich Medical Centre, Dr. v. Hauner Children's Hospital, Department of Paediatric Gastroenterology, Munich, Germany, ⁶Unidad para el Cuidado Integral de la Enfermedad Inflamatoria Intestinal Pediátrica, Sección de Gastroenterología, Hepatología y Nutrición Paediatrica, Hospital Sant Joan de Déu, Department of Paediatric Gastroenterology, Barcelona, Spain, ⁷Centre for Clinical Research, Västmanland Hospital, Västerås, Department of Paediatric Gastroenterology, Stockholm, Sweden, ⁸Bristol Royal Hospital for Children, Department of Paediatric Gastroenterology, Bristol, United Kingdom, ⁹Polish-American Children's Hospital, Jagiellonian University Medical College, Department of Paediatrics, Gastroenterology and Nutrition, Cracow, Poland, ¹⁰Bnai Zion Medical Center, Paediatric Day Care Unit, Department of Paediatrics, Haifa, Israel, ¹¹Athens University, First Department of Paediatrics, Athens, Greece, ¹²Second Faculty of Medicine, Charles University and University Hospital Motol, Department of Paediatric Gastroenterology, Prague, Czech Republic, ¹³"Iuliu Hatieganu" University of Medicine and Pharmacy, Second Paediatric Clinic, Children's Emergency Hospital, Department of Paediatric Gastroenterology, Cluj-Napoca, Romania, ¹⁴"La Sapienza" University, Department of Paediatric Gastroenterology, Rome, Italy, ¹⁵Semmelweis University, Department of Paediatric Gastroenterology, Budapest, Hungary, ¹⁶Université Paris Descartes, Sorbonne Paris Cité, Hôpital Necker Enfants Malades, Department of Paediatric Gastroenterology, Paris, France, ¹⁷Referral Center for Paediatric Gastroenterology, Children's Hospital Zagreb, School of Medicine, University of Zagreb, Zagreb, Croatia, Croatia, ¹⁸Children's Hospital, University Central Hospital and University of Helsinki, Department of Paediatric Gastroenterology, Helsinki, Finland, ¹⁹University Hospital of Wales, Department of Paediatric Gastroenterology, Cardiff, United Kingdom, ²⁰Meyer Children's Hospital, Department of Paediatric Gastroenterology, Florence, Italy, ²¹University Hospital Brussels, UZ Brussels, Department of Paediatric Gastroenterology and Nutrition, Brussels, Belgium, ²²Children's Research Centre, University Children's Hospital, Department of Paediatric Gastroenterology and Nutrition, Zurich, Switzerland, ²³Hospital São João, Paediatric Gastroenterology Unit, Porto, Portugal, ²⁴University Hospital Hvidovre, Department of Paediatrics, Hvidovre, Denmark, ²⁵Medical University of Graz, Paediatric Gastroenterology, Graz, Austria, ²⁶The Wolfson Medical Center, Tel-Aviv University, Department of Paediatric Gastroenterology, Tel-Aviv, Israel</p>
---------------	--

Friday, March 18, 2016, cont.

19:01 - 19:08	<p>DOP063: Measurement of endoscopic severity in a Crohn's Disease multi-centre paediatric inception cohort: Poor correlation of SES-CD with PCDAI N. Carman¹, P. Church¹, H. Huynh², D. Mack³, K. Jacobson⁴, A. Otley⁵, J. de Bruyn⁶, W. El-Matery⁷, C. Deslandres⁸, M. Carroll², E. Wine², E. Benchimol³, J. van Limbergen⁵, A. Griffiths¹, T. Walters¹</p> <p>¹The Hospital for Sick Children, Toronto, Canada, ²University of Alberta, Edmonton, Canada, ³Children's Hospital of Eastern Ontario, Ottawa, Canada, ⁴British Columbia Children's Hospital, Vancouver, Canada, ⁵IWK Health Centre, Halifax, Canada, ⁶Alberta Children's Hospital, Calgary, Canada, ⁷University of Manitoba, Winnipeg, Canada, ⁸Sainte-Justine University Hospital Center, Montreal, Canada</p>
---------------	---

<p>Digital Oral Presentation Session 8 - Pharmacokinetics of IBD therapies Room G102-G103, Level 1 Shomron Ben-Horin, Ramat Gan, Israel Yehuda Chowers, Haifa, Israel</p>	
18:05 - 19:05	<p>DOP064: Addition of an immunomodulator can reverse antibody formation and loss of response in patients treated with adalimumab B. Ungar¹, M. Yavzori¹, O. Picard¹, E. Fudim¹, U. Kopylov¹, E. Del Tedesco², S. Paul², Y. Chowers³, R. Eliakim¹, S. Ben-Horin¹, X. Roblin²</p> <p>¹Sheba Medical Center & Sackler School of Medicine, Gastroenterology, Tel Hashomer, Israel, ²CHU de Saint-Etienne, Service de Gastrologie-Entérologie-Hépatologie, Saint-Etienne, France, ³Rambam Health Care Campus, Bruce & Ruth Rappaport School of Medicine, Technion Institute of Technology, Department of Gastroenterology, Haifa, Israel</p>
18:12 - 18:19	<p>DOP065: Less anti-infliximab antibody formation in paediatric Crohn's patients on concomitant immunomodulators H. Kansen¹, P. van Rheenen², R. Houwen¹, W. Tjon A Ten³, G. Damen⁴, A. Kindermann⁵, J. Escher⁶, V. Wolters¹</p> <p>¹University Medical Centre-Wilhelmina Children's Hospital, Department of Paediatric Gastroenterology, Utrecht, Netherlands, ²University of Groningen, University Medical Centre Groningen, Department of Paediatric Gastroenterology, Groningen, Netherlands, ³Maxima Medical Centre, Department of Paediatric Gastroenterology, Veldhoven, Netherlands, ⁴Radboud University Medical Centre-Amalia Children's Hospital, Department of Paediatric Gastroenterology, Nijmegen, Netherlands, ⁵Emma Children's Hospital, Academic Medical Center, Department of Paediatric Gastroenterology, Amsterdam, Netherlands, ⁶Erasmus Medical Centre-Sophia Children's Hospital, Department of Paediatric Gastroenterology, Rotterdam, Netherlands</p>
18:19 - 18:26	<p>DOP066: Disappearance of anti-drug antibodies to infliximab and adalimumab after addition of an immunomodulator in patients with Inflammatory Bowel Disease A. Strik¹, G. van den Brink¹, C. Ponsioen¹, R. Mathot², M. Löwenberg¹, G. D'Haens¹</p> <p>¹Academic Medical Center, Gastroenterology and Hepatology, Amsterdam, Netherlands, ²Academic Medical Center (AMC), Hospital Pharmacy, Amsterdam, Netherlands</p>
18:26 - 18:33	<p>DOP067: Factors influencing infliximab and adalimumab antibody formation and 6 month retrospective follow-up in a tertiary IBD Centre J. Digby-Bell¹, B. Warner¹, E. Johnston¹, N. Unsworth², Z. Arkir², J. Sanderson¹, P. Irving¹</p> <p>¹Guy's and St Thomas' NHS Foundation Trust, Gastroenterology, London, United Kingdom, ²Guy's and St Thomas' NHS Foundation Trust, Reference Chemistry, Biomedical Sciences, Viapath, London, United Kingdom</p>

Friday, March 18, 2016, cont.

18:33 - 18:40	<p>DOP068: Insufficient infliximab exposure predisposes to immunogenicity and enhanced clearance of infliximab in IBD J.F. Brandse¹, D.R. Mould², Y.K. Ashruf¹, O. Smeekes¹, S. Kuin¹, A. Strik¹, G.R. van den Brink¹, G.R. D'Haens¹</p> <p>¹Academic Medical Center, Inflammatory Bowel Disease Center, Amsterdam, Netherlands, ²Projections Research Inc, Phoenixville, United States</p>
18:40 - 18:47	<p>DOP069: Dose optimisation using drug and antibody levels can benefit 50% patients prescribed anti TNF therapy compared to empiric dose adjustment P. Harrow¹, C. Skinner¹, T. Hoque¹, A. Ibarra¹, J. Lindsay^{1,2}</p> <p>¹Barts Health NHS Trust, The Royal London Hospital, London, United Kingdom, ²Blizard Institute, Barts and The London School of Medicine and Dentistry, Centre for Immunobiology, London, United Kingdom</p>
18:47 - 18:54	<p>DOP070: The relationship between vedolizumab drug concentrations at or before week 6 and remission at week 14 in Ulcerative Colitis patients from GEMINI 1 X. Roblin¹, M.T. Osterman², S. Glover³, U. Navaneethan⁴, M.A. Popa⁵, T. Wyant⁶, A. James⁷, K. Lasch⁵, M. Rosario⁶</p> <p>¹CHU de Saint-Etienne, Saint-Etienne, France, ²Hospital of the University of Pennsylvania and the Presbyterian Medical Center of Philadelphia, Philadelphia, United States, ³Southeastern Center for Inflammatory Bowel Diseases/Affiliate Faculty Biomedical Engineering, University of Florida, Gastroenterology, Hepatology, and Nutrition, Florida, United States, ⁴Center for Interventional Endoscopy, Florida Hospital, Florida, United States, ⁵Takeda Pharmaceuticals U.S.A., Inc, Deerfield, United States, ⁶Takeda Pharmaceuticals International Co, Cambridge, United States, ⁷Takeda Development Centre Europe Ltd, London, United Kingdom</p>
18:54 - 19:01	<p>DOP071: Tofacitinib plasma concentration monitoring is not needed for optimisation of induction therapy in moderate to severe Ulcerative Colitis: Results of pooled exposure-response analyses of Phase 3 induction studies A. Mukherjee¹, S. Tsuchiwata², C. Deng³, C. Vong⁴, R. Xie³, S.W. Martin⁴, D. Yu⁵, D. Woodworth⁵, W. Niezychowski⁵, C. Su⁵</p> <p>¹Pfizer Inc, Groton, United States, ²Pfizer Japan Inc, Tokyo, Japan, ³Pfizer Inc, Shanghai, China, ⁴Pfizer Inc, Cambridge, United States, ⁵Pfizer Inc, Collegeville, United States</p>
19:01 - 19:08	<p>DOP072: Association of ustekinumab trough concentrations with clinical, biochemical and endoscopic outcomes R. Battat¹, U. Kopylov², T. Bessissow¹, A. Bitton¹, A. Cohen³, M. Martel¹, E.G. Seidman⁴, W. Afif⁴</p> <p>¹McGill University Health Center, Gastroenterology, Montreal, Canada, ²Sheba Medical Center, Gastroenterology, Tel Hashomer, Israel, ³Jewish General Hospital, Department of Gastroenterology, Montreal, Canada, ⁴McGill University, Division of Gastroenterology, Montreal Quebec, Canada</p>

Friday, March 18, 2016, cont.

Digital Oral Presentation Session 9 - Predicting IBD and IBD-related neoplasia Room G104-G105, Level 1 Laurent Beaugerie, Paris, France Dana Duricová, Prague, Czech Republic	
18:05 - 19:05	
18:05 - 18:12	DOP073: Incidental diagnosis of Inflammatory Bowel Disease through bowel cancer screening: A 7-year experience U. Nosegbe ¹ , J.A. Scott ¹ , R.O. Butcher ^{1,2} , A.M. Abbas ¹ , R.C. Prudham ¹ , R. George ¹ , J. Limdi ^{1,2} ¹ The Pennine Acute Hospitals NHS Trust, Manchester, United Kingdom, ² University of Manchester, Institute of Inflammation and Repair, Manchester Academic Health Sciences Centre, Manchester, United Kingdom
18:12 - 18:19	DOP074: Incidence & prediction of fistula formation in England K. Sahnna ¹ , A. Askari ¹ , S. Adegbola ¹ , P. Tozer ¹ , R. Phillips ¹ , A. Hart ² , O. Faiz ² ¹ St Mark's Hospital, Colorectal Surgery, London, United Kingdom, ² St Mark's Hospital, IBD/Physiology, London, United Kingdom
18:19 - 18:26	DOP075: Looking beyond symptoms and disease activity to define disease severity in Inflammatory Bowel Disease: Results of an IOIBD specialist panel C. Siegel ¹ , C. Whitman ² , B. Spiegel ² , B. Feagan ³ , B. Sands ⁴ , E. Loftus ⁵ , R. Panaccione ⁶ , G. D'Haens ⁷ , C. Bernstein ⁸ , R. Geary ⁹ , S. Ng ¹⁰ , G. Mantzaris ¹¹ , B. Sartor ¹² , M. Silverberg ¹³ , R. Riddell ¹³ , I. Koutroubakis ¹⁴ , C. O'Morain ¹⁵ , P. Lakatos ¹⁶ , D. McGovern ² , J. Halfvarson ¹⁷ , W. Reinisch ¹⁸ , G. Rogler ¹⁹ , W. Kruis ²⁰ , C. Tysk ¹⁷ , S. Schreiber ²¹ , S. Danese ²² , W. Sandborn ²³ , A. Griffiths ²⁴ , B. Moum ²⁵ , C. Gasche ²⁶ , F. Pallone ²⁷ , S. Travis ²⁸ , J. Panés ²⁹ , J.-F. Colombel ⁴ , S. Hanauer ³⁰ , L. Peyrin-Biroulet ¹ ¹ Geisel School of Medicine at Dartmouth, Inflammatory Bowel Disease Center, Lebanon, United States, ² Cedars-Sinai Medical Center, Los Angeles, United States, ³ Roberts Clinical Trials, London, Canada, ⁴ Icahn School of Medicine at Mount Sinai, New York, United States, ⁵ Mayo Clinic, Rochester, United States, ⁶ University of Calgary, Calgary, Canada, ⁷ Academic Medical Center, Amsterdam, Netherlands, ⁸ University of Manitoba, Winnipeg, Canada, ⁹ University of Otago, Christchurch, New Zealand, ¹⁰ Chinese University of Hong Kong, Hong Kong, Hong Kong, ¹¹ Evangelismos-PolyCliniki-Ophthalmiatreion Hospital, Athens, Greece, ¹² University of North Carolina, Chapel Hill, United States, ¹³ Mount Sinai Hospital, Toronto, Canada, ¹⁴ University Hospital Heraklion, Crete, Greece, ¹⁵ Charlemont Clinic, Dublin, Ireland, ¹⁶ Semmelweis University, Budapest, Hungary, ¹⁷ Örebro University, Örebro, Sweden, ¹⁸ McMaster University Medical Center, Department of Gastroenterology, Hamilton, Canada, ¹⁹ University Hospital Zurich, Clinic for Hepatology and Gastroenterology, Zurich, Switzerland, ²⁰ University of Cologne, Clinic for Internal Medicine, Köln, Germany, ²¹ Universitätsklinikum Schleswig-Holstein Kiel, Clinic for Internal Medicine, Kiel, Germany, ²² Humanitas University, Milan, Italy, ²³ University of California San Diego, San Diego, United States, ²⁴ Hospital for Sick Children, Toronto, Canada, ²⁵ Oslo University, Oslo, Norway, ²⁶ Medical University and General Hospital Vienna, Vienna, Austria, ²⁷ University Rome, Rome, Italy, ²⁸ Oxford University Hospital, Oxford, United Kingdom, ²⁹ Hospital Clinic de Barcelona, Barcelona, Spain, ³⁰ Northwestern Feinberg School of Medicine, Chicago, United States, ³¹ CHU Nancy, Department of Gastroenterology and Hepatology, Vandoeuvre-Lès-Nancy, France

Friday, March 18, 2016, cont.

18:26 - 18:33	<p>DOP076: A Danish cross-sectional study: Autoimmune and chronic inflammatory disorders associated with Ulcerative Colitis M. Halling¹, T. Knudsen², J. Kjeldsen¹, J. Nielsen³, L. Koch Hansen⁴ ¹Odense University Hospital, Department of Gastroenterology, Odense, Denmark, ²Esbjerg Hospital, Department of Gastroenterology and Hepatology, Esbjerg, Denmark, ³Odense University Hospital, Department of Clinical Epidemiology, Odense, Denmark, ⁴Vejle Hospital, Department of Gastroenterology and Hepatology, Vejle, Denmark</p>
18:33 - 18:40	<p>DOP077: ImmunoChip analysis identifies multiple susceptibility loci for collagenous colitis G. Roda¹, H. Jianzhong², Z. Zhongyang³, J. Torres¹, A. Chen⁴, R. Petras⁵, D. Pardi⁶, A. Juga⁷, G. Levi³, W. Cao⁸, F. Rieder⁹, I. Gordon¹⁰, K. Hao³, N. Harpaz¹¹, J. Cho¹², J.-F. Colombel¹², I. Peter³ ¹Icahn School of Medicine, Gastroenterology, New York, United States, ²Icahn School of Medicine, New York, United States, ³Icahn School of Medicine at Mount Sinai, Medicine, New York, United States, ⁴Icahn School of Medicine at Mount Sinai, Gastroenterology, New York, United States, ⁵Ameripath, Pathology, Cleveland, United States, ⁶Mayo Clinic, Gastroenterology, Rochester, United States, ⁷New York-Presbyterian, Pathology, New York, United States, ⁸University of Rochester, Pathology, Rochester, United States, ⁹University of Cleveland, Gastroenterology, Cleveland, United States, ¹⁰Cleveland Clinic, Department of Anatomic Pathology, Cleveland, United States, ¹¹Icahn School of Medicine at Mount Sinai, Department of Gastroenterology, New York, United States, ¹²Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States</p>
18:40 - 18:47	<p>DOP078: Risk of malignancy in paediatric Inflammatory Bowel Disease: Results from the DEVELOP registry M. Dubinsky¹, J. Hyams², R. Baldassano³, R. Colletti⁴, S. Cucchiara⁵, J. Escher⁶, W. Faubion⁷, J. Fell⁸, B. Gold⁹, A. Griffiths¹⁰, S. Koletzko¹¹, S. Kugathasan¹², J. Markowitz¹³, F. Ruemmele¹⁴, G. Veerman¹⁵, H. Winter¹⁶, N. Masel¹⁷, K. Tang¹⁸, M. Thayu¹⁸ ¹Mount Sinai, Icahn School of Medicine, New York, United States, ²Connecticut Children's Medical Center, Hartford, United States, ³The Children's Hospital of Philadelphia, Philadelphia, United States, ⁴University of Vermont Children's Hospital, Burlington, United States, ⁵Sapienza University of Rome/University Hospital, Rome, Italy, ⁶Erasmus Mc-Sophia Children's Hospital, Rotterdam, Netherlands, ⁷Mayo Clinic, Rochester, United States, ⁸Chelsea and Westminster Hospital, London, United Kingdom, ⁹Children's Center for Digestive Health Care, Atlanta, United States, ¹⁰Hospital for Sick Children, University of Toronto, Department of Paediatrics, Toronto, Canada, ¹¹Ludwig Maximilians Universität München, Munich, Germany, ¹²Emory University, Atlanta, United States, ¹³Cohen Children's Medical Center of New York, New York, United States, ¹⁴Hôpital Necker-Enfants Malades, Paris, France, ¹⁵Universitair Ziekenhuis, Brussels, Belgium, ¹⁶MassGeneral Hospital for Children, Boston, United States, ¹⁷DOCS, Durham, United States, ¹⁸Janssen Scientific Affairs, LLC, Horsham, United States</p>
18:47 - 18:54	<p>DOP079: Predictors of first neoplastic colonic lesion in patients with Inflammatory Bowel Disease undergoing colonoscopic surveillance J. Kirchgerner¹, M. Svrcek², C. Landman¹, A. Bourrier¹, I. Nion-Larmurier¹, H. Sokol¹, J. Cosnes¹, J.-F. Flejou², L. Beaugerie¹ ¹Saint-Antoine Hospital, AP-HP, Gastroenterology, Paris, France, ²Saint-Antoine Hospital, AP-HP, Pathology, Paris, France</p>

Friday, March 18, 2016, cont.

18:54 - 19:01	<p>DOP080: Final results of a randomised study comparing high definition colonoscopy alone with high definition dye spraying and electronic virtual chromoendoscopy using iSCAN for detection of colonic neoplastic lesions during IBD surveillance colonoscopy M. Iacucci¹, M. Fort Gasia¹, A. Oluseyi¹, R. Panaccione¹, S. Gui X², S. Urbanski³, P. Minoo³, S. Ghosh¹ ¹University of Calgary, Gastroenterology, Calgary, Canada, ²University of Calgary, Pathology, Calgary, Canada, ³University of Calgary, Calgary, Canada</p>
19:01 - 19:08	<p>DOP081: Outcomes of colitis-associated dysplasia after referral from the community to a tertiary centre D. Rubin, N. Krugliak Cleveland, D. Rodriguez University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, United States</p>

<p>Digital Oral Presentation Session 10 - Biomarker discovery in IBD Room G106-G107, Level 1 Jonas Halfvarson, Örebro, Sweden Charlie Lees, Edinburgh, United Kingdom</p>	
18:05 - 19:05	<p>DOP082: PEA immunoassay technology identifies novel serum biomarkers that can diagnose and classify Inflammatory Bowel Diseases: IBD Character Consortium R. Kalla¹, A. Ocklind², C. Petré³, N. Nordberg², N. Kennedy¹, N. Ventham¹, E. Pettersson², D. Bergemalm³, J. Lindström⁴, S. Vatn⁴, H. Hjortswang⁵, E. Nimmo¹, H. Drummond¹, P. Ricanek⁶, F. Dahl⁴, D. Wilson¹, J. Jahnsen⁴, F. Gomollón⁷, M. Pierik⁸, J. Söderholm⁹, M. Vatn⁴, J. Halfvarson³, on behalf of the IBD Character Consortium¹, J. Satsangi¹ ¹University of Edinburgh, Gastroenterology, Edinburgh, United Kingdom, ²Olink, Bioscience, Uppsala, Sweden, ³Örebro University, Department of Gastroenterology, Faculty of Medicine and Health, Örebro, Sweden, ⁴Oslo University Hospital, Department of Gastroenterology, Oslo, Norway, ⁵Linköping University Hospital, Department of Gastroenterology, Linköping, Sweden, ⁶Akershus University Hospital, Department of Gastroenterology, Lorenskog, Norway, ⁷University of Zaragoza, Gastroenterology, Zaragoza, Spain, ⁸Maastricht University Medical Center (MUMC), Department of Gastroenterology and Hepatology, Maastricht, Netherlands, ⁹Linköping University Hospital, Department of Surgery, Linköping, Sweden</p>
18:12 - 18:19	<p>DOP083: Faecal calprotectin improves the predictive power of 3 practical indices for mucosal healing among patients with Crohn's Disease: Results from PREDICT W. Sandborn¹, R. Panaccione², J.-F. Colombel³, E. Louis⁴, A. Robinson⁵, K. Wallace⁵, M. Bereswill⁶, M. Shapiro⁵, N. Chen⁵, M. Skup⁵, S. Wang⁵, R. Thakkar⁵, J. Chao⁵ ¹University of California, San Diego, La Jolla, United States, ²University of Calgary, Medicine, Calgary, Canada, ³Centre Hospitalier Universitaire de Lille, Lille, France, ⁴University of Liège, Liège, Belgium, ⁵AbbVie Inc, North Chicago, United States, ⁶AbbVie Deutschland GmbH & Co. KG, Ludwigshafen, Germany</p>
18:19 - 18:26	<p>DOP084: Identification of a potential new prognostic biomarker to select IBD patients that fail standard therapy M.S. Pereira¹, S. Campos¹, A.M. Dias¹, I. Pedroto², C.A. Reis^{1,3}, L. Maia², R. Marcos-Pinto^{2,3}, P. Lago², S.S. Pinho^{1,3} ¹Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP) & Institute for Research and Innovation in Health (i3S), Porto, Portugal, ²Centro Hospitalar do Porto, Department of Gastroenterology, Porto, Portugal, ³Institute of Biomedical Sciences of Abel Salazar (ICBAS), University of Porto, Porto, Portugal</p>

Friday, March 18, 2016, cont.

18:26 - 18:33	<p>DOP085: Ileocolonic involvement and diagnosis is related to fragments of the extracellular matrix measured in serum of patients with Crohn's Disease J.H. Mortensen¹, M.D. Jensen², J. Kjeldsen², A. Krag², M. Karsdal¹, A.-C. Bay-Jensen¹</p> <p>¹Nordic Bioscience, Biomarkers & Research, Herlev, Denmark, ²Odense University Hospital, Department of Gastroenterology, Odense, Denmark</p>
18:33 - 18:40	<p>DOP086: Faecal chitinase 3-like 1 is a reliable marker as accurate as faecal calprotectin in detecting endoscopic activity in adult patients with Inflammatory Bowel Diseases A. Buisson^{1,2}, E. Vazeille^{1,2}, R. Minet Quinard³, M. Goutte^{1,2}, D. Bouvier³, F. Goutorbe¹, B. Pereira⁴, N. Barnich², G. Bommelaer^{1,2}</p> <p>¹University Hospital Estaing, Gastroenterology Department, Clermont-Ferrand, France, ²UMR 1071 Inserm/Université d'Auvergne, USC-INRA 2018, Microbes, Intestine, Inflammation and Susceptibility of the host, Clermont-Ferrand, France, ³University Hospital G. Montpied, Biochemistry Laboratory, Clermont-Ferrand, France, ⁴GM – Clermont-Ferrand University and Medical Center, Biostatistics Unit, Clermont-Ferrand, France</p>
18:40 - 18:47	<p>DOP087: MMP degraded type III collagen is a novel serological biomarker for penetrating (Montreal B3) Crohn's Disease W.T. van Haaften^{1,2}, J.H. Mortensen³, M.A. Karsdal³, A.-C. Bay-Jensen³, G. Dijkstra², P. Olinga¹</p> <p>¹University of Groningen, Department of Pharmaceutical Technology and Biopharmacy, Groningen, Netherlands, ²University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, Netherlands, ³Nordic Bioscience, Biomarkers and Research, Herlev, Denmark</p>
18:47 - 18:54	<p>DOP088: Inflammatory biomarkers in serum discriminate Crohn's Disease and Ulcerative Colitis from healthy controls E. Andersson¹, D. Bergemalm¹, R. Kruse¹, M. D'Amato², D. Repsilber¹, J. Halfvarson¹</p> <p>¹Örebro University, Faculty of Medicine and Health, Örebro, Sweden, ²Karolinska Institutet, Department of Medicine, Solna, Sweden</p>
18:54 - 19:01	<p>DOP089: Microbiota profiles in treatment naïve Norwegian IBD and non-IBD patients. Part of the EU IBD character consortium P. Ricanek¹, S. Vatn¹, T. Lindahl², E. Cierniejewska², J. Jahnsen¹, C. Casen², M.H. Vatn¹</p> <p>¹Akershus University Hospital, Department of Gastroenterology, Lørenskog/Nordbyhagen, Norway, ²Genetic Analysis AS, Oslo, Norway</p>
19:01 - 19:08	<p>DOP090: The role of the microbiome in clinical response to golimumab in Ulcerative Colitis C. Monast¹, S. Telesco, K. Li, K. Hayden, C. Brodmerkel</p> <p>Janssen R & D, LLC, Spring House, United States</p>



European
Crohn's and Colitis
Organisation

New ECCO Guidelines & Topical Reviews



Stay tuned with JCC online 2016!

ECCO Guidelines

- ECCO Extra-Intestinal Manifestations Consensus
- ECCO Crohn's Disease Consensus Update
- ECCO-ESCP Consensus on Surgery in CD

ECCO Topical Reviews

- Fibrostenosing Crohn's Disease
- IBD in Elderly
- Environmental Factors in IBD
- Research Gaps in Diet in IBD

ECCO is looking forward to your visit to JCC online, which also provides free access to all Guidelines publications!

Marcus Harbord
ECCO GuiCom Chair

Laurence Egan
JCC Editor-in-Chief

Scan and contact the ECCO Office
www.ecco-ibd.eu



Basic Science

■ P001

Comparison of in vivo T cell homing to the inflamed gut with the etrolizumab surrogate antibody FIB504 and vedolizumab in a humanised mouse model

S. Zundler, A. Fischer, R. Atreya, C. Neufert, I. Atreya, M.F. Neurath
University of Erlangen-Nuremberg, Department of Medicine I, Erlangen, Germany

■ P002

Beneficial effects of blocking EphBs-ephrinBs forward signalling in a murine Crohn's Disease (CD) model

A. Grandi, I. Zini, M. Tognolini, V. Ballabeni, E. Barocelli, **S. Bertoni**
University of Parma, Department of Pharmacy, Parma, Italy

■ P003

Activation of ER stress in the intestinal mucosa of Crohn's Disease patients

A. Coope, J.D. Botezelli, M.L.S. Ayrizono, L.A. Velloso, R.F. Leal
University of Campinas, Coloproctology Unit, Surgery Department, Campinas, Brazil and others

■ P004

Exon-level microarrays identify alternative splicing for ICAM3 in Crohn's Disease

S. Verstockt, M. Vancamelbeke, B. Verstockt, F. Schuit, M. Ferrante, S. Vermeire, I. Cleynen, I. Arijis
KU Leuven, Department of Human Genetics, Leuven, Belgium and others

■ P005

Variability in vedolizumab exposure between patients with Inflammatory Bowel Disease

A. Gils, **E. Dreesen**, M. Peeters, E. Brouwers, M. Ferrante, G. Van Assche, S. Vermeire
KU Leuven, Department of Pharmaceutical and Pharmacological Sciences, Leuven, Belgium and others

■ P006

Correlation of small intestinal permeability, faecal calprotectin and barrier genes in multiple-affected families with Inflammatory Bowel Disease

M. Vancamelbeke, V. Ballet, A. Luybaerts, T. Vanuytsel, M. Ferrante, R. Farré, K. Verbeke, S. Vermeire, I. Cleynen
University Hospitals Leuven - KU Leuven, Department of Clinical and Experimental Medicine, Translational Research Centre for Gastrointestinal Disorders (TARGID), Leuven, Belgium and others

■ P007

IL-36 α expression is elevated in Ulcerative Colitis and promotes colonic inflammation

S.E. Russell, R.M. Horan, A.M. Stefanska, A. Carey, G. Leon, M. Aguilera, D. Statovci, T. Moran, P.G. Fallon, F. Shanahan, E.K. Brint, **S. Melgar**, S. Hussey, P.T. Walsh
Trinity College Dublin, Dublin, Ireland and others

■ P008

Targeting of TSLP by miR-31 may play an important role in mucosal healing, in Ulcerative Colitis

S. Whiteoak, A. Claridge, T. Sanchez-Elsner, J.F. Cummings
University of Southampton, Clinical and Experimental Sciences, Southampton, United Kingdom and others

■ P009

Lipid biomarkers to diagnose Crohn's Disease using metabolomic profiling approach in serum and faeces

N.S. Ding, M. Sarafian, R. Misra, P. Hendy, L. Penez, E. Holmes, A. Hart
St Mark's Hospital, IBD, London, United Kingdom and others

■ P010

Infliximab skews macrophages towards an IL10-high/IL12p40-low phenotype in an Fc region dependent manner

F. Bloemendaal, M. Wildenberg, A. Levin, P. Koelink, A.C. Vos, G. D'Haens, G. van den Brink
Academic Medical Center, Gastroenterology, Amsterdam, Netherlands and others

■ **P011**

Distinct inflammatory signatures in primary sclerosing cholangitis associated with Inflammatory Bowel Disease

A. Gwela, P. Siddhanathi, R.W. Chapman, C. Arancibia, S.P.L. Travis, F. Powrie, **A. Geremia**
John Radcliffe Hospital, Department of Translational Gastroenterology, Oxford, United Kingdom and others

■ **P012**

MAIT cell activation reflects mucosal inflammation in Ulcerative Colitis

K. Haga, A. Chiba, T. Shibuya, T. Osada, D. Ishikawa, T. Kodani, O. Nomura, S. Watanabe, S. Miyake
Juntendo University, Department of Gastroenterology, Tokyo, Japan and others

■ **P013**

Automated image analysis in the diagnosis of microscopic colitis: Validation and implications for diagnosis and research

P.J.H. Engel, L.K. Munck, U.H. Engel, S. Holck, A.-M. Kanstrup-Fiehn, M. Kristensson
Roskilde Hospital, Department of Pathology, Roskilde, Denmark and others

■ **P014**

Tofacitinib and a selective Janus Kinase 1 inhibitor are equally potent in suppressing human macrophage function and T cell proliferation

L. De Vries, M. Wildenberg, V. Ludbrook, G. D'Haens, W. De Jonge
Academic Medical Center (AMC), Gastroenterology & Hepatology, Amsterdam, Netherlands and others

■ **P015**

Interaction between enteric glia and myeloid cells as critical players in intestinal immune homeostasis

G. Govere, M. Stakenborg, M. van Winge, E. Labeeuw, G. Farro, M. Hao, P.J. Gomez Pinilla, G. Boeckstaens, G. Matteoli
KU Leuven, Department of Clinical and Experimental Medicine, Leuven, Belgium

■ **P016**

Guggulsterone ameliorates colitis by suppressing TREM-1 hyperactivation and modulating macrophage phenotypes

X. Che, K.C. Park, S.J. Park, Y.H. Kang, H.A. Jin, D.H. Seo, S.W. Kim, T.I. Kim, W.H. Kim, J.H. Cheon
Yonsei University, Internal Medicine and Institute of Gastroenterology, Seoul, South Korea and others

■ **P017**

Periostin aggravates the development of colitis-associated colon cancer in mice

S.-J. Koh, J.W. Kim, B.G. Kim, K.L. Lee, J.S. Kim
Seoul National University Boramae Hospital, Seoul National University College of Medicine, Internal Medicine, Seoul, South Korea and others

■ **P018**

Biologic functions between non-affected and affected margins of ileum samples from Crohn's Disease patients who will develop post-surgical recurrence

V. Loren, A. Garcia-Jaraquemada, A. Aterido, F. Kamberovic, A. Julià, Y. Zabana, A. Alonso, M. Mañosa, S. Marsal, E. Domènech, E. Cabré, J. Manyé
Health Sciences Research Institute of the "Germans Trias i Pujol" Foundation (IGTP), Inflammatory Bowel Disease Unit, Badalona, Spain and others

■ **P019**

Informing Ulcerative Colitis pathophysiology and outcomes through metabolic profiling

S. Fong, C. Le Roy, J. Sanderson, S. Claus
Guy's and St Thomas' NHS Foundation Trust, IBD Centre, London, United Kingdom and others

■ **P020**

The efficacy of tofacitinib and a selective Janus Kinase 1 inhibitor in dextran sulphate sodium colitis models

L. De Vries, F. van Leeuwen-Hilbers, P. van Hamersveld, V. Ludbrook, G. D'Haens, W. De Jonge
Academic Medical Center (AMC), Gastroenterology & Hepatology, Amsterdam, Netherlands and others

■ **P021**

Inflammatory monocytes are key regulators of colonic inflammation in murine and human IBD

G.-R. Jones, P. Cook, A. MacDonald, T. Fenton, A. Kelly, M. Travis, S. Campbell
University of Edinburgh, Gastroenterology, Edinburgh, United Kingdom and others

■ **P022**

Parthenolide enhances the efficacy of anti-tumour effect of balsalazide in human colon cancer cells and colitis associated colorectal cancer by blockade of NF- κ B activation

G.S. Seo, S.-L. Kim, **S.W. Kim**
Wonkwang University College of Medicine, Internal Medicine, Iksan, South Korea and others

■ **P023**

Development of methods to investigate effects of narrow spectrum kinase inhibitors on cellular phosphorylation of kinase substrates

S. Sirohi, M. Foster, M. Fyfe, Y. Solanke, S. Webber, C. Walshe
Topivert Pharma, London, United Kingdom

■ **P024**

Therapeutic potential of the human amniotic fluid mesenchymal stem cells/stroma cells secreted molecules in a mice model of colitis

M. Gazouli, E. Legaki, M. Roubelakis, A. Lazaris, G. Karamanolis, E. Marinos, G. Theodoropoulos
School of Medicine, University of Athens, Biology, Athens, Greece and others

■ **P025**

Tonsil-derived mesenchymal stem cell ameliorate intestinal fibrosis in chronic murine colitis model

E.M. Song, S.-A. Jung, S.-E. Kim, K.E. Lee, J.Y. Chang, H.M. Son, M.S. Ryu, Y.H. Joo, C.H. Tae, C.M. Moon, H.-K. Jung, K.-N. Shim, I.H. Jo, Y.S. Yu
Ewha Womans University School of Medicine, Department of Internal Medicine, Ewha Medical Research Institute, Seoul, South Korea and others

■ **P026**

Characterisation of mucosal CD4+ T cells in peripheral blood of healthy controls and paediatric Inflammatory Bowel Disease patients

M. Joosse, C. Menckeberg, L. de Ruyter, H. Raatgeep, L. van Berkel, F. Muskens, R. Hendriks, R. Hoogenboezem, T. Cupedo, L. de Ridder, H. Escher, S. Veenbergen, J. Samsom
Erasmus MC, Laboratory of Paediatrics, Division of Gastroenterology and Nutrition, Rotterdam, Netherlands and others

■ **P027**

Characterisation of human intestinal dendritic cells and macrophages through the lower gastrointestinal tract

T. Bernardo, A.C. Marin, P. M Linares, M. Jiménez, M. Chaparro, J.P. Gisbert
Hospital Universitario de La Princesa, IIS-IP and CIBERehd, Gastroenterology Unit, Madrid, Spain

■ **P028**

Inflammatory Bowel Disease is associated with cytoskeleton rearrangement in the epithelial cells

A. Portyanko, P. Perevoschikov, K. Ruksha, **J. Gorgun**
Belarusian State Medical University, Department of Pathology, Minsk, Belarus and others

■ **P029**

Intestinal mesenchymal-specific IKK2 promotes initiation of colitis and colitis-associated cancer

V. Koliaraki, M. Pasparakis, G. Kollias
BSRC "Alexander Fleming", Vari, Greece and others

■ **P030**

Development of small bowel tissue phantom for microultrasound (μ US) investigation

T. Anbarasan, C.E.M. Démoré, H. Lay, M.R.S. Sunoqrot, R. Poltarjonoks, S. Cochran, B.F. Cox
University of Dundee, Dundee, United Kingdom and others

■ **P031**

STAT6 deficiency alters macrophage polarisation and promotes fibrosis in a murine model of chronic inflammation

P. Salvador, D. Ortiz-Masiá, D.C. Macias-Ceja, J. Cosín-Roger, L. Gisbert-Ferrándiz, C. Hernández, S. Calatayud, M.D. Barrachina-Sancho
University of Valencia, Valencia, Spain and others

■ **P032**

IFN- γ controls the immunomodulatory properties of bone marrow mesenchymal stem cells via a microRNA29a/STAT-3 dependent mechanism

A. Oikonomopoulos, P. Lacey, T. Tomakili, D. Iliopoulos, D.W. Hommes
UCLA Center for Inflammatory Bowel Diseases, Division of Digestive Diseases, Los Angeles, United States and others

■ **P033**

Anti-TNF- α therapy normalises aberrant cytokine production and homing profile of circulating dendritic cells in Crohn's Disease

P. Hendy, D. Reddi, D. Bernardo, L. Durant, A. Noble, N. English, S. Knight, A. Hart
St Mark's Hospital, Gastroenterology, London, United Kingdom and others

■ **P034**

Immunoregulatory properties of human adipose derived stem cells in inflammatory diseases. Differences between Crohn's Disease and obesity

C. Serena, N. Keiran, M. Millan, M. Ejarque, R. Fradera, E. Espin, K. Roche, J. Vendrell, S. Fernandez-Veledo
Health Institute Pere Virgili, Research Unit, Tarragona, Spain and others

■ **P035**

Lamina propria CD4+LAP+ Foxp3- regulatory cells are involved in limiting the disease extension in Ulcerative Colitis

A. Butera, A. Amendola, M. Sanchez, S. Piroli, A. Pronio, D. De Nitto, R. Pica, **M. Boirivant**
Istituto Superiore di Sanità, Department of Infectious, Parasitic and Immune-mediated Diseases, Roma, Italy and others

■ **P036**

Colon targeted delivery of tofacitinib inhibits oxazolone-induced colitis in mice, despite low systemic exposure

F. Shen, P. Brassil, S. Hegde, D. Beattie
Theravance Biopharma, South San Francisco, United States

■ **P037**

Remodelling events preceding clinical onset of intestinal inflammation reveal the predictive power of the extracellular matrix

E. Shimshoni, R. Afik, L. Puricelli, A. Shenoy, T. Geiger, A. Podestà, I. Sagi
Weizmann Institute of Science, Biological Regulation, Rehovot, Israel and others

■ **P038**

Revised roles of matrix metalloproteinase/MMP-9 in Inflammatory Bowel Diseases/IBD: From target to biomarker

M. de Bruyn, C. Breynaert, I. Arijs, G. De Hertogh, K. Geboes, G. Thijs, J. Hu, J. Van Damme, B. Arnold, M. Ferrante, S. Vermeire, G. Van Assche, J. Ceuppens, G. Opdenakker
Rega Institute for Medical Research, KU Leuven, Department of Microbiology and Immunology, Leuven, Belgium and others

■ **P039**

Expression of the liver homing receptor CXCR3+ on colonic CD8+ T lymphocytes in patients with primary sclerosing cholangitis provides a possible link between colonic and biliary duct inflammation

M. Lampinen, A. Fredricsson, J. Vessby, A. Wanders, F. Rorsman, M. Carlsson
Uppsala University, Medical Sciences, Uppsala, Sweden and others

■ **P040**

Sonic hedgehog inhibitor prevented colitis-associated cancer via concerted mechanisms of IL-6/gp130 inhibition, 15-prostaglandin dehydrogenase induction, Bcl-2 abrogation, and tumorsphere inhibition

K.B. Hahm, N. Kangwan, Y.J. Kim

CHA University, Gastroenterology, Seongnam, South Korea and others

■ **P041**

Automated image analysis as a diagnostic tool in discriminating between subgroups of microscopic colitis

A.-M. Kanstrup-Fiehn, M. Kristensson, U.H. Engel, L.K. Munck, S. Holck, **P.J.H. Engel**

Roskilde Hospital, Department of Pathology, Roskilde, Denmark and others

■ **P042**

Circulating IL9 in Inflammatory Bowel Disease: Possible marker of mucosal non-healing?

K. Neubauer, M. Krzystek-Korpacka, M. Matusiewicz, M. Zawadzki, I. Bednarz-Misa, S. Górska, W. Witkiewicz, A. Gamian

Wroclaw Medical University, Gastroenterology and Hepatology, Wroclaw, Poland and others

■ **P043**

Inhibition of miR-142-5P ameliorates disease in mouse models of experimental colitis

N. Duijvis, C. Kunne, M. Slaman, F. van Dooren, E. Vogels, S. Meijer, K. Fluiter, P. Moerland, A. te Velde
Academic Medical Center (AMC), Tytgat Institute for Liver and Intestinal Research, Amsterdam, Netherlands and others

■ **P044**

Roles of IL-33 on murine colitis and M2 macrophage differentiation in Inflammatory Bowel Diseases

D.H. Seo, M.S. Kawk, X. Che, H.W. Ma, J.H. Kim, D.H. Kim, T.I. Kim, W.H. Kim, S.W. Kim, J.H. Cheon

Yonsei University, Department of Internal Medicine and Institute of Gastroenterology, College of Medicine, Seoul, South Korea and others

■ **P045**

The relationship between thiol/disulphide and Inflammatory Bowel Disease

H. Akinci, Y. Coskun, O. Erel, M. Hamamci, F. Karaahmet, S. Kilincalp, M. Alisik, I. Yuksel

Diskapi Yildirim Beyazit Education and Research Hospital, Gastroenterology, Ankara, Turkey and others

■ **P046**

Therapeutic effects of mouse bone marrow-derived single clonal mesenchymal stem cells (mMSCs) in a mouse model of Inflammatory Bowel Disease

K.B. Hahm, S.U. Song, S.H. Park

CHA University, Gastroenterology, Seongnam, South Korea and others

■ **P047**

Enterocytes and dendritic cells both contribute to the intestinal inflammation in paediatric Inflammatory Bowel Diseases

C. Strisciuglio, S. Vitale, L. Pisapia, E. Miele, P. Barba, A. Vitale, S. Cenni, G. Del Pozzo, R. Troncone, A. Staiano, C. Gianfrani

Second University of Naples, Department of Woman, Child and General and Specialized Surgery, Naples, Italy and others

■ **P048**

Cigarette smoke impairs intestinal epithelial cell polarity development and morphogenesis

L.J. Klunder, T. Blokzijl, R. Ferreira, K.-N. Faber, G. Dijkstra, S.C.D. van Ijzendoorn

University Medical Center Groningen, Department of Cell Biology, Groningen, Netherlands and others

■ **P049**

Prevalence and factors associated with vitamin D deficiency in patients with Inflammatory Bowel Disease on biologic therapies

K. Sugrue, D. Fitzgerald, M. Buckley, J. McCarthy, **D. Farrell**

Mercury University Hospital, Department of Gastroenterology, Cork, Ireland

■ **P050**

Proinflammatory action of 5-HT in colon epithelial cell response to gut bacteria through NOX2 induction

J.-A. Kim, S. Banskota, S. Regmi, P. Grung, B.-S. Jeong, H.W. Chang
Yeungnam University, College of Pharmacy, Gyeongsan, South Korea

■ **P051**

Chemokines CXCL17, CCL20 and CXCR5 receptor are over-expressed in the colonic mucosa from patients with active Ulcerative Colitis: CXCL17 is a potential marker of histological remission

J. Yamamoto-Furusho, E. Iturriaga-Goyon, G. Fonseca-Camarillo
IBD Clinic, Instituto Nacional de Ciencias Medicas y Nutricion, Gastroenterology, Mexico, Mexico and others

■ **P052**

Intestinal total bacteria concentration and translocation of bacteria in Inflammatory Bowel Disease

S. Vrakas, **M. Gazouli**, K. Mountzouris, G. Michalopoulos, G. Karamanolis, G. Papatheodoridis, C. Tzathas
Tzaneion General Hospital, Gastroenterology Department, Piraeus, Greece and others

■ **P053**

Histological and immunohistochemical indicators of progression towards malignancy in Ulcerative Colitis

C. Popp, G. Micu, M. Cioplea, L. Sticlaru, G. Pop, B. Mateescu, F. Staniceanu, S. Zurac, L. Nichita
Colentina University Hospital, Pathology, Bucuresti, Romania and others

■ **P054**

Soluble GPVI is raised in patients with Inflammatory Bowel Disease and anaemia

S.J. Montague, **A. Chauhan**, E.E. Gardiner, R.K. Andrews, S.P. Watson, T. Iqbal
Institute of Biomedical Research, University of Birmingham, Centre for Cardiovascular Sciences, College of Medical and Dental Sciences, Birmingham, United Kingdom and others

■ **P055**

Galectin-3 plays protective roles in intestinal Behçet's disease

J.H. Kim, H.J. Lee, H.W. Ma, D.H. Seo, X. Che, D.H. Kim, S.W. Kim, J.H. Cheon
Yonsei University College of Medicine, Department of Internal Medicine and Institute of Gastroenterology, Seoul, South Korea and others

■ **P056**

Evaluation of oxidative stress in experimental model of Crohn's Disease under hyperbaric oxygen treatment

F.S. Nakutis, I. Nishitokukado, F.M.D. Santos, C. Ortiz-Agostinho, V.S. Nunes, A. Zonetti, **A. Sipahi**
Faculdade de Medicina da USP, Gastroenterologia Lim07, São Paulo, Brazil and others

■ **P057**

HLA B27 transgenic rat: A new animal model of postsurgical ileitis in Inflammatory Bowel Disease

A. Chau, C. Chater, S. Speca, M. Djouina, C. Dubuquoy, L. Dubuquoy, C. Neut, D. Koriche, P. Zerbib, F.R. Pruvot, P. Desreumaux, B. Pariente
Lille University North of France, INSERM U995, Department of Digestive Surgery and Transplantation, CHRU Lille, Lille, France and others

■ **P058**

Bacterial activation of thioguanine results in lymphocyte independent improvement in murine colitis

I. Oancea, I. Das, D. Aguirre de Cárcer, R. Movva, V. Schreiber, Y. Yang, M. Proctor, R. Wang, Y. Sheng, M. Lobb, P. Ó Cuiv, J.A. Duley, **J. Begun**, T.H.J. Florin
University of Queensland, Mater Research Institute, Brisbane, Australia and others

■ **P059**

Two new genetic mouse models for Ulcerative Colitis based on lateral tight junction disruption

W. Stremmel, S. Staffer, M. Schneider, H. Gan-Schreier, A. Wannhoff, A. Gauss, H. Wolburg, M. Bach, A. Swidsinski, T. Efferth
University Hospital of Heidelberg, Internal Medicine IV, Department of Gastroenterology, Heidelberg, Germany and others

■ **P060**

Alterations of brain structure in Crohn's Disease with extraintestinal manifestations

A. Thomann, W. Reindl, P. Thomann, C. Wolf, D. Hirjak, M. Griebel
Universitätsmedizin Mannheim, Department of Medicine II, Mannheim, Germany and others

■ **P061**

Creeping fat contains a unique T-cell compartment with potential impact on intestinal inflammation

L.I. Kredel, L.J. Jödicke, A.A. Kuehl, I. Freise, J. Gröne, B. Siegmund
Charité Universitätsmedizin Berlin, Campus Benjamin Franklin, Gastroenterology, Infectiology and Rheumatology, Berlin, Germany and others

■ **P062**

Critical role of the IL-33/ST2 axis in colitis-associated colorectal cancer

L.R. Lopetuso, C. De Salvo, L. Di Martino, W. Goodman, F. Scaldaferrì, A. Gasbarrini, T.T. Pizarro
Catholic University of the Sacred Heart, Internal Medicine, Gastroenterology Division, Rome, Italy and others

■ **P063**

Dissecting the role of rage in intestinal fibrosis

S. Speca, M. Body-Malapel, C. Fradin, M. Djouina, E. Boulanger, A.-M. Schmidt, P. Desreumaux, C. Vignal
Centre Hospitalier Régional Universitaire de Lille, Lille, France and others

■ **P064**

TOP1210 NSKI demonstrates superior activity and improved safety profile potential compared to corticosteroid and immunomodulators in preclinical models of colitis

C.A. Walshe, A. Rowley, M.R. Foster, Y. Solanke, S. Sirohi, M.C. Fyfe, S. Webber
Topivert Pharma Ltd, London, United Kingdom

■ **P065**

Molecular landscape of early Crohn's Disease using an integrated approach of mRNA/miRNA profiling and genomics

S. Verstockt, J. Van der Goten, M. Vancamelbeke, B. Verstockt, F. Schuit, P. Rutgeerts, M. Ferrante, S. Vermeire, I. Arijis, I. Cleynen
KU Leuven, Department of Human Genetics, Leuven, Belgium and others

■ **P066**

CCR2-monocytes are essential for the resolution of inflammation and tissue repair in colitis

M. Stakenborg, G. Goverse, G. Farro, P.J. Gomez-Pinilla, G.E. Boeckxstaens, **G. Matteoli**
KU Leuven, Department of Clinical and Experimental Medicine, Leuven, Belgium

■ **P067**

Angiogenic characterisation of Crohn's Disease mesenteric adipose tissue

M. Eddama, R. Cohen, M. Rodriguez-Justo, I. Evans, L. Shen, L. Clapp, M. Loizidou
University College London Hospital, Colorectal Surgery, London, United Kingdom and others

■ **P068**

Anti-fibrotic therapy for Crohn's Disease: In vitro proof of concept with a selective ROCK2 inhibitor, LYC-53976, in the treatment of human intestinal myofibroblasts in stiffness and transforming growth factor β models

E. Rodansky, X. Liu, L.A. Johnson, K. Demock, A.J. Celeste, L.L. Carter, **P.D.R. Higgins**
University of Michigan, Internal Medicine - Gastroenterology, Ann Arbor, Michigan, United States and others

■ **P069**

TD-1473, a novel, potent, and orally administered, GI-targeted, pan-Janus kinase (JAK) inhibitor

D. Beattie, P. Tsuruda, F. Shen, P. Brassil, C. Langrish, J. Janc, Z. Ren, R. Hudson, J. Smith, S. Hegde
Theravance Biopharma, South San Francisco, United States

■ **P070**

The influence of vitamin D on M1 and M2 macrophages in patients with Crohn's Disease

E. Seidman, S. Dionne
Research Institute of the McGill University Hospital, Gastroenterology, Montreal, Canada

■ **P071**

Improvement of experimental mouse models in Inflammatory Bowel Diseases using flexible video endoscopic colon evaluation

C. Gay, O. Martin Rodriguez, A. Daoui, S. Koch, P. Saas, S. Valmary Degano, S. Perruche, L. Vuitton
CHU Jean Minjoz, Gastroenterology, Besançon, France and others

■ **P072**

TREM-1 stimulation ameliorates colitis in mice

H.W. Ma, X. Che, D.H. Seo, J.H. Kim, D.H. Kim, T.I. Kim, W.H. Kim, S.W. Kim, J.H. Cheon
Yonsei University College of Medicine, Department of Internal Medicine and Institute of Gastroenterology, Seoul, South Korea and others

■ **P073**

TNF-alpha activity in plasma from patients with Inflammatory Bowel Disease under adalimumab and infliximab treatment evaluated in a cell-based assay

P. M Linares, H. De la Fuente, M. Chaparro, I. Guerra, P.L. Majano, M. Iborra, J.L. Cabriada, L. Bujanda, M. Barreiro-de Acosta, V. García-Sánchez, I. Marín-Jiménez, D. Bernardo, J.P. Gisbert
Hospital Universitario de La Princesa, IIS-IP and CIBERehd, Gastroenterology Unit, Madrid, Spain and others

■ **P074**

Association of colonic mucosal infiltration of IgG4 plasma cells with Ulcerative Colitis activity and presence of primary sclerosing cholangitis

F. Alborzi, Z. Azizi, N. Ebrahimi Daryani, F. Azmude Ardalan, N. Aletaha, R. Taslimi, N. Roshan
Tehran University of Medical Science, Gastroenterology, Tehran, Iran, Islamic Republic of and others

■ **P075**

Innate immunity in Inflammatory Bowel Disease and colon cancer

E. Lo Presti, R. Di Mitri, F. Dieli, F. Mocciaro, G. Pecoraro, G. Russo, S. Meraviglia
University of Palermo, Central Laboratory of Advanced Diagnosis & Biomedical Research (CLADIBIOR), Department of Biopathology, Palermo, Italy and others

■ **P076**

The role for T cells in the pathogenesis of Crohn's Disease-associated fistulae

R. Bruckner, M. Spalinger, G. Rogler, M. Scharl
University Hospital Zurich, Gastroenterology and Hepatology, Zurich, Switzerland

■ **P077**

The efficacy of tyrosine kinase inhibitor dasatinib on colonic mucosal damage in murine model of colitis

G. Can, S. Ayvaz, H. Can, I. Karaboğa, S. Demirtaş, H. Akşit, B. Yılmaz, U. Korkmaz, M. Kurt, T. Karaca
Abant İzzet Baysal University, Faculty of Medicine, Department of Gastroenterology, Bolu, Turkey and others

■ **P078**

Walnut extract ameliorates acute and chronic colitis in murine models of colitis

S.-J. Koh, K.L. Lee, J.W. Kim, B.G. Kim, Y.J. Jung
Seoul National University Boramae Hospital, Seoul National University College of Medicine, Internal Medicine, Seoul, South Korea

■ **P079**

Trehalose ameliorates colitis by increasing mucosal autophagy and M2 polarisation

J. Cosin-Roger, D. Ortiz-Masia, D.C. Macias-Ceja, P. Salvador, L. Gisbert-Ferrandiz, C. Hernandez, S. Calatayud, M.D. Barrachina
University of Valencia, Valencia, Spain and others

■ **P080**

Modulation of T cell glycosylation and the control of intestinal inflammation

A. M. Dias, A. Correia, M. Pereira, C. R. Almeida, M. Lima, R. Marcos-Pinto, M. Vilanova, C. A. Reis, P. Lago, S. S. Pinho
Institute of Molecular Pathology and Immunology of the University of Porto (IPATIMUP) & i3S – Instituto de Investigação e Inovação em Saúde, Glycobiology in Cancer, Porto, Portugal and others

■ **P081**

Evaluation of intestinal permeability with a triple sugar test in Inflammatory Bowel Disease

D. Mukhametova, **D. Abdulganieva**, S. Koshkin, S. Abdulhakov, A. Odintsova
Kazan State Medical University, Kazan, Russian Federation and others

■ **P082**

Anti TNF-alpha therapy and apoptosis

R. Zaharie, F. Zaharie, **A. Tantau**, B. Petrushev, M. Tantau
University of Medicine and Pharmacy, 3rd Medical Clinic, Cluj-Napoca, Romania and others

■ **P083**

Intestinal fatty acid binding protein as a biomarker of intestinal damage in children with coeliac and Crohn's Disease

C.M. Clark, A. Kountouri, M. MacKinder, R. Hansen, R.K. Russell, K. Gerasimidis
University of Glasgow, Human Nutrition, School of Medicine, Glasgow, United Kingdom and others

■ **P084**

Intestinal organoids derived from patients with Inflammatory Bowel Disease show unaltered transcriptional profiles when compared to healthy controls

M. Noben, N. Hendriks, G. Van Assche, S. Vermeire, C. Verfaillie, M. Ferrante
KU Leuven, Translational Research Center for Gastrointestinal Disorders (Targid), Leuven, Belgium and others

■ **P085**

Altered proportions of myeloid and plasmacytoid dendritic Cells in children with Inflammatory Bowel Disease

M.F. Elshal, A.M. Aldahlawi, **O.I. Saadah**, J.P. McCoy
Faculty of Sciences, King Abdulaziz University, Biochemistry Department, Jeddah, Saudi Arabia and others

■ **P086**

Glycosylation of T cells as a new molecular biomarker in Inflammatory Bowel Disease: An opportunity for new therapeutic strategies

A. M. Dias, M. Pereira, R. Marcos-Pinto, A. Correia, M. Vilanova, C. Reis, P. Lago, **S. S. Pinho**
IPATIMUP/i3S, University of Porto, Glycobiology in Cancer, Porto, Portugal and others

■ **P087**

Contributions of monocytes to gut inflammation in acute and chronic colitis models

F. Becker, F.N. Gavins, T. Vowinkel, I. Tsunoda, E. Rijcken, D.V. Ostanin, J.S. Alexander
University Hospital Muenster, Department of General and Visceral Surgery, Muenster, Germany and others

■ **P088**

Loss of intestinal desmoglein 2 promotes chemically and pathogenic induced colitis

A. Gross, L. Pack, S. Kant, C. Krusche, G. Sellge, C. Trautwein, R. Leube, P. Strnad
University Hospital Aachen, Medicine III, Aachen, Germany and others

■ **P089**

Stimulation of the ω -3 docosahexaenoic acid metabolism via MFSD2A as a novel therapy for Inflammatory Bowel Disease

F. Ungaro, C. Correale, P. Corsetto, L. Massimino, P. Fonteyne, C. Tacconi, K.R. Maddipati, A. Rizzo, S. D'Alessio, S. Danese
Humanitas Research Institute, Laboratory of Immunology in Gastroenterology, Milan, Italy and others

■ **P090**

Differences in expression of G Protein-coupled Receptor 55 (GPR55) in patients with Crohn's Disease and Ulcerative Colitis

M. Włodarczyk, A. Sobolewska-Włodarczyk, A. Cygankiewicz, D. Jacenik, W. Krajewska, K. Stec-Michalska, A. Piechota-Polanczyk, J. Fichna, M. Wisniewska-Jarosinska
Medical University of Lodz, Department of Gastroenterology, Lodz, Poland and others

■ **P091**

Sonic hedgehog inhibitor prevented colitis-associated cancer via stem inhibition

K.B. Hahm, Y.J. Kim

CHA University, Gastroenterology, Seongnam, South Korea and others

■ **P092**

Characterisation of the lymphoid stress surveillance response performed by human colon resident $\gamma\delta$ T cells

R.J. Dart, R. Woolf, P.M. Irving, A.C. Hayday

Francis Crick Institute, Immunosurveillance Lab, London, United Kingdom and others

■ **P093**

15-d-PGJ2 – a possible regulator of iron homeostasis

J. Martin, S. Ulrich-Rueckert, J. Stein

Interdisciplinary Crohn Colitis Centre Rhein-Main, Frankfurt/Main, Germany and others

■ **P094**

Human neutrophil elastase shows increased elastolytic activity in Ulcerative Colitis and contributes to loss of function of anti-TNF-alpha agents in Ulcerative Colitis

P. Giffrida, K. Kok, A. Di Sabatino, P. Biancheri, A. Vanoli, G. Mazza, R. Curciarello, A. Pasini, N. Aronico, M. Pinzani, G.R. Corazza, T.T. MacDonald

Fondazione IRCCS Policlinico San Matteo, University of Pavia, First Department of Medicine, Pavia, Italy and others

■ **P095**

Immune compromised mice develop colitis upon denervation of the superior mesenteric nerve

R. Willemze, L. Nijhuis, O. Welting, J. Folgering, H. Darwinkel, D. Chew, A. Sridhar, J. Witherington, J. Seppen, S. Heinsbroek, W. de Jonge

Academic Medical Center (AMC), Tytgat Institute for Liver and Intestinal Research, Amsterdam, Netherlands and others

■ **P096**

Low dose naltrexone reduces in vitro endoplasmic reticulum stress and stimulates wound healing in intestinal epithelial cells

G. Fuhler, M. Lie, P. Dimitrijevic, C.J. van der Woude, M. Peppelenbosch

Erasmus MC University Medical Center Rotterdam, Gastroenterology and Hepatology, Rotterdam, Netherlands

■ **P097**

MicroRNA23a is overexpressed in the colonic epithelium in Crohn's Disease

R. Felwick, G. Dingley, T. Sanchez-Elsner, J. Collins, F. Cummings

University of Southampton, Clinical and Experimental Sciences, Southampton, United Kingdom and others

■ **P098**

Anti-fibrotic effects of a novel small compound that promotes the nuclear translocation of YB-1 in a mouse model of colorectal fibrosis

J. Imai, K. Hozumi, Y. Inagaki, T. Mine

Tokai University School of Medicine, Gastroenterology, Isehara, Japan and others

■ **P099**

Inhibitory effect of 6-aminopyridin-3-ol analogs on TNF- α -induced monocyte-colon epithelial cell adhesion and TNBS-induced rat colitis

B.-S. Jeong, S. Banskota, P. Grung, T.-G. Nam, J.-A. Kim

Yeungnam University, College of Pharmacy, Gyeongsan, South Korea and others

■ **P100**

Effects of a narrow spectrum kinase inhibitor (NSKI) and selective kinase inhibitors on the intestinal pro-inflammatory immune response in Ulcerative Colitis

M.R. Foster, P. Biancheri, Y. Solanke, S. Sirohi, M.C. Fyfe, A. Rowley, T.T. MacDonald, E. Wood, S. Webber, C.A. Walshe

Topivert Pharma Ltd, London, United Kingdom and others

■ **P101**

Functional translation of IBD-associated genetic variation in patient-derived intestinal epithelial cells

W. Vanhove, K. Nys, I. Arijis, I. Cleynen, G. Van Assche, M. Ferrante, S. Vermeire
KU Leuven, Translational Research Center for Gastrointestinal Disorders (TARGID), Department of Clinical and Experimental Medicine, Leuven, Belgium and others

■ **P102**

α-Defensins(aDef) 1-3 are specific plasmatic markers for Crohn's Disease (CD) at diagnosis and tissue α-Def 5 methylation is a pathogenic mechanism for aDef-5 down regulation in CD

E. Cerrillo, I. Moret-Tatay, M. Iborra, E. Sáez-González, E. Busó, D. Ramos, L. Tortosa, P. Nos, **B. Beltrán**
Hospital Universitario La Fe, Gastroenterology, Valencia, Spain and others

■ **P103**

Selective M1 macrophage polarisation in Crohn's Disease, in comparison to intestinal tuberculosis: A novel observation

P. Das, S. Pilli, T. Kumar, R. Rampal, I.A. Khan, A.K. Singh, D. Kumar, **V. Ahuja**
All India Institute of Medical Sciences, Pathology, New Delhi, India and others

■ **P104**

Risk factors associated with the negativisation of anti-HBs antibodies in Inflammatory Bowel Disease patients

A.C. Marin, M. Chaparro, M. Ramas, R. Ribot, P. M Linares, J.R. Villagrasa, D. Bernardo, J.P. Gisbert
Hospital Universitario de La Princesa, IIS-IP and CIBERehd, Gastroenterology Unit, Madrid, Spain and others

■ **P105**

Inhibition of cytokine release from HT-29 cells and Ulcerative Colitis biopsies is potentiated by combination of selective kinase inhibitors and such effects are mimicked by TOP1210, a narrow spectrum kinase inhibitor (NSKI)

M.R. Foster, P. Biancheri, S. Sirohi, Y. Solanke, M.C. Fyfe, A. Rowley, T.T. MacDonald, E. Wood, S. Webber, C.A. Walshe
Topivert Pharma Ltd, London, United Kingdom and others

■ **P106**

Maintenance treatment with granulocyte/monocyte adsorption in patients with Inflammatory Bowel Disease and an initial response to treatment. A Swedish long term prospective registry study

A. Lindberg, S. Lindgren, M. Lördal, S. Nilsson, H. Svensson, **P. Karlen**
Department of Clinical Science, Karolinska Institutet, Danderyd Hospital, Stockholm, Sweden, Stockholm, Sweden and others

■ **P107**

IL-34 – and IL-36 family – expressing cytotoxic T cells and plasmacytoid dendritic cells are increased in patients with active IBD

G. Fonseca Camarillo, E. Iturriaga Goyon, J. Furuzawa Carballeda, J. Yamamoto Furusho
Instituto Nacional de Ciencias Médicas y Nutrición, Inflammatory Bowel Disease Clinic, Department of Gastroenterology, Mexico, Mexico and others

■ **P108**

Cytokine levels differ during pregnancy among women with Ulcerative Colitis and Crohn's Disease

V.W. Huang, N. Hotte, L. Ambrosio, K. Smith, J. Bal, R. Foshaug, K.I. Kroeker, B. Halloran, L. Dieleman, R.N. Fedorak, K. Madsen
University of Alberta, Gastroenterology, Edmonton, Canada and others

■ **P109**

Effect of dysbiosis on the growth and colitis susceptibility in DSS colitis model

C.S. Eun, D.S. Han, A.R. Lee, Y.R. Lee
Hanyang University Guri Hospital, Gastroenterology, Guri, South Korea

■ P110

Cigarette smoke modulates the effect of dextran sulfate sodium (DSS)-induced colitis on subpopulation of T cells in blood and colon in mice

J. Daniluk, U. Daniluk, M. Rusak, J. Reszec, M. Dabrowska, A. Dabrowski
Medical University of Bialystok, Department of Gastroenterology and Internal Medicine, Bialystok, Poland and others

Clinical: Diagnosis and outcome

■ P111

Differences in therapies and intestinal resection rates between adult and elderly onset Crohn's Disease

C. Alexakis, S. Saxena, V. Chhaya, E. Cecil, R. Pollok
St George's Hospital, Gastroenterology, London, United Kingdom and others

■ P112

Validation of the Simplified Geboes Score for Ulcerative Colitis

A. Jauregui-Amezaga, Y. Das, T. Lobatón, B. Lemmens, T. Bessissow, M. Ferrante, G. Van Assche, R. Bisschops, K. Geboes, G. De Hertogh, S. Vermeire
University Hospitals Leuven, Gastroenterology, Leuven, Belgium and others

■ P113

Quality of life in paediatric Crohn's Disease: Data from Imagekids study

V.M. Navas-López, J. Martín-de-Carpi, A. Grant, T.D. Walters, F. Ruemmele, D. Mack, M. Sladek, R. Shamir, R. Shaoul, S. Saeed, R.K. Russell, R. Cytter-Kuint, A. Griffiths, D. Turner, A. Otley
Paediatric Gastroenterology and Nutrition Unit., Hospital Materno Infantil, Málaga, Spain and others

■ P114

Predictors of clinical response during adalimumab therapy in Crohn's Disease patients: A German non-interventional study

I. Blumenstein, R. Atreya, G. Greger, B. Bokemeyer, P. Nurwakagari, M.F. Neurath, B. Wittig
Goethe-University Frankfurt, Gastroenterology, Frankfurt am Main, Germany and others

■ P115

Standardising assessment and documentation of pouchoscopy

V.A. van der Ploeg, **Y. Maeda**, O.D. Faiz, A.L. Hart, S.K. Clark
St Mark's Hospital, Department of Surgery, Harrow, United Kingdom and others

■ P116

Usefulness of consecutive faecal calprotectin measurements to predict relapse in Inflammatory Bowel Disease patients under maintenance treatment with anti-TNF therapy: A prospective longitudinal cohort study

R. Ferreira, M. Barreiro-de Acosta, A. Lorenzo, J.E. Dominguez-Munoz
University Hospital Santiago de Compostela, Gastroenterology, Santiago, Spain

■ P117

Comparison between calprotectin and HMGB1 as faecal biomarkers of intestinal inflammation in paediatric and adult Inflammatory Bowel Disease

F. Palone, R. Vitali, L. Stronati, R. D'Inca, A. Armuzzi, B. Barberio, C. Felice, D. Pugliese, A. Dilillo, M. Mennini, S. Cucchiara
ENEA, Department of Radiobiology and Human Health, Rome, Italy and others

■ P118

Difference of health-related quality of life (HRQoL) between East and South Asia incident Inflammatory Bowel Disease patients and factors associated with improvement of HRQoL at follow up: Analysis of an Asia-Pacific population-based cohort

H. Chan, D. Ong, Z. Zeng, W. Tang, J. Ching, K.L. Goh, I. Hilmi, P. Pisespongsa, S. Aniwani, J. Limsrivilai, J. De Silva, M. Niriella, Y.F. Wang, Ö. Qin, K. Wu, M. Abdullah, M. Simadibrata, H.H. Yu, K.K. Ng, K.L. Ling, M.H. Chen, J.J. Sung, S. Ng
Institute of Digestive Disease, The Chinese University of Hong Kong, Hong Kong, Hong Kong and others

■ P119

Diagnostic performance of different calprotectin assays

A.A. Wulandari, J. Schulz, F. Hartmann, A. Dignass, **J. Stein**
DGD Clinics Sachsenhausen, Frankfurt/Main, Germany and others

■ **P120**

Faecal calprotectin and S100A12 detect the early response to treatment by quantifying colonic inflammation in patients with Ulcerative Colitis

T. Kobayashi, T. Toyonaga, S. Kuronuma, O. Takeuchi, M. Nakano, E. Saito, S. Umeda, N. Watanabe, T. Hibi

Kitasato University Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan

■ **P121**

Patients' point of view regarding acceptability and usefulness of Inflammatory Bowel Diseases monitoring tools: Results from a nationwide multicenter study (the ACCEPT study)

A. Buissou, F. Gonzalez, F. Poullenot, S. Nancey, E. Sollellis, M. Fumery, B. Pariente, M. Flamant, A. Bourreille, G. Bonnaud, S. Mathieu, A. Thevenin, M. Duruy, J. Filippi, F. L'hopital, F. Luneau, V. Michalet, J. Genès, A. Achim, E. Cruzille, G. Bommelaer, D. Laharie, L. Peyrin-Biroulet, B. Pereira, M. Nachury, G. Bouguen

University Hospital Estaing, Gastroenterology Department, Clermont-Ferrand, France and others

■ **P122**

Role of diffusion-weighted imaging (DWI) in MRI-enterography for the evaluation of surgical risk in patients with Crohn's Disease

A. Testa, A. Rispo, P. Mainenti, D. Musto, N. Imperatore, M. Rea, O.M. Nardone, M.L. Taranto, F. Castiglione
University "Federico II" of Naples, Department of Clinical Medicine and Surgery, Naples, Italy and others

■ **P123**

Significance of serological markers in the disease course of Ulcerative Colitis

G. Kovacs, N. Sipeki, K. Palatka, I. Altorjay, K. Fechner, G.L. Norman, Z. Shums, G. Veres, P.L. Lakatos, M. Papp

University of Debrecen, Clinical Center, Department of Internal Medicine, Division of Gastroenterology, Debrecen, Hungary and others

■ **P124**

Systematic review of the impact of psychological morbidity and associated risk factors in young people with Inflammatory Bowel Disease

A.J. Brooks, G. Rowse, A. Ryder, E.J. Peach, B.M. Corfe, A.J. Lobo

Sheffield Teaching Hospitals NHS Foundation Trust, Academic Department of Gastroenterology, Sheffield, United Kingdom and others

■ **P125**

Investigating the small bowel in paediatric Crohn's Disease: Prospective comparative study between small intestine contrast ultrasonography (SICUS) and magnetic resonance imaging (MRI)

F. Civitelli, F. Maccioni, S. Oliva, M. Aloia, A. Dilillo, E. Casciani, F. Viola, S. Cucchiara

Sapienza University, Paediatric Gastroenterology and Liver Unit, Rome, Italy and others

■ **P126**

IBD-related malignancies and mortalities observed in 2015 – first results from the prospective nationwide Hungarian registry

T. Molnar, F. Nagy, P. Fitz, L. Lakatos, P. Miheller, T. Szamosi, A. Vincze, J. Banai, A. Kovács, J. Novák, A. Salamon, A. Szepes, N. Szigeti, M. Juhász, K. Müllner, O. Kadenczki, M. Rutka, A. Bálint, R. Bor, A. Milassin, Z. Szepes, K. Farkas

University of Szeged, 1st Department of Medicine, Szeged, Hungary and others

■ **P127**

Predictive role of penetrating disease behaviour, ileal localisation, female gender and plexitis in the postoperative recurrence of Crohn's Disease

A. Milassin, A. Sejben, Z. Reisz, L. Tiszlavicz, G. Lázár, R. Bor, A. Bálint, M. Rutka, Z. Szepes, K. Farkas, T. Molnár

University of Szeged, First Department of Internal Medicine, Szeged, Hungary and others

■ **P128**

Faecal calprotectin has an acceptable sensitivity for detecting small bowel Crohn's Disease: Results from real-world clinical practice

J. Wu, E. Harrison, C.S. Chey, H. Johnson, S. Weaver, S. McLaughlin

The Royal Bournemouth and Christchurch Hospitals NHS Foundation Trust, Gastroenterology, Bournemouth, United Kingdom

■ **P129**

Factors associated with anxiety and depression in Korean IBD patients

S.-K. Park, Y.S. Jung, D.I. Park

Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea

■ **P130**

Anxiety and depression may lead to poor health related quality of life in patients with Inflammatory Bowel Disease (IBD)

U. Chauhan, Y. Farbod, D. Armstrong, S.L. Halder, S. Kaasalainen, J.K. Marshall, J. Popov, F. Tse, P. Moayyedi

McMaster University Medical Centre, Digestive Disease, Hamilton, Canada and others

■ **P131**

Predicting early endoscopic recurrence after ileocolic resection for Crohn's Disease

S. Monteiro, T. Cúrdia Gonçalves, P. Boal Carvalho, M.J. Moreira, J. Cotter

Hospital da Senhora da Oliveira-Guimarães, Gastroenterology, Guimarães, Portugal and others

■ **P132**

Vitamin D status and body composition in children and adolescents

D. Mager, M. Carroll, E. Wine, C. Kluthe, P. Medvedev, M. Chen, J. Wu, J. Turner, K. Macdonald, K. Siminoski, **H. Huynh**

University of Alberta, Department of Agricultural, Food & Nutritional Science, Edmonton, Canada and others

■ **P133**

Usefulness of magnetic resonance enterography on medical decision making in patients with Inflammatory Bowel Disease after a 1 year follow-up

L. Ramos, M. Carrillo Palau, I. Alonso, **A. Hernandez Camba**, N. Hernandez Alvarez-Buylla, A. Márques, L. Goya, A. González-Palau, E. Quintero Carrion

Hospital Universitario de Canarias, Gastroenterology, La Laguna, Santa Cruz de Tenerife, Spain and others

■ **P134**

Illness perceptions and outcomes in patients with Inflammatory Bowel Disease: Is coping a mediator?

S. van Erp, L. Brakenhoff, M. Vollmann, D. van der Heijde, R. Veenendaal, H. Fidder, D. Hommes, A. Kaptein, A. van der Meulen- de Jong, M. Scharloo

Leiden University Medical Center, Gastroenterology and Hepatology, Leiden, Netherlands and others

■ **P135**

Serum Chitinase 3-like-1 (CHI3L1) and faecal calprotectin levels for non-invasive disease activity assessment in IBD patients during pregnancy

H. Schweistein, T. Adar, S. Shteingart, A. Raveh, S. Granovsky- Grisaru, E. Goldin, **A. Shitrit**

Shaare Zedek Medical Center, Digestive Diseases Institute, Jerusalem, Israel and others

■ **P136**

Validation of Ulcerative Colitis Endoscopic Index of Severity (UCEIS) in Korea

Y.J. Lee, E.S. Kim, K.B. Cho, S. Han, S.K. Kim, H.S. Lee, E.Y. Kim, J.T. Jung, J.G. Kwon, S.G. Kwak, B.I. Jang, K.O. Kim, S.H. Lee, W.J. Kim, Y.G. Kim, C.H. Yang, Y.J. Jung

Keimyung University School of Medicine, Daegu, South Korea and others

■ **P137**

The oxido-reductases enzymes (TDO2 and SOD2) in colonic mucosa are markers associated with histological activity and clinical course in Ulcerative Colitis

J. Yamamoto-Furusho, L. Salazar-Salas, G. Fonseca-Camarillo

IBD Clinic, Instituto Nacional de Ciencias Medicas y Nutricion, Gastroenterology, Mexico, Mexico

P138**Results of dysplasia surveillance programme with chromoendoscopy for Inflammatory Bowel Disease (IBD). Do we have to biopsy all lesions?**

J.F. Muñoz, M. García-Alvarado, B. Sicilia, M. Sierra, N. Fernandez, L. Arias, J. Barrio, B. Velayos, L. Hernández-Villalba

Complejo Asistencial Universitario de Salamanca, Gastroenterology, Salamanca, Spain and others

P139**Gut bacterial DNA translocation is an independent risk factor of flare at short-term in patients with Crohn's Disease (ADATHEC study)**

O. Juanola, A. Gutiérrez, P. Zapater, L. Sempere, M. García, R. Laveda, A. Martínez, M. Scharl, J.M. González-Navajas, P. Piñero, R. Wiest, **R. Francés**

CIBERehd, Instituto de Salud Carlos III, Madrid, Spain and others

P140**Biopsies taken from mucosa surrounding dysplastic lesions found during IBD surveillance show a low rate of dysplasia**

J. Ten Hove, E. Mooiweer, A. Van der Meulen, E. Dekker, J. Offerhaus, C. Ponsioen, B. Oldenburg

University Medical Center Utrecht, Utrecht, Netherlands and others

P141**Comparison of diagnostic accuracy of videocapsule endoscopy and CT/MR enterography in patients with established small-bowel Crohn's Disease**

P. Andrade, H. Cardoso, R. Gaspar, J. Santos-Antunes, M. Marques, S. Lopes, G. Macedo

Centro Hospitalar São João, Gastroenterology, Oporto, Portugal

P142**Second generation colon capsule endoscopy (C2) is highly accurate to detect mucosal lesions: A prospective study in over 100 patients with Ulcerative Colitis**

H.Y. Shi, F.K. Chan, J.Y. Ching, A. Higashimori, H. Chan, K. Lam, A. Chan, J. Chan, R. Tang, J.C. Wu, J.J. Sung, S.C. Ng

The Chinese University of Hong Kong, Hong Kong, Hong Kong

P143**Quality in IBD care: Measure, educate and improve. A real-life survey**

C. Viganò, G. Meucci, S. Saibeni, C.C. Cortelezzi, A. Amato

Spedale San Gerardo, UOC Gastroenterologia, Monza, Italy and others

P144**TNF-inhibitor use and efficacy in upper-GI Crohn's Disease: Results from a multicentre retrospective study**

W. Bos, E.H. Lamers, B. Oldenburg, A.E. van der Meulen - de Jong, G. Dijkstra, M. Pierik, Q. van der Vliet, A.M. van der Aalst, K. van der Aalst, J.J. ten Thije, M. van der Have, H.H. Fidder

University Medical Centre Utrecht, Department of Gastroenterology and Hepatology, Utrecht, Netherlands and others

P145**Migraine is the most frequent extra-intestinal manifestation in patients with Inflammatory Bowel Disease**

X. Moisset, G. Bommelaer, M. Boube, L. Ouchchane, M. Goutte, M. Dapoigny, R. Dallel, A. Guttman, P. Clavelou, **A. Buisson**

University Hospital G Montpied, Neurology Department, Clermont-Ferrand, France and others

P146**Risk factors of clinical relapse in patients with Ulcerative Colitis in clinical and endoscopic remission**

M. Calafat, T. Lobatón, A. Hernández-Gallego, M. Mañosa, P. Torres-Rodríguez, E. Cabré, I. Ojanguren, E. Domènech

Hospital Universitari Germans Trias I Pujol, Department of Gastroenterology CIBEREHD, Badalona, Spain and others

■ **P147**

The valuation of the Short Inflammatory Bowel Disease Questionnaire (SIBDQ) for use in economic evaluations

P. Petryszyn, P. Piotrowski, P. Ekk-Cierniakowski, A. Staniak, M. Well
Wroclaw Medical University, Clin Pharmacology, Wroclaw, Poland and others

■ **P148**

Simultaneous positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) with MRI enterography for monitoring activity of inflammation in patients with Crohn's Disease – a pilot study

K. Beiderwellen, B. Gomez, P. Heusch, G. Gerken, M. Ruenzi, A. Bockisch, T. Lauenstein, **J. Langhorst**
University of Duisburg-Essen, Department of Diagnostic and Interventional Radiology and Neuroradiology, University Hospital Essen, Essen, Germany and others

■ **P149**

Intestinal perfusion measurements with contrast enhanced ultrasound and dynamic contrast enhanced MR enterography: A comparison study

R. Wilkens, D.A. Peters, A.H. Nielsen, V.P. Hovgaard, H. Glerup, K. Krogh
Silkeborg Regional Hospital, Diagnostic Centre, University Research Clinic for Innovative Patient Pathways, Silkeborg, Denmark and others

■ **P150**

Zinc deficiency is associated with increased disease-related morbidity in Crohn's Disease patients

S.S. Siva, D.T. Rubin, G. Gulotta, K. Wroblewski, J. Pekow
The University of Chicago Inflammatory Bowel Disease Centre, Inflammatory Bowel Disease, Chicago, United States and others

■ **P151**

Ulcerative Colitis patients with zinc deficiency are at higher risk for disease-related complications

S.S. Siva, D.T. Rubin, G. Gulotta, K. Wroblewski, J. Pekow
The University of Chicago Inflammatory Bowel Disease Centre, Inflammatory Bowel Disease, Chicago, United States and others

■ **P152**

Faecal calprotectin 100ug/g and 50ug/g predict endoscopic and histologic remission: A prospective study in quiescent Ulcerative Colitis

H.Y. Shi, F.K. Chan, A. Higashimori, A. Chan, J.Y. Ching, J.C. Wu, J.J. Sung, S.C. Ng
The Chinese University of Hong Kong, Hong Kong, Hong Kong

■ **P153**

Type of treating physician is associated with long-term disease outcome in the prospective Belgian paediatric Crohn's Disease registry (BELCRO)

L. Wauters, F. Smets, E. De Greef, P. Bontems, I. Hoffman, B. Hauser, P. Alliet, W. Arts, H. Peeters, S. Van Biervliet, I. Paquot, E. Van de Vijver, M. De Vos, P. Bossuyt, J.-F. Rahier, O. Dewit, T. Moreels, D. Franchimont, V. Muls, F. Fontaine, E. Louis, J.-C. Coche, J. Paul, F. Baert, S. Vermeire, G. Veereman
UZ Leuven, Gastroenterology and Hepatology, Leuven, Belgium and others

■ **P154**

Temporal relationship of pregnancy to long term disease course and pregnancy and foetal outcomes: North Indian IBD cohort study

R.K. Padhan, S. Kumar, S. Kedia, R. Dhingra, V.P. Mouli, S. Bopanna, S. Shrivastav, L. Kurrey, V. Sreenivas, G. Makharia, V. Ahuja
All India Institute of Medical Sciences, Gastroenterology, New Delhi, India and others

■ **P155**

Thrombophilias and thromboembolic events in a population of patients with Inflammatory Bowel Disease

J. Pinho, D. Martins, P. Sousa, P. Ministro, E. Cancela, R. Araújo, A. Castanheira, A. Silva
Centro Hospitalar Tondela/Viseu, Viseu, Portugal

■ **P156**

Association between perinuclear anti-neutrophil cytoplasmic antibody status and clinical characteristics and outcomes of Ulcerative Colitis: A meta-analysis

H.J. Lee, J.J. Park, H.J. Kim

Severance Hospital, Yonsei University College of Medicine, Internal Medicine, Seoul, South Korea and others

■ **P157**

Usefulness of, and factors influencing, the Ulcerative Colitis Endoscopic Index of Severity (UCEIS) for the evaluation of short-term treatment response

K. Kawagishi, K. Yokoyama, K. Kobayashi

Kitasato University School of Medicine, Gastroenterology, Sagamihara, Japan

■ **P158**

Comparison of 4L polyethylene glycol and 2L polyethylene glycol plus ascorbic acid in patients with inactive Ulcerative Colitis; randomised, single blind, multicentre study

E.S. Kim, B.I. Jang, K.O. Kim, E.Y. Kim, S.W. Jeon, H.S. Lee, J. Heo, Y.J. Lee, H.J. Kim

Keimyung University School of Medicine, Internal Medicine, Daegu, South Korea and others

■ **P159**

The utility and benefit of procalcitonin to assess disease activity and severity in Crohn's Disease and intestinal Behcet disease

E. Hayashi, M. Saruta, S. Arihiro, M. Matsuoka, M. Mitsunaga, D. Ide, T. Iwasaki, **M. Ogawa**, R. Sawada, Y. Nagata, T. Kato, H. Tajiri

The Jikei University School of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Tokyo, Japan

■ **P160**

Do positive psychological factors affect the perception of health-related quality of life (QOL) in Inflammatory Bowel Disease (IBD) patients?

M. Lozano Lanagan, L. Camacho Martel, R. Camargo Camero, J. Lopez Megias, G. Alcain Martinez

Hospital Quiron, Malaga, Spain and others

■ **P161**

Ultrasound as a primary imaging modality for follow up of Crohn's Disease in pregnant women: Initial results

A. Shitrit, A. Keinan, B. Koslowsky, E. Goldin, K.R. Cytter

Shaare Zedek Medical Center, Digestive Diseases Institute, Jerusalem, Israel and others

■ **P162**

Outcome of 114 patients admitted with acute severe Ulcerative Colitis over 5 years at a district general hospital

K. Wade, **H. Johnson**, S. Weaver, S. McLaughlin

Royal Bournemouth Hospital, Department of Gastroenterology, Bournemouth, United Kingdom

■ **P163**

Assessment of the Inflammatory Bowel Disease-Fatigue (IBD-F) patient self-assessment scale in a Greek population of outpatients with IBD

I. Varbobitis, **S.I. Siakavellas**, C. Kosmidis, I. Koutsounas, G. Bamias

Laikon Hospital, Academic Department of Gastroenterology, Athens, Greece

■ **P164**

Which patients are at risk for clinical relapse in Ulcerative Colitis? - A prospective study

P. Boal Carvalho, F. Dias de Castro, M. Barbosa, S. Monteiro, T. Cúrdia Gonçalves, B. Rosa, M.J. Moreira,

J. Cotter

Hospital Senhora da Oliveira, Gastroenterology, Guimarães, Portugal and others

■ **P165**

Assessment of oxidative stress parameters for the disease activity evaluation in patients with Ulcerative Colitis

B. Canbakan, E. Koroglu, K. Atay, M. Tuncer, H. Senturk

Istanbul University Cerrahpasa Medical School, Gastroenterology, Istanbul, Turkey and others

■ **P166**

Venous thromboembolism with Inflammatory Bowel Disease

L. Mouelhi, O. Daboussi, M. Ben Khelifa, F. Houissa, K. El Jery, Y. Said, M. Salem, R. Dabbech, T. Najjar
Charles Nicolle Hospital, Gastroenterology, Tunis, Tunisia

■ **P167**

Real-world treatment persistence with vedolizumab in Crohn's Disease and Ulcerative Colitis patients

M. Raluy, K. Fraeman, R. Donaldson, M. Reynolds, M. Smyth, D. Demuth, **J.M. Khalid**
Evidera, Hammersmith, United Kingdom and others

■ **P168**

Inter-observer agreement in bowel ultrasonography for diagnostic assessment in patients with Crohn's Disease

E. Calabrese, T. Kucharzik, C. Maaser, G. Maconi, D. Strobel, S. Wilson, F. Zorzi, K. Novak, D. Bruining, M. Iacucci, M. Watanabe, E. Lolli, C. Chiamonte, S. Hanauer, R. Panaccione, F. Pallone, S. Ghosh
University of Rome Tor Vergata, Gastroenterology Unit, Department of Systems Medicine, Rome, Italy and others

■ **P169**

A consensus of outcome measures to monitor and enhance the quality of an IBD surgical service provision - results from a pan-European, multi-centre, Delphi study

P. Morar, N. Sevdalis, C. Edwards, A. Hart, W. Bemelman, J. Warusavitarne, O. Faiz
St Mark's Hospital, Colorectal Surgery & IBD Unit, London, United Kingdom and others

■ **P170**

Faecal osteoprotegerin correlates with disease activity and predicts disease relapse in paediatric Inflammatory Bowel Disease

F. De Voogd, L. Burgess, R. Geary, A. Day
University of Otago, Paediatrics/Gastroenterology, Christchurch, New Zealand and others

■ **P171**

Natural history of perianal Crohn's Disease: Long-term follow-up on a population-based cohort

M.-L. Rabilloud, A.-L. Mallet, L. Siproudhis, E. Bajeux, J.-F. Viel, I. Tron, J.-F. Bretagne, M. Robaszekiewicz, **G. Bouguen**
Université Rennes 1 & CHU Pontchaillou Rennes, Service des Maladies de l'Appareil Digestif, Rennes, France and others

■ **P172**

Incidence and risk factors of serious viral infections in Inflammatory Bowel Disease

A. Wisniewski, C. Landman, J. Kirchgessner, A. Bourrier, I. Nion-Larmurier, H. Sokol, P. Seksik, J. Cosnes, L. Beaugerie
Hôpital Saint-Antoine AP-HP, Department of Gastroenterology and Nutrition, Paris, France and others

■ **P173**

Comparison of clinical outcomes between young and adult-onset Ulcerative Colitis: A multi-centre KASID study

S.-K. Park, J.Y. Kim, D.S. Han, K.-C. Huh, C.K. Lee, J.E. Shin, J.H. Kim, Y.S. Kim, Y. Jung, S.-A. Jung, H.J. Song, H.J. Jang, D.I. Park
Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea and others

■ **P174**

Capsule endoscopy findings and faecal calprotectin levels predict clinical relapse in patients with quiescent small bowel Crohn's Disease

S. Ben-Horin, **U. Kopylov**, A. Lahat, D. Yablecovitch, S. Neuman, N. Levhar, E. Klang, B. Avidan, B. Weiss, H. Yanai, I. Dotan, Y. Chowers, M.M. Amitai, R. Eliakim
Chaim Sheba Medical Center, Gastroenterology, Ramat Gan, Israel and others

■ **P175**

Rates of colectomy in Ulcerative Colitis (UC) through time in a Latin-American unit of IBD

A. Sambuelli, A. Gil, S. Negreira, S. Goncalves, S. Huernos, M. Bellicoso, P. Chavero, P. Tirado, A. Cabanne
IBD Section - Hospital Bonorino Udaondo, Medicine, Buenos Aires, Argentina and others

■ P176***Correlation of biomarkers to simultaneous Positron Emission Tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) with MRI enterography and endoscopy for monitoring activity of inflammation in patients with Crohn's Disease*****J. Langhorst**, J. Boone, A. Rueffer, G. Dobos, K. Beiderwellen, T. Lauenstein

University of Duisburg-Essen, Integrative Gastroenterology, Kliniken Essen-Mitte, Essen, Germany and others

■ P177***Fecal metalloprotease 9 is a reliable biomarker compared to faecal calprotectin in detecting endoscopic activity in patients with Inflammatory Bowel Diseases*****A. Buisson**, E. Vazeille, R. Minet Quinard, M. Goutte, D. Bouvier, F. Goutorbe, B. Pereira, N. Barnich, G. Bommelaer

University Hospital Estaing, Gastroenterology Department, Clermont-Ferrand, France and others

■ P178***MRI characteristics of proctitis in Crohn's Disease in correlation with endoscopy*****C. Tutein Nolthenius**, S. Bipat, B. Mearadji, A. Spijkerboer, A. Montauban van Swijndregt, C. Ponsioen, J. Stoker

Academic Medical Center (AMC), Radiology, Amsterdam, Netherlands and others

■ P179***New approach to endoscopic mucosal healing of Ulcerative Colitis using linked colour imaging, a novel endoscopic enhancement system*****K. Uchiyama**, T. Takagi, Y. Toyokawa, Y. Hotta, M. Tanaka, Y. Naito, Y. Itoh

Kyoto Prefectural University of Medicine, Molecular Gastroenterology and Hepatology, Kyoto, Japan

■ P180***The activity of glutathione peroxidase and superoxide dismutase in the blood serum and saliva in patients with Crohn's Disease*****K. Szczeklik**, R. Domagała-Rodacka, P. Mach, **D. Cibor**, J. Pytko-Polończyk, T. Rodacki, D. Owczarek

Jagiellonian University Medical College, Department of Integrated Dentistry, Kraków, Poland and others

■ P181***Accuracy of non-invasive tests in the initial diagnostic work-up of paediatric Inflammatory Bowel Diseases*****F. Civitelli**, M. Aloj, A. Dilillo, S. Oliva, L. Stronati, F. Viola, S. Cucchiara

Sapienza University, Paediatric Gastroenterology and Liver Unit, Rome, Italy

■ P182***Stimulation with chenodeoxycholic acid and meal may increase power of biochemical tests for diagnosis of bile acid diarrhoea*****C. Borup**, S. Wildt, M. Damgaard, J. Graff, P. Nordine Bouchelouche, D. Rainteau, J.J. Rumessen, L.K. Munck

Hvidovre University Hospital, Department of Medical Gastroenterology, Hvidovre, Denmark and others

■ P183***Loss of anti-TNF drugs into faeces and its impact on anti-TNF serum levels and clinical response in Crohn's Disease (CD) patients*****M. Chaparro**, I. Guerra, L. Bujanda, J.L. Cabriada, C. Taxonera, I. Marín-Jiménez, P. M Linares, M. Ramas, J.P. Gisbert

Hospital Universitario de La Princesa, IIS-IP and CIBERehd, Gastroenterology Unit, Madrid, Spain and others

■ P184***A novel automated calprotectin analysis method increases the diagnostic accuracy of the test*****T. Lehto**, P. Hedberg, T. Vaskivuo

University of Oulu and Northern Finland Laboratory Centre Nordlab, Oulu, Finland

■ **P185**

Capsule endoscopic findings for the diagnosis of Crohn's Disease: A case-control study

M. Esaki, T. Matsumoto, S. Yamamoto, T. Kinjo, K. Kinjo, K. Togashi, K. Watanabe, S. Nouda, S. Ashizuka, M. Nakamura, Y. Suzuki
Kyushu University, Medicine and Clinical Science, Fukuoka, Japan and others

■ **P186**

Does PR3-ANCA positive Ulcerative Colitis represent a novel subset?

J. Li, S. Zhang, H. Lv, H. Yang, Y. Li, Y. Li, J. Qian
Peking Union Medical College Hospital, Gastroenterology, Beijing, China and others

■ **P187**

Cognitive behavioural profiles from patients on biologics: Not what you might think

I.Y. Liew, G. Chung-Faye, P. Dubois, L. Medcalf, A. Simpson, J. Hutton, C. Jordan, M. Hotopf, **B. Hayee**
King's College Hospital NHS Foundation Trust, Gastroenterology, London, United Kingdom and others

■ **P188**

Incidence and clinical features of perianal diseases in patients with Ulcerative Colitis in Korea

Y.S. Choi, W.J. Kim, J.K. Kim, K.-H. Song, H.-J. Jung
Daehang Hospital, Gastroenterology, Seoul, South Korea and others

■ **P189**

Serial monitoring of faecal calprotectin for the assessment of endoscopic recurrence in asymptomatic patients after ileocolonic resection for Crohn's Disease: A long-term prospective study

T. Yamamoto, T. Shimoyama, S. Umegae, K. Matsumoto
Yokkaichi Hazu Medical Centre, Inflammatory Bowel Disease Centre, Yokkaichi, Japan

■ **P190**

Colonic neuroendocrine carcinoma in Ulcerative Colitis: A case report

D. Chaaro, M.F. Guerra Veloz, M.B. Maldonado Perez, L. Castro Laria, F. Argüelles Arias, P. Hergueta Delgado, E. Rodriguez Zarco, A. Vallejo Benitez, F.J. Pellicer Bautista, A. Caunedo Álvarez
University Hospital Virgen Macarena, Gastroenterology and Hepatology Department, Seville, Spain and others

■ **P191**

The endoscopic and pathological features of cytomegalovirus colitis in Ulcerative Colitis

H. Yang, H. Lv, J. Gian
Peking Union Medical College Hospital, Department of Gastroenterology, Beijing, China and others

■ **P192**

The impact of bariatric surgery on the course of Inflammatory Bowel Disease

R. Fausel, L. Roque Ramos, R. Ungaro, J. Torres, J.-F. Colombel
Icahn School of Medicine at Mount Sinai, Department of Medicine, New York City, United States and others

■ **P193**

Delayed diagnosis increases the risk of abdominal surgery in Crohn's Disease

D.-W. Lee, **J.S. Koo**, E.S. Kim, B. Keum, Y.J. Jeon
Korea University College of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Seoul, South Korea

■ **P194**

Post operative recurrence of Crohn's Disease after resection ileo- coecal: Prevalence and risk factors

A. Hammami, A. Ben Slama, M. Ksaa, H. Jaziri, M. Ben Rejeb, M. Ben Mabrouk, A. Souguir, I. Ben Mansour, S. Ajmi, A. Brahem, A. Jmaa
Hospital University of Sahloul, Gastroenterology, Sousse, Tunisia and others

■ **P195**

Predicting surgical strategy in ileal Crohn's Disease – the construction and validation of an evidence-based, end-user informed radiological staging tool

P. Morar, E. Mainta, S. Arora, R. Ilangovan, A. Hart, A. Gupta, J. Warusavitarne, O. Faiz
St Mark's Hospital, Colorectal Surgery & IBD Unit, London, United Kingdom and others

■ **P196**

Withdrawn

■ **P197**

Use of 6-thioguanine nucleotide concentration test in the management of patients with Crohn's Disease in Korea

T.J. Kim, J. Lee, E.R. Kim, S.N. Hong, D.K. Chang, Y.-H. Kim
Samsung Medical Center, Seoul, South Korea

■ **P198**

Faecal calprotectin level correlates well with balloon assisted endoscopy and computed tomography enterography findings in the small bowel Crohn's Disease

T. Arai, **K. Takeuchi**, A. Yamada, M. Miyamura, R. Ishikawa, Y. Suzuki
Toho University, Sakura Medical Centre, Division of Gastroenterology, Department of Internal Medicine, Sakura, Japan and others

■ **P199**

Predictive factors of surgery and bowel damage during the course of Crohn's Disease: A population-based study

M.-L. Rabilloud, J.-F. Bretagne, E. Bajeux, L. Siproudhis, J.-F. Viel, I. Tron, **G. Bouguen**
Université Rennes 1 & CHU Pontchaillou Rennes, Service des Maladies de l'Appareil Digestif, Rennes, France and others

■ **P200**

Predictors of post-operative recurrence of ileal Crohn's Disease

M.N. Quraishi, M. Widlak, N. Bhala, N. Sharma, T.H. Iqbal
University Hospital Birmingham, Department of Gastroenterology, Birmingham, United Kingdom and others

■ **P201**

Disability and health related quality of life in patients with moderate-severe Ulcerative Colitis: Impact of restorative proctocolectomy versus medical treatment with anti-TNF agents

S. van Gennep, S. Sahami, W. Bemelman, C. Buskens, A. D'Hooore, A. de Buck van Overstraeten, M. Ferrante, S. Vermeire, G. D'Haens, M. Löwenberg
Academic Medical Center (AMC), Department of Gastroenterology and Hepatology, Amsterdam, Netherlands and others

■ **P202**

Meta-analysis: Accuracy of interferon- γ release assays in differentiating intestinal tuberculosis from Crohn's Disease in Asia

H. Xu, Y. Li, J. Qian
Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Department of Gastroenterology, Beijing, China and others

■ **P203**

Duodenal lesions in postoperative Ulcerative Colitis

M. Sako, N. Yoshimura, M. Takazoe
Tokyo Yamate Medical Center, Center for Inflammatory Bowel Disease, Tokyo, Japan

■ **P204**

Ultrasound elastography-derived shear wave velocity helps distinguish acutely inflamed from fibrotic bowel in patients with Crohn's Disease receiving surgery

R. Mao, Y. Chen, B. Chen, Y. He, X. Xie, Z. Zeng, S. Ben-Horin, **M. Chen**, X. Xie
The First Affiliated Hospital, Sun Yat-sen University, Department of Gastroenterology, Guangzhou, China and others

■ **P205**

Prevalence of anaemia in a nationwide cohort of elderly onset Ulcerative Colitis patients

D. Patel, **N. Khan**

Mercy Catholic Medical Center, Internal Medicine, Philadelphia, United States and others

■ **P206**

Combined positron emission tomography and magnetic resonance imaging (PET-MRI) in the diagnostics of Inflammatory Bowel Disease – a preliminary report

J. Koffert, J. Virtanen, S. Kauhanen, J. Kempainen, J. Sundström, M. Kallajoki, M. Voutilainen

Turku University Hospital, Turku PET Centre, Turku, Finland and others

■ **P207**

Disease activity is associated with indicators of impaired nutritional status in IBD outpatients

C. Spooren, M. Wierikx, T. van den Heuvel, A. Masclee, M. Pierik, D. Jonkers

Maastricht University Medical Center+, Internal Medicine - Division Gastroenterology-Hepatology, Maastricht, Netherlands and others

■ **P208**

Prevalence of chronic peri-pouch sepsis in patients treated as primary idiopathic pouchitis

V.A. van der Ploeg, **Y. Maeda**, O.D. Faiz, A.L. Hart, S.K. Clark

St Mark's Hospital, Department of Surgery, Harrow, United Kingdom and others

■ **P209**

Extraintestinal manifestations are a prognostic factor in patients with Inflammatory Bowel Disease

P. Sousa, D. Martins, J. Pinho, R. Araújo, E. Cancela, A. Castanheira, P. Ministro, A. Silva

Centro Hospitalar Tondela-Viseu, Gastroenterology, Viseu, Portugal

■ **P210**

Telemedicine for Inflammatory Bowel Disease patients with MyIBDcoach: Description of the myIBDcoach trial

M. de Jong, A. van der Meulen-de Jong, M. Romberg-Camps, M. Becx, T. Markus, J. Maljaars, N.

Mahmmod, W. Hameeteman, A. van Bodegraven, E. Keulen, J. Wilbrink, D. Jonkers, A. Masclee, M. Pierik

Maastricht University Medical Centre+, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Maastricht, Netherlands and others

■ **P211**

Anti-TNF drugs levels and correlation with short-term clinical remission in Crohn's Disease (CD) patients: Results from the Predicrohn Study

M. Chaparro, I. Guerra, M. Iborra, J.L. Cabriada, L. Bujanda, C. Taxonera, V. García-Sánchez, I. Marín-

Jiménez, M. Barreiro-de Acosta, I. Vera, M.D. Martín-Arranz, B. Hernández-Breijo, F. Mesonero, L.

Sempere, F. Gomollón, J. Hinojosa, F. Bermejo, B. Beltrán, I. Rodríguez-Lago, J.M. Banales, D. Olivares, P.

Aguilar-Melero, L. Menchén, R. Ferreiro, I. Blazquez, B. Benítez García, L. Guíjarro, P. M Linares, M. Ramas,

J.P. Gisbert

Hospital Universitario de La Princesa, IIS-IP and CIBERehd, Gastroenterology Unit, Madrid, Spain and others

■ **P212**

Inflammatory Bowel Disease (IBD) patients seem to develop non-alcoholic steatohepatitis (NASH) independently from an altered metabolic profile or active bowel disease

A. Sartini, M. Bianchini, S. Gitto, M. Di Girolamo, A. Bertani, A. Merighi, E. Villa

Gastroenterology Unit, Azienda Ospedaliero-Universitaria di Modena, Policlinico, Modena, Italy

■ **P213**

Predicting outcome of paediatric Crohn's Disease: Role of clinical, endoscopic and imaging findings at the diagnosis

M. Aloï, F. Civitelli, S. Oliva, E. Casciani, G. D'Arcangelo, A. Spatolatore, F. Viola, S. Cucchiara

Sapienza University of Rome, Paediatric Gastroenterology and Liver Unit, Rome, Italy and others

P214
Inflammatory Bowel Disease and endometriosis: Is there a relationship?

M. Fortuna, A. Variola, R. Montanari, G. Ruffo, P. Bocus, A. Geccherle
 Sacro Cuore Don Calabria Hospital, Multispecialistic Centre for Recto-Perineal Diseases (IBD Unit),
 Department of Gastroenterology, Negrar, Italy and others

P215
The influence of disease activity on birth outcomes in patients with Inflammatory Bowel Disease: Meta-analysis

J.J. Park, H.J. Kim, M.-A. Kim
 Gangnam Severance Hospital, Yonsei University College of Medicine, Internal Medicine, Seoul, South
 Korea and others

P216
Natural course of Inflammatory Bowel Disease in a Turkish cohort: A single tertiary centre experience in Ankara (2006 - 2015)

I. Yuksele, Y. Coskun, H. Akinci, M. Hamamci, E. Erarslan, Y. Ustun, Z. Simsek, S. Coban
 Diskapi Yildirim Beyazit Education and Research Hospital, Gastroenterology, Ankara, Turkey and others

P217
Risk factors of primary sclerosing cholangitis and cirrhosis in Ulcerative Colitis

Z. Azizi, Y. Farbod, S. Javid, **N. Ebrahimi Daryani**, V. Basirat
 Iran University of Medical Sciences, Tehran, Iran, Islamic Republic of and others

P218
Oral manifestations in Inflammatory Bowel Disease patients under anti-TNF treatment

M. Barreiro-de Acosta, P. Rio, R. Ferreira, M.J. Bouza, M.d.C. Pombo, A. Lorenzo, M. Gallas, J.E.
 Dominguez-Munoz
 University Hospital Santiago de Compostela, Gastroenterology, Santiago, Spain and others

P219
Accuracy of imaging for the preoperative measurement of the ileocolonic Crohn's Disease length: Results of a prospective cohort study

A. Brouquet, A.-S. Rangheard, J. Ifergan, T. Lazure, F. Carbonnel, C. Penna, S. Benoist
 Bicêtre Hospital - Université Paris Sud, Oncologic and Digestive Surgery, Le Kremlin Bicêtre, France
 and others

P220
Total colonoscopy is needed to establish the diagnosis of lymphocytic colitis - results from a single centre retrospective cohort

C. Csóka, P. Miheller, A. A. Csontos, T. Micsik, K. Hagymási, L. Herszényi, M. Juhász, D. Lippai, E. Mihály, K.
 Müllner, A.M. Németh, Z. Péter, F. Sipos, H. Székely, Z. Tulassay, G. Valcz, **A.V. Patai**
 Semmelweis University, 2nd Department of Medicine, Budapest, Hungary and others

P221
Crohn's Disease activity evaluation based on imaging studies and biomarkers

G. Piotrowicz, J. Kowczanow, M. Kaszubowski, E. Szurowska, G. Rydzewska
 Self-Dependent Health Care Unit of Ministry of Interior, Gastroenterology, Gdansk, Poland and others

P222
The onset of clinical manifestations in patients with Inflammatory Bowel Disease

V. Nóbrega, J. Silva, B. Brito, I. Silva, M.C. Silva, A. Pimentel, F. Fortes, **B.C. da Silva**, N. Almeida, V. Surlo,
 J. Mota, G. Santana
 Universidade do Estado da Bahia, Medicine, Salvador, Brazil and others

P223
Bowel damage in Crohn's Disease: Direct comparison of ultrasonography- and magnetic resonance-based Lemann index

N. Imperatore, A. Rispo, A. Testa, P. Mainenti, G.D. De Palma, M. Rea, O.M. Nardone, G. Luglio, P. Gervetti,
 M.L. Taranto, F. Castiglione
 University "Federico II" of Naples, Department of Clinical Medicine and Surgery, Naples, Italy and
 others

■ **P224**

Primary sclerosing cholangitis in the Swiss Inflammatory Bowel Disease Cohort: Prevalence, risk factors, and long-term follow-up

M. Fraga, N. Fournier, E. Safroneeva, V. Pittet, A. Nydegger, S. Vavricka, D. Moradpour, A. Schoepfer
CHUV - Centre Hospitalier Universitaire Vaudois, Department of Gastroenterology and Hepatology, Lausanne, Switzerland and others

■ **P225**

Cross-sectional evaluation of transmural healing in patients with Crohn's Disease on maintenance treatment with biologics

A. Testa, A. Rispo, P. Mainenti, N. Imperatore, G.D. De Palma, M. Rea, F. Maione, O.M. Nardone, M.L. Taranto, F. Castiglione
University "Federico II" of Naples, Department of Clinical Medicine and Surgery, Naples, Italy and others

■ **P226**

The first validated post-operative endoscopic Crohn's Disease index: The POCER index. Identification of key endoscopic prognostic factors

P. De Cruz, M. Kamm, A. Hamilton, K. Ritchie, A. Gorelik, D. Liew, I. Lawrance, J. Andrews, P. Bampton, P. Gibson, M. Sparrow, R. Leong, T. Florin, R. Gearry, G. Radford-Smith, F. Macrae, H. Debinski, W. Selby, I. Kronborg, M. Johnston, R. Woods, R. Elliott, S. Bell, S. Brown, W. Connell, P. Desmond
University of Melbourne, Gastroenterology, Melbourne, Australia and others

■ **P227**

Faecal calprotectin reductions in patients achieving mucosal healing with vedolizumab induction therapy in GEMINI 1

J.D. Lewis, W. Reinisch, B. Bressler, A. Parikh, H. Yang, M. Rosario, A. Roseth, S. Danese, B.G. Feagan, B.E. Sands, P. Ginsburg, T. Dassopoulos, J. Xu, T. Wyant
University of Pennsylvania Perelman School of Medicine, Gastroenterology, Philadelphia, PA, United States and others

■ **P228**

Prevalence of malnutrition and nutritional characteristics of patients with Inflammatory Bowel Disease

M.J. Casanova, M. Chaparro, B. Molina, O. Merino, O. Nuevo-Siguairo, C. Dueñas-Sadornil, A.M. García-Albert, D. Hervías, X. Calvet, L. Bujanda, G.E. Rodríguez, M. Montoro, L. Castro-Laria, M. Barreiro-de Acosta, M. Van Domselaar, J.M. Huguet, P. Ramírez de la Piscina, J. Barrio, A. Algaba, A.D. Ávila, S. Torra, L. Pozzati, F.J. Martínez-Cerezo, M. Calvo, M. Charro, P. López-Serrano, M.R. Arribas-López, M. Muñoz Vicente, M.L. Rincón, A.C. Peláez, E. Castro, A. García-Herola, R. Batanero, A. Castaño-García, P. Robledo-Andrés, M.B. Gómez-Sánchez, A. Figuerola, J.M. Banales, L. Díaz-Hernández, I. Vázquez, F. Arguelles-Arias, E. Marti-Bonmati, F. Bermejo, P. Serrano, I. Megias-Rangil, M. Campderá, A. Barragán, A. Merchante, J.P. Gisbert
Hospital Universitario de La Princesa, IIS-IP and CIBERehd, Gastroenterology Unit, Madrid, Spain and others

■ **P229**

Evidence of content validity and psychometric properties of SF-36 for measuring health-related quality of life of patients with Crohn's Disease

A. Yarlaz, M. White, M. Ingham, D. Naessens, C. Han
Optum, Lincoln, United States and others

■ **P230**

Elevated angiopoietins independent of TNF α regulation appear to play a key role in immune mediated angiogenesis in IBD

M. Hussey, G. Holleran, K. Grooteman, S. Smith, D. McNamara
Adelaide and Meath Hospital, Trinity College Dublin, Gastroenterology, Trinity Academic Gastroenterology Group, Dublin, Ireland and others

■ **P231**

Development of a small bowel capsule endoscopic index of severity in patients with Crohn's Disease

A. Bourreille, A. Attar, V. Maunoury, M. Simon, A. Aubourg, M. Fumery, J.-M. Reimund, C. Reenaers, I. Nion-Larmurier, B. Bonaz, J. Filippi, O. Dewit, X. Dray, J. Moreau, R. Altwegg, X. Roblin, C. Stefanescu, J.-Y. Mary

CHU Nantes, Institut des Maladies de l'Appareil Digestif, Nantes, France and others

■ **P232**

Paediatric Crohn's Disease and its disability over time: A study performed with a new paediatric Lémann Index. Preliminary data from a tertiary paediatric IBD centre

G. Bodini, S. Arrigo, A. Bizzocchi, E.G. Giannini, V. Savarino, E. Savarino, A. Barabino

University of Genoa, Internal Medicine Department, Genoa, Italy and others

■ **P233**

Management of patients with quiescent Crohn's Disease based on capsule endoscopy Crohn's Disease activity index

T. Omori, B. Iizuka, H. Kashiwagi, T. Hara, T. Kuriyama, A. Ito, M. Yonezawa, K. Tokushige

Tokyo Women's Medical University, Gastroenterology, Tokyo, Japan

■ **P234**

The diagnostic yield of small bowel capsule endoscopy in postsurgical Crohn's Disease

N. Viazis, L. Varitimadhis, M. Galanopoulos, A. Tsigaridas, M. Chanias, S. Anastasiadis, I. Tziortziotis, C. Pontas, E. Tsoukali, P. Karatzas, D. Karamanolis

Evangelismos Hospital, Gastroenterology Department, Athens, Greece

■ **P235**

The association between serum vitamin D status and disease activity in paediatric Inflammatory Bowel Disease

E. O'Neill, T. Raftery, A.M. Broderick, B. Bourke, S. Hussey

University College Dublin, Dublin 4, Ireland and others

■ **P236**

Faecal calprotectin is a poor predictor of IBD relapse during pregnancy

S. Kanis, A. de Lima, V. van Oorschot, C. van der Woude

Erasmus Medical Center, Gastroenterology and Hepatology, Rotterdam, Netherlands

■ **P237**

Ionising radiation exposure in patients with Crohn's Disease: Estimation and risk factors

M. Barbosa, T. Gonçalves, M.J. Moreira, J. Cotter

Hospital da Senhora da Oliveira, Gastroenterology, Guimaraes, Portugal and others

■ **P238**

Vitamin D deficiency in Inflammatory Bowel Disease: Is malabsorption to blame?

J. Schembri, S. Chetcuti, S. Vella, P. Ellul

Mater Dei Hospital, Gastroenterology, Msida, Malta

■ **P239**

Hospitalisations and characteristics of patients with Ulcerative Colitis and Crohn's Disease treated with vedolizumab in real-world clinical practice: Results from a multi-centre study

M. Reynolds, N. Alam, M. Raluy, B. Gardstein, D. O'Hara, M. Smyth, **J.M. Khalid**

Evidera, Lexington, United States and others

■ **P240**

Microscopic colitis, are there any predictors?

I.G. Moraru, R. Vadan, L. Gheorghe, M. Dumbrava, G. Becheanu

3rd Department of Gastroenterology, Clinical Hospital Fundeni, Bucharest, Gastroenterology, Bucharest, Romania and others

■ **P241**

Risk factors associated with perianal Crohn's Disease in Korean children

E. Ryoo, K. Lim, H. Tchah

Gachon University, Gil Hospital, Paediatrics, Incheon, South Korea

■ **P242**

Performance of the BÜHLMANN Quantum Blue® infliximab point-of-care assay dedicated for therapeutic drug monitoring of serum infliximab trough levels

T. Schuster, E. Keller, S. Kräuchi, F. Bantleon, J. Weber, M. Schneider
BÜHLMANN Laboratories AG, Schönenbuch, Switzerland

■ **P243**

Developing a protocol to conduct a student-driven study across Europe: EuroSurg-1 study

G. Pellino on behalf of EuroSurg Collaborative
Second University of Naples, Unit of Colorectal Surgery, Naples, Italy

■ **P244**

Is prognostic utility of rapid faecal calprotectin test equal in all Inflammatory Bowel Disease (IBD) subtypes? Retrospective analysis based on endoscopic indices

A. Moniuszko, D. Koziel, S. Gluszek, G. Rydzewska
Central Clinical Hospital of the Ministry of Interior, Department of Gastroenterology with Inflammatory Bowel Diseases Subdivision, Warsaw, Poland and others

■ **P245**

Influence of activity of Ulcerative Colitis in the orocecal transit time measured by H2 breath test after administration of lactulose

F. Casellas, P. Rodríguez, A. Aparici, M.J. Pérez, V. Robles, C. Herrera de Guise, N. Borrueal
Hospital Universitari Vall d'Hebron, Unitat Atenció Crohn-Colitis, Barcelona, Spain and others

■ **P246**

Impact of Inflammatory Bowel Disease on work-related outcomes and activity impairment and its relation with health-related quality of life

L. Camacho, R. Camargo, S. López, F. Fernández, V. Amo, R. Olmedo, G. Alcain
Hospital Virgen de la Victoria, Gastroenterology, Málaga, Spain and others

■ **P247**

Unanticipated small bowel Crohn's Disease in elderly patients revealed by videocapsule endoscopy

C.-Y. Chao, C.-F. Duchatellier, E. Seidman
Research Institute of the McGill University Hospital, Gastroenterology, Montreal, Canada

■ **P248**

Prevalence of testing and impact of severity of anaemia on testing for iron deficiency in a nationwide cohort of anaemic Ulcerative Colitis patients

D. Patel, N. Khan
Mercy Catholic Medical Center, Internal Medicine, Philadelphia, United States and others

■ **P249**

Clinical significance of endoscopic mucosal healing in patients with Ulcerative Colitis

K.O. Kim, B.I. Jang, S.H. Shon, D.E. Jeong, C.H. Yang
Yeungnam University College of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Daegu, South Korea and others

■ **P250**

Frequency of extraintestinal manifestation in the early signs and symptoms of IBD

M.C. Silva, **B.C. da Silva**, J. Silva, B. Brito, I. Silva, V. Nóbrega, F. Fortes, A. Pimentel, N. Almeida, V. Surlo, J. Mota, G. Santana
Universidade do Estado da Bahia, Medicine, Salvador, Brazil and others

■ **P251**

Comparison of three magnetic resonance enterography indices for detection of activity and severity in Crohn's Disease

I. Alfaro, I. Ordás, S. Rodríguez, J. Castro, A. López, T. Pérez, A. Cofiño, A. Ramírez-Morros, M. Gallego, R. Barastegui, A. Giner, M. Masamunt, E. Ricart, J. Rimola, J. Panés
Hospital Clínic de Barcelona, Department of Gastroenterology, Barcelona, Spain and others

P252
Is the time for chromoendoscopy spreading in dysplasia surveillance of Inflammatory Bowel Diseases? A systematic review with meta-analysis

A. Iannone, G. Losurdo, M. Barone, E. Ierardi, A. Di Leo, M. Principi
University of Bari, DETO, Bari, Italy

P253
Incidental diagnosis of Inflammatory Bowel Disease in a British bowel cancer screening cohort: 6-year clinical outcome follow-up of the first reported cohort

J. Scott, U. Nosegbe, R. Butcher, A. Abbassi, R. Prudham, R. George, J. Limdi
Penine Acute Hospitals NHS Trust, Gastroenterology, Manchester, United Kingdom and others

P254
Clinical implications of low-grade dysplasia detected during surveillance of IBD patients: A closer look at chromoendoscopy and high-definition white light endoscopy

J. Ten Hove, E. Mooiweer, A. Van der Meulen, E. Dekker, C. Ponsioen, B. Oldenburg
University Medical Center Utrecht, Utrecht, Netherlands and others

P255
Life virus vaccines in infants with intrauterine exposure to biologics

B. Truta, J. Canner, J. Efron, B. Safar
Johns Hopkins University, Baltimore, United States

P256
Autoimmune pancreatitis associated with Inflammatory Bowel Disease: A multicentric study of the GETAID

D. Lorenzo, F. Maire, C. Stefanescu, J.M. Gornet, P. Seksik, J.C. Grimaud, B. Bournet, P. Marteau, A. Amiot, D. Laharie, C. Trang, B. Coffin, G. Bellaiche, G. Cadiot, C. Reenaers, A. Racine, S. Viennot, A. Pauwels, G. Bouguen, G. Savoye, A.L. Pelletier, G. Pineton de Chambrun, P. Lahmek, S. Nahon, V. Abitbol
Hôpital Cochin AP-HP, Paris, France and others

P257
Relationship between ocular vascular changes, malondialdehyde and vascular endothelial growth factor levels in Inflammatory Bowel Disease

N. Sengul Samanci, S. Poturoglu, C. Samanci, **A.E. Duman**, A. Ciftcibasi Ormeci
Haseki Training and Research Hospital, Internal Medicine, Istanbul, Turkey and others

P258
Prospective follow up of serologic responses in Ulcerative Colitis patients with an ileal pouch reveals they are stable over time and do not correlate with the clinical phenotype of the pouch

I. Goren, L. Yahav, H. Tulchinsky, I. Dotan
Tel aviv medical center, IBD Center, Department of Gastroenterology and Liver Diseases, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel and others

P259
The need for surgery in stricturing ileal CD is linked to clinical and imaging factors but independent of NOD2 genotype

P. Bossuyt, C. Debeuckelaere, T. Billiet, I. Cleynen, A. de Buck van Overstraeten, A. Wolthuis, M. Ferrante, G. Van Assche, A. D'Hoore, S. Vermeire
University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium and others

P260
Diagnostic value of capsule endoscopy in small bowel Crohn's Disease following normal radiological imaging

E. Eliadou, J. Brooks, S. Levison, H.Y. Lee
Central Manchester Foundation Trust, Gastroenterology, Manchester, United Kingdom

P261
Clinical predictors of a frequently relapsing disease course under 5-ASA among Ulcerative Colitis patients initially responding to induction therapy with 5-ASA and/or steroids

K. Atay, Y. Erzin, I. Hatemi, T. Eskazan, I. Serin, S. Bozcan, N. Demir, A.F. Celik
Istanbul University Cerrahpasa Medical School, Gastroenterology, Istanbul, Turkey

■ **P262**

Influence of a positive family history on the clinical course of Inflammatory Bowel Disease

S.W. Hwang, M.S. Kwak, W.S. Kim, J.-M. Lee, S.H. Park, H.-S. Lee, D.-H. Yang, K.-J. Kim, B.D. Ye, J.-S. Byeon, S.-J. Myung, Y.S. Yoon, C.S. Yu, J.-H. Kim, S.-K. Yang
University of Ulsan College of Medicine, Asan Medical Center, Department of Gastroenterology, Seoul, South Korea and others

■ **P263**

Prognostic value of the magnitude of cytomegalovirus reactivation evaluated by immunohistochemistry in patients with Ulcerative Colitis

A. Clos, P. Rodríguez-Martínez, M. Manyosa, A. Ruiz-Cerulla, M.J. Paúles, J. Llaó, J. Gordillo, C. Fumagalli, T. Lobatón, I. Ojanguren, E. Cabré, J. Guardiola, **E. Domènech**
Hospital Universitari Germans Trias i Pujol, Gastroenterology, Badalona, Spain and others

■ **P264**

Meta-analytic bayesian model for differentiating intestinal tuberculosis from Crohn's Disease utilising clinical, endoscopic, and cross-sectional imaging findings, and the interferon-gamma releasing assay

J. Limsrivilai, A. Shreiner, **P.D. Higgins**
Mahidol University, Bangkok, Thailand and others

■ **P265**

IBD patients with PSC frequently have subclinical endoscopic and histologic activity

N. Krugliak Cleveland, D. Rubin, K. Meckel, A. Tran, A. Gonsalves, J. Gaetano, K. Williams, B. Jabri, J. Pekow
University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, United States

■ **P266**

How disease extent can be included in the endoscopic activity index of Ulcerative Colitis: The panMayo Score, a promising scoring system

A. Bálint, K. Farkas, Z. Szepes, F. Nagy, M. Szücs, L. Tiszlavicz, R. Bor, A. Milassin, M. Rutka, A. Fábrián, T. Molnár
University of Szeged, 1st Department of Medicine, Szeged, Hungary and others

■ **P267**

Are Ulcerative Colitis outpatients at nutritional risk?

M. Lopes, A. Lyra, R. Rocha, C. Factum, L. Sales, L. Mello, C. Lima, **B.C. da Silva**, G. Santana
Federal University of Bahia, Post-graduate Programme in Medicine and Health, Salvador, Brazil and others

■ **P268**

A questionnaire on the diagnosis of microscopic colitis in Denmark

P.J.H. Engel, S. Holck, U.H. Engel
Roskilde Hospital, Department of Pathology, Roskilde, Denmark and others

■ **P269**

Colonic metaplasia of the ileum as a predictive marker of clinical recurrence in Crohn's Disease: A prospective study at 4 years

M. Ascolani, C. Mescoli, M. Ruggie, S. Onali, G. Sica, C. Petruzzello, G. Palmieri, E. Calabrese, A. Ruffa, F. Pallone, M. Ruggie, **L. Biancone**
University "Tor Vergata" of Rome, Department of Systems Medicine, Rome, Italy and others

■ **P270**

Association of macro/micro nutrients with endoscopic disease activity in patients with Inflammatory Bowel Disease suggests possible protective role for dietary components

A. Mohammadi, O.B. Kelly, S. Maltais, R. Milgrom, M.S. Silverberg
Mount Sinai Hospital, Toronto, Canada

■ **P271**

Epidemiological characteristics and factors associated with ulcerative proctitis progression

A. Dimitriu, S. Necula, B. Cotruta, L. Gheorghe, C.S. Pop
Clinical Institute Fundeni, Department of Gastroenterology, Bucharest, Romania and others

■ **P272**

Azathioprine drug monitoring and faecal calprotectin levels in Ulcerative Colitis

C. Keil, L. Püschel, A. Otte, M.P. Manns, O. Bachmann
Hannover Medical School, Dept. of Gastroenterology, Hepatology, and Endocrinology, Hannover, Germany and others

■ **P273**

Risk factors and clinical outcomes associated with cytomegalovirus colitis in patients with acute severe Ulcerative Colitis

H.-S. Lee, H.J. Lee, H. Seo, M. Seo, E.M. Song, S.W. Hwang, S.H. Park, D.-H. Yang, K.-J. Kim, B.D. Ye, J.-S. Byeon, S.-J. Myung, S.-K. Yang
Asan Medical Center, University of Ulsan College of Medicine, Health Screening and Promotion Center, Seoul, South Korea and others

■ **P274**

Malignancy in perianal Crohn's Disease

F. Ficari, S. Scaringi, F. Giudici, D. Zambonin, C. Di Martino, F. Tonelli, P. Bechi
Careggi University Hospital, Surgery and Translational Medicine, Florence, Italy and others

■ **P275**

High incidence of clinically relevant findings at routinely performed bowel ultrasound in asymptomatic Inflammatory Bowel Disease patients

Z. Zelinkova, B. Repakova, B. Kadleckova
St. Michael's Hospital, Gastroenterology Department, Bratislava, Slovakia and others

■ **P276**

Faecal calprotectin is well correlated with quantitative faecal immunochemical test in UC but not in infectious colitis

H.-S. Kim, J.H. Seong, H.M. Kim, J. Kim
Yonsei University Wonju College of Medicine, Division of Gastroenterology and Hepatology, Wonju, South Korea and others

■ **P277**

Prediction of Crohn's Disease activity using contrast-enhanced sonography

M. Bialecki, A. Sławińska, A. Liebert, **M. Kłopotcka**, Z. Serafin
Nicolaus Copernicus University in Toruń, Collegium Medicum in Bydgoszcz, Department of Radiology and Diagnostic Imaging, Bydgoszcz, Poland and others

■ **P278**

Real time histology at endoscopy - virtual electronic chromoendoscopy and probe confocal laser endomicroscopy can assess fine details of inflammatory changes in Ulcerative Colitis patients

M. Iacucci, S. Gui X, A. Oluseyi, R. Panaccione, M. Fort Gasia, S. Ghosh
University of Calgary, Gastroenterology, Calgary, Canada and others

■ **P279**

Crohn's Disease-associated small bowel carcinomas show distinctive histologic and phenotypic features: An Italian multicentric study

A. Di Sabatino, A. Vanoli, F. Grillo, C. Mescoli, G. Nesi, P. Giuffrida, C. Papi, O. Luinetti, G. Sampietro, G. Latella, P. Fociani, F. Tonelli, R. Cannizzaro, L. Coppola, R. D'Inca, G. Monteleone, L. Biancone, G. Solina, V. Villanacci, M. Martini, A. Orlandi, A. Rizzo, M. Salemme, M. Astegiano, P. Migliora, M. Rugge, R. Fiocca, G.R. Corazza, E. Solcia
Fondazione IRCCS Policlinico San Matteo, University of Pavia, First Department of Medicine, Pavia, Italy and others

■ **P280**

Endoscopic training leads to a significant increase in agreement of endoscopic scoring for Inflammatory Bowel Disease (IBD): Final results of the IGBDEndo educational project

M. Daperno, M. Comberlato, F. Bossa, L. Biancone, A. Bonanomi, A. Cassinotti, R. Cosentino, R. Mangiarotti, G. Lombardi, A. Papa, R. Pica, M. Rabagliati, L. Grassano, M. Gasparini, G. Pagana, R. D'Inca, A. Orlando, F. Rizzello
AO Ordine Mauriziano, Gastroenterology Unit, Torino, Italy and others

■ **P281**

One simple question is sufficient for measuring medication adherence in Inflammatory Bowel Disease patients using self-report

M. Severs, M.-J. Mangen, H. H Fidder, M.E. van der Valk, M. van der Have, A. A van Bodegraven, C. HM Clemens, G. Dijkstra, J. M Jansen, D. J de Jong, N. Mahmmmod, P. C van de Meeberg, A. E van der Meulen- de Jong, M. Pierik, C. Y Ponsioen, M. JL Romberg- Camps, P. D Siersema, J.R. Vermeijden, J. van der Woude, P.N. Zuithoff, B. Oldenburg
University Medical Centre Utrecht, Gastroenterology and Hepatology, Utrecht, Netherlands and others

■ **P282**

The long term effect of the biologics in newborns

B. Truta, J. Canner, J. Efron, B. Safar
Johns Hopkins University, Baltimore, United States

■ **P283**

Development, validation and clinical application of a novel tool to measure disease-related knowledge in patients with Inflammatory Bowel Disease: IBD-KNOW

H. Yoon, S.-K. Yang, H. So, K.E. Lee, S.H. Park, S.-A. Jung, C.M. Shin, Y.S. Park, N. Kim, D.H. Lee
Seoul National University Bundang Hospital, Internal Medicine, Seongnam-si, South Korea and others

■ **P284**

Jejunal Crohn's Disease: Characteristics, detection rate, outcome and need of immunomodulators in a retrospective single-centre study

A. Ruffa, C. Petruzzello, E. Angelucci, G. Sica, S. Onali, A. Rossi, E. Calabrese, E. Lolli, F. Pallone, **L. Biancone**
University "Tor Vergata" of Rome, Department of Systems Medicine, Rome, Italy and others

■ **P285**

Extraintestinal manifestations of Crohn's Disease have a major influence on anxiety levels and coping skills

D. Schwartz, E. Chernin, D. Greenberg, O. Sarid, V. Slonim-Nevo, M. Friger, H. Vardi, S. Odes
Soroka UMC, Gastroenterology, Beer Sheva, Israel and others

■ **P286**

Long-term follow-up of polypoid dysplasia and assessment of peri-polyp biopsies of flat mucosa in patients with IBD-colitis

N. Krugliak Cleveland, D. Huo, F. Sadiq, A. Sofia, J. Marks, D. Rubin
University of Chicago Medicine, Inflammatory Bowel Disease Center, Chicago, United States

■ **P287**

Differentiating neoplastic and non neoplastic raised lesions (polyps and pseudopolyps) in long-standing Ulcerative Colitis: Results from a prospective systematic study using virtual chromoendoscopy with i-SCAN and the Kudo classification

A. Cassinotti, S. Ardizzone, P. Fociani, M. Nebuloni, P. Molteni, G. Maconi, S. Carmagnola, A. Dell'Era, A. Massari, R. de Franchis, P. Gambitta
Luigi Sacco University Hospital, Gastroenterology Unit, Milan, Italy and others

■ **P288**

A real-world study of outcomes in biologic-naive patients with Crohn's Disease and Ulcerative Colitis initiating vedolizumab

M. Raluy, N. Alam, R. Donaldson, M. Smyth, J.M. Khalid
Evidera, Hammersmith, United Kingdom and others

■ **P289**

Cytomegalovirus reactivation in Ulcerative Colitis is related to severe inflammatory activity

E. Zagorowicz, M. Bugajski, A. Mróz, A. Pietrzak, A. Magdziak, P. Wieszczy
Institute of Oncology, Gastroenterology, Warsaw, Poland and others

■ **P290**

Pre-operative anti-glycan antibodies and anti-glycan antibodies developing after pouch surgery in patients with Ulcerative Colitis correlate with pouch complications – a prospective longitudinal case series

I. Goren, L. Yahav, H. Tulchinsky, I. Dotan

Tel Aviv Medical Center, IBD Center, Department of Gastroenterology and Liver Diseases, Tel Aviv Sourasky Medical Center, Tel Aviv, Israel and others

■ **P291**

Sacroiliitis is underrecognised in Inflammatory Bowel Disease and is associated with previous arthritis and inflammatory Crohn's phenotype

O. Kelly, N. Li, J. Chan, R. Inman, M. Silverberg

Mount Sinai Hospital, Centre For Inflammatory Bowel Disease, Toronto, Canada and others

■ **P292**

Development of a predictive model for the diagnosis of Crohn's Disease when ileocolonoscopy is insufficient - a multicentre study

P. Boal Carvalho, M. Marques, B. Rosa, H. Cardoso, F. Machado, G. Macedo, J. Cotter

Hospital Senhora da Oliveira, Gastroenterology, Guimarães, Portugal and others

■ **P293**

Delayed timing of post-operative colonoscopy within 1 year does not predict a more severe Rutgeerts score

S. Singh, J. Pang, C. Seow, Y. Leung, K. Novak, R. Panaccione, G. Kaplan

University of Calgary, Gastroenterology, Calgary, Canada and others

■ **P294**

Distress in Inflammatory Bowel Disease: Development of a new assessment tool

L. Dibley, W. Czuber-Dochan, S. Woodward, P. Bassett, J. Sturt, C. Norton

King's College London, Florence Nightingale Faculty of Nursing & Midwifery, London, United Kingdom and others

■ **P295**

The Ulcerative Colitis endoscopic index of severity is useful to predict medium- to long-term prognosis in Ulcerative Colitis patients with clinical remission

M. Arai, M. Naganuma, S. Sugimoto, H. Kiyohara, K. Ohno, M. Mutaguchi, K. Mori, K. Nanki, S. Mizuno, R. Bessho, Y. Nakazato, N. Inoue, H. Ogata, Y. Iwao, T. Kanai

Keio University School of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Tokyo, Japan and others

■ **P296**

Evaluation of the new liaison faecal calprotectin assay

N. Hammoudi, H. Manceau, C. Stefanescu, D. Debuyser, Y. Bouhnik, H. Puy, **K. Peoc'h**

APHP HUPNVS Beaujon, Department of Gastroenterology and Nutrition, Clichy, France and others

■ **P297**

Ulcerative Colitis and proximal extension of the disease: A subgroup with worse prognosis?

P. Sousa, D. Martins, J. Pinho, R. Araújo, E. Cancela, A. Castanheira, P. Ministro, A. Silva

Centro Hospitalar Tondela-Viseu, Gastroenterology, Viseu, Portugal

■ **P298**

Comparison of the familial and sporadic cases of Inflammatory Bowel Diseases in long term follow up regarding step-up treatment, clinical and biochemical parameters

S. Bozcan, I. Hatemi, Y. Erzin, G. Ayan, A. Satman, T. Gundogdu, K. Atay, N. Demir, A.F. Celik

Istanbul University Cerrahpasa Medical School, Gastroenterology, Istanbul, Turkey

■ **P299**

Is quality of life different between Crohn's Disease patients submitted to early surgery or immunosuppression?

R. Barosa, M. Patita, G. Nunes, C. Carreira, C. Cruz, C. Boal, A.I. Vieira, J. Freitas

Hospital Garcia de Orta, Gastroenterology, Almada, Portugal

■ **P300**

Predictors of a second surgery in patients with Crohn's Disease: Are we following the right path?

S. Raimundo Fernandes, S. Bernardo, C. Baldaia, P. Moura Santos, A. Rita Gonçalves, A. Valente, L. Correia, J. Velosa
Centro Hospitalar Lisboa Norte, Gastroenterology, Lisbon, Portugal

■ **P301**

Gender influencing attitudes to IBD: A questionnaire investigating the impact of IBD on body-image, sexual function and family planning

K. Boland, M. Forry, N. Godwin, E. Tatro, F.E. Murray, G.C. Harewood, S. Patchett, A. O Toole
Beaumont Hospital, Department of Gastroenterology and Hepatology, Dublin, Ireland

■ **P302**

Faecal calprotectin correlates with small bowel inflammatory activity detected by capsule endoscopy in patients with established Crohn's Disease

M. Barbosa, S. Monteiro, T. Gonçalves, M.J. Moreira, B. Rosa, J. Cotter
Hospital da Senhora da Oliveira, Gastroenterology, Guimaraes, Portugal and others

■ **P303**

Factors associated with the development of extraintestinal manifestations in patients with Ulcerative Colitis

J. Yamamoto-Furusho, G. Sanchez-Morales
IBD Clinic, Instituto Nacional de Ciencias Medicas y Nutricion, Gastroenterology, Mexico, Mexico and others

■ **P304**

Patients with perianal Crohn's Disease have poor disease outcomes after primary bowel resection

Y.M. Han, J.W. Kim, J.H. Kim, S.-J. Koh, H. Yoon, C. Lee, J.P. Im, J.S. Kim
Seoul National University College of Medicine, Department of Internal Medicine and Liver Research Institute, Seoul, South Korea and others

Clinical: Therapy and observation

■ P305

No increased risk for infections with thiopurine-induced leucopenia in Inflammatory Bowel Disease patients without a variant in thiopurine S-methyltransferase

M. Broekman, M. Coenen, C. van Marrewijk, G. Wanten, L. Derijks, S. Vermeulen, D. Wong, O. Klungel, A. Verbeek, P. Hooymans, H. Scheffer, H.-J. Guchelaar, D. de Jong
Radboud University Medical Center, Department of Gastroenterology, Nijmegen, Netherlands and others

■ P306

The real-life experience of vedolizumab efficacy and safety in Ulcerative Colitis: A prospective observational multicentre cohort study

A. Amiot, L. Peyrin-Biroulet, C. Stefanescu, J.C. Grimaud, J. Filippi, B. Pariente, X. Roblin, R. Altwegg, D. Laharie, P. Marteau, A. Buisson, C. Trang-Poisson, S. Nancey, G. Savoye, S. Viennot, H. Brixix-Benmansour, F. Carbonnel, Y. Bouhnik
Henri Mondor Hospital, Gastroenterology, Creteil, France and others

■ P307

Safety, efficacy, and pharmacokinetics of golimumab in patients with moderately to severely active Ulcerative Colitis: PURSUIT-SC long term extension

W. Reinisch, P. Gibson, W.J. Sandborn, B. Feagan, C. Marano, R. Strauss, J. Johanns, H. Zhang, L. Padgett, O.J. Adedokun, J.-F. Colombel, J. Collins, P. Rutgeerts, D. Tarabar
Universitätsklinik für Innere Medizin III, Vienna, Austria and McMaster University, Hamilton, Canada and others

■ P308

Predictors of loss of response to adalimumab therapy; the importance of therapeutic drug monitoring in Inflammatory Bowel Diseases

Z. Kurti, Z. Vegh, M. Rutka, L. Gonczi, K. Farkas, K. Gecse, P.A. Golovics, B. Szalay, T. Molnar, P. Lakatos
Semmelweis University, 1st Department of Medicine, Budapest, Hungary and others

■ P309

High infliximab trough levels are associated with better control of inflammation in IBD

D. Drobne, T. Kurent, P. Rajar, M. Slak, M. Kozelj, G. Novak, N. Smrekar, S. Plut, A. Smid, J. Osredkar, B. Stabuc, I. Ferkolj
University Medical Centre Ljubljana, Department of Gastroenterology and Hepatology, Ljubljana, Slovenia and others

■ P310

Patient-reported quality of life during golimumab induction for moderate to severe Ulcerative Colitis in the United Kingdom: Results from the GO-COLITIS study

P. Irving, C. Probert, D.R. Gaya, P.J. Hamlin, S. Sebastian, G. Gillespie, H. Tate, C. Wheeler
Guy's and St Thomas' Hospitals, London, United Kingdom and others

■ P311

No difference in immunogenicity of the original and biosimilar infliximab in patients with Inflammatory Bowel Disease: Short-term results

K. Malickova, **D. Duricova**, M. Kolar, M. Bortlik, V. Hrubá, N. Machkova, K. Mitrova, M. Lukas jr., M. Lukas
1st Medical Faculty and General Teaching Hospital, Charles University, Institute of Medical Biochemistry and Laboratory Diagnostics, Prague, Czech Republic and others

■ P312

Has IBD specialists' awareness of biosimilar monoclonal antibodies changed? Results from a survey among ECCO members

S. Danese, G. Fiorino, P. Michetti
Humanitas Research Hospital, IBD Center, Gastroenterology, Rozzano, Milan, Italy and others

■ **P313**

Comparison of accelerated infliximab induction vs standard induction treatment in acute severe Ulcerative Colitis

M. Choy, D. Seah, A. Gorelik, F. Macrae, M. Sparrow, W.R. Connell, G. Moore, D. Van Langenberg, P. De Cruz
Austin Health, Department of Gastroenterology, Melbourne, Australia and others

■ **P314**

Proposal for an anti-TNF-exit strategy based on trough serum level

U. Helwig, F. Lutter, N. Koppka, S. Schreiber
University of Kiel, Medical Practice for Internal Medicine, Oldenburg, Germany and others

■ **P315**

Impact of age on beliefs about and adherence to medications in patients with Inflammatory Bowel Disease: Results from the ALIGN study

P. Michetti, L. Peyrin-Biroulet, M.S. Silverberg, E. Louis, J. Weinman, J. Sommer, J. Petersson, B. Pappalardo, P. Nurwakagari
IBD Centre La Source-Beaulieu, Lausanne, Switzerland and others

■ **P316**

Prognosis of patients with Inflammatory Bowel Disease in clinical remission after de-escalation of infliximab maintenance therapy from 8 to 12 weeks

J.M. Vázquez-Morón, **B. Benítez-Rodríguez**, H. Pallarés-Manrique, M. Ramos-Lora
Hospital General Juan Ramón Jiménez, Gastroenterology Unit, Huelva, Spain

■ **P317**

Health care costs associated with standard Inflammatory Bowel Disease care in Australia and opportunities to improve care: A tertiary centre study

B. Jackson, R. Ma, A. Gorelik, D. Con, D. Liew, P. De Cruz
Austin Health, Gastroenterology, Melbourne, Australia and others

■ **P318**

Does anti-tumor necrosis factor therapy decrease the risk of initial intestinal resection after the diagnosis of Crohn's Disease? A retrospective single centre study

Y. Nagata, M. Esaki, A. Hirano, J. Umeno, Y. Maehata, T. Torisu, T. Moriyama, T. Matsumoto, T. Kitazono
Graduate School of Medical Sciences, Kyushu University, Department of Medicine and Clinical Science, Fukuoka, Japan and others

■ **P319**

Combining anti-inflammatory treatment with antiviral treatment in severe CMV positive Ulcerative Colitis does not affect colectomy rate: A retrospective European multicentre study

U. Kopylov, K. Papamichael, K. Katsanos, M. Waterman, A. Bar-Gil Shitrit, T. Boysen, F. Portela, A. Peixoto, A. Szilagyi, M. Silva, G. Maconi, O. Har-Noy, P. Bossuyt, G. Mantzaris, M. Barreiro de Acosta, M. Chaparro, D. Christodoulou, R. Eliakim, J.-F. Rahier, F. Magro, S. Ben-Horin, X. Roblin
Sheba Medical Center, Gastroenterology, Tel Hashomer, Israel and others

■ **P320**

Clinical and economic impact of short infliximab infusion protocol in patients with Inflammatory Bowel Diseases (IBD): A multicentre study

M. Cappello, G. Costantino, A.C. Privitera, F. Bossa, A. Lauria, L. Grossi, M.B. Principi, N. Della Valle, M.A. Veneziano, D. Crocchiolo
University of Palermo, Gastroenterology Section, DiBiMis, Palermo, Italy and others

■ **P321**

Mucosal healing in a cohort of IBD paediatric patients in clinical remission

F.P. Giugliano, **C. Strisciuglio**, M. Martinelli, M. Andreozzi, S. Cenni, A. Staiano, E. Miele
University Federico II, Department of Translational Medical Science, Section of Paediatrics, Naples, Italy and others

■ **P322**

Complications to parenteral therapy in patients with intestinal failure due to Inflammatory Bowel Disease. A retrospective cohort study

R. Lorentsen, L.K. Munck, **S. Wildt**

Køge University Hospital, and Faculty of Health Sciences, University of Copenhagen, Section of Gastroenterology, Medical department, Køge, Denmark

■ **P323**

Prevalence of vitamin D deficiency in patients with IBD

N. Toke, P. Kakkadasam Ramaswamy, B. Sebastian, S. Mathai, C. Panackel

Medical Trust Hospital, Department of Gastroenterology, Ernakulam, India

■ **P324**

Comparative short and long-term efficacy of infliximab and adalimumab in patients with Ulcerative Colitis refractory to corticosteroids: A retrospective study

N. Yoshimura, M. Sako, M. Takazoe

Tokyo Yamate Medical Centre, Department of Internal Medicine, Tokyo, Japan

■ **P325**

Efficacy, safety and long-term outcome of endoscopic dilation therapy for stricturing Crohn's Disease of the upper gastrointestinal tract - A combined analysis of 127 endoscopic balloon dilation procedures

D. Bettenworth, M.M. Mücke, A. Singh, R. Lopez, F. Rieder

University Hospital Münster, Department of Medicine B, Münster, Germany and others

■ **P326**

Validation of CUCQ-8 questionnaire for quality of life assessment in IBD patients

C. McGinley, C. Mowat, M. Groome, J. Todd, N. Reynolds

University of Dundee, Dundee, United Kingdom and others

■ **P327**

Biosimilar infliximab in real-life Crohn's Disease's anti-TNF alpha naïve patients: A comparative observational cohort study (SIMRECRO study)

L. Carvalho Lourenço, V. Anapaz, A.M. Oliveira, J. Branco, M. Cardoso, C. Graça Rodrigues, L. Santos, D.

Horta, A. Martins, J. Reis

Hospital Prof. Dr. Fernando Fonseca, Serviço de Gastrenterologia, Amadora, Portugal

■ **P328**

Factors related to short- and long-term treatment results and usefulness of infliximab for refractory Ulcerative Colitis

Y. Takada, S. Yasukawa, R. Amano, M. Yasaka, N. Takatsu, Y. Yano, F. Hirai

Fukukuoka University Chikushi hospital, Chikushino-shi, Japan

■ **P329**

Infliximab biosimilar in the treatment of Inflammatory Bowel Disease: A Japanese single cohort observational study

S. Hamanaka, T. Nakagawa, H. Koseki, T. Sakurai, T. Taida, K. Okimoto, K. Saito, D. Maruoka, T. Matsumura,

T. Katsuno, M. Arai, O. Yokosuka

Graduate School of Medicine, Chiba University, Department of Gastroenterology and Nephrology, Chiba city, Japan

■ **P330**

Vitamin D insufficiency in patients with Inflammatory Bowel Disease

M.d.C. Martos Plasencia, C. Verdejo Gil, R.H. Lorente Poyatos, E. De la Santa Belda, M. Peña Gómez, R.

Salmoral Luque, B. López Viedma, J. Olmedo Camacho

University Hospital of Ciudad Real, Gastroenterology and Hepatology Department, Ciudad Real, Spain

■ **P331**

Allopurinol and azathioprine co-therapy or thioguanine dose splitting: Shifting the shunters in the mercaptopurine pathway in a paediatric IBD population: A single centre experience

S. Chadokufa, A. Lozinsky Rolnik, S. Sider, N. Acton, B. Huggett, N. Shah, F. Kiparissi

Great Ormond Street Hospital, Gastro, London, United Kingdom and others

■ **P332**

Influence of mesalamine maintenance therapy on progression of ulcerative proctitis in Korea

Y.S. Choi, **W.J. Kim**, H.-J. Jung, J.K. Kim, K.-H. Song
Daehang Hospital, Gastroenterology, Seoul, South Korea and others

■ **P333**

Long term efficacy and safety of thiopurines in patients with steroid dependent Ulcerative Colitis: A retrospective investigation

Y. Yokoyama, T. Sato, M. Kawai, Y. Kita, K. Kamikozuru, T. Miyazaki, M. Iimuro, N. Hida, S. Nakamura
Hyogo College of Medicine, Department of Inflammatory Bowel Disease, Division of Internal Medicine, Nishinomiya, Japan

■ **P334**

Evolution of a long term follow up cohort of Crohn's Disease with complex perianal fistulae: From antibiotic to combined AZA and anti-TNF based treatment ending up clinical and radiological healing with or without stoma

Y. Erzin, K. Ercaliskan, I. Hatemi, K. Atay, S. Bozcan, N. Demir, A.F. Celik
Istanbul University Cerrahpasa Medical School, Gastroenterology, Istanbul, Turkey

■ **P335**

Cancer recurrence with immunosuppressive therapy in immune mediated diseases: A systematic review and meta-analysis

E. Shelton, D. Laharie, F. Scott, R. Mamtani, J. Lewis, J.-F. Colombel, A. Ananthakrishnan
Massachusetts General Hospital, Boston, United States and others

■ **P336**

French prospective, longitudinal observational study of the therapeutic management of mild to moderate Ulcerative Colitis (Optimum study): Follow-up at 3 years

S. Nahon, G. Bonnaud, F. Bahbah
Centre Hospitalier Le Raincy, Montfermeil, France and others

■ **P337**

Anti-TNF alpha therapy is associated with rapid reduction of circulating monocyte numbers and blunted monocyte pro-inflammatory response in patients with Crohn's Disease

S. Slevin, C. Denny, A. Ribeiro, R. Ceredig, M. Griffin, L. Egan
National University of Ireland Galway, REMEDI, Galway, Ireland and others

■ **P338**

Rate and predictors of mucosal healing in patients with Ulcerative Colitis treated with thiopurines: Results of a multicentric cohort study

C. Prioux-Klotz, S. Nahon, A. Amiot, L. Sinayoko, C. Galéano-Cassaz, S. Chaussade, P. Lahmek, V. Abitbol
C.H.U. Cochin, Paris, France and others

■ **P339**

The efficacy of intravenous iron therapy in IBD patients with active disease is not influenced by the degree of inflammatory activity

A. Walper, A. Dignass, J. Stein
Medice Arzneimittel GmbH, Iserlohn, Germany and others

■ **P340**

Post-operative clinical recurrence in Crohn's Disease patients: The practiccrohn study

E. Domènech, V. García, M.D. Martín Arranz, M. Barreiro-de Acosta, A. Gutiérrez, L. Cea-Calvo, C. Romero, B. Juliá
Hospital Universitari Germans Trias i Pujol and CIBERehd, Gastroenterology Unit, Badalona, Spain and others

■ **P341**

Analytical performance of a new iPhone-based patient monitoring system comparable to ELISA for measuring faecal calprotectin in IBD patients

K.F. Wintgens, A.A. Wulandari, A. Dignass, F. Hartmann, J. Stein
Immundiagnostik AG, Bensheim, Germany and others

■ P342***Tryptophan as a biomarker for the course of IBD and anti-TNF α response***

B. Brandt, S. Nikolaus, N. Al-Massad, J. Bethge, D. Schuldt, S. Szymczak, F. Thieme, G.H. Waetzig, M. Krawczak, R. Junker, P. Rosenstiel, S. Schreiber
UKSH Kiel, Department of Internal Medicine I, Kiel, Germany and others

■ P343***The prevalence of irritable bowel syndrome-type symptoms in paediatric Inflammatory Bowel Disease and the relationship with biochemical markers of disease activity***

K. Diederer, **D. Hoekman**, T. Hummel, T. de Meij, B. Koot, M. Tabbers, A. Vlieger, A. Kindermann, M. Benninga
Academic Medical Center (AMC), Department of Paediatric Gastroenterology, Amsterdam, Netherlands and others

■ P344***Non-adherence to medical therapy is associated with hospitalisations and the development of active disease in Inflammatory Bowel Disease***

M. Severs, H. H Fidler, M.-J. Mangen, M.E. van der Valk, M. van der Have, A. A van Bodegraven, C. HM Clemens, G. Dijkstra, J. M Jansen, D. J de Jong, N. Mahmmod, P. C van de Meeberg, A. E van der Meulen- de Jong, M. Pierik, C. Y Ponsioen, M. JL Romberg- Camps, P.D Siersema, J.R. Vermeijden, J. van der Woude, P.N. Zuithoff, B. Oldenburg
University Medical Centre Utrecht, Gastroenterology and Hepatology, Utrecht, Netherlands and others

■ P345***The great continental divide: Use of anti-TNF therapy in paediatric IBD is significantly different in North America compared to other parts of the world***

P. Church, J. Hyams, F. Ruemmele, L. de Ridder, D. Turner, **A. Griffiths**, on behalf of the International Paediatric IBD Network (PIBDNet)
Hospital for Sick Children, University of Toronto, Department of Gastroenterology, Hepatology and Nutrition, Toronto, Canada and others

■ P346***Soluble transferrin receptor (sTfR) and its relation to anaemia in Inflammatory Bowel Disease***

R. Dudkowiak, K. Neubauer, E. Poniewierka
Wroclaw Medical University, Department of Gastroenterology and Hepatology, Wroclaw, Poland

■ P347***Identification of a cut-off for persistent anti-infliximab antibodies as a predictor of response to infliximab monotherapy***

L. Del Nero, G. Bodini, E. Giannini, J. Anjali, V. Savarino, E. Savarino
University of Genoa, Internal medicine department, Genoa, Italy and others

■ P348***Novel model of care: The impact of a combined IBD & antenatal clinic***

C. Selinger, N. Carey, G. Ulivi, L. Walker, F. Shaik, T. Glanville
St James University Hospital, Gastroenterology, Leeds, United Kingdom and others

■ P349***The effects of smoking on thiopurine metabolism***

B. Warner, E. Johnston, S. Fong, P. Blaker, M. Arenas-Hernandez, A. Marinaki, J. Sanderson
Guy's and St Thomas' NHS Foundation Trust, Gastroenterology, London, United Kingdom and others

■ P350***The use of concomitant immunomodulators with adalimumab therapy in paediatric Crohn's Disease***

K. Benkov, G. Russell, C. Samson, S. Steiner, E.C. King, J. Pratt, S. Eichner, R.B. Colletti, & ImproveCareNow Network
Icahn School of Medicine at Mount Sinai, Division of Paediatric Gastroenterology, New York, United States and others

■ **P351**

Faecal calprotectin correlates well with extent of active endoscopic inflammation in patients with Ulcerative Colitis

D. Chayut, M. Kaplan, Y. Chowers, **M. Waterman**

The Technion - Israel Institute of Technology, B. Rappaport Faculty of Medicine, Haifa, Israel and others

■ **P352**

Melanoma in a population based Australian Inflammatory Bowel Disease cohort

G. Hume

University of Queensland, School of Medicine, Brisbane, Australia

■ **P353**

Endoscopy-based management within the first year after surgery decreases the risk of clinical and surgical postoperative recurrences in Crohn's Disease

A.-L. Boucher, B. Pereira, S. Decousus, M. Goutte, F. Goutorbe, A. Dubois, J. Gagnière, C. Borderon, J. Joubert, D. Pezet, M. Dapoigny, P. Dechelotte, G. Bommelaer, **A. Buisson**

University Hospital Estaing, Gastroenterology Department, Clermont-Ferrand, France and others

■ **P354**

A prospective randomized Study: 2 mg/kg/d of azathioprine is an appropriate dosage for Chinese patients with Crohn's Disease

Y. Zhang, J. Xia, Q. Cao

Sir Runrun Shaw Hospital, Zhejiang University School of Medicine, Department of Gastroenterology, Hangzhou, China

■ **P355**

Examining maintenance care following infliximab salvage therapy for acute severe Ulcerative Colitis

D. Seah, M. Choy, A. Gorelik, F. Macrae, M. Sparrow, W.R. Connell, G. Moore, D. Van Langenberg, P. De Cruz

Austin Health, Department of Gastroenterology, Melbourne, Australia and others

■ **P356**

Efficacy and safety of certolizumab pegol in Crohn's Disease patients with loss of response or intolerance to previous AntiTNF

I. Ferrer Bradley, I. Marín, N. Maroto, M. Mora, E. Hinojosa, B. López, L. Menchén, J. Hinojosa

Hospital de Manises, Gastroenterology, Valencia, Spain and others

■ **P357**

Do you think that complementary and alternative medicine use is frequent among IBD patients? - Forget it! - Results from a comparative study

M. Rutka, T. Ferenci, F. Nagy, Z. Szepes, K. Farkas, A. Bálint, R. Bor, A. Milassin, Z. Lénárt, T. Molnar

University of Szeged, 1st Department of Medicine, Szeged, Hungary and others

■ **P358**

Six year adalimumab efficacy in steroid-dependent Crohn's Disease patients: A prospective "real life" study

S. Renna, M. Cappello, R. Dimitri, F. Mocciano, M. Mazza, M. Giunta, M. Mendolaro, E. Orlando, M. Affronti, A. Craxi, M. Cottone, A. Orlando

"Villa Sofia-Cervello" Hospital, Division of Internal Medicine, Palermo, Italy and others

■ **P359**

Correlation of simple laboratory tests with clinical disease activity scores in IBD

O. Tayfur Yurekli, H. Koseoglu, M. Basaran, N.S. Buyukasik, a. Demirezer Bolat, **F.E. Akin**, m. Tahtaci, e. Selvi, O. Ersoy

Ankara Ataturk Research and Education Hospital, Gastroenterology, Ankara, Turkey

■ P360

A randomised, assessor-blinded, multi-centre trial comparing the efficacy, safety and tolerability of a new tailored dosing regimen to day-before dosing regimen of colon cleansing agent used prior to colonoscopy

R. Kiesslich, C. Angelin, K. Raymond, W. Man A Hing, J. Masure, M. Stoltenberg

Helios Dr. Horst Schmidt Kliniken, Department of Internal Medicine II, Wiesbaden, Germany and others

■ P361

Adherence to faecal calprotectin test in patients with Inflammatory Bowel Disease

C. Marechal, I. Gastin, C. Baumann, B. Dirrenberger, J.-L. Gueant, L. Peyrin-Biroulet

University hospital, Gastro-enterology, Vandoeuvre-les-Nancy, France and others

■ P362

Anti-virus treatment against CMV in patients with Ulcerative Colitis by the PCR monitoring for mucosal CMV-DNA

M. Tanaka, T. Takagi, Y. Toyokawa, Y. Hotta, K. Uchiyama, Y. Naito, Y. Itoh

Kyoto Prefectural University of Medicine, Graduate School of Medical Science, Department of Molecular Gastroenterology and Hepatology, 465 Kajii-cho, Kawaramachi-Hirokoji, Kamigyo-ku, Kyoto, Japan

■ P363

Efficacy and safety of golimumab in patients with Ulcerative Colitis: A prospective multicentre study

D. Varvara, G. Costantino, A.C. Privitera, B. Principi, M. Cappello, S. Mazzuoli, P. Paiano, A. Tursi, P. Paese,

W. Fries, A. Andriulli, **F. Bossa**

IRCCS Casa Sollievo della Sofferenza, Gastroenterology, San Giovanni Rotondo, Italy and others

■ P364

The efficacy of initial treatment with infliximab without previous conventional therapy in patients with moderate to severe Ulcerative Colitis

O. Prymak

Medical Clinical Investigational Center of Medical Center LLC Health Clinic, Vinnytsia, Ukraine

■ P365

Real-world effectiveness of adalimumab in patients with Ulcerative Colitis

A. Armuzzi, C. Taxonera, J. Panes, P. Lakatos, N. Fisseha, B. Pappalardo

Complesso Integrato Columbus-Gemelli University Hospital Foundation, IBD Unit, Rome, Italy and others

■ P366

Escherichia coli Nissle 1917 in Ulcerative Colitis treatment: Systematic review and meta-analysis

G. Losurdo, A. Iannone, A. Contaldo, E. Ierardi, A. Di Leo, M. PRINCIPI

University of Bari, DETO, Bari, Italy

■ P367

Lower quality of life, more active disease and increased healthcare costs due to non-adherence in Inflammatory Bowel Disease

M. Severs, M.-J. Mangen, H. H Fidler, M.E. van der Valk, M. van der Have, A. A van Bodegraven, C. HM Clemens, G. Dijkstra, J. M Jansen, D. J de Jong, N. Mahmmod, P. C van de Meeberg, A. E van der Meulen- de Jong, M. Pierik, C. Y Ponsioen, M. JL Romberg- Camps, P. D Siersema, J.R. Vermeijden, J. van der Woude, P.N. Zuithoff, B. Oldenburg

University Medical Centre Utrecht, Gastroenterology and Hepatology, Utrecht, Netherlands and others

■ P368

Risk factors for serious infections in elderly patients receiving infliximab and other Crohn's Disease therapies: TREAT™ registry data

G. Lichtenstein, W. Langhoff, **B. Feagan**, R. Cohen, B. Salzberg, J. Popp, R. Nissinen, W.J. Sandborn

University of Pennsylvania Perelman School of Medicine, Division of Gastroenterology, Philadelphia, United States and others

■ **P369**

Improvement in patient-reported outcomes in two phase 3 studies of tofacitinib in patients with moderately to severely active Ulcerative Colitis

J. Panés, C. Su, A. Marren, D. Yu, D. Woodworth, H. Zhang, P. Healey
Hospital Clínicas de Barcelona, IDIBAPS, CIBERehd, Barcelona, Spain and others

■ **P370**

Treatment patterns in a managed care project with Inflammatory Bowel Disease patients in Germany: CEDnetz-Study

B. Bokemeyer, J. Langbrandtner, P. Jessen, J. Büning, S. Schreiber, H. Raspe, A. Hüppe
Gastroenterology Practice Minden, University Hospital Schleswig-Holstein, Department of General Internal Medicine I, Kiel, Germany, Minden, Germany and others

■ **P371**

Concentrations of 6-thioguanine nucleotide correlate with both infliximab and adalimumab levels in patients with Inflammatory Bowel Disease on combination therapy

O. Kelly, A. Trajkovski, A. Weizman, G. Nguyen, A.H. Steinhart, M. Silverberg, K. Croitoru
Mount Sinai Hospital, Centre For Inflammatory Bowel Disease. Suite 437, Toronto, Canada

■ **P372**

A multi-centre, double-blind, placebo controlled, parallel group, proof of concept study to evaluate the efficacy, safety and tolerability of the S1P receptor modulator KRP203 in subjects with moderately active refractory Ulcerative Colitis

H.H. Radeke, J. Stein, W. Kruis
Interdisciplinary Crohn Colitis Centre Rhein-Main, Frankfurt/Main, Germany and others

■ **P373**

Adjunctive hyperbaric oxygen therapy promotes successful healing in patients with refractory Crohn's Disease

M. Ribeiro Feitosa, **R.S. Parra**, O. Feres Filho, J. J. Ribeiro da Rocha, O. Féres
University of Sao Paulo, Surgery and Anatomy, Ribeirao Preto SP, Brazil and others

■ **P374**

Efficacy of a micronised, dispersible ferric pyrophosphate in children with anaemia associated with Inflammatory Bowel Disease

A. Wegner, G. Mierzwa, S. Wiecek, A. Korlatowicz- Bilar, M. Dadalski, B. Korczowski, J. Kierkus
Public Children's Clinical Hospital, Warszawa, Poland and others

■ **P375**

Long-term outcomes after primary infliximab treatment failure in patients with Inflammatory Bowel Disease

S. Buhl, C. Steenholdt, M. Borghede, M. Rasmussen, J. Brynskov, O. Ø. Thomsen, M.A. Ainsworth
Copenhagen University Hospital, Herlev, Dept. of Gastroenterology, Herlev, Denmark

■ **P376**

Therapy refractory Ulcerative Colitis patients may benefit from appendectomy; early result from the PASSION study

S. Sahami, C. Buskens, D. Winter, S. Martin, P. Tanis, G. van den Brink, M. Löwenberg, G. Cullen, H. Mulcahy, G. Doherty, C. Ponsioen, G. D'Haens, W. Bemelman
Academic Medical Center, Surgery, Amsterdam, Netherlands and others

■ **P377**

Serum adalimumab trough levels required for mucosal healing during maintenance therapy in patients with Crohn's Disease

H. Imaeda, Y. Morita, T. Fujimoto, K. Takahashi, M. Shioya, A. Nishida, O. Inatomi, S. Bamba, M. Sasaki, T. Tsujikawa, M. Sugimoto, A. Andoh
Shiga University of Medical Science, Department of Medicine, Otsu, Japan

■ **P378**

The outcomes of a clinical care pathway for IBD surgery

A. Platt, A. Lightner, R. Jacobs, D. Sagar, W. van Deen, T. Hommes, S. Reardon, J. Sack, D. Hommes
UCLA Center for Inflammatory Bowel Diseases, Department of Digestive Diseases, Los Angeles, United States and others

■ **P379**

Inflammatory Bowel Disease-induced chronic abdominal pain can be ameliorated by transcranial direct current stimulation

M.S. Prüb, A. Farmer, B. Siegmund

Charité - University Hospital Berlin, Campus Benjamin Franklin, Department of Gastroenterology, Berlin, Germany

■ **P380**

Comparative study of infliximab and adalimumab induction therapy for clinical remission and mucosal healing in paediatric patients with active Crohn's Disease

E. Szymanska, M. Dadalski, S. Szymanska, W. Grajkowska, M. Pronicki, K. Jaroslaw

Children's Memorial Health Institute, Department of Paediatrics, Nutrition and Metabolic Disorders,, Warsaw, Poland and others

■ **P381**

An observational study of adverse events of patients with IBD receiving parenteral iron

A. Wilson, E. Murray, G.B. Turner

Belfast Trust, Belfast, United Kingdom

■ **P382**

Comparison of efficacy and safety of biosimilar infliximab to originator infliximab in children with Inflammatory Bowel Disease

R. Muhammed, L. Whyte, S. Protheroe, R. Bremner, W. Haller, T. Wong

Birmingham Children's Hospital, Gastroenterology, Birmingham, United Kingdom

■ **P383**

Short- and long-term outcomes of infliximab and calcineurin inhibitor treatment for steroid-refractory Ulcerative Colitis

S. Motoya, M. Miyakawa, M. Nasuno, H. Tanaka

Sapporo-Kosei General Hospital, IBD center, Sapporo, HOKKAIDO, Japan

■ **P384**

The usefulness of salazosulfapyridine for patients with Ulcerative Colitis refractory to mesalazine

T. Yoshino, S. Yazumi

Kitano Hospital, Division of Gastroenterology and Hepatology, Digestive Disease Center, Osaka, Japan

■ **P385**

Predictors of tissue healing in Ulcerative Colitis patients treated with anti-TNF

N. Viazis, M. Giakoumis, G. Bamias, D. Goukos, T. Koukouratos, J. Anastasiou, K. Katopodi, S. Ladas, D. Karamanolis

Evangelismos Hospital, Gastroenterology Department, Athens, Greece and others

■ **P386**

Anti-TNF alpha as induction and maintenance therapy in Ulcerative Colitis patients in the BioColitis Registry in Germany

B. Bokemeyer, T. Krummenerl, C. Maaser, J. Büning, R. Atreya, A. Lügering, U. Helwig, P. Jessen, P. Hartmann, S. Schreiber

Gastroenterology Practice Minden, University Hospital Schleswig-Holstein, Department of General Internal Medicine I, Kiel, Germany, Minden, Germany and others

■ **P387**

Does standard therapy in paediatric Crohn's Disease really prevent our patients from the need of early initiation of anti-TNF treatment?

P. Dominguez Sánchez, G. Pujol Muncunill, S. Pinillos Pison, V. Vila Miravet, J. Martín de Carpi

Unit for the Comprehensive Care of Paediatric Inflammatory Bowel Disease, Department of Paediatric Gastroenterology, Hepatology and Nutrition, Hospital Sant Joan de Déu, Barcelona, Spain

■ **P388**

Clinical care pathways are needed to decrease variability in the management of the hospitalised Ulcerative Colitis patient

S. Shah, S. Naymagon, B. Cohen, B. Sands, M. Dubinsky

Mount Sinai Hospital, Gastroenterology, New York, United States

■ **P389**

The value of oxidative stress parameters to predict histological severity in Ulcerative Colitis

B. Canbakan, K. Atay, E. Koroglu, M. Tuncer, H. Senturk
Istanbul University Cerrahpasa Medical School, Gastroenterology, Istanbul, Turkey and others

■ **P390**

To double dose or not to double dose? That is the question: Single centre experience in the use of infliximab antibodies and levels in a paediatric IBD (pIBD) cohort

B. Huggett, S. Sider, S. Chadokufa, N. Acton, N. Shah, F. Kiparissi
Great Ormond Street Hospital, London, United Kingdom

■ **P391**

Gender differences in adalimumab continuation rates: Results of a Crohn's Disease cohort

M. Lie, J. Kreijne, J. van der Woude
Erasmus MC, Gastroenterology and Hepatology, Rotterdam, Netherlands

■ **P392**

Comparing the accuracy and ease of use of self-administered "Malnutrition Universal Screening Tool" (MUST) to screening by a health care professional using MUST to explore malnutrition rates in an outpatient Inflammatory Bowel Disease clinic

S. Zacharopoulou-Otapasidou, K. Keetarut, S. Bloom, S. McCartney
University College London Hospital, Nutrition and Dietetics Department, London, United Kingdom and others

■ **P393**

Investigation of Crohn's Disease patients receiving anti-TNF α therapy after surgery for intestinal stenosis

T. Kuriyama, B. Iizuka, H. Kashiwagi, T. Hara, A. Ito, T. Omori, M. Yonezawa, K. Tokushige
Tokyo Women's Medical University, Gastroenterology, Tokyo, Japan

■ **P394**

Psychosexual dysfunction in a cohort of Greek Inflammatory Bowel Disease patients in clinical remission: Preliminary results

D. Xanthis, K. Soufleris, E. Gavalas, P. Anyfanti, G. Chatzinakos, N. Grammatikos, A. Tsimperidis, O. Giouleme
Aristotle University of Thessaloniki, Second Propedeutic Department of Internal Medicine, Thessaloniki, Greece

■ **P395**

Real life prospective experience with adalimumab in Ulcerative Colitis in Italy: Preliminary results of a pilot study

M. Daperno, A. Armuzzi, D. Pugliese, A. Lavagna, P. Gionchetti, F. Rizzello
AO Ordine Mauriziano, Gastroenterology Unit, Torino, Italy and others

■ **P396**

Cyclosporin A efficacy in a paediatric Ulcerative Colitis - A retrospective single centre study

M. Osiecki, M. Dadalski, J. Kierkus
The Children's Memorial Health Institute, Gastroenterology, Hepatology, Feeding Disorders and Paediatrics, Warsaw, Poland

■ **P397**

Efficacy and safety of sequential rescue therapy with infliximab and tacrolimus in patients with corticosteroid-refractory Ulcerative Colitis

K. Matsuoka, E. Saito, T. Fujii, K. Takenaka, F. Iwamoto, M. Kimura, M. Nagahori, K. Ohtsuka, M. Watanabe
Tokyo Medical and Dental University, Department of Gastroenterology and Hepatology, Tokyo, Japan

■ **P398**

The costs of care for patients with Ulcerative Colitis: Effect of adalimumab on health care resources utilisation in clinical practice from INSPIRADA

S. Travis, B. Feagan, L. Peyrin-Biroulet, R. Panaccione, S. Danese, A. Lazar, A. Robinson, J. Petersson, M. Bereswill, M. Skup, N. Chen, S. Wang, R. Thakkar, J. Chao
Oxford University Hospitals, Oxford, United Kingdom and others

■ **P399**

Testing patients initiating anti-TNF α agents for mycobacterial infection using interferon-gamma release assays (IGRA): The combined experience of a large dermatology and Inflammatory Bowel Disease service

S. Rajagopal, K. Greveson, S. McBride, A. Waite, M. Lipman, C. Murray
University College London, Medicine, London, United Kingdom and others

■ **P400**

Anti-TNF treatment for extraintestinal manifestations of Inflammatory Bowel Disease in the Swiss IBD Cohort Study

T. Greuter, L. Biedermann, G. Rogler, E. Safroneeva, A. Schoepfer, S. Vavricka
University Hospital Zurich, Division of Gastroenterology and Hepatology, Zurich, Switzerland and others

■ **P401**

Confocal laser endomicroscopy predicts response in patients with acute Inflammatory Bowel Disease undergoing anti-integrin therapy with vedolizumab

M. Ellrichmann, J. Bethge, G. Aust, A. Arlt, B. Brandt, S. Zeissig, S. Nikolaus, K. Aden, S. Schreiber
University Hospital Schleswig-Holstein, Campus Kiel, Medical Department I, Kiel, Germany and others

■ **P402**

A novel high-dose mesalazine tablet is as effective as conventional low-dose mesalazine tablets in inducing remission in patients with mildly to moderately active Ulcerative Colitis (UC): A double-blind, double-dummy, multicentre, randomised trial

A. Dignaß, R. Schnabel, J. Romatowski, V. Pavlenko, A. Dorofeyev, J. Derova, L. Jonaitis, T. Nacak, R. Greinwald
Agaplesion Markus Krankenhaus, Dept. of Medicine I, Frankfurt a. M., Germany and others

■ **P403**

Combined therapy with anti-TNF and immunomodulator is superior to monotherapy for post-operative prophylaxis in Crohn's Disease after intestinal resection: A retrospective analysis from a tertiary centre

A. O'Connor, J. Taylor, N. Scott, C. Selinger, J. Hamlin, A. Ford
Leeds Gastroenterology Institute, Leeds, United Kingdom and others

■ **P404**

Real-life experience with golimumab in Ulcerative Colitis patients according to prior anti-TNF use

C. Taxonera, F. Bertoletti, C. Rodriguez, I. Marin, J. Arribas, P. Martinez-Montiel, M. Sierra, L. Arias, M. Rivero, A. Juan, E. Iglesias, N. Mancañido, J.L. Perez-Calle, A. Algaba, M. Barreiro-de Acosta, A. Gutierrez, F. Argüelles, D. Busquets, M. Chaparro, C. Alba, D. Olivares, M. Calvo, J.P. Gisbert
Hospital Clinico San Carlos, IBD Unit, Madrid, Spain and others

■ **P405**

Infliximab trough level measured during treatment induction may be predictive of the loss of response to Infliximab during treatment maintenance in Inflammatory Bowel Disease patients: A longitudinal observational retrospective study

C. Liefverinckx, C. Minsart, A. Cremer, L. Amininejad, J.-F. Toubeau, E. Quertinmont, J. Deviere, A. Van Gossum, D. Franchimont
Erasme Hospital, Gastro-enterology, Brussels, Belgium and others

■ **P406**

AlphaE+ cells have increased expression of inflammatory markers and are correlated in the ileum and colon

R. Ichikawa, J. Eastham-Anderson, A. Scherl, J. Hackney, L. Orozco, W. Faubian, J. Mansfield, J. Kirby, C. Lamb, **M. Keir**
Genentech, Inc., a member of the Roche Group, South San Francisco, United States and others

■ **P407**

Clinical manifestations of thiopurine S-methyltransferase variants in Korean paediatric patients with Inflammatory Bowel Disease

M. Kim
Inje University College of Medicine, Ilsan Paik Hospital, Paediatrics, Goyang-si, Gyeonggi-do, South Korea

■ **P408**

Are pharmacokinetics more unfavourable in IBD patients aged over 60 years?

L. Rinaldi, **N. Williet**, E. Del tesesco, c. Jarlot, J.M. Phelip, s. Paul, X. Roblin
Gastroenterology, Saint Etienne, France and others

■ **P409**

Impact of biological therapy in postoperative morbidity in elective surgical resections in Crohn's Disease

P.G. Kotze, M.P. Saab, B. Saab, L.M.S. Kotze, M. Olandoski, L.V. Pinheiro, C.A.R. Martinez, M.L.S. Ayrazono, D.O. Magro, C.S.R. Coy
Catholic University of Paraná, Colorectal Surgery Unit - Cajuru University Hospital, Curitiba, Brazil and others

■ **P410**

Segmental endoscopic scoring improves outcome prediction in acute severe colitis

S. Raimundo Fernandes, P. Santos, C. Moura, P. Marques da Costa, J. Rita Carvalho, C. Baldaia, A. Valente, A. Rita Gonçalves, P. Moura Santos, L. Correia, J. Velosa
Centro Hospitalar Lisboa Norte, Gastroenterology, Lisbon, Portugal

■ **P411**

Four-year efficacy and safety of azathioprine treatment in the maintenance of steroid-free remission in Inflammatory Bowel Disease patients

C. Cassieri, R. Pica, E.V. Avallone, G. Brandimarte, M. Zippi, P. Crispino, G. Lecca, C. Corrado, P. Vernia, P. Paoluzi, E.S. Corazziari
"Sapienza" University, Internal Medicine and Medical Specialties, Rome, Italy and others

■ **P412**

Evolution of patients with Ulcerative Colitis who withdraw the maintenance treatment with mesalazine

A. Algaba, I. Guerra, D. Bonillo, M. Hernández, A. Granja, P. Bernal, F. Berrmejo
Hospital Universitario de Fuenlabrada, Gastroenterology, Madrid, Spain

■ **P413**

Withdrawn

■ **P414**

Usefulness of ultrasonography in the assessment of postoperative recurrence of Crohn's Disease

M. Murakami, T. Kanemura, A. Haga, R. Kubota, K. Yaguchi, M. Nishio, S. Tsuda, T. Ogashiwa, Y. Kogure, K. Kasahara, K. Hirai, Y. Fukuno, M. Jin, A. Hanzawa, H. Yonezawa, K. Sakamaki, K. Numata, H. Kimura, R. Kunisaki
Yokohama City University Medical Centre, Inflammatory Bowel Disease Centre, Yokohama, Japan and others

■ **P415**

Therapeutic drug monitoring of thiopurines in the management of Asian patients with Inflammatory Bowel Disease

S.W. Chuah, P. Delord, N. Sutiman, W.F. Leong, S.C. Kong, B. Schwender, P.W. Chan, H.H. Shim, E. Salazar, E.H. Ong, H.Y. Aw, J.L. Hartono, W.C. Lim, C. Ong, P.L. Ong, K.L. Ling, B. Chowbay
Singapore General Hospital, Department of Gastroenterology and Hepatology, Singapore, Singapore and others

■ **P416**

An online educational portal is effective in improving knowledge regarding reproduction and IBD

K. Wierstra, K. Smith, J. Bal, L. Ambrosio, K.I. Kroeker, L. Dieleman, B. Halloran, R.N. Fedorak, K.-A. Berga, **V.W. Huang**
University of Alberta, Edmonton, Canada and others

■ **P417**

Ulcerative Colitis: Let's talk about extent

A. Vaz, M. Eusébio, A. Antunes, P. Queirós, T. Gago, T. Belo, P. Caldeira, H. Guerreiro
Centro Hospitalar do Algarve, Faro, Portugal

■ **P418**

Ulcerative Colitis and end-stage liver disease in children with primary sclerosing cholangitis

P. Czubkowski, M. Wozniak, J. Pawlowska, I. Jankowska, J. Kierkus

The Children's Memorial Health Institute, Department of Gastroenterology, Hepatology, Feeding Disorders and Paediatrics, Warsaw, Poland

■ **P419**

Efficacy of vedolizumab in patients with Inflammatory Bowel Disease and failure of anti-TNF-antibodies

C. Höög, M. Eberhardson, S. Almer

Karolinska Institute, Stockholm, Sweden

■ **P420**

Does vedolizumab change mural vascularisation in Ulcerative Colitis and is there a correlation with endoscopic findings?

D. Klett, D. Strobel, D. Wildner, R. Atreya, M.F. Neurath, R.S. Görtz

Friedrich-Alexander University Erlangen-Nürnberg, Department of Medicine I, Erlangen, Germany

■ **P421**

Skin side-effects of biologic therapy and systemic drugs in patients with Inflammatory Bowel Diseases

K. Juzlova, K. Koblova, J. Herzogova, **M. Bortlik**, D. Duricova, M. Lukas

2nd Faculty of Medicine, Charles University, Department of Dermatovenereology, Prague, Czech Republic and others

■ **P422**

Risks and clinical features of active tuberculosis developed in patients with Inflammatory Bowel Disease receiving anti-tumor necrosis factor therapy

J.W. Lee, **C.H. Choi**

Chung-Ang University College of Medicine, Internal Medicine, Seoul, South Korea

■ **P423**

Paediatric Crohn's Disease patients with refractory psoriasis treated with a combination of infliximab and ustekinumab

C. Olbjørn, J.B. Rove, J. Jahnsen

Akershus University Hospital, Department of Paediatric and Adolescent Medicine, Lørenskog, Norway and others

■ **P424**

Surgery for children with Crohn's Disease

M. Stefanowicz, H. Ismail, G. Kowalewski, A. Kowalski, J. Kierkuś, P. Kaliciński

Children's Memorial Health Institute, Department of Paediatric Surgery and Organ Transplantations, Warszawa, Poland and others

■ **P425**

Comparison of therapeutic choices in biologic experienced Crohn's Disease and Ulcerative Colitis patients in Europe: Discontinuation rates due to disease improvements

A. Franceschetti, A. Baskett, H. McKenzie

Ipsos Healthcare, London, United Kingdom and others

■ **P426**

Post-induction adalimumab drug levels predict clinical and laboratory remission at week 24 in patients with Crohn's Disease

E. Zittan, O.B. Kelly, B. Kabakchiev, G.C. Nguyen, K. Croitoru, A.H. Steinhart, M.S. Silverberg

Mount Sinai Hospital, Zane Cohen Centre for Digestive Diseases; Division of Gastroenterology, Department of Medicine, University of Toronto, Toronto, Canada and others

■ **P427**

The real-life experience of vedolizumab efficacy and safety in Crohn's Disease: A prospective observational multicentre cohort study

A. Amiot, J.C. Grimaud, X. Treton, J. Filippi, B. Pariente, L. Peyrin-Biroulet, A. Noureille, A. Buisson, F. Carbonnel, A. Bourrier, S. Nancey, X. Roblin, P. Marteau, R. Altwegg, J. Moreau, A. Aubourg, G. Savoye, A.L. Pelletier, M. Fumery, B. Bonaz, Y. Bouhnik
Henri Mondor Hospital, Gastroenterology, Creteil, France and others

■ **P428**

Tofacitinib pharmacokinetics and durability of drug exposure in moderate to severe Crohn's Disease patients in phase 2 induction and maintenance studies

A. Mukherjee, C. Deng, R. Xie, S.W. Martin, G. Chan, M. Moscariello, W. Niezychowski, **E. Maller**
Pfizer Inc, Groton, United States and others

■ **P429**

The effects of psychiatric treatment in patients with Inflammatory Bowel Disease; a prospective study

O. Yanartas, H.T. Kani, E. Bicakci, Y. Bez, M. Banzragch, Z. Senkal, I. Kilic, O. Atug, K. Kuscu, N. Imeryuz, **H. Akin**
Marmara University, Psychiatry, Istanbul, Turkey and others

■ **P430**

Prognostic significance of serial faecal calprotectin in Inflammatory Bowel Disease

Y. Zhulina, Y. Cao, K. Amcoff, M. Carlson, C. Tysk, **J. Halfvarson**
Örebro University, Department of Gastroenterology, Faculty of Medicine and Health, Örebro, Sweden and others

■ **P431**

Transabdominal ultrasonography to assess intestinal wall thickness and vascularity appears to predict therapeutic effects of steroid treatment in moderate to severe Ulcerative Colitis patients

T. Ogashiwa, M. Murakami, S. Tsuda, M. Nishio, Y. Kogure, K. Kasahara, K. Hirai, Y. Fukuno, M. Jin, A. Hanzawa, H. Yonezawa, K. Numata, H. Kimura, R. Kunisaki
Yokohama City University Medical centre, Inflammatory Bowel Disease Centre, Yokohama, Japan and others

■ **P432**

Patient perspectives on biosimilars: An EFCCA Survey

L. Peyrin-Biroulet, S. Lönnfors, S. Danese, X. Roblin, L. Avedano, M. Greco
University Hospital of Nancy, Department of Gastroenterology, Nancy, France and others

■ **P433**

Canadian patient and caregiver perspectives on subsequent entry biologics / biosimilars for Inflammatory Bowel Disease

G. Attara, R. Bailey, B. Bressler, J. Marshall, R. Panaccione, G. Aumais
Gastrointestinal Society, Vancouver, Canada and others

■ **P434**

Close rectal versus TME in patients with Inflammatory Bowel Disease undergoing proctocolectomy or colectomy proctectomy

J. de Groof, O. van Ruler, P. Tanis, W. Bemelman, C. Buskens
Academic Medical Center, Surgery, Amsterdam, Netherlands

■ **P435**

Liver injury associated with anti-TNF therapy in paediatric IBD

A. Ricciuto, B.M. Kamath, T. Walters, P. Church, S.C. Ling, K. Frost, A. Griffiths
Hospital for Sick Children, Division of Gastroenterology, Hepatology and Nutrition, Toronto, Canada

■ **P436**

Adalimumab dose escalation is effective and well tolerated in Crohn's Disease patients with secondary loss of response to adalimumab

N. Duveau, M. Nachury, M. Boualit, R. Gerard, J. Branche, V. Maunoury, P. Desreumaux, B. Pariente
CHU de Lille, Department of Gastroenterology, Lille, France

■ **P437**

Confidence, acceptance, and friendship: The three winners at Camp Purple Live 2015

A. McCombie, R. Gearry, R. Lopez, S. Lönnfors, A. Day

University of Otago, Department of Surgery, Christchurch, New Zealand and others

■ **P438**

The Inflammatory Bowel Disease disability index applied to ileal pouch anal anastomoses in New Zealand

Y. Lee, **A. McCombie**, R. Gearry, F. Frizelle, J. Williman, R. Leong, T. Eglinton

University of Otago, Department of Surgery, Christchurch, New Zealand and others

■ **P439**

Effectiveness of a training programme on motivational interviewing (MI) skills applied to Inflammatory Bowel Disease (IBD) management

M. Daperno, F. Mocciaro, F. Caprioli, M. Fantini, S. Leone, M. Comberlato, V. Quercia

AO Ordine Mauriziano, Gastroenterology Unit, Torino, Italy and others

■ **P440**

Staged surgical management of complicated ileo-colonic Crohn's Disease

A.P. Mishreki, F.G. Bergin

Royal Victoria Infirmary, Colorectal Surgery, Newcastle Upon Tyne, United Kingdom

■ **P441**

Conjoint analysis for quantification of Inflammatory Bowel Disease patients' preferences for outcome metrics

W.K. van Deen, D. Nguyen, N. Duran, E. Kane, M.G. van Oijen, D.W. Hommes

UCLA Center for Inflammatory Bowel Diseases, Division of Digestive Diseases, University of California, Los Angeles, United States and others

■ **P442**

Evaluation of safety and efficacy of laparoscopic surgery for Ulcerative Colitis

M. Yamamoto, K. Kurachi, T. Harada

Hamamatsu Univ. School of Medicine, 2nd Department of Surgery, Hamamatsu, Japan

■ **P443**

National treatment strategy in Inflammatory Bowel Diseases in Hungary: Results from the National Health Insurance Fund Prescription Database

Z. Kurti, L. Gonczi, P.A. Golovics, B. Lovasz, P. Fadgyas-Freyler, J. Gimesi-Orszagh, G.B. Korponai, Z. Vegh, P. Lakatos

Semmelweis University, 1st Department of Medicine, Budapest, Hungary and others

■ **P444**

High dose intravenous iron isomaltoside infusion is not associated with an increase in intact fibroblast growth factor 23 (iFGF23) in patients with Inflammatory Bowel Disease (IBD)

J.F. Dahlerup, S. Lindgren

Aarhus University Hospital, Department of Hepatology and Gastroenterology, Aarhus, Denmark and others

■ **P445**

Early outcomes for adolescent Inflammatory Bowel Disease patients treated in a transition clinic

I. Avni- Biron, **G. Fraser**, Y. Rosenbach, R. Shamir, A. Assa, L. Lichtenstein, O. Ben-Bassat

Rabin Medical Centre and University of Tel Aviv, Gastroenterology, Petach Tikva, Israel and others

■ **P446**

Effects of CYP3A5 genotype on efficacy and safety of tacrolimus in refractory Ulcerative Colitis – Experience from a tertiary referral centre

E. Saito, T. Kobayashi, M. Nakano, T. Toyonaga, S. Kuronuma, O. Takeuchi, H. Serizawa, N. Watanabe, T. Hibi

Kitasato University Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan

■ **P447**

Seasonal variations in vitamin D concentrations in a single-centre IBD series

P. Vernia, G. Burrelli Scotti, M.T. Afferi, V. Vaiarello
Sapienza - University of Rome, Gastroenterologia A, Rome, Italy

■ **P448**

IBD-nurse in patients' health status assessment: Data from a pilot study comparing ability of IBD-nurse and gastroenterologist in using IBD-clinical scores

F. Mocciano, R. Di Mitri, G.M. Pecoraro, D. Scimeca, G. Russo, F. Bossa, V. Costanza, D. Varvara, M.A. Profita, G. Profeta, G. Martino
ARNAS Civico-Di Cristina-Benfratelli Hospital, Gastroenterology and Endoscopy Unit, Palermo, Italy and others

■ **P449**

Efficacy and safety of switching between originator and biosimilar infliximab in patients with Inflammatory Bowel Disease in practical clinic: Results to 6 months

L. Diaz Hernández, G.E. Rodríguez González, M. Vela González, C.A. Tardillo Marín, C.Y. Rodríguez Díaz, L. Arranz Hernández, J.A. Montero Delgado, M. San Juan Acosta, F. Pérez Hernández
Hospital Universitario Ntra. Sra. Candelaria, Gastroenterology, Santa Cruz de Tenerife, Spain and others

■ **P450**

A gender comparison of the association between coping strategies and perceived social support in Crohn's Disease patients

O. Sarid, V. Slomin-Nevo, D. Greenberg, M. Friger, D. Schwartz, H. Vardi, R. Sergienko, E. Chernin, **S. Odes**
Ben-Gurion University of the Negev, Social Work, Beer Sheva, Israel and others

■ **P451**

The efficacy of infliximab in tacrolimus non-responder with UC

T. Miyazaki, N. Hida, T. Sato, M. Kawai, K. Kamikozuru, T. Takagawa, Y. Yokoyama, M. Iimuro, K. Hori, S. Nakamura
Hyogo College of Medicine, Division of Internal Medicine Department of Inflammatory Bowel Disease, Nishinomiya, Japan

■ **P452**

Safety and efficacy of infliximab biosimilar (Remsima®) in Crohn's Disease patients in clinical practice: Results after 6 months' treatment

M.F. Guerra Veloz, F. Argüelles Arias, R. Perea Amarillo, L. Castro Laria, M.B. Maldonado Pérez, A. Benítez Roldán, V. Merino, G. Ramirez, A. Vilches Arenas, A. Caunedo Álvarez
Unidad de Gestión Clínica de Aparato Digestivo Hospital Universitario Virgen Macarena, Seville, Spain and others

■ **P453**

Insufficient vaccination and inadequate immunisation rates among Korean patients with Inflammatory Bowel Diseases

H.H. Ryu, H.-S. Lee, **B.D. Ye**, N.Y. Kim, E.J. Youn, J.Y. Park, E. Kang, S.W. Hwang, S.H. Park, D.-H. Yang, K.-J. Kim, J.-S. Byeon, S.-J. Myung, S.-K. Yang
University of Ulsan College of Medicine, Asan Medical Center, Gastroenterology, Seoul, South Korea and others

■ **P454**

Combo therapy in infliximab-resistant Inflammatory Bowel Disease Patients: Data from a tertiary referral centre

S. Renna, G. Rizzuto, E. Orlando, M. Affronti, M. Cottone, A. Orlando
"Villa Sofia-Cervello" Hospital, Division of Internal Medicine, Palermo, Italy

■ **P455**

The impact of concurrent HIV-1 infection on the management of patients with Inflammatory Bowel Disease

T.H. Ho, R. Fausel, J. Torres, J.J. Yang, T.H. Swartz, J.A. Aberg, J.-F. Colombel, **S. Mehandru**
Icahn School of Medicine at Mount Sinai, New York, United States

P456
Efficacy and safety of TNF antagonist for the treatment of internal fistulising Crohn's Disease

A. Huguet, A.-L. Mallet, V. Desfourneaux, L. Siproudhis, J.-F. Bretagne, **G. Bouguen**

Université Rennes 1 & CHU Pontchaillou Rennes, Service de chirurgie digestive, Rennes, France and others

P457
Complications and disease recurrence after primary ileocecal resection in paediatric Crohn's Disease: A multicentre cohort analysis

K. Diederer, L. de Ridder, P. van Rheenen, V. Wolters, L. Mearin, G. Damen, T. de Meij, H. van Wering, L. Tseng, M. Oomen, J. de Jong, M. Benninga, A. Kindermann

Academic Medical Center, Department of Paediatric Gastroenterology and Nutrition, Amsterdam, Netherlands and others

P458
Multidisciplinary working when developing the UK IBD standards and IBD audit

A. St. Clair Jones, S. Murray

Brighton and Sussex University Hospitals NHS Trust, Pharmacy, Brighton, United Kingdom and others

P459
Risk of relapse after azathioprine (AZA) discontinuation in Inflammatory Bowel Disease (IBD) patients in maintained remission

M. Iborra, B. Navarro, X. Cortes, M. Boscá, T. Blazquez, J. Herreras, G. Trejo, B. Beltrán, P. Nos

Hospital Universitari i Politecnic La Fe, Gastroenterology, Valencia, Spain and others

P460
Impact of fertility treatment on Inflammatory Bowel Disease outcomes

M. Bejaoui, C. Landman, J. Kirchgesner, A. Bourrier, I. Nion-Larmurier, H. Sokol, L. Beaugerie, J. Cosnes, P. Seksik

Saint Antoine Hospital, Gastroenterology & Nutrition, Paris, France

P461
Clinical benefit of adalimumab after surgery in the treatment of complex perianal Crohn's Disease: A tertiary referral centre experience

G. Solina, S. Renna, E. Orlando, M. Affronti, M. Cottone, A. Orlando

"Villa Sofia-V. Cervello" Hospital, Division of Surgery, Palermo, Italy and others

P462
Adalimumab improves treatment satisfaction with medication and work productivity among patients with Ulcerative Colitis in a clinical practice setting: Results from INSPIRADA

S. Travis, B. Feagan, L. Peyrin-Biroulet, R. Panaccione, S. Danese, A. Lazar, A. Robinson, J. Petersson, M. Bereswill, M. Skup, N. Chen, S. Wang, R. Thakkar, J. Chao

Oxford University Hospitals, Oxford, United Kingdom and others

P463
Combination therapy of fresh faecal microbial transplantation and antibiotics for Ulcerative Colitis

D. Ishikawa, T. Osada, K. Haga, T. Kodani, T. Shibuya, S. Watanabe

Juntendo University, Department of Gastroenterology, Tokyo, Japan

P464
Assessing medication adherence in patients with Inflammatory Bowel Disease. What do we choose? Self-adherence scales or pharmacy rates?

M.L. De Castro, L. Sanromán, A. Martín, N. Martínez, M. Figueira, V. Hernández, J.R. Pineda, J. Martínez-Cadilla, S. Pereira, V. Del Campo, J.-I. Rodríguez-Prada

Hospital Alvaro Cunqueiro. Complejo Hospitalario Universitario de Vigo. CHUVI, Gastroenterology, Vigo, Spain and others

■ **P465**

Indication-specific feasibility assessment of a placebo-controlled randomised mesalazine withdrawal study for paediatric patients with Ulcerative Colitis

N. Croft, W. Faubion, D. Tierens, J. Dewulf, D. Bwirire, D. Stefani-Hunyady, **F. Cataldi**

Blizard Institute, Barts and The London School of Medicine and Dentistry, Centre for Immunobiology, London, United Kingdom and others

■ **P466**

Relapse rates of Inflammatory Bowel Disease patients in deep and clinical remission after discontinuing anti-tumor necrosis factor alpha therapy: A prospective single-centre open-label study

T. Hlavaty, A. Krajcovicova, J. Letkovsky, I. Sturdik, T. Koller, J. Toth, M. Huorka

Comenius University, Faculty of Medicine and University Hospital Bratislava, 5th Department of Internal Medicine, Bratislava, Slovakia

■ **P467**

The validation of the Crohn's and Ulcerative Colitis questionnaire-12 plus (CUCQ-12 plus): A short quality of life measure for Inflammatory Bowel Disease

S. Shwana, L. Alrubaiy, H. Hutchings, J. Williams, A. Protheroe, K. Mortier

Prince Charles Hospital, Gastroenterology, Merthyr Tydfil, United Kingdom and others

■ **P468**

Long-term efficacy and safety of thiopurine in biologic-naïve Japanese patients with Ulcerative Colitis: A multicentre retrospective study

T. Takagi, M. Matsuura, S. Yamada, S. Bamba, Y. Hotta, K. Uchiyama, Y. Naito, H. Nakase, A. Andoh, T.

Kawamura, S. Katsushima, T. Kusaka, H. Obata, T. Kogawa

Kyoto Prefectural University of Medicine, Molecular Gastroenterology and Hepatology, Kyoto, Japan and others

■ **P469**

Changes in peripheral blood lymphocyte subsets induced by azathioprine in Crohn's Disease patients

A. Labidi, M. Fekih, N. Ben Mustapha, S. Ben Amor, M. Serghini, L. Kallel, J. Boubaker, A. Filali

La Rabta University Hospital, Gastroenterology, Tunis, Tunisia

■ **P470**

Early change in faecal calprotectin during anti-TNF α initiation is strongly predictive of outcome in Crohn's Disease

P. Pavlidis, G. Chung-Faye, P. Dubois, I. Bjarnason, B.H. Hayee

King's College Hospital, Department of Gastroenterology, London, United Kingdom

■ **P471**

Safety analysis of multimatrix mesalazine among patients with Ulcerative Colitis or recurrent diverticulitis ≥ 55 years of age

G. Lichtenstein, K. Barrett, D. Stefani-Hunyady, **F. Cataldi**, J. Raskin

University of Pennsylvania Health System, Inflammatory Bowel Disease Center, Philadelphia, United States and others

■ **P472**

Faecal calprotectin as a biomarker of early mucosal healing in patients with Ulcerative Colitis naïve to adalimumab treatment

C. Muñoz Villafranca, A. Perez de Arenaza, L. Gómez, R. Higuera, A. Munagorri, M.A. Ogueta, S. Ibañez,

J. Ortiz de Zárate, O. Merino, C. Rodríguez, O. Nante, P. Arreba, P. Ramirez de la Piscina, I. Rodríguez, A.

Bernal, J.A. Arévalo, J.L. Cabriada

Hospital Universitario de Basurto, Aparato Digestivo, Bilbao, Spain and others

■ **P473**

Clinical and biochemical factors that influence response in inflammatory disease patients receiving tacrolimus

I. Rodríguez - Lago, O. Merino, O. Nantes, C. Muñoz, U. Aguirre, J.L. Cabriada

Galdakao Hospital, Gastroenterology, Galdakao, Spain and others

■ **P474**

Assessing the position of systemic tacrolimus in the treatment of Inflammatory Bowel Disease – Systematic review and meta-analysis

M. Lie, J. Kreijne, B. Hansen, J. van der Woude
Erasmus MC, Gastroenterology and Hepatology, Rotterdam, Netherlands

■ **P475**

Gastroenterological and rheumatological chronic patients: Are there differences in individual welfare and quality of life? A cross-observational study

A. Stefani, **M.G. Vettorato**, G. Lorenzon, T. Marcon, F. Simonetti, A. Rigo, E.V. Savarino, E. De Marchi, R. D'Inca, G.C. Sturniolo
University of Padua, Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, Padua, Italy

■ **P476**

Fermentable carbohydrates (FODMAPs) as triggers of functional gastrointestinal symptoms in patients with quiescent Inflammatory Bowel Disease: A double-blind, placebo-controlled, randomised, cross-over re-challenge trial

S. Cox, A. Prince, C. Myers, P.M. Irving, J.O. Lindsay, M.C. Lomer, K. Whelan
King's College London, School of Medicine, Diabetes and Nutritional Sciences Division, London, United Kingdom and others

■ **P477**

Impact of tumour necrosis factor antagonists on avoiding surgery in stricturing Crohn's Disease: A tertiary centre real-life experience

M. Allocca, G. Fiorino, C. Bonifacio, A. Spinelli, A. Repici, A. Malesci, L. Balzarini, S. Danese
Humanitas Research Hospital, IBD Center, Gastroenterology, Rozzano, Milan, Italy and others

■ **P478**

How often is high-dose budesonide necessary for maintenance treatment of collagenous colitis? Efficacy of azathioprine to maintain budesonide-free clinical remission

F. Fernández-Bañares, M. Piqueras, D. Guagnozzi, V. Robles, A. Ruiz-Cerulla, M.J. Casanova, J.P. Gisbert, D. Busquets, A. Lucendo, Y. Arguedas, L. Fernández
Hospital Universitari Mutua Terrassa, Gastroenterology, CIBERehd, Terrassa, Spain and others

■ **P479**

Hepcidin and the risk of malnutrition in Inflammatory Bowel Disease (IBD)

R. Dudkowiak, K. Neubauer, E. Poniewierka
Wroclaw Medical University, Department of Gastroenterology and Hepatology, Wroclaw, Poland

■ **P480**

Goals of treatment: Preferences of Inflammatory Bowel Disease patients

F. Casellas, C. Herrera de Guise, V. Robles, E. Navarro, N. Borrueal
Hospital Universitari Vall d'Hebron, Unitat Atenció Crohn-Colitis, Barcelona, Spain and others

■ **P481**

Impact of anti-TNF α therapy with daily physical activity in patients with Crohn's Disease

F.A. Lucca, C. Malaguti, A.L. Cabalzar, L.A. Chebli, **T.C.R. Ribeiro**, P.D. Gaburri, J.M.F. Chebli
Universidade Federal de Juiz de Fora, Gastroenterology, Juiz de Fora, Brazil

■ **P482**

Different characteristics of Inflammatory Bowel Disease patients between tertiary referral centres and secondary hospitals

K.H. Song, Y.J. Lee, K.O. Kim, H.S. Lee, E.S. Kim, J.I. Koo, J.S. Jeong, W.S. Seo
Goo Hospital, General Surgery, Daegu, South Korea and others

■ **P483**

Differences in biologic therapy utilisation amongst early and late onset Inflammatory Bowel Disease

S. Raimundo Fernandes, C. Baldaia, P. Moura Santos, A. Rita Gonçalves, A. Valente, L. Correia, J. Velosa
Centro Hospitalar Lisboa Norte, Gastroenterology, Lisbon, Portugal

■ **P484**

Access to biologics and biosimilars across 11 EU countries

P. Lakatos, E. Domenech, H. Kellner, J. Marsal, H. Fowler, C. Agboton, N. Georgitseas, M. Cassese, S. Anwar, A. Venugopal, P. Audhya
Semmelweis University, Budapest, Hungary and others

■ **P485**

The combination of mesenchymal stem cells and infliximab reduces the recurrence rate of Crohn's Disease

O. Knyazev, **N. Fadeeva**, A. Kagramanova, P. Shcherbakov, I. Ruchkina, A. Parfenov, A. Konoplyannikov
Moscow Clinical Research Center, Department of Inflammatory Bowel Disease, Moscow, Russian Federation and others

■ **P486**

Intrapatient variability in adalimumab drug levels within and across cycles in Crohn's Disease

M. Ward, L. Beswick, P. Thwaites, J. Hogg, G. Rosella, J. Reynolds, D. Van Langenberg, P. Gibson, M. Sparrow
Alfred Hospital, Gastroenterology, Melbourne, Australia and others

■ **P487**

The effect of a coordinated care programme for Inflammatory Bowel Diseases on health care utilisation

W.K. van Deen, M. Skup, A. Centeno, N. Duran, P. Lacey, D. Jatulis, E. Esrailian, M.G. van Oijen, D.W. Hommes
UCLA Center for Inflammatory Bowel Diseases, Division of Digestive Diseases, University of California, Los Angeles, United States and others

■ **P488**

IBS-type symptoms in patients with quiescent Inflammatory Bowel Disease are unrelated to ongoing inflammation

D. Hoekman, J. Zeevenhooven, G. D'Haens, M. Benninga
Academic Medical Center (AMC), Department of Paediatric Gastroenterology, Amsterdam, Netherlands and others

■ **P489**

Predicting mucosal state with faecal calprotectin in children with Crohn's Disease

M. Meglicka, M. Szczepanski, M. Dadalski, J. Kierkus
The Children's Memorial Health Institute, Department of Gastroenterology, Hepatology, Feeding Disorders and Paediatrics, Warsaw, Poland and others

■ **P490**

Clinicians' adherence to ECCO Guidelines in the clinical care of adults with Inflammatory Bowel Disease

B. Jackson, D. Con, P. De Cruz
Austin Health, Gastroenterology, Melbourne, Australia

■ **P491**

In patients with active Ulcerative Colitis, cytapheresis spares corticosteroids, and reduces hospitalisation time: Therapeutic outcomes in 181 consecutive patients

O. Nomura, T. Osada, T. Shibuya, D. Ishikawa, K. Haga, N. Sakamoto, S. Watanabe
Juntendo University, Department of Gastroenterology, Tokyo, Japan

■ **P492**

Perioperative complications have long term impact on quality of life after restorative proctocolectomy

Y. Lee, **A. McCombie**, R. Vanamala, R. Geary, F. Frizelle, E. McKay, J. Williman, T. Eglinton
University of Otago, Department of Surgery, Christchurch, New Zealand and others

■ **P493**

Prevalence and risk factors for postoperative septic complications in Crohn's Disease

M. Guasch, A. Clos, M. Manyosa, T. Lobatón, J.R. Gómez, M. Piñol, E. Cabré, J. Troya, **E. Domènech**
Hospital Universitari Germans Triás i Pujol, Gastroenterology, Badalona, Spain and others

■ **P494****Phenotypic analysis revealed features of disease severity in familial versus sporadic cases of Inflammatory Bowel Disease**

G. Maurizi, **M. Giannotta**, V. Almerigogna, S. Biagini, A. Cozzi, G. Macrì, M. Milla
AOU Careggi, Regional Referral Center of Inflammatory Bowel Disease - Clinical Gastroenterology Division, Florence, Italy

■ **P495****Biosimilar infliximab is effective and safe in Inflammatory Bowel Disease patients naïve to anti-TNF therapy: A tertiary centre experience**

M. Bortlik, M. Kolar, D. Duricova, K. Malickova, V. Hrubá, N. Machkova, K. Mitrova, M. Lukas, M. Lukas
Iscare, IBD Clinical and Research Center, Prague, Czech Republic and others

■ **P496****Adalimumab treatment reduces extraintestinal manifestations in patients with moderate to severe Crohn's Disease: A pooled analysis**

E.J. Louis, R. Löfberg, W. Reinisch, D. Schwartz, J.-F. Maa, S. Berg, B. Huang, A.W. Wang, A.M. Robinson,
B. Pappalardo
University of Liège and CHU, Liège, Belgium and others

■ **P497****Clinical features and outcomes of tuberculosis in Inflammatory Bowel Disease patients treated with anti-TNF therapy as compared with the general population**

J. Kim, J.P. Im, J.-J. Yim, C.K. Lee, D.I. Park, C.S. Eun, S.-A. Jung, J.E. Shin, K.-M. Lee, J.H. Cheon
Seoul National University College of Medicine, Department of Internal Medicine and Liver Research Institute, Seoul, South Korea and others

■ **P498****Re-phrasing the question: A novel simple tool for a more accurate evaluation of IBD patients' adherence to therapy**

T. Engel, G. Ben-Haim, N. Levhar, R. Eliakim, S. Ben-Horin
Sheba Medical Center/Tel Hashomer, Sackler School of Medicine, Tel-Aviv University, Gastroenterology, Ramat Gan, Israel and others

■ **P499****Long-term outcomes of infliximab and predictors of response in 213 patients with Ulcerative Colitis: A hospital-based cohort study from Korea**

H. Seo, S.H. Park, K. Chang, G.-U. Kim, E.M. Song, M. Seo, H.-S. Lee, S.W. Hwang, D.-H. Yang, B.D. Ye, J.-S. Byeon, S.-J. Myung, S.-K. Yang
Asan Medical Center, University of Ulsan College of Medicine, Department of Gastroenterology, Seoul, South Korea and others

■ **P500****Capsule endoscopy reveals small intestinal mucosal Crohn's Disease healing after treatment with adalimumab: Preliminary results of the SIMCHA study**

E. Seidman, U. Kopylov, C.-Y. Chao, M. Girardin, M. Starr
Research Institute of the McGill University Hospital, Gastroenterology, Montreal, Canada and others

■ **P501****Abdominal obesity in paediatric Crohn's Disease is associated with adipokine dysregulation**

D. Thangarajah, K.E. Chapell, S. Mandalia, G. Frost, J.M. Fell
Imperial College, Section of Academic Neonatal Medicine, London, United Kingdom and others

■ **P502****Persistence of remission among patients with Inflammatory Bowel Disease after adalimumab therapy is stopped: Economic and clinical implications**

X. Cortés, J.R. MOLÉS, S. Fernández, J. Clofent, M. Moreno, J. Rodriguez, J. Primo
Hospital de Sagunto, Valencia, Spain and others

■ **P503**

Tacrolimus vs anti-tumour necrosis factor agents for moderately to severely active Ulcerative Colitis: A retrospective observational study

T. Yamamoto, T. Shimoyama, S. Umegae, K. Matsumoto

Yokkaichi Hazu Medical Centre, Inflammatory Bowel Disease Centre, Yokkaichi, Japan

■ **P504**

Stability observations in tacrolimus suppositories

M. Lie, E. Jansen, P. Hoeben, R. Zaal, D. Hodes, M. Rosman, W. Loos, J. van der Woude

Erasmus MC, Gastroenterology and Hepatology, Rotterdam, Netherlands and others

■ **P505**

The effect of using a question prompt list in outpatient clinic consultations in a Dutch IBD population

N. Peek-Kuijt, M. de Jong, N. Srivastava, R. Veenendaal, P. Maljaars, L. van Bodegom-Vos, A. Linn, A. van der Meulen-de Jong

Leiden University Medical Centre, Department of Gastroenterology and Hepatology, Leiden, Netherlands and others

■ **P506**

Serum infliximab and antibodies to infliximab (ATI) levels in Crohn's Disease (CD) and Ulcerative Colitis (UC) patients on long-term maintenance therapy

M. Waterman, H. Bar Yoseph, B. Ungar, S. Ben - Horin, Y. Chowers

Rambam Health Care Campus, Department of Gastroenterology, Haifa, Israel and others

■ **P507**

Clinical role, optimal timing and frequency of measurement of serum infliximab levels and anti-infliximab antibody titers in patients with Inflammatory Bowel Disease

R. Bor, K. Farkas, A. Bálint, A. Milassin, M. Rutka, M. Matuz, F. Nagy, A. Fábíán, Z. Szepes, T. Molnar

University of Szeged, First Department of Medicine, Szeged, Hungary and others

■ **P508**

Pregnancy outcomes in patients with Inflammatory Bowel Disease experiencing flare ups during foetal development

Y. Yokoyama, H. Tanaka, T. Miyazaki, T. Sato, M. Kawai, Y. Kita, K. Kamikozuru, M. Iimuro, N. Hida, S. Nakamura

Hyogo College of Medicine, Department of Inflammatory Bowel Disease, Division of Internal Medicine, Nishinomiya, Japan and others

■ **P509**

What is the effect of IBD on sedation rates at colonoscopy?

M. Walshe, C. Moran, G. Horgan, G. Cullen, H. Mulcahy, G. Doherty

St Vincent's University Hospital, Department of Gastroenterology and Centre for Colorectal Disease, Dublin, Ireland

■ **P510**

Skin anergy and latent tuberculosis in Inflammatory Bowel Disease patients

C. Herrera de Guise, V. Robles, N. Borruel, E. Navarro, F. Casellas

Unitat d'Atenció Crohn-Colitis. Hospital Universitari Vall d'Hebron, Digestive Diseases Research, Barcelona, Spain

■ **P511**

Utilisation and efficacy of oral iron therapy in patients with iron deficiency anaemia in a nationwide cohort of Ulcerative Colitis patients

D. Patel, N. Khan

Mercy Catholic Medical Center, Internal Medicine, Philadelphia, United States and others

■ **P512**

The prevalence and risk factors of gallstone disease in patients with Ulcerative Colitis

B.I. Jang, K.O. Kim, C.H. Yang, Y.H. Jung

Yeungnam University College of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Daegu, South Korea and others

■ **P513**

Comparison of infliximab the originator and biosimilars in treatment of Crohn's Disease: A Polish cohort study

E. Zagorowicz, J. Kierkuś, M. Kłopocka, K. Stec-Michalska, R. Talar-Wojnarowska, L. Łykowska-Szuber, I. Detka-Kowalska, A. Meder, A. Pietrzak, D. Maj, M. Kowalski, J. Wójcik, W. Ruczak, T. Artukowicz, M. Włodarczyk, A. Śliwczyński, M. Gonciarz
Institute of Oncology, Gastroenterology, Warsaw, Poland and others

■ **P514**

Proximal extension of distal lesions in patients with Ulcerative Colitis

T. Sato, M. Kawai, K. Kamikozuru, Y. Kita, Y. Yokoyama, T. Takagawa, T. Miyazaki, M. Imuro, N. Hida, K. Hori, S. Nakamura
Hyogo College of Medicine, Department of Inflammatory Bowel Disease, Nishinomiya, Japan and others

■ **P515**

Biosimilar candidate ABP 501: Immunogenicity results from two phase 3 studies

P. Kaur, E. Krishnan, N. Zhang, A. Kaliyaperumal
Amgen, Inc., Biosimilars Division, Thousand Oaks, California, United States and others

■ **P516**

A prospective 24-week mucosal healing and deep remission assessment of small bowel and colonic Crohn's Disease as detected by colon capsule endoscopy

S. Oliva, S. Cohen, F. Civitelli, M. Aloï, F. Viola, E. Casciani, F. Maccioni, C. Hassan, P. Papoff, S. Cucchiara Sapienza - University of Rome, Department of Paediatrics, Paediatric Gastroenterology and Liver Unit, Rome, Italy and others

■ **P517**

Cognitive-behavioural therapy has no effect on disease activity but improves quality of life in subgroups of patients with Inflammatory Bowel Disease short-term: A randomised controlled trial with a 24-month follow-up

A. Mikocka-Walus, **J. Andrews**, P. Bampton, D. Hetzel, P. Hughes, A. Esterman
University of York, Health Sciences, York, United Kingdom and others

■ **P518**

Aberrant adipose tissue partitioning with abdominal obesity, defined by MRI, is a hallmark of paediatric Crohn's Disease

D. Thangarajah, K.E. Chapell, S. Mandalia, G. Frost, J.M. Fell
Imperial College, Section of Academic Neonatal Medicine, London, United Kingdom and others

■ **P519**

Efficacy and safety of biosimilar of infliximab (Inflixtra) in adult patients with Crohn's Disease during one year of treatment followed by 6 months of observation - One centre retrospective study

M. Kaniewska, G. Rydzewska
Central Clinical Hospital of the Ministry of Interior, Department of Gastroenterology, Warsaw, Poland and others

■ **P520**

Therapeutic drug monitoring in 45 children with IBD on maintenance infliximab treatment

H. Rolandsdotter, P. Marits, U. Sundin, A.-C. Wikström, U. Fagerberg, Y. Finkel, **M. Eberhardson**
Sachs' Children and Youth Hospital, Dept of Gastroenterology, Stockholm, Sweden and others

■ **P521**

AntiTNF serum level and clinical, radiological or endoscopic response in luminal and perianal Crohn's Disease. Results of the OPTIMIZA study

A. Echarri, R. Ferreiro, R. Fraga, J. Cid, M. Barreiro de Acosta, S. Pereira, J. Pineda, D. Carpio, S. Soto, E. Castro, J. Gallego, B. Gonzalez, A. Carmona
Complejo Hospitalario Ferrol, Gastroenterology, Ferrol, Spain and others

■ **P522**

A multicentre open-label study assessing pharmacokinetics, efficacy, and safety of subcutaneous golimumab in paediatric patients with moderately-severely active Ulcerative Colitis

D. Turner, G. Veereman, J. Hyams, A. Griffiths, D. Chan, O.J. Adedokun, L. Damaraju, R. Strauss Shaare Zedek Medical Center, The Hebrew University of Jerusalem, The Juliet Keidan Institute of Paediatric Gastroenterology and Nutrition, Jerusalem, Israel and others

■ **P523**

Identifying "at risk" Inflammatory Bowel Disease patients who may be targeted with a new adjuvanted herpes zoster subunit vaccine

W. Bye, M. Sparrow, S. J Connor, J. M Andrews, K. Ellard, W. Ng, G. Hume, S. Antoniadis, A. J Walsh St Vincent's Hospital, Department of Gastroenterology, Sydney, Australia and others

■ **P524**

Pharmacokinetics of sdalimumab in paediatric subjects with moderate versus severe Crohn's Disease in IMAGINE-1

R. Singh, B. Kluender, A. Robinson, A. Lazar, R. Thakkar, N. Mostafa AbbVie, North Chicago, United States and others

■ **P525**

The combined cell therapy and anticytokine therapy of adalimumab promotes deep remission (immunobiological and histology) of Crohn's Disease

O. Knyazev, **A. Kagramanova**, S. Khomeriki, A. Konoplyannikov, K. Noskova, N. Fadeeva, A. Parfenov Moscow Clinical Research Center, Department of Inflammatory Bowel Disease, Moscow, Russian Federation and others

■ **P526**

Sampling not at trough: Adalimumab serum drug and antibody levels remain relatively stable in-between injections

B. Ungar, M. Yavzori, O. Picard, E. Fudim, U. Kopylov, Y. Chowers, R. Eliakim, S. Ben-Horin Sheba Medical Center & Sackler School of Medicine, Gastroenterology, Tel Hashomer, Israel and others

■ **P527**

Frequency and predictors of azathioprine induced pancreatitis among IBD patients: Results of a tertiary referral centre

N. Demir, T. Eskazan, Y. Erzin, I. Hatemi, S. Bozcan, K. Atay, A.F. Celik Istanbul university Cerrahpasa medical school, Gastroenterology, Istanbul, Turkey and others

■ **P528**

Comparison of short-term and long-term outcomes between anti-TNF-antibodies and tacrolimus for refractory UC patients

T. Ishida, T. Ueo, R. Narita, M. Motomura, Y. Yanai, K. Wada, H. Honda, S. Inoue, K. Murakami Oita Red Cross Hospital, Department of Gastroenterology, Oita, Japan and others

■ **P529**

Efficacy and safety of infliximab versus adalimumab in the treatment of Crohn's Disease – The McGill experience

T. Al-Taweel, M. Strohl, U. Kopylov, L. Paradis-Suprenant, M. Almainany, M. Martel, A. Bitton, W. Afif, T. Bessisow Mubarak Al-Kabeer Hospital, Haya Al-Habeeb Gastroenterology Center, Hawally, Kuwait and others

■ **P530**

Efficacy of biosimilar infliximab induction therapy in paediatric patients with Crohn's Disease – 1.5 years of experience

J. Siczekowska, A. Plocek, A. Banaszkiwicz, D. Jarzebicka, A. Gawronska, E. Toporowska-Kowalska, J. Kierkus The Children's Memorial Health Institute, Department of Gastroenterology, Hepatology, Feeding Disorders and Paediatrics, Warsaw, Poland and others

■ **P531**

Inflammatory bowel disease and fatigue: The effect of physical activity and/or omega-3 supplementation

A. McNelly, I. Nathan, M. Monti, G. Grimble, **C. Norton**, F. Bredin, W. Czuber-Dochan, S. Berliner, M. Gay, M. Darvell, H. Terry, A. Forbes
UCL, Centre for Gastroenterology and Nutrition, London, United Kingdom and others

■ **P532**

Effectiveness of balloon dilation using single balloon enteroscopy in multiple small bowel stricture

J.-S. Kim, Y.-S. Cho
Catholic University of Korea, Department of internal medicine, Seoul, South Korea and others

■ **P533**

Assessment of 6-thioguanine nucleotide metabolite level in Inflammatory Bowel Disease patients treated with azathioprine

K. Pavlovska, M. Slaninka Miceska, P. Mishevaska, J. Tonic Ribarska, E. Atanasovska, I. Kikerkov, L. Efremovska, M. Petrushevska
Medical faculty, Department of preclinical and clinical pharmacology and toxicology, Skopje, Macedonia, the former Yugoslav Republic of and others

■ **P534**

Risk factors for infusion reactions of infliximab in patients with Crohn's Disease

Y. Inaba, M. Taruishi, M. Fujiya, Y. Saitoh
Asahikawa City Hospital, Gastroenterology, Asahikawa, Japan and others

■ **P535**

Major nutritional diagnoses amongst outpatient IBD patients

A. Ferguson, C. Rogge, E. Gruber, R. Jennings, M. Carrie, J. Roberts, T. Lee
Illawarra Shoalhaven Local Health District, Nutrition and Dietetics, Wollongong, Australia and others

■ **P536**

Does Lémann Index reflect the quality of life in Crohn's Disease patients on treatment with biological therapy?

G. Pellegatta, G. Bodini, E. Giannini, C. De Maria, I. Baldissarro, V. Savarino, E. Savarino
University of Genoa, Department of Gastroenterology and Internal Medicine, Genoa, Italy and others

■ **P537**

Weight and body composition compartments do not predict thiopurine metabolite levels

D. Holt, B. Strauss, G. Moore
Monash Health, Department of Gastroenterology & Hepatology, Clayton, Australia and others

■ **P538**

Hypophosphataemia after different intravenous iron infusion drugs

P. Bager, J. F. Dahlerup
Aarhus University Hospital, Department of Hepatology and Gastroenterology, Aarhus, Denmark and others

■ **P539**

Clinical experience with vedolizumab in anti-TNF refractory IBD patients

B. Christopher, O. Aoko, A. O'Toole, S. Patchett, C. Smyth, S. Sengupta, R. Farrell
Connolly Hospital Blanchardstown, Department of Gastroenterology, Dublin, Ireland and others

■ **P540**

Efficacy and safety of adalimumab in the treatment of Inflammatory Bowel Disease in children

G. De Caro, C. Madia, F. Gaiani, A. Fugazza, B. Bizzarri, A. Ghiselli, F. Fornaroli, F. Vincenzi, G.L. de' Angelis
Azienda Ospedaliero Universitaria di Parma, Gastroenterologia ed Endoscopia Digestiva, Parma, Italy

■ **P541**

Cyclosporine therapy is effective in acute severe steroid refractory Ulcerative Colitis

R. Iliaz, S. Evirgen, F. Akyuz, B. Cavus, B. Pinarbasi, C. Karaca, K. Demir, F. Besisik, **S. Kaymakoglu**
Istanbul University, Department of Gastroenterology, Istanbul, Turkey and others

■ **P542**

Per oral antiviral treatment with valganciclovir for patients with cytomegalovirus-positive Ulcerative Colitis in the outpatient setting: Report of five cases

H. Tamaki, T. Noda, S. Arasawa, M. Izuta, A. Kubo, C. Ogawa, T. Matsunaka, M. Shibatoge
Takamatsu Red Cross Hospital, Gastroenterology, Takamatsu, Japan

■ **P543**

Cannabis use patterns in patients with IBD

T. Naftali, L. Bar Lev Schlieder, J. Hirsch, I. Lish, F. Benjaminov, F. Konikoff
Meir medical center, Gastroenterology, Kfar Saba, Israel and others

■ **P544**

Prospective observational study on IBD patients treated with infliximab biosimilars: Preliminary results of the PROSIT-BIO cohort of the IG-IBD

G. Fiorino, **N. Manetti**, A. Variola, F. Bossa, G. Rizzuto, L. Guidi, G. Maconi, S. Ghione, L. Cantoro, G. Lorenzon, W. Fries, M.L. Annunziata, F. Costa, M.M. Terpin, B. Principi, C. Cortelezzi, L. Biancone, A. Amato, P. Occhipinti, S. Mazzuoli, S. Ardizzzone, M. Di Girolamo, P. Alvisi, G. Meucci, L. Caserta, S. Saibeni, C. Petruzzellis, A. Ronchetti, M. Cappello, F. Castiglione, S. Danese, A. Massella, D. Varvara, A. Orlando, A. Armuzzi, A. Massari, P. Lionetti, A. Kohn, R. D'Incà, M. Vecchi, L. Bertani, V. Annese on behalf of IG-IBD Humanitas Research Hospital and University, Gastroenterology and IBD Center, Rozzano, Italy and others

■ **P545**

The impact of total and free anti-drug antibodies on infliximab pharmacokinetics between two drug administrations

L. Roque Ramos, R. Barosa, A. Nunes, A. Regalado, A. Vieira, J. Freitas, J. Demengeot, **S. Garcês**
Hospital Garcia de Orta, Gastroenterology, Almada, Portugal and others

■ **P546**

Psychiatric disorder, iron deficiency, active disease and female gender are independent risk factors for fatigue in patients with Ulcerative Colitis

B. Jonefjäll, M. Simrén, A. Larsson, L. Öhman, **H. Strid**
Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Department of Internal Medicine and Clinical Nutrition, Gothenburg, Sweden and others

■ **P547**

Effectiveness of patient education in Inflammatory Bowel Disease

A. Berding, C. Witte, B. Kaltz, R. Weiland, A. Reusch, H. Faller
German Crohn's and Colitis Association (DCCV e.V.), Berlin, Germany and others

■ **P548**

Anti-TNF monotherapy for Crohn's Disease: A 13-year multicentre experience

L. Peyrin-Biroulet, J. Salleron, **J. Filippi**, C. Reenaers, O. Antunes, V. Filipe, E. Louis, X. Hébuterne, X. Roblin
Nancy University Hospital, Université de Lorraine, Nancy 1, Inserm U954 and Department of Gastroenterology, Vandoeuvre-lès-Nancy, France and others

■ **P549**

Adalimumab improves growth velocity in children with Crohn's Disease naïve to anti-TNF treatment

J. Martín-de-Carpi, E. Llerena, M. Navalón-Rubio, G. Pujol Muncunill, D. Gil-Ortega, V. Varea, C. Sierra-Salinas, V.M. Navas-López
Unit for the Comprehensive Care of Paediatric Inflammatory Bowel Disease. Department of Paediatric Gastroenterology, Hepatology and Nutrition, Barcelona, Spain and others

■ **P550**

Patients' perceptions about thiopurines are associated with early discontinuation in patients with Inflammatory Bowel Diseases

M. Broekman, M. Coenen, O. Klungel, C. van Marrewijk, G. Wanten, L. Derijks, S. Vermeulen, D. Wong, A. Verbeek, P. Hooymans, H. Scheffer, H.-J. Guchelaar, M. Bouvy, D. de Jong
Radboud University Medical Center, Department of Gastroenterology, Nijmegen, Netherlands and others

P551
Comparison of four assay kits for measuring infliximab trough levels and antibodies to infliximab in patients with Inflammatory Bowel Disease

I. Perez, L. Fernandez, S. Sanchez-Ramón, C. Alba, D. Olivares, J.L. Mendoza, E. Rey, **C. Taxonera**
Hospital Clínico San Carlos, IBD Unit, Madrid, Spain and others

P552
Development and validation of a tandem liquid chromatographic mass spectrometric (LC-MS/MS) assay for the measurement of vedolizumab (VLZ) levels in patient serum

C. Christ, A. Dignass, F. Hartmann, J. Stein
Immundiagnostik AG, Bensheim, Germany and others

P553
Clinical and surgical recurrences in Crohn's Disease (CD): A-15 year follow-up cohort study from Northern Italy tertiary centre

L. Campanati, G.-E. Nita, A. Indriolo, F. Rubertà, E. Poiasina, P. Ravelli, L. Ansaloni
Papa Giovanni XXIII Hospital, I General Surgery Unit, Bergamo, Italy and others

P554
A negative screening does not eliminate tuberculosis risk under anti-TNF treatment in Inflammatory Bowel Disease: A descriptive study

Y. Abitbol, D. Laharie, J. Cosnes, M. Allez, S. Nancey, A. Amiot, A. Aubourg, M. Fumery, R. Altwegg, P. Michetti, E. Chanteloup, P. Seksik, V. Abitbol, C. Baudry, M. Flamant, G. Bouguen, C. Stefanescu, A. Bourrier, G. Bommelaer, N. Dib, M.A. Bigard, S. Viennot, X. Hébuterne, J.M. Gornet, P. Marteau, Y. Bouhnik, S. Nahon
Groupe hospitalier de Montfermeil, Montfermeil, France and others

P555
Failure of infliximab treatment in Crohn's Disease is associated with the presence of fibrosis

J. de Bruyn, J. Steenkamer, M. Wildenberg, S. Meijer, W. Bemelman, G. van den Brink, G. D'Haens
Academic Medical Center, Gastroenterology & Hepatology, Amsterdam, Netherlands and others

P556
Endogenous conversion of ω -6 to ω -3 polyunsaturated fatty acids in fat-1 mice attenuated intestinal polyposis by either inhibiting COX-2/ β -catenin signaling or activating IL-18

K.B. Hahm, Y.J. Kim, J.M. Park
CHA University, Gastroenterology, Seongnam, South Korea and others

P557
The value of mercaptopurine therapy after failing azathioprine in Inflammatory Bowel Disease patients

B. Meijer, M. Seinen, N. Leijte, C. Mulder, A. van Bodegraven, N. de Boer
VU University Medical Center, Gastroenterology and Hepatology, Amsterdam, Netherlands and others

P558
Long-term scheduled therapy with infliximab in Inflammatory Bowel Disease: A single-centre observational study

C. Felice, P.M. Ferraro, M. Marzo, D. Pugliese, A. Papa, G.L. Rapaccini, L. Guidi, A. Armuzzi
Catholic University of the Sacred Heart, Internal Medicine and Gastroenterology Unit, Complesso Integrato Columbus, Rome, Italy and others

P559
Awareness of human papilloma virus infection among women with Inflammatory Bowel Diseases – Results from patients' survey

V. Suchá, B. Kadleckova, B. Repakova, K. Ototova, L. Jurgos, S. Kinova, Z. Zelinkova
Outpatient Department of Gastroenterology, Jurgos s.r.o., Bratislava, Slovakia and others

P560
Concomitant granulocyte and monocyte adsorption apheresis accelerates clinical efficacy and mucosal healing of colonic lesions in patients with active Crohn's Disease

S. Yasukawa, **F. Hirai**, Y. Takada, Y. Yano
Fukuoka University Chikushi Hospital, Department of Gastroenterology, Chikushino, Japan

■ **P561**

A first-in-human randomized double-blind placebo-controlled clinical trial of a novel narrow spectrum kinase inhibitor

A. Rowley, A. Duggal, **M. Taylor**, M. Foster, Y. Solanke, S. Sirohi, C. Walshe, S. Webber, P. Irving, S. Travis
Topivert Pharma Ltd, London, United Kingdom and others

■ **P562**

Effectiveness and safety of golimumab in inducing remission in outpatient Ulcerative Colitis patients: A first "real life" experience in primary gastroenterology centres in Italy

A. Tursi, L. Allegretta, N. Della Valle, Y. Hadad, **A. Penna**, G. Pranzo, C. Ricciardelli, P. Paiano, M. Picchio
Azienda Sanitaria Locale BAT, Servizio di Gastroenterologia Territoriale, Andria, Italy and others

■ **P563**

Subtotal colectomy for Ulcerative Colitis: Distinct short-term and long-term advantages of the laparoscopic approach

N. Buchs, A. Bloemendaal, C. Wood, N. Mortensen, R. Guy, B. George
Oxford University Hospitals, Department of Colorectal Surgery, Oxford, United Kingdom and others

■ **P564**

Ipilimumab-induced Colitis: Clinical, endoscopic and histological characteristics

S.I. Siakavellas, G. Bamias, I. Delladetsima, M. Perdiki, M. Gizis, G.L. Daikos, H. Gogas
Laikon Hospital, Academic Department of Gastroenterology, Athens, Greece and others

■ **P565**

Maintenance of clinical remission in IBD patients after discontinuation of anti-TNF agents, an Italian experience

R. Monterubbianesi, F. Furfaro, G. Costantino, C. Bezzio, D. Giannarelli, W. Fries, G. Maconi, A. Kohn
AO San Camillo Forlanini, Gastroenterology Operative Unit, Rome, Italy and others

■ **P566**

Are relatives aware of IBD patients' worries?

L. Fernández-Salazar, E. Berroa, B. Antolín, J.M. González
Hospital Clínico Universitario, Gastroenterology, Valladolid, Spain

■ **P567**

Functional outcomes and factors influencing quality of life in patients with Ulcerative Colitis after total proctocolectomy with ileal pouch-anal anastomosis

K. Watanabe, M. Nagao, T. Abe, H. Karasawa, S. Ohnuma, H. Musha, T. Naitoh, M. Unno
Tohoku University Graduate School of Medicine, Department of Surgery, Sendai, Japan

■ **P568**

Health-related quality of life, work productivity, and satisfaction with treatment among IBD patients receiving adalimumab mono- versus adalimumab combo-therapy

S. Wang, R. Jakubanis, J. Piercy, M. Skup
AbbVie Inc., North Chicago, United States and others

■ **P569**

Nutritional status in a cohort of paediatric patients with Inflammatory Bowel Disease at diagnosis

N. Egea Castillo, G. Pujol, K. Rosales, A. Gutierrez, D. Garcia-Arenas, V. Vila, S. Pinillos, J. Martin de Carpi
Hospital Sant Joan de Déu, Gastroenterology, Barcelona, Spain and others

■ **P570**

More than 10 years of experience of use: Methotrexate in Crohn's Disease at Macarena Hospital, Sevilla, Spain

M.F. Guerra Veloz, M.B. Maldonado Pérez, A. Caunedo Álvarez, L. Castro Laria, J.L. Cotrina Lino, F. Argüelles Arias, A. Flores Cucho, M. Romero Gómez
Unidad de Gestión Clínica de Aparato Digestivo Hospital Universitario Virgen Macarena, Seville, Spain and others

■ **P571**

Beliefs about medicines questionnaire assessing medication adherence in patients with Inflammatory Bowel Disease

M.L. De Castro, A. Martín, L. Sanromán, N. Martínez, M. Figueira, V. Hernández, J.R. Pineda, S. Pereira, J. Martínez-Cadilla, V. Del Campo, J.-I. Rodríguez-Prada
Hospital Alvaro Cunqueiro. Complejo Hospitalario Universitario de Vigo.CHUVI, Gastroenterology, Vigo, Spain and others

■ **P572**

Dysplasia in Inflammatory Bowel Disease – Is endoscopic mucosal resection ready for prime-time?

D. Branquinho, F. Portela, P. Freire, M. Ferreira, S. Mendes, M. Ferreira, C. Sofia
Coimbra University Hospital Centre, Gastroenterology, Coimbra, Portugal

■ **P573**

Assessment of serum C-reactive protein, faecal lactoferrin, and faecal calprotectin in patients with Crohn's Disease: Results from the UNITI-1 and UNITI-2 ustekinumab induction studies

C. Gasink, Y. Lang, D. Jacobstein, J. Johanns, P. Rutgeerts, W. de Villiers, J.-F. Colombel
Janssen R & D, LLC, Spring House, United States and others

■ **P574**

Effect of adalimumab on clinical outcomes and health-related quality of life among patients with Ulcerative Colitis in a clinical practice setting: Results from INSPIRADA

S. Travis, B. Feagan, L. Peyrin-Biroulet, R. Panaccione, S. Danese, A. Lazar, A. Robinson, J. Petersson, M. Bereswill, M. Skup, N. Chen, S. Wang, R. Thakkar, J. Chao
Oxford University Hospitals, Oxford, United Kingdom and others

■ **P575**

Efficacy of faecal diversion in managing refractory perianal or colonic Crohn's Disease

I. Parisi, R. Vega, S. McCartney, C. Hart, S. Bloom
University College London Hospital, Department of Gastroenterology, London, United Kingdom and others

■ **P576**

Long-term efficacy and safety of adalimumab in paediatric patients with Crohn's Disease

W.A. Faubion, M. Dubinsky, F.M. Ruemmele, J. Escher, J. Rosh, J.S. Hyams, S. Eichner, Y. Li, N. Reilly, A.M. Robinson, A. Lazar
Mayo Clinic, Rochester, United States and others

■ **P577**

Croatian database from 5 centers - Efficacy and safety of infliximab biosimilar in treatment of IBD patients

N. Turk, M. Brinar, D. Grgic, A. Kunovic, R. Prijic, V. Borzan, B. Sincic Mijandrusic, M. Crncevic Urek, M. Banic, I. Tadin Hadina, Z. Puljiz, M. Simunic, N. Rustemovic, S. Cukovic Cavka, Z. Krznaric
University Hospital Center "Zagreb", Gastroenterology and hepatology, Zagreb, Croatia and others

■ **P578**

Changes of practice in ileoanal pouch surgery in a single referral centre

A. Germain, A. de Buck van Overstraeten, A. Wolthuis, A. D'Hoore
University Hospital of Nancy, Department of Digestive Surgery, Nancy, France and others

■ **P579**

Combined therapy of tacrolimus and vedolizumab in severe refractory Ulcerative Colitis

N.-A. Dietrich, F. Baer, A. Dignass, B. Bokemeyer, K. Fellermann, J. Buening
University Hospital of Schleswig-Holstein, Luebeck, Internal Medicine, Luebeck, Germany and others

■ **P580**

Inflammatory Bowel Disease patients' preference for disease treatment factors

J. Gregor, **M. Williamson**, D. Dajnowiec, B. Sattin, E. Sabot, B. Salh
Western University and London Health Sciences Centre, London, Canada and others

■ **P581**

Bleeding after side-to-side isoperistaltic stricturoplasty for Crohn's Disease: Is still a major surgical complication?

F. Giudici, S. Scaringi, F. Ficari, D. Zambonin, C. Di Martino, M. Fazi, F. Tonelli, P. Bechi
Careggi University Hospital, Surgery and Translational Medicine, Florence, Italy and others

■ **P582**

Predictive value of infliximab trough levels in quiescent Inflammatory Bowel Disease under maintenance infliximab therapy

M. Bejaoui, F. Charbit-Henrion, C. Landman, H. Sokol, A. Bourrier, I. Nion-Larmurier, J. Cosnes, L. Beaugerie, P. Seksik
Saint Antoine Hospital, Gastroenterology & Nutrition, Paris, France

■ **P583**

Real world use and effectiveness of golimumab for Ulcerative Colitis in Canada

B. Bressler, **M. Williamson**, F. Camacho, B. Sattin, A.H. Steinhart
University of British Columbia, Vancouver, Canada and others

■ **P584**

Relapse risk and predictors for relapse in a real-life cohort of IBD patients after discontinuation of anti-TNF therapy

S. Bots, S. Kuin, M. Löwenberg, C. Ponsioen, G. van den Brink, G. D'Haens
Academic Medical Center (AMC), Department of Gastroenterology and Hepatology, Amsterdam, Netherlands

■ **P585**

Systematic literature review of clinical trials that assess the efficacy of biologic drugs in the treatment of extra intestinal manifestations in Inflammatory Bowel Disease

G. Van Assche, L. Peyrin-Biroulet, D. Gomez-Ulloa, L. Garcia-Alvarez, N. Lara, C. Black, **S. Kachroo**
University Hospitals Leuven, Department of Gastroenterology, Leuven, Belgium and others

■ **P586**

Cyclophosphamide pulse therapy in severe refractory Crohn's disease

F. Baer, T. Krause, A. Stallmach, N. Teich, C. Maaser, J. Maul, U. Helwig, K. Fellermann, J. Buening
University hospital of Luebeck, Department of Internal Medicine I, Luebeck, Germany and others

■ **P587**

SuPREMe-CD Study: Surgical prevention of anastomotic recurrence by excluding mesentery in Crohn's Disease. Preliminary results and trial protocol

G. Luglio, M.C. Giglio, A. Rispo, R. Peltrini, M. Sacco, V. Sollazzo, C. Bucci, E. Spadarella, F. Terracciano, G.D. De Palma, L. Bucci
Federico II University of Naples, Department of Clinical Medicine and Surgery, Naples, Italy

■ **P588**

Test characteristics of commonly used clinical and biochemical markers predicting mucosal healing and active inflammation in Ulcerative Colitis – Faecal calprotectin is clearly superior

K. Carlsen, R. Goll, H. Elsberg, T. Thorkilgaard, L. Maagaard, S.S. Wergeland, J. Florholmen, C. Jakobsen, V. Wewer, L.B. Riis, P.S. Munkholm
Herlev Hospital, Department of Pathology, Herlev, Denmark and others

■ **P589**

Clinical analysis of the postoperative bowel function in elderly patients with Ulcerative Colitis

R. Futatsuki, A. Sugita, K. Koganei, K. Tatsumi, H. Kuroki, K. Yamada, K. Arai, H. Kimura, T. Fukushima
Yokohama Municipal Citizens Hospital, Inflammatory Bowel Disease Center, Department of Surgery, Yokohama, Japan and others

■ **P590**

Therapeutic drug monitoring is a new tool for improving the care of patients treated by anti-TNF alpha: Does this apply to children with Inflammatory Bowel Diseases?

M. Chavannes, P. Jantchou, F. Gervais, R. Robitaille, V. Marchand, C. Deslandres
Sainte Justine University Hospital, Paediatric Gastroenterology, Montreal, Canada and others

P591**Satisfaction with treatment among IBD patients receiving subcutaneous biologic treatment and infused biologic treatment**

S. Wang, J. Piercy, R. Jakubanis, M. Skup
AbbVie Inc., North Chicago, United States and others

P592**Absenteeism and presenteeism among Crohn's Disease patients: Results from a real-world cohort in Israel**

D. Schwartz, D. Greenberg, E. Chernin, H. Vardi, M. Friger, O. Sarid, V. Slonim-Nevo, S. Odes
Soroka UMC, Gastroenterology, Beer Sheva, Israel and others

P593**Bone mineral density in a Spanish cohort of Inflammatory Bowel Disease patients**

J. Miranda-Bautista, M.D. Perez-Valderas, A. Caballero-Marcos, A. Diaz-Redondo, I. Marin-Jimenez, L. Menchen
Hospital General Universitario "Gregorio Marañón", Gastroenterology Unit, Madrid, Spain and others

P594**Infliximab for active Ulcerative Colitis: A prospective study on patients' short term response and long term outcome**

U. Nieminen, U. Turunen, P. Arkkila, T. Sipponen, M. Färkkilä
Helsinki University Hospital, Department of Gastroenterology, Helsinki, Finland and others

P595**More than 10 years of experience of use methotrexate in Ulcerative Colitis at Macarena Hospital. Sevilla- Spain.**

M.F. Guerra Veloz, M.B. Maldonado Pérez, A. Caunedo Álvarez, L. Castro Laria, J.L. Cotrina Lino, F. Argüelles Arias, A. Flores Cucho, M. Romero Gómez
Unidad de Gestión Clínica de Aparato Digestivo Hospital Universitario Virgen Macarena, Seville, Spain and others

P596**Analysis on adverse drug reactions of 103 Inflammatory Bowel Disease patients using thalidomide**

P. Xiang, S. Ming-li, G. Xiang, Z. Ming
The Sixth Affiliated Hospital, Sun Yan-sen University, Department of Gastroenterology, Guangzhou, China and others

P597**Body composition: A biomarker of therapeutic outcome in patients with Crohn's Disease**

N.S. Ding, G. Malietzis, P.F. Lung, W. Yip, L. Penez, T. Ganeshanathan, S.M. Gabe, J.T. Jenkins, A. Hart
St Mark's Hospital, IBD, London, United Kingdom and others

P598**Dietetic intervention and nutritional status in adult patients with Crohn's Disease. Preliminary results**

A. Dell'Era, V.F. Bernardo De Almeida, L. Cioni, A. Massari, F. Muzio
UOC Gastroenterologia, Ospedale L. Sacco. Università degli Studi di Milano, Dipartimento di Scienze Biomediche e Cliniche, Milano, Italy and others

P599**Clinical practice and outcomes of iron isomaltoside administration in anaemic patients with Crohn's Disease and Ulcerative Colitis**

J. Stein, H. Hartmann, A. Walper
Crohn's and Colitis Center, Gastroenterology, Frankfurt, Germany and others

P600**Safety and efficacy of infliximab biosimilar (Remsima®) in Ulcerative Colitis disease patients in clinical practice: Results after 6 months treatment**

M.F. Guerra Veloz, F. Argüelles Arias, R. Perea Amarillo, L. Castro Laria, M.B. Maldonado Pérez, A. Benítez Roldán, V. Merino, G. Ramirez, A. Vilches Arenas, A. Caunedo Álvarez
Unidad de Gestión Clínica de Aparato Digestivo Hospital Universitario Virgen Macarena, Seville, Spain and others

■ **P601**

The efficacy of GSK2586184, a novel selective Janus Kinase1 inhibitor, in patients with moderate to severely active Ulcerative Colitis

L. De Vries, F. van Leeuwen-Hilbers, C. Verseijden, J. Duarte, K. Hicks, J. Patel, V. Ludbrook, W. De Jonge, G. D'Haens

Academic Medical Center (AMC), Gastroenterology & Hepatology, Amsterdam, Netherlands and others

■ **P602**

Health-related quality of life improves during one year of postoperative prophylactic drug therapy after ileocecal intestinal resection in Crohn's disease patients: Results of the APPRECIÀ randomized trial

C. Taxonera, A. Lopez-Sanroman, M.I. Vera, P. Nos

Hospital Clínico San Carlos, IBD Unit, Madrid, Spain and others

■ **P603**

Response and remission rates with up to 3 years of vedolizumab treatment in patients with Crohn's Disease

S. Vermeire, B.G. Feagan, R. Mody, A. Previtali, B. Abhyankar

University Hospital Gasthuisberg, Gastroenterology, Leuven, Belgium and others

■ **P604**

The negative role of the antibodies developed against the first anti-TNF during the switch towards a second anti-TNF requires the use of an associated immunosuppressive agent

C. Verot, E. Del Tedesco, J.M. Phelip, L. Peyrin Biroulet, X. Roblin

CHU Saint Etienne, Saint Etienne, France and others

■ **P605**

Impact of medication type on patients' health-related quality of life in Crohn's Disease

D. Schwartz, D. Greenberg, E. Chernin, O. Sarid, V. Slonim-Nevo, M. Friger, H. Vardi, S. Odes

Soroka UMC, Gastroenterology, Beer Sheva, Israel and others

■ **P606**

Histological healing in Ulcerative Colitis with mesalazine and its prognostic role

G. Frieri, B. Galletti, M. Di Ruscio, R. Tittoni, A. Capannolo, G. Latella, L. Sollima, P. Leocata, S. Necozone, A. Viscido

University Of L'Aquila, L'Aquila, Italy

■ **P607**

Infliximab trough levels and anti-drug antibodies after induction predict long term clinical remission in Infliximab-treated patients with Inflammatory Bowel Disease

G. Bodini, L. Del Nero, E.G. Giannini, S. Tolone, N. De Bortoli, J. Anjali, I. Baldissarro, V. Savarino, E. Savarino

University of Genoa, Internal Medicine Department, Genoa, Italy and others

■ **P608**

Systematic literature review of observational studies that assess the effectiveness of biologic drugs in the treatment of extraintestinal manifestations in Inflammatory Bowel Disease

L. Peyrin-Biroulet, G. Van Assche, D. Gomez-Ulloa, L. Garcia-Alvarez, N. Lara, C. Black, **S. Kachroo**

Lorraine University, Gastroenterology Department, Vandoeuvre, France and others

■ **P609**

Efficacy and safety of adalimumab in paediatric patients with Crohn's Disease aged 10 years and younger: Subanalysis of IMAGINE 1

F. Ruemmele, M. Dubinsky, J. Hyams, S. Eichner, J.-F. Maa, A. Lazar, A. Robinson, G. Alperovich

Universite Sorbonne Paris-Cite, Hospital Necker-Enfants Malades, Paris, France and others

■ **P610**

Factors associated with anti-TNF therapy failure in patients with Crohn's Disease (CD). Does the type of drug have any influence?

I. Baston, M. Barreiro-de Acosta, D. De la Iglesia, R. Ferreira, A. Lorenzo, J.E. Dominguez-Munoz

University Hospital Santiago de Compostela, Gastroenterology, Santiago, Spain

■ **P611**

Baseline fecal MMP-9 level correlates to endoscopic sub-score and post-treatment level correlates to mucosal healing in moderate to severe Ulcerative Colitis patients

B. Feagan, B. Levesque, **J. Woo**, G. Chen, H. Wang, Y. Xiao, E. Huntzicker, D. French, V. Smith, S.D. Patterson, M. Subramanian, B. Kanwar, W. Sandborn, B.R. Bhandari
Robarts Clinical Trials, London, Ontario, Canada and others

■ **P612**

Presence and severity of ulcerations in Crohn's Disease does not contribute to response for induction therapy with infliximab in children

M. Dadalski, A. Wegner, E. Szymanska, J. Kierkus
Children's Memorial Health Institute, Gastroenterology, Hepatology, Feeding Disorders and Paediatrics, Warsaw, Poland and others

■ **P613**

Regulators of glucocorticoid metabolism in Inflammatory Bowel Disease and predicting response to steroid therapy

M. Hussey, A. Cannon, G. Holleran, J. O'Sullivan, M. Sherlock, D. McNamara
Aelaide and Meath Hospital, Trinity College Dublin, Gastroenterology, Trinity Academic Gastroenterology Group, Dublin, Ireland and others

■ **P614**

Real world use of adalimumab in UK patients with Ulcerative Colitis: An observational retrospective study

G. Watts, **R. Arasaradnam**, S. Travis, A. Sharma, A. Awasthi, J. Limdi, T. Finney-Hayward
Wythenshaw Hospital, Manchester, United Kingdom and others

■ **P615**

Efficacy and safety of granulocyte, monocyte/macrophage adsorptive apheresis in steroid-dependent active UC with insufficient response or intolerance to immunosuppressant's and/or biological therapies (the ART trial): Final results

A. Dignass, A. Akbar, B. Bonaz
Agaplesion Markus Hospital, Department of Medicine I, Frankfurt, Germany and others

■ **P616**

Early Infliximab drug levels predict perianal fistula response to treatment

Y. Davidov, B. Ungar, O. Haj Natour, M. Yavzori, Y. Chowers, R. Eliakim, S. Ben-Horin, **U. Kopylov**
Sheba Medical Center, Gastroenterology, Tel Hashomer, Israel and others

■ **P617**

Immunogenicity after switching from reference infliximab to biosimilar in children with Crohn disease

J. Siczekowska, D. Jarzebicka, G. Oracz, M. Meglicka, M. Dadalski, J. Kierkus
The Children's Memorial Health Institute, Department of Gastroenterology, Hepatology, Feeding Disorders and Paediatrics, Warsaw, Poland

■ **P618**

A Mayo endoscopic subscore of 0 predicts long-term remission in patients with Ulcerative Colitis treated with mesalazine

R. Sakemi, H. Tanaka, M. Miyakawa, M. Nasuno, S. Motoya
Sapporo Kosei General Hospital, IBD Center, Sapporo, Japan and others

■ **P619**

Routine assessment of Inflammatory Bowel Diseases clinical presentations: A prerequisite to check for treatment recommendations

M. Timmer, F. Froehlich, P. Michetti, M.H. Maillard, A. Schoepfer, C. Mottet, B. Burnand, **V. Pittet**
Institute of Social and Preventive Medicine, Healthcare Evaluation Unit, Lausanne, Switzerland and others

■ **P620**

Assessment of predictors of the need for biologic therapy in patients with Inflammatory Bowel Disease: A single tertiary center experience

S. Raimundo Fernandes, L. Correia, P. Moura Santos, A. Rita Gonçalves, A. Valente, C. Baldaia, J. Velosa
Centro Hospitalar Lisboa Norte, Gastroenterology, Lisboa, Portugal

■ **P621**

Long-term safety of in utero exposure to anti-TNF α drugs for the treatment of Inflammatory Bowel Diseases (IBD): Interim results of the TEDDY study

M. Chaparro, M, F. Magro, E. Savarino, Y. Zabana, D. Pugliese, A. Bar-Gil Shitrit, S. Fernandes, P. López-Serrano, M.J. Casanova, L. Fernández-Salazar, A. Gutierrez, R. Vicente, E. Gravito-Soares, C. Rodriguez, L. Sebkova, D. Lissner, A. Magarotto, I. Rodriguez-Lago, J.M. Huguete, M.T. Diz-Lois Palomares, G. Fiorino, I. Guerra, G. Mantzaris, M. Silva, O. Bartolo, M.G. Donday, M. Ramas, J. Martín de Carpi, J.P. Gisbert
Hospital Universitario de la Princesa, IIS-IP y CIBEREHD, Department of Gastroenterology, Madrid, Spain and others

■ **P622**

In a Dutch real life IBD cohort with 90% prior anti-TNF failure, Vedolizumab showed a 25% remission rate: A retrospective multicenter study

R.Y. Gabriëls, A.P.J. de Graaf, M.A.C. Meijssen, J.M. Götz, P.B. Mensink, M.G.V.M. Russel, H.M. Dulleman, R.W.F. ter Steege, R.K. Weersma, G. Dijkstra
University of Groningen, University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, Netherlands and others

■ **P623**

Withdrawn

■ **P624**

Effectiveness and safety of vedolizumab for the induction of remission in Inflammatory Bowel Disease

M. Chaparro, M. Sierra-Ausin, F. Mesonero, N. Maroto, C. Fernandez de Castro, V. García-Sánchez, A.J. Lucendo, D. Busquets, M. Barreiro-de Acosta, I. Marín-Jiménez, B. Beltrán, L. Ruiz Belmonte, F. Bermejo, M. Mínguez, R. Pajares, J.R. Pineda, B. Sicilia, D. Martín-Rodríguez, A. Gutiérrez, S. Rubio, I. García Tercero, M. Piqueras, D. Ginard, B. Jucha, C. Muñoz Villafranca, M.D. Martín-Arranz, L. Martí Romero, E.M. Fernández Bonilla, A. Echarri, J.F. Forcelledo, M.G. Donday, M. Ramas, J.P. Gisbert
Hospital Universitario de La Princesa, IIS-IP and CIBERehd, Gastroenterology Unit, Madrid, Spain and others

■ **P625**

Frequency and clinical factors associated with histologic remission in patients with Ulcerative Colitis: A retrospective cohort study in a Latin American country

J. Yamamoto-Furusho, G. Sanchez-Morales
IBD Clinic, Instituto Nacional de Ciencias Medicas y Nutricion, Gastroenterology, Mexico, Mexico and others

■ **P626**

Prevalence of Inflammatory Bowel Disease among patients with psoriasis and incidence of serious infections in this subset: Results from the PSOLAR registry

E. Loftus, Jr, M. Augustin, R. Bissonnette, G. Krueger, S. Calabro, W. Langhoff, J. Popp, K. Goyal, **S. Sloan**
Mayo Clinic Rochester, Department of Gastroenterology, Rochester, United States and others

■ **P627**

What is the need for, and acceptability of, routine, integrated psychological care in an established Inflammatory Bowel Disease (IBD) service? Early data from a new initiative in clinical IBD care

T. Lores, C. Goess, R. Grafton, J. Hughes, L. Cronin, A. Mikocka-Walus, A. Chur-Hansen, A. Burke, K. Collins, J. Andrews
Royal Adelaide Hospital, Gastroenterology, Adelaide, Australia and others

■ **P628**

Patient reported adherence rates to topical therapies in Ulcerative Colitis

P. Hendy, M. Shuvo, A. Hart
St Mark's Hospital, Gastroenterology, London, United Kingdom and others

■ **P629**

Improvement of nutritional status and growth velocity as an additional benefit from using the exclusive enteral nutrition (EEN) to induce remission in children with active Crohn's Disease (CD)

M. Matuszczyk, M. Meglicka, P. Landowski, B. Sordyl, E. Czkwaniec, J. Kierkuś
The Children's Memorial Health Institute, Department of Gastroenterology, Hepatology, Feeding Disorders and Paediatrics, Warsaw, Poland and others

■ **P630**

Screening for latent and previous infectious diseases in IBD patients – a must for correct treatment decisions?

M. Ardesia, S. Maisano, G. Costantino, A. Alibrandi, W. Fries
University of Messina, Department of Clinical and Experimental Medicine, Messina, Italy and others

■ **P631**

Long term outcome of colorectal cancer in Crohn's and Ulcerative Colitis: A comparative study

S. Scaringi, C. Di Martino, F. Giudici, D. Zambonin, F. Tonelli, F. Ficari, P. Bechi
Careggi University Hospital, Surgery and Translational Medicine, Florence, Italy and others

■ **P632**

Serum vedolizumab assay at Week 6 predicts sustained clinical remission and lack of recourse to optimisation in IBD

N. Williet, S. Paul, E. Del Tedesco, J.M. Phelip, X. Roblin
CHU Saint Etienne, Saint Etienne, France and others

■ **P633**

Quality of life in paediatric Inflammatory Bowel Disease patients in a self-administered telemedicine randomized clinical study

K. Carlsen, C. Jakobsen, L.F. Hansen, A. Paerregaard, T. Kallemose, L.B. Riis, P.S. Munkholm, V. Wewer
Hvidovre Hospital, Paediatric, Hvidovre, Denmark and others

■ **P634**

Escalation of IFX therapy in paediatric versus adult IBD patients – results from a prospective single-center cohort study

D. Winter, C. van der Woude, J. Escher
Children's Hospital Erasmus MC Sophia, Department of Paediatric Gastroenterology, Rotterdam, Netherlands and others

■ **P635**

Personalized prophylactic use of thiopurines prevented surgical recurrence in patients with Crohn's Disease after intestinal resection

X. Luo, R. Mao, B. Chen, Y. He, Z. Zeng, **M. Chen**
The First Affiliated Hospital, Sun Yat-sen University, Department of Gastroenterology, Guangzhou, China

■ **P636**

Patient support programme is well accepted and could help adherence in IBD patients

G. Lorenzon, M.G. Vettorato, E. De Marchi, O. Bartolo, R. Caccaro, F. Cavallin, G. Girardin, A. Rigo, F. Simonetti, E.V. Savarino, G.C. Sturniolo, R. D'Inca
University of Padua, Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, University of Padua, Padua, Italy, Padua, Italy and others

■ **P637**

Pharmacokinetics of golimumab in patients with moderate to severe Ulcerative Colitis

S. Berends, A. Strik, P. van Egmond, H. Brandse, R. Mathôt, G. D'Haens, M. Löwenberg
Academic Medical Center (AMC), Hospital Pharmacy, Amsterdam, Netherlands and others

■ **P638**

Assessment of IMPACT III emotional and social functioning domain scores in adalimumab-treated paediatric patients with Crohn's Disease

A. Grant, A. Otley, J. Escher, J.S. Hyams, J.-F. Maa, G. Alperovich, A. Lazar, A.M. Robinson, A.W. Wang, S. Eichner
IWK Health Centre, Nova Scotia, Canada and others

■ **P639**

Faecal Microbiota Transplantation (FMT) as a rescue therapy for steroid-dependent and/or non-responsive patients with Ulcerative Colitis (UC): A pilot study

T. Karakan, M. İbiş, M. Cindoruk, Z.G. Sargin, N. Alizadeh
Gazi University, Gastroenterology, Ankara, Turkey

■ **P640**

Co-detection of infliximab and antibodies in an ECLIA assay among IBD patients treated with infliximab

R. Colman, D. Rubin

University of Chicago Medicine Inflammatory Bowel Disease Center, Chicago, United States and others

■ **P641**

Vitamin D levels during remission are associated with the risk of clinical relapse in patients with Ulcerative Colitis

J.M. Gubatan, S. Mitsuhashi, T. Zenlea, L. Rosenberg, S. Robson, A. Moss

Beth Israel Deaconess Medical Center, Harvard Medical School, Division of Gastroenterology, Department of Medicine, Boston, United States

■ **P642**

Adalimumab and postoperative complications of intestinal resections in Crohn's disease: A case-matched study

P.G. Kotze, B. Saab, M.P. Saab, L.V. Pinheiro, M.L.S. Ayrizono, C.A.R. Martinez, D.O. Magro, M. Olandoski, L.M.S. Kotze, C.S.R. Coy

Catholic University of Paraná, Colorectal Surgery Unit - Cajuru University Hospital, Curitiba, Brazil and others

■ **P643**

Safety and efficacy of daily granulocyte and monocyte adsorptive apheresis in 50 consecutive patients with active Ulcerative Colitis: A prospective study

T. Yamamoto, T. Shimoyama, S. Umegae, K. Matsumoto

Yokkaichi Hazu Medical Centre, Inflammatory Bowel Disease Centre, Yokkaichi, Japan

■ **P644**

Influence of Anti-TNF- α therapy on pregnancy related outcomes and immunity of the children in women with Inflammatory Bowel Disease

K.E. Lee, S.-A. Jung, S.H. Park, C.M. Moon, S.Y. Shim, E.S. Kim, S.J. Cho, S.-E. Kim, K.B. Cho, S.-K. Yang

Ewha Womans University School of Medicine, Department of Internal Medicine, Seoul, South Korea and others

■ **P645**

Efficacy and safety of biosimilar of infliximab in rescue therapy in adult patients with severe Ulcerative Colitis

M. Kaniewska, G. Rydzewska

Central Clinical Hospital of the Ministry of Interior, Department of Gastroenterology, Warsaw, Poland and others

■ **P646**

Has there been a change in the treatment of Crohn's Disease over the years? Comparison of two prospective cohorts in a tertiary referral center

O. Icht, H. Yanai, Y. Ron, G. Rosner, A. Yaron, A. Waizbard, S. Fishman, I. Dotan

IBD Center, Department of Gastroenterology and Liver Diseases, Tel Aviv Sourasky Medical Center, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel and others

■ **P647**

Efficacy and safety of endoscopic balloon dilation for symptomatic intestinal Crohn's Disease strictures

A. Casadei, E. Cavargini, L. Samperi, **D. Valpiani**, I. Manzi, E. Ricci

U.O. Gastroenterologia ed Endoscopia digestiva Ospedale "G.B. Morgagni", Dipartimento di Medicina specialistica, Forlì, Italy

■ **P648****Impact of high dose vitamin D3 supplementation in treatment of Crohn's Disease in remission: A randomized double-blind controlled study**

N. Narula, M. Cooray, R. Anglin, Z. Muqtadir, A. Narula, J. Marshall
McMaster University, Gastroenterology, Hamilton, ON, Canada

■ **P649****Crohn's Disease patients with high body mass index present more frequent and rapid loss of response to infliximab**

L. Guerbau, R. Gerard, N. Duveau, P. Desreumaux, M. Boualit, J. Branche, V. Maunoury, L. Libier, S. Cattan, C. Gower-Rousseau, A. Cotteau-Leroy, M. Nachury, B. Pariente
Centre Hospitalier Universitaire de Lille, Lille, France

■ **P650****Patient perceptions of food-based dietary treatment of Crohn's Disease; A survey of paediatric patients previously treated with exclusive enteral nutrition**

V. Svolos, K. Gerasimidis, V. Garrick, L. Curtis, J. Hay, E. Buchanan, R. Russell, R. Hansen
Human Nutrition, School of Medicine, College of Medical, Veterinary and Life Sciences, University of Glasgow, Glasgow Royal Infirmary, Glasgow, United Kingdom and others

■ **P651****Postoperative complications after intestinal resection in Crohn's Disease: Analysis from the Practicoh study**

E. Domènech, M. Barreiro-de Acosta, A. Gutiérrez, V. García, M.D. Martín Arranz, L. Cea-Calvo, C. Romero, B. Juliá
Hospital Universitari Germans Trias i Pujol and CIBERehd, Gastroenterology Unit, Badalona, Spain and others

■ **P652****The prevalence of latent tuberculosis and hepatitis B found after systematic screening of patients starting with biological therapy in a low-endemic area**

M. de Jong, D. Roosen, A. Peters, A. Masclee, V. Verstraeten, A. van Tubergen, M. Pierik
Maastricht University Medical Centre+, Department of Internal Medicine, division of Gastroenterology and Hepatology, Maastricht, Netherlands and others

■ **P653****Prevalence and factors associated with fatigue in patients with Inflammatory Bowel Disease: A multicenter study**

C. Chavarria-Herbozo, M.J. Casanova, M. Barreiro-de Acosta, M. Chaparro, E. Ezquiaga, L. Bujanda, M. Rivero, F. Arguelles-Arias, M.D. Martín-Arranz, M.P. Martínez-Montiel, M. Valls, R. Ferreiro, J. Llaó, I. Moraleja-Yudego, F. Casellas, B. Antolin-Melero, X. Cortés, R. Plaza, J.R. Pineda, M. Navarro-Llavat, S. García-López, P. Robledo-Andrés, I. Marín-Jiménez, E. Iglesias-Flores, O. Merino, F. Bermejo, M.R. Arribas-López, J.M. Banales, B. Castro, L. Castro-Laria, R. Honrubia, P. Almela, J.P. Gisbert
Hospital Universitario de La Princesa, IIS-IP and CIBERehd, Gastroenterology Unit, Madrid, Spain and others

■ **P654****Factors associated with non-adherence to medical therapy in Inflammatory Bowel Disease**

M.L. De Castro, N. Martínez, A. Martín, L. Sanromán, M. Figueira, V. Hernández, J.R. Pineda, J. Martínez-Cadilla, S. Pereira, V. Del Campo, J.-I. Rodríguez-Prada
Hospital Alvaro Cunqueiro. Complejo Hospitalario Universitario de Vigo.CHUVI, Gastroenterology, Vigo, Spain and others

■ **P655****Biosimilar infliximab CT-P13 treatment in patients with Inflammatory Bowel Diseases: A one-year, single-center retrospective study**

T. Hlavaty, A. Krajcovicova, I. Sturdik, J. Letkovsky, T. Koller, J. Toth, M. Huorka
Comenius University, Faculty of Medicine and University Hospital Bratislava, 5th Department of Internal Medicine, Bratislava, Slovakia

■ **P656**

Infliximab therapy for intestinal, neuro, and vascular Behçet's disease: Efficacy, safety, and pharmacokinetics in a multicenter prospective study

T. Hibi, S. Hirohata, H. Kikuchi, U. Tateishi, N. Sato, K. Ozaki, K. Kondou, Y. Ishigatsubo
Kitasato University Kitasato Institute Hospital, Center for Advanced IBD Research and Treatment, Tokyo, Japan and others

■ **P657**

Health-related quality of life of patients with Inflammatory Bowel Disease is increased during treatment with biological therapy

A.S. Holdam, **P. Bager**, J.F. Dahlerup
Aarhus University Hospital, Department of Hepatology and Gastroenterology, Aarhus, Denmark

■ **P658**

Long-term outcome of endoscopic balloon dilation for ileocolonic Crohn's strictures

T. Taida, T. Nakagawa, S. Hamanaka, H. Koseki, T. Sakurai, K. Okimoto, K. Saito, D. Maruoka, T. Matsumura, M. Arai, T. Katsuno, O. Yokosuka
Chiba University, Department of Gastroenterology and Nephrology, Chiba, Japan

■ **P659**

A feasibility study with the telemedicine tool myBiologicalcoach in The Netherlands

M. de Jong, A. van Tubergen, A. Peters, A. Masclee, V. Verstraeten, M. Pierik
Maastricht University Medical Centre+, Department of Internal Medicine, division of Gastroenterology and Hepatology, Maastricht, Netherlands and others

Epidemiology

■ P660

A Danish cross-sectional study: Autoimmune and chronic inflammatory disorders associated with Crohn's Disease

M. Halling, J. Kjeldsen, T. Knudsen, J. Nielsen, L. Koch Hansen
Odense University Hospital, Department of Gastroenterology, Odense, Denmark and others

■ P661

Abscess and Fistula in Crohn's Disease

K. Sahnan, A. Askari, S. Adegbola, P. Tozer, R. Phillips, A. Hart, O. Faiz
St Mark's Hospital, Colorectal Surgery, London, United Kingdom and others

■ P662

Evolution of IBD incidence, disease phenotype, and mortality; 20 years of epidemiologic research in the Dutch population based IBDSL cohort

T. van den Heuvel, S. Jeuring, M. Zeegers, D. van Dongen, A. Wolters, A. Masclee, M. Romberg-Camps, L. Oostenbrug, M. Pierik, D. Jonkers
Maastricht University Medical Centre+, Division of Gastroenterology and Hepatology, Maastricht, Netherlands and others

■ P663

Time trends in the epidemiology and outcome of perianal and rectovaginal fistulizing Crohn's Disease – results from the population-based IBDSL cohort

S. Jeuring, K. Göttgens, R. Sturkenboom, M. Romberg-Camps, L. Oostenbrug, J. Melenhorst, L. Stassen, A. Masclee, D. Jonkers, M. Pierik, S. Breukink
Maastricht University Medical Centre+, Internal Medicine - Division of Gastroenterology and Hepatology, Maastricht, Netherlands and others

■ P664

Natural history of Crohn's Disease in elderly patients diagnosed over the age of 70 years: A population-based study

M. Fumery, B. Pariente, H. Sarter, C. Charpentier, L. Armengol-Debeir, J.-L. Dupas, H. Coevoet, L. Peyrin-biroulet, C. Gower-Rousseau, G. Savoye
Amiens University Hospital, Department of Gastroenterology and Hepatology, Amiens, France and others

■ P665

Familial aggregation of Inflammatory Bowel Disease on the Faroe Islands – A Faroese IBD cohort study

K.R. Nielsen, J. Olsen, G. Andorsdóttir, E. Gislason, J. Burisch
The National Hospital of the Faroe Islands, Medical Department, Tórshavn, Faroe Islands and others

■ P666

Fruit consumption may protect against the development of intestinal inflammation via modification of microbial composition

L. Godny, N. Maharshak, L. Yahav, N. Fliss-Isakov, U. Gophna, H. Tulchinsky, I. Dotan
Tel Aviv Sourasky Medical Center, IBD center, Department of Gastroenterology and Liver Diseases, affiliated to the Sackler Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel and others

■ P667

The clinical features of patients with newly diagnosed moderate to severe Ulcerative Colitis in Korea: A population-based inception cohort study (the MOSAIK cohort)

C.K. Lee, S.N. Hong, J.P. Im, B.D. Ye, J.M. Cha, S.-A. Jung, K.-M. Lee, D.I. Park, Y.T. Jeon, Y.S. Park, H.J. Kim, Y.J. Kim, T.O. Kim, G.S. Seo, E.S. Kim, J.S. Koo, J.S. Kim, B.I. Jang, J.E. Shin, J.W. Kim, Y.S. Park, J.H. Cheon, Y.S. Kim, H.S. Kim, J. Lee, J.J. Park, G.A. Song, C.S. Eun, S.J. Shin, K.C. Huh, H.-S. Kim, C.H. Choi, H.S. Kim, Y. Kim
Kyung Hee University School of Medicine, Internal Medicine, Seoul, South Korea and others

■ **P668**

Medical therapy, surgery and hospitalisation rates during the 2- and 3-year follow-up of the 2011 ECCO-EpiCom cohort

Z. Vegh, J. Burisch, I. Kaimakliotis, D. Duricova, K. Carlsen, K.R. Nielsen, D.K. Christodoulou, L. Lakatos, S. Odes, R. D'Inca, G. Kiudelis, S. Turcan, F. Magro, A. Goldis, V. Hernandez, S. Bell, E. Langholz, P. Munkholm, P. Lakatos

Semmelweis University, 1st Department of Medicine, Budapest, Hungary and others

■ **P669**

The prevalence of alexithymia in Inflammatory Bowel Disease: A systematic review and meta-analysis

C. Hopkins, C. Moulton

Berkshire Healthcare NHS Foundation Trust, Prospect Park Hospital, Reading, United Kingdom and others

■ **P670**

Mortality and its predictors in Inflammatory Bowel Disease: A hospital-based cohort study from Korea 1977-2013

H.-S. Lee, J.W. Choe, H.J. Lee, K. Chang, G.-U. Kim, S.W. Hwang, S.H. Park, D.-H. Yang, K.-J. Kim, B.D. Ye, J.-S. Byeon, S.-J. Myung, S.-K. Yang

Asan Medical Center, University of Ulsan College of Medicine, Health Screening and Promotion Center, Seoul, South Korea and others

■ **P671**

Pregnancy and IBD: Do we provide enough patient education? A British study of 1324 women

I. Carbery, **C. Selinger**

St James University Hospital, Gastroenterology, Leeds, United Kingdom

■ **P672**

Eosinophilia of the gut. Is it Inflammatory Bowel Disease?

S. Chetcuti Zammit, J. Gauci, M. Cachia, K. Sapiano, P. Ellul

Mater Dei Hospital, Gastroenterology, Msida, Malta and others

■ **P673**

A model of Inflammatory Bowel Disease (IBD) population based registry; Incidence of IBD in Romagna Region

D. Valpiani, **I. Manzi**, L. Samperi, S. Gasperoni, O. Triossi, M. Di Marco, A. De Padova, L. Solmi, C. Bernabini, O. Giuliani, S. Giorgetti, F. Falcini, E. Ricci

AUSL Romagna, presidio di Forlì, Gastroenterologia ed Endoscopia Digestiva, Forlì, Italy and others

■ **P674**

Clinical features of thrombosis in patients with Crohn's Disease followed at Clinical Hospital of University of São Paulo, Brazil

A. Ribas Andrade, L. Leite Barros, M. Azevedo, A. Sipahi, **A. Zonetti de Arruda Leite**

University of São Paulo, Medical School, Department of Gastroenterology, São Paulo, Brazil

■ **P675**

Clinical characteristics of Crohn's Disease and Ulcerative Colitis patients who switched from an anti-TNF- α agent or natalizumab to vedolizumab or an alternative anti-TNF- α

H. Liang, S. Manne, J. Shick, S. Yu, G. Fusco, **P. Dolin**

Takeda Development Center Americas, Inc., Deerfield, United States and others

■ **P676**

Influence of hypoxia on healthy volunteers and patients with Inflammatory Bowel Disease

S. Vavricka, P. Ruiz-Castro, L. Biedermann, M. Madanchi, S. Scharl, M. Scharl, G. Rogler, J. Zeitz

University Hospital Zurich, Department of Gastroenterology and Hepatology, Zurich, Switzerland and others

■ **P677**

Use and predictors of complementary and alternative medicine (CAM) in patients with Inflammatory Bowel Disease – results of a multicenter study of the Austrian IBD Study Group (ATISG)

H.P. Gröchenig, C. Dejaco, G. Eckhard, T. Feichtenschlager, T. Haas, A. Kirchgatterer, R. Koch, O. Ludwiczek, A. Mayer, W. Miehsler, P. Papay, P.-G. Peters, R. Platzer, G. Reicht, P. Steiner, T. Waldhör, H. Wenzl, H. Fuchssteiner, J. Gartner, G. Novacek
Krankenhaus Barmherzige Brüder, Innere Medizin, St. Veit an der Glan, Austria and others

■ **P678**

Factors associated with voluntary childlessness in women with IBD

C. Selinger, J. Ghorayeb, A. Madill
St James University Hospital, Gastroenterology, Leeds, United Kingdom and others

■ **P679**

Mental health is associated with disease course in a subgroup of IBD patients with Crohn's Disease and Ulcerative Colitis: A multi-center observational study by the Osaka Gut Forum

M. Araki, S. Shinzaki, H. Iijima, S. Hiyama, T. Yamada, S. Arimitsu, M. Komori, N. Shibukawa, A. Mukai, S. Nakajima, K. Kinoshita, T. Miyagi, S. Kitamura, Y. Murayama, H. Ogawa, Y. Yasunaga, M. Oshita, E. Masuda, H. Tanimukai, M. Tsujii, T. Takehara
Osaka University Graduate School of Medicine, Department of Gastroenterology and Hepatology, 2-2 Yamadaoka, Suita, Japan and others

■ **P680**

Aetiological risk factors for developing paediatric Inflammatory Bowel Disease in a prospective cohort

I. Yu, E. O'Neill, R. Stanley, A. Carey, S. Kiernan, M. Hamzawi, K. Driscoll, S. Quinn, A.M. Broderick, B. Bourke, T. Rafferty, S. Hussey
University College Dublin, Academic Centre for Paediatric Research, School of Medicine and Medical Science, Dublin, Ireland and others

■ **P681**

Long-term outcomes of a cohort of Crohn's disease patients with idiopathic lymphopenia

V. Roales, C. Alba, J.L. Mendoza, D. Olivares, E. Rey, **C. Taxonera**
Hospital Clinico San Carlos, IBD Unit, Madrid, Spain and others

■ **P682**

Clinical characteristics of Crohn's Disease or Ulcerative Colitis patients who initiated vedolizumab or an anti-TNF- α as first biologic therapy

H. Liang, S. Manne, J. Shick, S. Yu, G. Fusco, **P. Dolin**
Takeda Development Center Americas, Inc., Deerfield, United States and others

■ **P683**

Skin lesions in patients with Inflammatory Bowel Disease from southern Brazil: An epidemiologic study

H. Amarante, G. Reis, A. Szczypkowski, G. Quadros, M. Peretti, M. Mukai
Hospital de Clínicas of Federal University of Parana, Gastroenterology, Curitiba, Brazil and others

■ **P684**

A shift to outpatient expenditures in healthcare costs for Inflammatory Bowel Disease: A population-based study in Korea (2010-2014)

C.K. Lee, S.Y. Rhee, H.J. Kim, S.J. Oh, C.H. Oh, W.-M. Lim
Kyung Hee University School of Medicine, Internal Medicine, Seoul, South Korea and others

■ **P685**

Vitamin D levels in newly diagnosed UC are lower in South Asians than White Europeans – could this be contributing to the increasing incidence of UC in South Asians?

R. Misra, U. Selvarajah, O. Faiz, J. Burisch, P. Munkholm, N. Arebi
St. Marks Academic Institute, Gastroenterology, London, United Kingdom and others

■ **P686**

Characteristics of small bowel cancer associated with Crohn's Disease

M. Shinozaki

The Institute of Medical Science, The University of Tokyo, Department of Surgery, Tokyo, Japan

■ **P687**

The impact of Inflammatory Bowel Disease on patients' caregivers

A. Zand, A. Platt, W.K. Van Deen, D.W. Hommes

UCLA Center for Inflammatory Bowel Diseases, Division of Digestive Diseases, Los Angeles, United States

■ **P688**

Is smoking cessation linked to new Ulcerative Colitis cases? A retrospective cohort based hypothesis

M. Grueber, N. Fournier, L. Biedermann, S. Vavricka, A. Schöpfer, C. Clair Willi, M. Allez, A.J. Macpherson, P. Juillerat

Inselspital, Bern, Department of Gastroenterology, Bern, Switzerland and others

■ **P689**

An observational study on Crohn's Disease activity pattern and long term outcomes of management strategies in the routine clinical setting in Greece

G. Paspatis, S. Potamianos, K. Triantafyllou, C. Tzathas, G. Theocharis, S. Michopoulos, E. Akriviadis, J. Karagiannis, G. Alexopoulou, A. Boubougianni, A. Kouloumenta, S. Ladas

Department of Gastroenterology, Benizelion General Hospital, Heraklion, Greece and others

■ **P690**

Worries of patients with Inflammatory Bowel Disease: An indicator of well-being? Results of survey among 1096 participants in a European bilingual clinical cohort

V. Pittet, C. Vaucher, F. Froehlich, B. Burnand, P. Michetti, M.H. Maillard

Institute of Social and Preventive Medicine, Healthcare Evaluation Unit, Lausanne, Switzerland and others

■ **P691**

Frequency of anaemia and anemia subtypes in East-West European inception cohort – an ECCO-EpiCom cohort study

J. Burisch, U. Gerdes, S. Almer, S. Čuković-Čavka, S. Sebastian, I. Kaimakliotis, D. Duricova, N. Pedersen, R. Salupere, K.R. Nielsen, P. Manninen, K.H. Katsanos, S. Odes, V. Andersen, R. D'Inca, L. Kupcinkas, S. Turcan, F. Magro, A. Goldis, K. Kofod Vinding, E. Belousova, K. Ladefoged, Y. Bailey, V. Hernandez, J. Halfvarson, N. Arebi, O. Shonova, M.L. Hoivik, B. Moum, E. Langholz, P.L. Lakatos, P. Munkholm, J.F. Dahlerup

North Zealand University Hospital, Department of Gastroenterology, Frederikssund, Denmark and others

■ **P692**

Co-exposure of microscopic colitis associated drugs does not affect paracellular permeability in vitro

B.P.M. Verhaegh, F. de Vries, D. Keszthelyi, J.G. Kuiper, A.A.M. Masclee, M.J. Pierik, D.M.A.E. Jonkers

Maastricht University Medical Center+, Internal Medicine - Division of Gastroenterology-Hepatology, Maastricht, Netherlands and others

■ **P693**

Inflammatory Bowel Disease in Norway 1999 to 2014: Increasing prevalence and local geographical differences

M.L. Hoivik, B. Moum, T. Glomsaker

Oslo University Hospital, Department of Gastroenterology, Oslo, Norway and others

■ **P694**

Nationwide prevalence of Inflammatory Bowel Diseases in Hungary. A population-based study based on the National Health Insurance Fund database

Z. Kurti, L. Gonczi, P.A. Golovics, B. Lovasz, P. Fadgyas-Freyler, J. Gimesi-Orszagh, G.B. Korponai, Z. Vegh, P. Lakatos

Semmelweis University, 1st Department of Medicine, Budapest, Hungary and others

■ **P695**

Use of infliximab and associated costs in Inflammatory Bowel Disease patients: An analysis of real-life health claims data in The Netherlands

D. Hoekman, S. Bots, M. Benninga, H. Smeets, G. D'Haens, M. Löwenberg
Academic Medical Center (AMC), Department of Paediatric Gastroenterology, Amsterdam, Netherlands and others

■ **P696**

First results and information model from the Parelnoer Institute IBD biobank: A nationwide standardised Inflammatory Bowel Disease collection by all University Medical Centers in the Netherlands

L.M. Spekhorst, F. Imhann, E.A.M. Festen, A.A. van Bodegraven, N.K.H. de Boer, G. Bouma, H.H. Fidder, G.R.A.M. D'Haens, F. Hoentjen, D.W. Hommes, D.J. de Jong, M. Lowenberg, A.E. van der Meulen-de Jong, B. Oldenburg, M. Pierik, C.Y. Ponsioen, P.C. Stokkers, M.C. Visschedijk, C.J. van der Woude, G. Dijkstra, R.K. Weersma
University of Groningen and University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, Netherlands and others

■ **P697**

Highlighting of epidemic areas of Crohn's Disease in a population-based registry over 22 years: Genetic or environmental cause?

M. Genin, C. Vignal, F. Vasseur, M. Fumery, G. Savoye, M. Body-Malapel, C. Preda, H. Sarter, L. Peyrin-Biroulet, P. Desreumaux, C. Gower-Rousseau
University Hospital, Lille, France and others

■ **P698**

Incidence and disease course of Inflammatory Bowel Disease diagnosed incidentally during a colorectal cancer screening programme. A retrospective multicentre study: Preliminary results

I. Rodríguez-Lago, O. Merino, J. Carrascosa, M. Fernández - Calderón, A. Maiz, A. Muñagorri, P. Arriba, R. Higuera, E. Zapata, I. Moraleja, I. Montalvo, I. Portillo, J.L. Cabriada
Galdakao Hospital, Gastroenterology, Galdakao, Spain and others

■ **P699**

Health related quality of life in Inflammatory Bowel Disease in a Danish population-based inception cohort

L. Christiansen, F. Bendtsen, J. Burisch, M. Kajbaek Vester-Andersen
Hvidovre University Hospital, Department of Gastroenterology, Hvidovre, Denmark

■ **P700**

Incidence and phenotype at diagnosis in very early-onset paediatric Inflammatory Bowel Disease: A population-based study (1988-2011)

E. Bequet, H. Sarter, M. Fumery, L. Armengol-Debeir, B. Pariente, D. Ley, C. Spyckerelle, H. Coevoet, L. Peyrin-Biroulet, **G. Savoye**, T. Dominique, C. Gower-Rousseau
Centre Hospitalier Régional Universitaire, Gastroentérologie pédiatrique, Lille, France and others

■ **P701**

Prevalence of positive anti-tissue transglutaminase antibodies in Inflammatory Bowel Disease patients

F. Casellas, C. Herrera de Guise, V. Robles, N. Borrueal
Hospital Universitari Vall d'Hebron, Unitat Atenció Crohn-Colitis, Barcelona, Spain and others

■ **P702**

The impact of disease activity on adverse birth outcomes in a nationwide cohort of woman treated with biologics for chronic Inflammatory Bowel Disease during pregnancy

H. Kammerlander, J. Nielsen, J. Kjeldsen, T. Knudsen, S. Friedman, B. Nørgård
University of Southern Denmark, Center for Clinical Epidemiology, Odense, Denmark and others

■ **P703**

De novo IBD is a significant risk factor for primary sclerosing cholangitis recurrence after liver transplantation

L. Bajer, E. Sticova, P. Macinga, R. Janousek, P. Trunecka, J. Spicak, P. Drastich
Institute for Clinical and Experimental Medicine, Hepatogastroenterology, Prague, Czech Republic and others

■ **P704**

Dairy products, dietary calcium and the risk of Inflammatory Bowel Disease: Results from a European prospective cohort investigation

J. Opstelten, M. Leenders, V. Dik, S. Chan, F. van Schaik, P. Siersema, B. Bueno-de-Mesquita, A. Hart, B. Oldenburg
University Medical Centre Utrecht, Department of Gastroenterology and Hepatology, Utrecht, Netherlands and others

■ **P705**

Long term outcomes and predictors of disabling disease of a population-based cohort of incident Crohn's Disease diagnosed between 1995 and 1997

M.-L. Rabilloud, J.-F. Bretagne, E. Bajeux, L. Siproudhis, J.-F. Viel, I. Tron, M. Robaszekiewicz, G. Bouguen
Université Rennes 1 & CHU Pontchaillou Rennes, Service des Maladies de l'Appareil Digestif, Rennes, France and others

■ **P706**

The long-term risk of complicated gallstone disease necessitating cholecystectomy after ileal resection in Crohn's Disease patients

J.C. Goet, B.E. Hansen, K. Bierman, A. Gijsbers, C.J. van der Woude, W.R. Schouten, H.R. van Buuren, A.C. de Vries
Erasmus MC, Gastroenterology and Hepatology, Rotterdam, Netherlands and others

■ **P707**

Healthcare expectations of patients with Inflammatory Bowel Disease: A survey among 1089 participants in a European bilingual clinical cohort

V. Pittet, C. Vaucher, M.H. Maillard, F. Froehlich, B. Burnand, P. Michetti
Institute of Social and Preventive Medicine, Healthcare Evaluation Unit, Lausanne, Switzerland and others

■ **P708**

Determinants of job stress in patients with Inflammatory Bowel Disease

P. Schreiner, L. Biedermann, J.-B. Rossel, V. Pittet, R. von Känel
University Hospital of Zurich, Internal Medicine, Zurich, Switzerland and others

■ **P709**

Patients' perceptions on patient-physician communication and influence of hospital size among Spanish patients with Ulcerative Colitis. UC-LIFE survey

X. Calvet, A. López-Sanromán, F. Argüelles-Arias, L. Cea-Calvo, B. Juliá, C. Romero, D. Carpio
Corporació Sanitària Universitària Parc Taulí, Digestive Disease Department. Departament de Medicina. Universitat Autònoma de Barcelona. CIBEREHD – Instituto de Salud Carlos III, Sabadell, Spain and others

■ **P710**

Evolution of the incidence of Inflammatory Bowel Disease in the south of Spain in two periods

D. Chaaro, J.M. Benitez, R. Perea Amarillo, F. Argüelles Arias, L. Castro Laria, M.B. Maldonado Perez, V. García Sanchez, E. Iglesias Flores, A. Benitez Roldan, A. Caunedo Álvarez
University Hospital Virgen Macarena, Gastroenterology and Hepatology Department, Seville, Spain and others

■ **P711**

Clinical characteristics of patients with Crohn's Disease or Ulcerative Colitis treated with vedolizumab – a real-world data analysis

H. Liang, S. Manne, J. Shick, S. Yu, G. Fusco, **P. Dolin**
Takeda Development Center Americas, Inc., Deerfield, United States and others

■ P712***Examination of the relationship between disease activity, psychological distress and patient reported outcome measures in an IBD cohort.***

B. Jackson, D. Con, A. Gorelik, D. Liew, P. De Cruz
Austin Health, Gastroenterology, Melbourne, Australia and others

■ P713***Exploring the epidemiological aspects of IBD: Preliminary data from "EPIMICI" study in San Marino***

L.R. Lopetuso, A. Piscaglia, L. Laterza, V. Gerardi, S. Boccia, E. Leoncini, E. Sacchini, A. Armuzzi, A. Gasbarrini, M.L. Stefanelli
Catholic University of Sacred Heart, Internal Medicine Department, Gastroenterology Division, Rome, Italy and others

■ P714***Risk factors for vitamin D, zinc, and selenium deficiency in the patients with Inflammatory Bowel Disease***

Y.M. Han, **H. Yoon**, S. Lim, M.-K. Sung, C.M. Shin, Y.S. Park, N. Kim, D.H. Lee, J.S. Kim
Seoul National University College of Medicine, Department of Internal Medicine and Liver Research Institute, Seoul, South Korea and others

■ P715***Hepatobiliary and pancreatic manifestations in patients with Inflammatory Bowel Disease: Retrospective study from north-western Greece***

F. Fousekis, K. Katsanos, D. Christodoulou, E. Tsianos
Medical school, university of Ioannina, Internal medicine and hepatology & gastroenterology, Ioannina, Greece

■ P716***A well maintained IBD registry can help assess & optimize treatment for the local population: 10 years' experience in an Indian IBD registry cohort***

R. Banerjee, U. Basavaraju, B. Adigopula, N. Reddy
Asian Institute of Gastroenterology, Inflammatory Bowel Disease, Hyderabad, India and others

■ P717***Predictive factors for unfavorable disease course in Inflammatory Bowel Diseases – data analysis of almost 1000 patients from a Hungarian tertiary IBD centre***

K. Farkas, T. Nyári, A. Bálint, R. Bor, A. Milassin, **M. Rutka**, Z. Szepes, F. Nagy, T. Molnár
University of Szeged, 1st Department of Medicine, Szeged, Hungary and others

■ P718***Faecal calprotectin combined with faecal lactoferrin in predicting the endoscopic outcomes of patients with moderate to severe Crohn's Disease receiving infliximab: A pilot study***

J. Wu, W. Huang
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine, Gastroenterology, Shanghai, China and others

Genetics

■ P719

Identification of a genetic risk variant in the WWOX gene associated with recurrent fibrostenotic Crohn's Disease

M.C. Visschedijk, L.M. Spekhorst, G. Dijkstra, E.S. van Loo, D.J. de Jong, A.E. van der Meulen-de Jong, H.W. Verspaget, C.Y. Ponsioen, V.B. Nieuwenhuijs, B. Oldenburg, M. Pierik, N.K.H. de Boer, C.J. van der Woude, F. Imhann, R. Alberts, S. van Sommeren, K.N. Faber, C.M. Aldaz, R.K. Weersma, E.A.M. Festen
University of Groningen and University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, Netherlands and others

■ P720

Increased mitochondrial DNA copy number and higher expression of energy metabolic genes predict Ulcerative Colitis carcinogenesis

T. Tanaka, T. Kobunai, T. Watanabe
University of Tokyo, Division of Surgical Oncology, Department of Surgery, Tokyo, Japan and others

■ P721

The biological and clinical relevance of anti-metalloproteinase-9 antibody (GS-5745) in treatment of Ulcerative Colitis patients

B.R. Bhandari, S. Lee, **X. Zhao**, E. Huntzicker, X. Guo, Z. Jiang, D. Ge, D. French, M. Subramanian, J.G. McHutchison, B. Kanwar, B. Levesque, W. Sandborn
Delta Research Partners, LLC, Monroe, Louisiana, United States and others

■ P722

Clinical and genetic characterisation of patients with graft-vs.-host disease after allogeneic hematopoietic cell transplantation suggests a role for JAK2, IL2RA and HLA-DRB1

S. van Sommeren, H.M. de Jonge, J. Kuball, L. te Boome, E. Vellenga, G. Huls, R. Weersma
University Medical Center Groningen, Department of Gastroenterology and Hepatology MDL BB41, Groningen, Netherlands and others

■ P723

NUDT15 R139C genotype is a determinant of thiopurines-induced leukopenia in Chinese patients with Crohn's Disease

X. Zhu, **K. Chao**, X. Wang, P. Hu, M. Huang, X. Gao
Sun Yat-sen University, School of Pharmaceutical Sciences, Guangzhou, China and others

■ P724

Common genetic predisposition between fatigue-related syndromes and Inflammatory Bowel Disease: A systematic review

J. Kreijne, G. Fuhler, C.J. van der Woude, M. Peppelenbosch
Erasmus MC, Gastroenterology and Hepatology, Rotterdam, Netherlands

■ P725

The common homozygous glutathione S-transferase Mu null genotype leads to higher 6-MMP levels in patients treated with azathioprine but not in those treated with 6-mercaptopurine

M. Broekman, M. Coenen, C. van Marrewijk, G. Wanten, H. Roelofs, L. Derijks, S. Vermeulen, O. Klungel, A. Verbeek, P. Hooymans, H. Scheffer, H.-J. Guchelaar, D. Wong, D. de Jong
Radboud University Medical Center, Department of Gastroenterology, Nijmegen, Netherlands and others

■ P726

TNFAIP6 is a disease activity marker in Inflammatory Bowel Disease

Q. Yu, S. Zhang, H. Wang, S. Ben-Horin, R. Mao, Y. Zhang, T. Feng, L. Li, B. Chen, Y. HE, **M. Chen**
The First Affiliated Hospital, Sun Yat-sen University, Department of Gastroenterology, Guangzhou, China and others

■ P727

Genome-wide methylation profiling of Crohn's Disease in women

N. Duijvis, A. Li Yim, J. Zhao, W. de Jonge, A. Mul, G. D'Haens, A. te Velde, P. Henneman
Academic Medical Center (AMC), Tytgat Institute for Liver and Intestinal Research, Amsterdam, Netherlands and others

■ **P728*****Inflammation-associated DNA methylation patterns in epithelium of Ulcerative Colitis***

A. Barnicle, C. Seoighe, A. Golden, J. Grealley, L. Egan
NUI Galway, Clinical Pharmacology, Galway, Ireland and others

■ **P729*****The clinical relevance of the CD-associated SNP within the gene locus encoding protein tyrosine phosphatase non-receptor type 22 in patients of the Swiss IBD Cohort***

J. Zeitz, M. Spalinger, L. Biedermann, J.-B. Rossel, M.C. Sulz, S.R. Vavricka, M. Fried, G. Rogler, M. Scharl
University Hospital Zurich, Division of Gastroenterology and Hepatology, Zürich, Switzerland and others

■ **P730*****Circulating microRNA223 is a new biomarker for Inflammatory Bowel Disease***

H. Wang, S. Zhang, Q. Yu, M. Li, Z. Zeng, Y. He, B. Chen, **M. Chen**
The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China

■ **P731*****Impact of the rs1143634 polymorphism in the gene coding for IL1 β on pharmacokinetic of infliximab in Inflammatory Bowel Disease patients***

J. Guardiola, L. Rodriguez-Alonso, A. Padullés, P. Ariadna, H. Colom, E. Santacana, C. Arajol, A. Ruiz-Cerulla, J. Bas, F. Morandeira, F. Rodriguez-Moranta, N. Padullés
Hospital Universitario de Bellvitge, Gastroenterology, L'Hospitalet de Llobregat, Spain and others

■ **P732*****Pooled resequencing of 122 Ulcerative Colitis genes in a large Dutch population suggests population-specific association of rare variants in MUC2***

M.C. Visschedijk, R. Alberts, S. Mucha, P. Deelen, D.J. de Jong, M. Pierik, A.E. van der Meulen-de Jong, C.J. van der Woude, A.A. van Bodegraven, B. Oldenburg, M. Lowenberg, G. Dijkstra, D. Ellinghaus, S. Schreiber, C. Wijmenga, M.A. Rivas, A. Franke, C.C. van Diemen, R.K. Weersma
University of Groningen and University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, Netherlands and others

■ **P733*****Genetic risk scores for risk and therapy response prediction in Slovenian Crohn's Disease patients***

K. Zupančič, K. Skok, K. Repnik, P. Skok, U. Potočnik
Medical faculty, University of Maribor, Center for human genetics and pharmacogenomics, Maribor, Slovenia and others

■ **P734*****Gene expression of SELENBP1 is up-regulated in the colonic mucosa and is associated with a long-term remission in patients with Ulcerative Colitis***

J. Yamamoto-Furusho, L. Salazar-Salas, G. Fonseca-Camarillo, R. Barreto
IBD Clinic, Instituto Nacional de Ciencias Medicas y Nutricion, Gastroenterology, Mexico, Mexico and others

Microbiology

■ P735

Exploring MECHANisms Of IBD traNsmission In Utero through the Microbiome: The MECONIUM Study Pilot

J. Torres, J. Hu, J. Coté-Daigneault, H. Panchal, C. Eisele, X. Bao, N. Nangia, C.-L. Chen, M. Dubinsky, J. George, A. Kornbluth, P. Legnani, J. Marion, E. Maser, T. Ullman, B. Jharap, J. Stone, J. Clemente, J.-F. Colombel, I. Peter
Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, Department of Medicine, New York, United States and others

■ P736

Composition of faecal microbiota in former UC patients after restorative proctocolectomy with and without episodes of pouchitis

P. Bours, S. Fuentes, C. Gerritsen, A. Masclee, H. Smidt, M. Pierik, D. Jonkers
Maastricht University Medical Center, Gastroenterology and Hepatology, Maastricht, Netherlands and others

■ P737

Host-microbiome interactions in primary sclerosing cholangitis

J. Sabino, S. Vieira-Silva, I. Cleynen, K. Machiels, M. Joossens, G. Falony, J. Wang, V. Ballet, M. Ferrante, G. Van Assche, S. Van Der Merwe, J. Raes, S. Vermeire
KU Leuven, Department of Clinical and Experimental Medicine, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium and others

■ P738

Disease activity related dysbiosis in Inflammatory Bowel Disease patients

M.E. Grasman, R.J. van der Borden, A.E. Budding, A. Eck, N.K. de Boer, G. Bouma, P.H. Savelkoul, A.A. van Bodegraven
VU University Medical Centre, Gastroenterology and Hepatology, Amsterdam, Netherlands and others

■ P739

Infections with C. difficile in IBD patients are difficult to treat and frequently recur

E. Gombotz, E. Leitner, I. Zollner-Schwetz, R. Krause, C. Kornschober, H. Wenzl, P. Kump, W. Petritsch, C. Högenauer
Medical University of Graz, Department of Internal Medicine, Division of Gastroenterology and Hepatology, Graz, Austria and others

■ P740

Toxin negative Clostridium Difficile colonisation and outcome in acute severe Ulcerative Colitis. A retrospective single centre study

K.S. Kok, S. Chan, E. Tsiouli, N. Elumogo, M. Tremelling
Norfolk and Norwich University Hospital, Department of Gastroenterology, Norwich, United Kingdom and others

■ P741

The gut microbiota in primary sclerosing cholangitis (PSC) and Inflammatory Bowel Disease (IBD): Correlations with disease and diet

J. Torres, C. Palmela, X. Bao, A.P. Krieger, V. Teixeira, S. Velho, C. Vieira, A. Oliveira, J. Pereira da Silva, P. Moura Santos, S. Itzkowitz, I. Peter, M. Cravo, J. Hu
Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, Department of Medicine, New York, United States and others

■ P742

Genetic risk for Crohn's Disease has little impact on intestinal microbiota composition

J. Sabino, S. Vieira-Silva, I. Cleynen, K. Nys, K. Machiels, M. Joossens, G. Falony, J. Wang, V. Ballet, M. Ferrante, G. Van Assche, S. Van Der Merwe, J. Raes, S. Vermeire
KU Leuven, Department of Clinical and Experimental Medicine, Translational Research Center for Gastrointestinal Disorders (TARGID), Leuven, Belgium and others

■ **P743**

Gut microbial gene richness is reduced in smokers with Crohn's Disease

J. Opstelten, J. Plassais, S. van Mil, B. Oldenburg, A. Cervino

University Medical Centre Utrecht, Department of Gastroenterology and Hepatology, Utrecht, Netherlands and others

■ **P744**

Proton pump inhibitors affect the gut microbiome

F. Imhann, M.J. Bonder, A. Vich Vila, J. Fu, Z. Mujagic, L. Vork, E.F. Tigchelaar, S.A. Jankipersadsing, M.C. Cenit, H.J.M. Harmsen, G. Dijkstra, L. Franke, R.J. Xavier, D. Jonkers, C. Wijmenga, R.K. Weersma, A. Zhernakova

University of Groningen and University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, Netherlands and others

■ **P745**

Clostridium difficile infection in Inflammatory Bowel Disease patients: Prevalence and risk factors

M. Su, H. Chen, **M. Zhi**, H. He, M. Zhang, J. Tang, J. Hu, Y. Zhang, N. Ding, L. Ma, H. Chen, X. Gao, P. Hu
The 6th Affiliated Hospital of Sun Yat-sen University, Department of Gastroenterology, Guangzhou, China

■ **P746**

Anti-inflammatory properties of Faecalibacterium prausnitzii in the absence and presence of cigarette smoke using a novel epithelium-gut microbe co-culture system

J. Z.H. von Martels, M. Sadaghian Sadabad, R. Van der Meer, A. N.J. Overbeeke, T. Blokzijl, H. J.M. Harmsen, G. Dijkstra, K.N. Faber

University Medical Center Groningen, Gastroenterology and Hepatology, Groningen, Netherlands and others

■ **P747**

Microbial communities of Crohn's Disease aphthous ulcers

C. O'Brien, D. Gordon, P. Pavli

Canberra Hospital, Gastroenterology and Hepatology Unit, Canberra, Australia and others

■ **P748**

Potential role of fusobacteria in Korean Inflammatory Bowel Disease patients

C.S. Eun, D.S. Han, A.R. Lee, Y.R. Lee

Hanyang University Guri Hospital, Gastroenterology, Guri, South Korea

■ **P749**

Not only butyrate-producing bacteria but possibly also bacteroides thetaiotaomicron protects against Ulcerative Colitis

S. Sitkin, T. Vakhitov, E. Tkachenko, T. Zhigalova, L. Oreshko, M. Suvorova

State Research Institute of Highly Pure Biopreparations, Department of Microbiology, St. Petersburg, Russian Federation and others

■ **P750**

Higher frequency of adherent-invasive escherichia coli within a subgroup of B2 phylogroup strains

C. O'Brien, D. Gordon, P. Pavli

Canberra Hospital, Gastroenterology and Hepatology Unit, Canberra, Australia and others

■ **P751**

Low enteric microbial diversity in patients with Ulcerative Colitis after pouch surgery having a mature normal ileal pouch may be predictive of pouchitis

N. Maharshak, N.A. Cohen, L. Reshef, H. Tulchinsky, U. Gophna, I. Dotan

Tel Aviv Medical Center, IBD Center, Department of Gastroenterology and Liver Diseases, Tel Aviv, Israel and others

■ **P752**

A reduction of the butyrate-producing microbiota in Asian patients with Ulcerative Colitis

Y.T. Jeon, **E.S. Kim**, B. Keum, J.S. Koo

Korea University College of Medicine, Division of Gastroenterology and Hepatology, Department of Internal Medicine, Seoul, South Korea

■ **P753**

Immunosuppression for Inflammatory Bowel Disease does not affect Epstein – Barr viral load in the short – term: Preliminary results

I. Rodríguez - Lago, O. Merino, M.J. López de Goicoechea, M. Aranzamendi, L. Zubiaurre, J. Ortiz de Zárate, A. Muñagorri, C.G. Cilla, J.L. Cabriada

Galdakao Hospital, Gastroenterology, Galdakao, Spain and others

■ **P754**

IBD phenotypes differ in gut mycobiota composition

P. Drastich, **L. Bajer**, K. Klimesova, M. Kostovcik, M. Kverka, J. Brezina, J. Spicak

Institute for Clinical and Experimental Medicine, Hepatogastroenterology, Prague, Czech Republic and others

■ **P755**

Effect of carboxylic acids of gut microbial origin on host cell proliferation in organotypic tissue cultures

T. Vakhitov, N. Chalisova, **S. Sitkin**

State Research Institute of Highly Pure Biopreparations, Department of Microbiology, St. Petersburg, Russian Federation and others

Nurses posters

■ N001

Telephone vs. Clinic follow-up in the management of patients with Inflammatory Bowel Disease - A nurse practitioner led study

U. Chauhan, D. Armstrong, S.L. Halder, J.K. Marshall, F. Tse, M.I. Pinto Sanchez, Y. Farbod, J. Popov, S. Kaasalainen, P. Moayyedi
McMaster University Medical Centre, Digestive Disease, Hamilton, Canada and others

■ N002

What are the factors related to depression in patients with Ulcerative Colitis in Japan?

A. Kawakami, M. Tanaka, N. Yamamoto-Mitani, M. Naganuma, S. Maeda, R. Kunisaki
Yokohama City University Medical Centre, Inflammatory Bowel Disease Centre, Yokohama, Japan and others

■ N003

Sexual dysfunction assessment in Inflammatory Bowel Disease patients

J. Barros, **R. Saad-Hossne**, L. Sasaki, J. Baima, M. Dorna, C. Sibia, F. Renosto, R. Silva, E. Farineli, R. Biondi
Paulista State University - Botucatu Medical School, Botucatu, Brazil and others

■ N004

Faecal incontinence in Inflammatory Bowel Disease and its association with anxiety and depression in an Irish tertiary centre

A. Keogh
University Hospital Galway, Galway, Ireland

■ N005

Adherence to outpatient follow-up visit in Inflammatory Bowel Disease patients

M.G. Vettorato, G. Lorenzon, S. Bellia, A. Rigo, O. Bartolo, G. Girardin, F. Simonetti, R. D'Inca, G.C. Sturniolo, E.V. Savarino
University of Padua, Gastroenterology Unit, Department of Surgery, Oncology and Gastroenterology, Padua, Italy

■ N006

Exploring fatigue in Inflammatory Bowel Disease – a descriptive phenomenological study

W. Czuber-Dochan, J. Armes, E. Ream, C. Norton
King's College London, Florence Nightingale Faculty of Nursing & Midwifery, London, United Kingdom and others

■ N007

Effects of introduction of an IBD nurse position on the quality of delivered care

S. Coenen, E. Weyts, S. Vermeire, M. Ferrante, M. Noman, V. Ballet, G. Van Assche
UZ Leuven, Gastroenterology, Leuven, Belgium

■ N008

Reasons for consultation of patients with Inflammatory Bowel Disease (IBD) in telephone helplines attended by nurses

E. Navarro Correal, Ó. Benítez Leiva, A. Dosal Galguera, M. Gallego Barrero, F. Murciano Gonzalo, E. Sánchez Pastor
Vall d'Hebron University Hospital, Gastroenterology, Barcelona, Spain and others

■ N009

Role of physical activity in Inflammatory Bowel Disease management. A systematic review of literature

N. Cano Sanz, M. Sierra, M.J. F. Gundín, P. Suarez
Hospital Universitario de León - CAULE, Gastroenterology - IBD unit, León, Spain

■ **N010**

A cluster randomized controlled trial testing the effect of a theoretical and evidence-based tailored multimedia intervention to improve medication adherence in IBD patients

A. Linn, L. van Dijk, J. van Weert, B. Gebeyehu, A. van Bodegraven, E. Smit
University of Amsterdam / Amsterdam School of Communication Research (ASCoR), Communication Science, Amsterdam, Netherlands and others

■ **N011**

Living with Inflammatory Bowel Disease: Results from focus group

U. Chauhan, J. Popov, D. Armstrong, Y. Farbod, S.L. Halder, S. Kaasalainen, J.K. Marshall, F. Tse, A. Wickson-Griffiths, P. Moayyedi
McMaster University Medical Centre, Digestive Disease, Hamilton, Canada and others

■ **N012**

Audit into oral steroid usage in IBD patients

G. Lloyd-Ford, A. Lewis, L. Hook
Aneurin Bevan University Health Board, Gastroenterology, Newport, United Kingdom

■ **N013**

A patient satisfaction survey of the telephone advice line service for the management of Inflammatory Bowel Disease

A. Kawakami, M. Waga, T. Tyrrell, H. Yarrow, M. O'Connor
St Mark's Hospital, Inflammatory Bowel Disease Unit, London, United Kingdom

■ **N014**

Patient reported experience measures (PREM) in IBD patients at the Stockholm Gastro Centre

S. Jaghult, S. Soto Villagran, D. Andersson
Karolinska Institutet, Department of clinical sciences, Stockholm, Sweden and others

■ **N015**

Educational themed evenings - do they make a difference for patients and relatives living with Inflammatory Bowel Disease

E. Kjær Mikkelsen, A. Bindesboell
Regionshospitalet Herning, Medical Department, Gastroenterology, Herning, Denmark

■ **N016**

Post-operative Crohn's care: A consistent approach?

H. Yarrow, M. O'Connor, N. Ding, N. Arebi, P. Morar
St Mark's Hospital, IBD Unit, London, United Kingdom and others

■ **N017**

Self-care of Inflammatory Bowel Disease may be associated with better well-being

U. Lovén Wickman, B. Riegel, P. Yngman Uhlin, H. Hjortswang, G. Hollman Frisman
Linköping University, Department of Primary Health Care in Kalmar County Council of Kalmar, Blomstermåla, Sweden and others

■ **N018**

Proactive triaging of new patients into outpatient clinic improves outcomes at the Royal Adelaide Hospital Inflammatory Bowel Disease Service

R. Grafton, J. Hughes, L. Cronin, J. Andrews
Royal Adelaide Hospital, Department of Gastroenterology and Hepatology, Adelaide, Australia and others

■ **N019**

The IBD dedicated day service planned by IBD specialist nurse: A good and time saving approach to IBD or suspect IBD patients

S. Biagini, **M. Giannotta**, V. Almerigogna, A. Cozzi, G. Macrì, M. Milla
AOU Careggi, Regional Referral Center of Inflammatory Bowel Disease - Clinical Gastroenterology Division, Florence, Italy

■ **N020**

Young and hospitalized – a qualitative study of young patients with Inflammatory Bowel Diseases and their experiences during hospitalization

R. Lindahl

Region Zealand, Gastroenterology, Køge, Denmark

■ **N021**

Patients' experience of the Irish Society for Colitis and Crohn's Disease (ISCC)

M. Forry, B. Lucas, M. Hamzawi, C. Davis, F. Troy, V. Power, P. McArdle

Beaumont Hospital, Gastroenterology, Dublin, Ireland and others

■ **N022**

Phone assistance by nursing consultation in an IBD unit. Ability to solve problems

N. Ruiz, R. Camargo, **G. Alcain**, D. Recio, R. Carreño

Hospital Virgen de La Victoria, Gastroenterology, Malaga, Spain and others

■ **N023**

Gangrenous pyoderma (pg) management by IBD nurses team

N. Ruiz, C. Rivas, **R. Camargo**, R. Bosch, R. Carreño, J.J. Daza, G. Alcain

Hospital Virgen de La Victoria, Gastroenterology, Malaga, Spain and others

■ **N024**

Nursing management at Crohn's Disease: Functional health pattern model

B.N. Ozgursoy Uran, Y. Yildirim, Y. Tokem, E. Saritas Yuksel, G. Arslan

Izmir Katip Celebi University, Health Science Faculty, Nursing Dep., Izmir, Turkey and others

■ **N025**

Topical administration infliximab. Role of nursing

N. Parrilla Galdon, L. Oltra Camps, E. Hinojosa del Valle, M. Mora Escrig, J. Hinojosa del Val


Hospital Manises, Unit IBD, Manises, Valencia, Spain and others



European
Crohn's and Colitis
Organisation

ECCO Scientific Platform

Register now &
browse through
profiles, groups
& studies!



The next level of ECCO Networking

ECCO Members can register on the ECCO Scientific Platform and use this web-based tool to

Create

- Your individual scientific profile
- Research groups
- Basic studies
- Clinical studies

Search by

- Persons/Groups/Institutes
- Keywords
 - Research interest
 - Technologies
 - Lab skills
- Country
- Etc.

Connect with

- Other users of the platform
- Representatives of research groups
- Mentors
- Institutes offering fellowships

Scan and visit

www.sp.ecco-ibd.eu



Educational programme

One of ECCO's aims is to promote education in the field of IBD and to improve the quality of care for IBD patients throughout Europe. Thus prior to and during the 11th Congress of ECCO in Amsterdam ECCO offers the following educational activities:

14th IBD Intensive Advanced Course

Date:	March 16-17, 2016
Time:	March 16, 2016: 08:00-15:30 March 17, 2016: 08:00-12:30
Organisation:	EduCom
Target audience:	Junior gastroenterologists
Registration:	Upon invitation
CME accreditation:	8 CME credits, upon return of an evaluation form distributed during the course.

Wednesday, March 16, 2016

Programme overview (as of February 15, 2016)

Room E104-105, Level 1, RAI Amsterdam

07:30 - 08:00	Arrival & distribution of voting pads
08:00 - 08:15	1: Welcome Séverine Vermeire, Leuven, Belgium Gerassimos Mantzaris, Athens, Greece
08:15 - 08:45	2: Pre-course test Peter Irving, London, United Kingdom
08:45 - 09:45	Session 1: Pathogenesis Lead discussant: James Lindsay, London, United Kingdom
08:45 - 09:00	3: IBD: The role of the exposome Jonas Halfvarsson, Örebro, Sweden
09:00 - 09:15	4: The genetics of IBD Miles Parkes, Cambridge, United Kingdom
09:15 - 09:30	5: The microbiome and IBD Philippe Seksik, Paris, France
09:30 - 09:45	Discussion
09:45 - 10:15	Coffee break
10:15 - 11:00	Session 2: Interactive case discussion Lead discussant: James Lindsay, London, United Kingdom
10:15 - 11:00	6: Case based discussion: Investigation and management of mild/moderate Crohn's Disease Case presentation: Timothy Raine, Cambridge, United Kingdom Discussion: Jane Andrews, Adelaide, Australia

Wednesday, March 16, 2016, cont.

Programme overview (as of February 15, 2016)

Room E104-105, Level 1, RAI Amsterdam

11:00 - 12:00		Session 3: Seminar session - Part I: Specialist topic in IBD
11:00 - 12:00		<p>EITHER: 7a: Managing IBD and pregnancy Janneke van der Woude, Rotterdam, The Netherlands Zuzana Zelinkova, Bratislava, Slovakia Room E104-105, Level 1, RAI Amsterdam OR 7b: Managing complications associated with anti-TNF therapy Shomron Ben-Horin, Ramat Gan, Israel Room E103, Level 1, RAI Amsterdam OR 7c: Managing extraintestinal manifestations of IBD Stephan Vavricka, Zürich, Switzerland Peter Lakatos, Budapest, Hungary Room E106, Level 1, RAI Amsterdam</p>
12:00 - 12:30		Lunch break
12:30 - 14:30		Session 3: Seminar session - Part II: Practical skills
12:30 - 13:30		<p>EITHER: 8a: Role of bowel ultrasonography in intestinal diseases Stephan Vavricka, Zürich, Switzerland Torsten Kucharzik, Lüneburg, Germany Room E104-105, Level 1, RAI Amsterdam OR 8b: Practical guide to interpreting MRI Gionata Fiorino, Milan, Italy Cristiana Bonifacio, Milan, Italy Room E103, Level 1, RAI Amsterdam OR 8c: Practical guide to endoscopy and IBD incl. chromo-endoscopy, balloon dilatation and reporting Matt Rutter, Stockton-on-Tees, United Kingdom Pierre Michetti, Lausanne, Switzerland Room E106, Level 1, RAI Amsterdam</p>
13:30 - 14:30		<p>EITHER: 9a: Role of bowel ultrasonography in intestinal diseases Stephan Vavricka, Zürich, Switzerland Torsten Kucharzik, Lüneburg, Germany Room E104-105, Level 1, RAI Amsterdam OR 9b: Practical guide to interpreting MRI Gionata Fiorino, Milan, Italy Cristiana Bonifacio, Milan, Italy Room E103, Level 1, RAI Amsterdam OR 9c: Practical guide to endoscopy and IBD incl. chromo-endoscopy, balloon dilatation and reporting Matt Rutter, Stockton-on-Tees, United Kingdom Pierre Michetti, Lausanne, Switzerland Room E106, Level 1, RAI Amsterdam</p>
14:30 - 15:30		Session 4: Interactive case discussion Lead discussant: Peter Irving, London, United Kingdom
14:30 - 15:30		<p>10: Tandem talk: IBD therapeutics targets and drugs: New and old Yehuda Chowers, Haifa, Israel James Lindsay, London, United Kingdom</p>

Thursday, March 17, 2016

Programme overview (as of February 15, 2016)

Room E104-105, Level 1, RAI Amsterdam

08:00 - 10:20	Session 5: Interactive case discussion and lecture session Lead discussant: Peter Irving, London, United Kingdom	
	08:00 - 09:00	11: Case based discussion: Fistulising Crohn's Disease: Medical and surgical approaches Antonio López-Sanromán, Madrid, Spain André D'Hoore, Leuven, Belgium
	09:00 - 10:00	12: Case based discussion: The patient with severe inflammatory Crohn's Disease Case presentation: Pieter Hindryckx, Ghent, Belgium Discussion: Laurence Egan, Galway, Ireland
	10:00 - 10:20	Discussion
10:20 - 10:45	Coffee break	
10:45 - 12:15	Session 6: Special scenarios Lead discussant: James Lindsay, London, United Kingdom	
	10:45 - 11:15	13: Peri-operative management of Crohn's Disease Michael Kamm, Melbourne, Australia
	11:15 - 11:45	14: Monitoring therapy with drug levels and antibody testing Peter Irving, London, United Kingdom
	11:45 - 12:15	15: The medical management of Acute Severe Ulcerative Colitis: Case based discussion Charlie Lees, Edinburgh, United Kingdom
12:15 - 12:30	16: Feedback & closing remarks Peter Irving, London, United Kingdom James Lindsay, London, United Kingdom	

1st School for Clinical Trialists

Date:	March 16, 2016
Time:	08:00-11:30
Organisation:	ClinCom & N-ECCO
Target audience:	Clinical trial nurses, IBD nurses and Allied health professionals
Registration:	For registered participants only. No onsite registration.
CME accreditation:	3 CME credits, upon return of an evaluation form distributed during the course.

Wednesday, March 16, 2016

Programme overview (as of February 15, 2016)

Room E102, Level 1, RAI Amsterdam

<i>Understanding the different types of clinical trials</i>	
08:00 - 08:15	1: Welcome & Introduction Ailsa Hart, London, United Kingdom
08:15 - 09:30	Session 1 Ailsa Hart, London, United Kingdom Karen Kemp, Manchester, United Kingdom
08:15 - 09:00	2: Clinical trial terminology & processes. Standard investigations Vipul Jairath, London, Canada
09:00 - 09:30	3: How to optimise recruitment to clinical trials in IBD Ailsa Hart, London, United Kingdom
09:30 - 10:00	Coffee break
10:00 - 11:20	Session 2 Palle Bager, Aarhus, Denmark Vipul Jairath, London, Canada
10:00 - 10:30	4: Setting up and running large nationwide IBD trials Tariq Ahmad, Exeter, United Kingdom
10:30 - 11:00	5: Tips & tricks for the IBD clinical research team Leen Van Der Biest, Leuven, Belgium Jolien Lefrère, Leuven, Belgium
11:00 - 11:20	6: What does the future hold for IBD clinical trials? Walter Reinisch, Vienna, Austria / Hamilton, Canada
11:20 - 11:30	7: Summary & closing remarks Palle Bager, Aarhus, Denmark

7th N-ECCO School

Date:	March 16, 2016
Time:	08:30-16:15
Organisation:	N-ECCO
Target audience:	IBD nurses – new to the specialty, Dietitians
Registration:	Upon invitation

Wednesday, March 16, 2016

Programme overview (as of February 15, 2016)

Room G104, Level 1, RAI Amsterdam

08:30 - 08:45	1: Welcome & Introduction Usha Chauhan, Hamilton, Canada
08:45 - 12:15	Session 1: Diagnosis and assessment Usha Chauhan, Hamilton, Canada Nicolette Wierdsma, Amsterdam, The Netherlands
08:45 - 09:30	2: Diagnosis, anatomy and physiology in IBD Bas Oldenburg, Utrecht, The Netherlands
09:30 - 10:15	3: Psychosocial implications of living with IBD Janette Gaarenstroom, Utrecht, The Netherlands
10:15 - 10:45	Coffee break
10:45 - 11:15	4: Surgery in IBD André D'Hoore, Leuven, Belgium
11:15 - 11:45	5: Medical treatment Ailsa Hart, London, United Kingdom
11:45 - 12:15	6: Adherence Palle Bager, Aarhus, Denmark
12:15 - 13:20	Lunch break

Wednesday, March 16, 2016, cont.

Programme overview (as of February 15, 2016)

Room G104, Level 1, RAI Amsterdam

13:20 - 14:50	Session 2: Case studies - Disease management Usha Chauhan, Hamilton, Canada Miranda Lomer, London, United Kingdom	
	13:20 - 14:05	7a: Workshop 1 – UC Management (Group A) Andreas Sturm, Berlin, Germany Room G104, Level 1, RAI Amsterdam 8a: Workshop 2 – CD Management (Group B) Nanne de Boer, Amsterdam, The Netherlands Room G105, Level 1, RAI Amsterdam
	14:05 - 14:50	7b: Workshop 1 – UC Management (Group B) Andreas Sturm, Berlin, Germany Room G105, Level 1, RAI Amsterdam 8b: Workshop 2 – CD Management (Group A) Nanne de Boer, Amsterdam, The Netherlands Room G104, Level 1, RAI Amsterdam
14:50 - 15:10	Coffee break	
15:10 - 16:10	Session 3: General management in IBD Usha Chauhan, Hamilton, Canada Konstantinos Gerasimidis, Glasgow, United Kingdom	
	15:10 - 15:40	9: Nutritional aspects in IBD Rotem Sigall-Boneh, Tel Aviv, Israel
	15:40 - 16:10	10: Nursing roles in IBD management Lydia White, Oxford, United Kingdom
16:10 - 16:15	11: Closing remarks Usha Chauhan, Hamilton, Canada	



European
Crohn's and Colitis
Organisation

ECCO Educational Workshops 2016

ECCO Workshops

-  **44th ECCO Workshop**
Aalesund, **Norway** - April 15, 2016
-  **45th ECCO Workshop**
Siofok, **Hungary** - June 3, 2016
-  **46th ECCO Workshop**
Helsinki, **Finland** - June 9, 2016
-  **47th ECCO Workshop**
Buenos Aires, **Argentina** - October 1, 2016
-  **48th ECCO Workshop**
Dubrovnik, **Croatia** - October 8, 2016
-  **49th ECCO Workshop**
Guangzhou, **China** - November 11, 2016

Spreading standards in IBD:
Your presence counts!

Scan and contact the ECCO Office
www.ecco-ibd.eu



3rd Basic ECCO: EduCational COurse for Industry

Date:	March 16, 2016
Time:	10:30-18:00
Organisation:	ClinCom
Target audience:	Corporate & Non-Corporate Members
Registration:	For registered participants only. No onsite registration.

Wednesday, March 16, 2016

Programme overview (as of February 15, 2016)

Room G106-107, Level 1, RAI Amsterdam

10:30 - 10:35	1: Welcome Séverine Vermeire, Leuven, Belgium
10:35 - 13:00	Session 1 Matthieu Allez, Paris, France
10:35 - 10:50	2: What is IBD? Marcus Harbord, London, United Kingdom
10:50 - 11:05	3: What is the difference between Ulcerative Colitis and Crohn's Disease? Tariq Ahmad, Exeter, United Kingdom
11:05 - 11:20	4: Who does it affect? Tine Jess, Copenhagen, Denmark
11:20 - 11:30	Question time
11:30 - 11:45	5: What causes IBD? Andreas Sturm, Berlin, Germany
11:45 - 12:00	6: How is IBD diagnosed? Emma Calabrese, Rome, Italy
12:00 - 12:15	7: What do patients think? Marcus Harbord, London, United Kingdom
12:15 - 12:30	8: How is care organised? Ailsa Hart, London, United Kingdom
12:30 - 12:45	9: What do IBD nurses do? Lydia White, Oxford, United Kingdom
12:45 - 13:00	Question time
13:00 - 14:00	Lunch break

Wednesday, March 16, 2016, cont.

Programme overview (as of February 15, 2016)

Room G106-107, Level 1, RAI Amsterdam

14:00 - 15:30		
Session 2 Rami Eliakim, Tel Hashomer, Israel		
14:00 - 14:15	10: What are the conventional treatment options?	Edyta Zagorowicz, Warsaw, Poland
14:15 - 14:30	11: What is the role of 5-ASA?	Gerassimos Mantzaris, Athens, Greece
14:30 - 14:45	12: Where do steroids fit in?	Fernando Magro, Porto, Portugal
14:45 - 15:00	13: Who gets immunomodulators?	Vipul Jairath, London, Canada
15:00 - 15:15	14: What about biological therapy?	Alessandro Armuzzi, Rome, Italy
15:15 - 15:30	15: Is there a role for dietary treatment?	Arie Levine, Tel Aviv, Israel
15:30 - 16:00 Coffee break		
16:00 - 17:15		
Session 3 Antonio López-Sanromán, Madrid, Spain		
16:00 - 16:15	16: When do patients need surgery?	Willem Bemelman, Amsterdam, The Netherlands
16:15 - 16:30	17: What does surgery mean?	Omar Faiz, London, United Kingdom
16:30 - 16:45	18: Is surgery a cure?	Gianluca Sampietro, Milan, Italy
16:45 - 17:00	19: Can postoperative treatment prevent recurrence?	Antonio López-Sanromán, Madrid, Spain
17:00 - 17:15	20: What happens after a pouch operation?	Zuzana Serclova, Prague, Czech Republic
17:15 - 18:00		
Session 4 Séverine Vermeire, Leuven, Belgium		
17:15 - 17:30	21: What is the risk of cancer?	Alessandro Armuzzi, Rome, Italy
17:30 - 17:45	22: What are the other complications of IBD?	Gionata Fiorino, Milan, Italy
17:45 - 18:00	23: Where is the unmet need for patients with IBD?	Fernando Magro, Porto, Portugal

3rd N-ECCO Research Forum

Date:	March 16, 2016
Time:	13:00-17:00
Organisation:	N-ECCO
Target audience:	IBD nurses and Allied health professionals
Registration:	For registered participants only. No onsite registration.

Wednesday, March 16, 2016

Programme overview (as of February 15, 2016)
Room E102, Level 1, RAI Amsterdam

13:00 - 13:20	1: Welcome & Introduction Karen Kemp, Manchester, United Kingdom
13:20 - 13:40	2: Research priorities – overview of findings from the Delphi survey Christine Norton, London, United Kingdom
13:40 - 14:40	3: Workshop 1: Using PICO to define research priorities Palle Bager, Aarhus, Denmark Karen Kemp, Manchester, United Kingdom
14:40 - 15:10	Coffee break
15:10 - 16:40	Workshop 2: Top 10 tips in research
15:10 - 15:40	4a: Literature searching (Group A) Kay Greveson, London, United Kingdom Room E102, Level 1, RAI Amsterdam 4b: Statistics made easy (Group B) Susanna Jäghult, Stockholm, Sweden Room G105, Level 1, RAI Amsterdam 4c: How to critique a paper (Group C) Palle Bager, Aarhus, Denmark Room E106, Level 1, RAI Amsterdam
15:40 - 16:10	5a: Literature searching (Group B) Kay Greveson, London, United Kingdom Room G105, Level 1, RAI Amsterdam 5b: Statistics made easy (Group C) Susanna Jäghult, Stockholm, Sweden Room E106, Level 1, RAI Amsterdam 5c: How to critique a paper (Group A) Palle Bager, Aarhus, Denmark Room E102, Level 1, RAI Amsterdam
16:10 - 16:40	6a: Literature searching (Group C) Kay Greveson, London, United Kingdom Room E106, Level 1, RAI Amsterdam 6b: Statistics made easy (Group A) Susanna Jäghult, Stockholm, Sweden Room E102, Level 1, RAI Amsterdam 6c: How to critique a paper (Group B) Palle Bager, Aarhus, Denmark Room G105, Level 1, RAI Amsterdam
16:40 - 17:00	7: Learning from today: Applying your research into clinical practice Palle Bager, Aarhus, Denmark Karen Kemp, Manchester, United Kingdom

1st ECCO Endoscopy Workshop

Date:	March 16, 2016
Time:	Industry sponsored satellite symposium: 11:45-12:45 Endoscopy Workshop: 13:00-18:00
Organisation:	EduCom
Target audience:	Physicians, Surgeons, Paediatricians
Registration:	For registered participants only. No onsite registration.
CME accreditation:	3 CME credits, upon return of an evaluation form distributed during the course.

Wednesday, March 16, 2016

Programme overview (as of February 15, 2016)

Room G103, Level 1, RAI Amsterdam

11:45 - 12:45	Industry sponsored satellite symposium Please refer to page 196
13:00 - 13:15	1: Welcome & Introduction Séverine Vermeire, Leuven, Belgium
	2: Pre-course test
13:15 - 14:15	3: Session 1: Assessment of endoscopic activity: Clinical trials and routine practice Chairs: Vito Annese, Florence, Italy Geert D'Haens, Amsterdam, The Netherlands Speaker: Konstantinos Katsanos, Ioannina, Greece
14:15 - 15:15	4: Session 2: Endoscopic surveillance for IBD associated colorectal cancer Chairs: Ailsa Hart, London, United Kingdom Antonio López-Sanromán, Madrid, Spain Speaker: Matt Rutter, Stockton-on-Tees, United Kingdom
15:15 - 15:45	Coffee break
15:45 - 16:45	5: Session 3: Endoscopic therapeutic intervention in IBD Chairs: Paolo Gionchetti, Bologna, Italy Peter Irving, London, United Kingdom Speaker: Marc Ferrante, Leuven, Belgium
16:45 - 17:45	6: Session 4: Small bowel endoscopy: Capsule vs. balloon enteroscopy Chairs: Rami Eliakim, Tel Hashomer, Israel Torsten Kucharzik, Lüneburg, Germany Speaker: Peter Lakatos, Budapest, Hungary
17:45 - 18:00	7: Post-course test & Concluding remarks James Lindsay, London, United Kingdom

2nd Advanced ECCO: EduCational COurse for Industry

Date: March 16, 2016
Time: 14:00-18:00
Organisation: ClinCom
Target audience: Corporate & Non-Corporate Members
Registration: For registered participants only. No onsite registration.

Wednesday, March 16, 2016

Programme overview (as of February 15, 2016)

Room Forum, Ground level, RAI Amsterdam

14:00 - 14:05	1: Welcome Séverine Vermeire, Leuven, Belgium
14:05 - 14:55	2: Session 1: Head-to-head comparative studies: Challenges & opportunities? William Sandborn, San Diego, United States Panel discussion: Laurent Peyrin-Biroulet, Vandoeuvre-lès-Nancy, France Anne Robinson, Highland, United States (AbbVie) Keith Usiskin, Summit, United States (Celgene)
14:55 - 15:45	3: Session 2: Patient reported outcomes measures. New data Keith Bodger, Liverpool, United Kingdom Panel discussion: Simon Travis, Oxford, United Kingdom Elmer Schabel, Bonn, Germany (EMA) Brihad Abhyankar, London, United Kingdom (Takeda)
15:45 - 16:15	Coffee break
16:15 - 17:05	4: Session 3: What challenges are faced by using cross-sectional imaging and histological endpoints in clinical trials? Julián Panés, Barcelona, Spain Vincenzo Villanacci, Brescia, Italy Panel discussion: Filip Baert, Roeselare, Belgium Gert De Hertogh, Leuven, Belgium Freddy Cornillie, Kriens, Switzerland (Merck)
17:05 - 17:55	5: Session 4: Disease-modification studies: Are we ready to start? Jean-Frédéric Colombel, New York, United States Panel discussion: Daniel Hommes, Los Angeles, United States Marc Ferrante, Leuven, Belgium Klaus Gottlieb, Rockville, United States (Synthetic Biologics)
17:55 - 18:00	6: Closing remarks Julián Panés, Barcelona, Spain

EU Project Forum



Date: March 16, 2016
Time: 15:00-18:15
Organisation: Governing Board
Target audience: Researchers, Clinicians, Basic Scientists
Registration: For registered participants only. No onsite registration.
CME accreditation: 3 CME credits, upon return of an evaluation form distributed during the course.

Wednesday, March 16, 2016

Programme overview (as of February 15, 2016)

Room G102, Level 1, RAI Amsterdam

15:00 - 15:05	1: Welcome and Introduction Filip Baert, Roeselare, Belgium
15:05 - 15:35	2: EU Funding Nassima Ferahtia, European Commission, Brussels, Belgium
15:35 - 16:05	Session 1: Sadel Raja Atreya, Erlangen, Germany Andreas Sturm, Berlin, Germany
15:35 - 15:45	3: Introduction: Nanofitins and the SADEL project Olivier Kitten, Nantes, France
15:45 - 15:55	4: Pharmacological profile of Nanofitins: Fit for oral Magali Zeisser-Labouebe, Geneva, Switzerland
15:55 - 16:05	5: In vivo oral administration of Nanofitins in IBD models Christel Rousseaux, Lille, France
16:05 - 17:40	Session 2: Biomarkers for clinical decision making in IBD, an unmet clinical need
16:05 - 16:35	IBD Character Jack Satsangi, Edinburgh, United Kingdom Morten Vatn, Oslo, Norway Jonas Halfvarson, Örebro, Sweden
16:05 - 16:15	6: Introduction to IBD Character Rahul Kalla, Edinburgh, United Kingdom
16:15 - 16:25	7: Proximity Extension Assay technology identifies novel serum biomarkers Niklas Nordberg, Uppsala, Sweden
16:25 - 16:35	8: A novel diagnostic test for determining microbial dysbiosis Christina Casén, Oslo, Norway
16:35 - 17:10	Coffee break

Wednesday, March 16, 2016, cont.

Programme overview (as of February 15, 2016)

Room G102, Level 1, RAI Amsterdam

17:10 - 17:40	IBD-BIOM Vito Annese, Florence, Italy Jack Satsangi, Edinburgh, United Kingdom
	17:10 - 17:20 9: Introduction to IBD-BIOM Gordon Lauc, Zagreb, Croatia
	17:20 - 17:30 10: The role of DNA methylation Nick Ventham, Edinburgh, United Kingdom
	17:30 - 17:40 11: The potential of glycomics as an IBD biomarker Gordon Lauc, Zagreb, Croatia Manfred Wuhrer, Leiden, The Netherlands
17:40 - 18:10	Session 3: Biocycle Britta Siegmund, Berlin, Germany Ailsa Hart, London, United Kingdom
	17:40 - 17:46 12: The global project Edouard Louis, Liège, Belgium
	17:46 - 17:52 13: The spare trial Erik Hertervig, Lund, Sweden
	17:52 - 17:58 14: The health care provider/patients survey Jean-Frédéric Colombel, New York, United States
	17:58 - 18:04 15: The biomarkers Jack Satsangi, Edinburgh, United Kingdom
	18:04 - 18:10 Discussion
18:10 - 18:15	16: Closing remarks Filip Baert, Roeselare, Belgium

9th Y-ECCO Career Workshop

Date:	March 16, 2016
Time:	16:00-18:00
Organisation:	Y-ECCO
Target audience:	Physicians, Surgeons, Paediatricians, IBD nurses
Registration:	For registered participants only. No onsite registration.
CME accreditation:	2 CME credits, upon return of an evaluation form distributed during the workshop.

Wednesday, March 16, 2016

Programme overview (as of February 15, 2016)

Room E104-105, Level 1, RAI Amsterdam

<i>Writing and reviewing scientific and clinical papers</i>	
16:00 - 16:15	1: Introduction to Y-ECCO and the workshop Timothy Raine, Cambridge, United Kingdom Nuha Yassin, London, United Kingdom
16:15 - 16:45	2: Session 1: Writing and reviewing a scientific paper Laurence Egan, Galway, Ireland
16:45 - 17:50	Session 2: Group session - Reviewing a scientific paper
	16:45 - 17:40 Group session – critiquing different extracts of papers
	17:40 - 17:50 3: Tips, tricks and pitfalls for peer reviewers Laurence Egan, Galway, Ireland
17:50 - 18:00	4: Feedback, Y-ECCO Abstract awards and Closing remarks Timothy Raine, Cambridge, United Kingdom Nuha Yassin, London, United Kingdom

5th S-ECCO IBD Masterclass in collaboration with ESCP



Date:	March 17, 2016
Time:	07:30-17:00
Organisation:	S-ECCO in collaboration with ESCP
Target audience:	Surgeons, Physicians, IBD nurses
Registration:	For registered participants only. No onsite registration.
CME accreditation:	6 CME credits, upon return of an evaluation form distributed during the workshop.

Thursday, March 17, 2016

Programme overview (as of February 15, 2016)

Room Forum, Ground level, RAI Amsterdam

<i>No man's land in IBD</i>	
07:30 - 07:40	1: Welcome Willem Bemelman, Amsterdam, The Netherlands
07:40 - 09:15	Session 1: Perianal disease Yves Panis, Clichy, France Paulo Kotze, Curitiba, Brazil
07:40 - 08:25	Debate 1: The simple transsphincteric fistula
07:40 - 07:50	2: Chronic seton Christianne Buskens, Amsterdam, The Netherlands
07:50 - 08:00	3: Biologicals William Sandborn, San Diego, United States
08:00 - 08:10	4: Surgery aiming at repair Oded Zmora, Tel Aviv, Israel
08:10 - 08:25	Discussion
08:25 - 08:45	Video
08:25 - 08:35	5: LIFT for Crohn's fistula Eloy Espin Basany, Barcelona, Spain
08:35 - 08:45	6: Advancement plasty for Crohn's fistula Zuzana Serdlova, Prague, Czech Republic
08:45 - 09:15	Debate 2: Symptomatic recto-vaginal fistula
08:45 - 08:55	7: Immediate proctectomy Emmanuel Tiret, Paris, France
08:55 - 09:05	8: Reconstructive repair Yves Panis, Clichy, France
09:05 - 09:15	Discussion
09:15 - 09:40	Coffee break

Thursday, March 17, 2016, cont.

Programme overview (as of February 15, 2016)

Room Forum, Ground level, RAI Amsterdam

09:40 - 11:25	Session 2: Hot potatoes in IBD Geert D'Haens, Amsterdam, The Netherlands Gianluca Sampietro, Milan, Italy	
09:40 - 10:10	Debate 3: Unsuspected Crohn's Disease during laparoscopy for appendicitis	
	09:40 - 09:50	9: Resect Eloy Espín Basany, Barcelona, Spain
	09:50 - 10:00	10: Do nothing and refer to the gastroenterologist Chaya Shwaartz, Tel Aviv, Israel
	10:00 - 10:10	Discussion
10:10 - 10:20	11: Video: Strictureplasty of the ileocolic valve André D'Hoore, Leuven, Belgium	
10:20 - 10:50	Debate 4: When does a drug work? Efficacy and clinical relevance	
	10:20 - 10:30	12: The gastroenterologist's view Geert D'Haens, Amsterdam, The Netherlands
	10:30 - 10:40	13: The surgeon's view Willem Bemelman, Amsterdam, The Netherlands
	10:40 - 10:50	Discussion
10:50 - 11:25	Trial Updates	
	10:50 - 10:57	14: Right hemicolectomy audit: Crohn's Disease Alaa El-Hussuna, Copenhagen, Denmark
	10:57 - 11:04	15: Pre- and post-operative anti-glycan antibodies correlate with pouch complications after pouch surgery for Ulcerative Colitis Hagit Tulchinsky, Tel Aviv, Israel
	11:04 - 11:11	16: SuPREMe-CD Study Gaetano Luglio, Naples, Italy
	11:11 - 11:18	17: Is quality of life different between Crohn's Disease patients submitted to early surgery or immunosuppression? Rita Barosa, Almada, Portugal
	11:18 - 11:25	18: Surgery for children with Crohn's Disease Marek Stefanowicz, Warsaw, Poland
11:25 - 12:25	Lunch break	
12:25 - 14:40	Session 3: Crohn's Disease Laurent Peyrin-Biroulet, Vandœuvre-lès-Nancy, France Emmanuel Tiret, Paris, France	
12:25 - 12:55	Debate 5: Limited ileocecal disease	
	12:25 - 12:35	19: Surgery Michel Adamina, Winterthur, Switzerland
	12:35 - 12:45	20: Biologicals Ailsa Hart, London, United Kingdom
	12:45 - 12:55	Discussion
12:55 - 13:10	21: LIRIC Trial Joline de Groof, Amsterdam, The Netherlands	

Thursday, March 17, 2016, cont.

Programme overview (as of February 15, 2016)

Room Forum, Ground level, RAI Amsterdam

13:10 - 13:40	Debate 6: Segmental versus total colectomy in Crohn's Disease	
13:10 - 13:20	22: Segmental resection	Gianluca Sampietro, Milan, Italy
13:20 - 13:30	23: Total colectomy	Antonino Spinelli, Milan, Italy
13:30 - 13:40	Discussion	
13:40 - 14:10	Debate 7: Clear margins are important in segmental resection of Crohn's Disease	
13:40 - 13:50	24: Only macroscopic	Nuha Yassin, London, United Kingdom
13:50 - 14:00	25: Radical resection	Nir Wasserberg, Petah Tikva, Israel
14:00 - 14:10	Discussion	
14:10 - 14:40	Debate 8: Prophylaxis after ileocolic resection	
14:10 - 14:20	26: For all	Paulo Kotze, Curitiba, Brazil
14:20 - 14:30	27: Selectively	Michael Kamm, Melbourne, Australia
14:30 - 14:40	Discussion	
14:40 - 15:05	Coffee break	
	Session 4: Ulcerative Colitis	
15:05 - 16:55	Willem Bemelman, Amsterdam, The Netherlands Peter Irving, London, United Kingdom	
15:05 - 15:35	Debate 9: Colectomy for low grade dysplasia	
15:05 - 15:15	28: Colectomy	Omar Faiz, London, United Kingdom
15:15 - 15:25	29: Surveillance	Janindra Warusavitarne, London, United Kingdom
15:25 - 15:35	Discussion	
15:35 - 15:55	30: Pathophysiology of cancer in IBD Gijs van den Brink, Amsterdam, The Netherlands	
15:55 - 16:25	Debate 10: Chronic Active Colitis: Early surgery or continued extensive medication	
15:55 - 16:05	31: Early surgery	André D'Hoore, Leuven, Belgium
16:05 - 16:15	32: Continued medication	Séverine Vermeire, Leuven, Belgium
16:15 - 16:25	Discussion	
16:25 - 16:45	33: Faecal biomarkers and their role in surgery in IBD Takayuki Yamamoto, Yokkaichi, Japan	
16:45 - 16:55	34: Video: TAMIS pouch Janindra Warusavitarne, London, United Kingdom	
16:55 - 17:00	35: Closing remarks Oded Zmora, Tel Aviv, Israel	



3rd ECCO-ESGAR Ultrasound Workshop

Date:	March 17, 2016
Time:	07:30-12:15
Organisation:	EduCom in collaboration with ESGAR
Target audience:	Physicians, Surgeons, Paediatricians
Registration:	For registered participants only. No onsite registration.
CME accreditaion:	3 CME credits, upon return of an evaluation form distributed during the course.



Thursday, March 17, 2016

Programme overview (as of February 15, 2016)

Room G103, Level 1, RAI Amsterdam

07:30 - 07:40	1: Welcome & Introduction S��verine Vermeire, Leuven, Belgium (ECCO)
07:40 - 08:40	2: Introductory lecture Torsten Kucharzik, L��neburg, Germany (ECCO) Stephan Vavricka, Z��rich, Switzerland (ECCO)
08:40 - 11:40	3: Hands-on open space in bowel ultrasonography Richard Beable, Portsmouth, United Kingdom (ESGAR) Steven Bots, Amsterdam, The Netherlands (ESGAR) Emma Calabrese, Rome, Italy (ECCO) Daniel Dindo, Z��rich, Switzerland (ECCO) Torsten Kucharzik, L��neburg, Germany (ECCO) Christian Maaser, L��neburg, Germany (ECCO) Giovanni Maconi, Milan, Italy (ECCO) Julien Puylaert, The Hague, The Netherlands (ESGAR) Gerhard Rogler, Z��rich, Switzerland (ECCO) Stephan Vavricka, Z��rich, Switzerland (ECCO) Emerald Room, Level 1, RAI Amsterdam
11:40 - 12:00	Question & answer session
12:00 - 12:15	4: Concluding remarks Torsten Kucharzik, L��neburg, Germany (ECCO) Stephan Vavricka, Z��rich, Switzerland (ECCO)

3rd EpiCom Workshop

Date:	March 17, 2016
Time:	08:00-11:30
Organisation:	EpiCom
Target audience:	Physicians, Paediatricians
Registration:	For registered participants only. No onsite registration.
CME accreditation:	3 CME credits, upon return of an evaluation form distributed during the workshop.

Thursday, March 17, 2016

Programme overview (as of February 15, 2016)

Room E103, Level 1, RAI Amsterdam

<i>Early lifestyle, microbiome and risk of IBD</i>	
08:00 - 08:10	1: Welcome & Introduction Tine Jess, Copenhagen, Denmark
08:10 - 10:10	Session 1 Vito Annese, Florence, Italy Ebbe Langholz, Hellerup, Denmark
08:10 - 08:30	2: Delivery and breastfeeding Zuzana Zelinkova, Bratislava, Slovakia
08:30 - 08:50	3: Infection and antibiotics Dana Duricova, Prague, Czech Republic
08:50 - 09:10	4: Vaccination Konstantinos Katsanos, Ioannina, Greece
09:10 - 09:30	5: Diet Vito Annese, Florence, Italy
09:30 - 09:50	6: Appendectomy Pia Munkholm, Copenhagen, Denmark
09:50 - 10:10	7: Smoking Peter Lakatos, Budapest, Hungary
10:10 - 10:30	Coffee break
10:30 - 11:30	Session 2: Workshop Dana Duricova, Prague, Czech Republic Pia Munkholm, Copenhagen, Denmark
10:30 - 11:00	Group work on creating the optimal project
11:00 - 11:30	8: Presentation and discussion of the case on migration Nuha Yassin, London, United Kingdom
11:30	9: Closure & farewell Tine Jess, Copenhagen, Denmark

5th ClinCom Workshop

Date:	March 17, 2016
Time:	08:30-12:10
Organisation:	ClinCom
Target audience:	Physicians, Surgeons, Paediatricians, Clinical researchers, Industry
Registration:	For registered participants only. No onsite registration.
CME accreditation:	3 CME credits, upon return of an evaluation form distributed during the workshop.

Thursday, March 17, 2016

Programme overview (as of February 15, 2016)

Room E102, Level 1, RAI Amsterdam

08:30 - 08:35	1: Welcome & Introduction Alessandro Armuzzi, Rome, Italy
08:35 - 09:55	Session 1: Balance safety – efficacy Vipul Jairath, London, Canada
08:35 - 08:55	2: What has meta-analysis taught us Jean-Frédéric Colombel, New York, United States
08:55 - 09:15	3: How to evaluate safety of biologics Geert D'Haens, Amsterdam, The Netherlands
09:15 - 09:35	4: Cluster randomised trials Vipul Jairath, London, Canada
09:35 - 09:55	5: How to choose your biologics in 2016 Michael Kamm, Melbourne, Australia
09:55 - 10:30	Coffee break
10:30 - 12:00	Session 2: Balance efficacy - costs Marc Ferrante, Leuven, Belgium
10:30 - 10:50	6: Methodology of cost efficacy Keith Bodger, Liverpool, United Kingdom
10:50 - 11:10	7: How to implement results of cost efficacy analysis in clinical practice? Ailsa Hart, London, United Kingdom
11:10 - 11:30	8: Comparing treatment strategies and cost effectiveness Daniel Hommes, Los Angeles, United States
11:30 - 12:00	9: From regulators to payers Elmer Schabel, Bonn, Germany (EMA) Barney Hawthorne, Cardiff, United Kingdom Alessandro Armuzzi, Rome, Italy Ailsa Hart, London, United Kingdom
12:00 - 12:10	10: Summary & closing remarks Fernando Magro, Porto, Portugal

Molecular aetiology of IBD

Date:	March 17, 2016
Time:	09:00-12:10
Organisation:	SciCom
Target audience:	Physicians, Surgeons, Paediatricians, Scientists
Registration:	For registered participants only. No onsite registration.
CME accreditation:	3 CME credits, upon return of an evaluation form distributed during the workshop.

Thursday, March 17, 2016

Programme overview (as of February 15, 2016)

Room G104-105, Level 1, RAI Amsterdam

<i>Learning from human models</i>	
09:00 - 10:40	Session 1 Charlie Lees, Edinburgh, United Kingdom Gijs van den Brink, Amsterdam, The Netherlands
09:00 - 09:10	1: Welcome & Introduction Charlie Lees, Edinburgh, United Kingdom
09:10 - 09:40	2: Human monogenetic IBD patients – Insights into disease pathogenesis Holm Uhlig, Oxford, United Kingdom
09:40 - 10:10	3: IBD as an epithelial wound healing defect Markus Neurath, Erlangen, Germany
10:10 - 10:40	4: IBD as a primary immune cell deficiency: B cells Gijs van den Brink, Amsterdam, The Netherlands
10:40 - 11:00	Coffee break
11:00 - 12:10	Session 2 Holm Uhlig, Oxford, United Kingdom Janneke Samsom, Rotterdam, The Netherlands
11:00 - 11:30	5: IBD as a primary immune cell deficiency: Macrophages and Dendritic cells Janneke Samsom, Rotterdam, The Netherlands
11:30 - 12:00	6: IBD as a primary immune cell deficiency: Neutrophils and complement Kaan Boztug, Vienna, Austria
12:00 - 12:10	7: Closing remarks Holm Uhlig, Oxford, United Kingdom

10th N-ECCO Network Meeting

Date:	March 17, 2016
Time:	N-ECCO Network Meeting: 09:00-17:00 Industry sponsored satellite symposium: 12:45-13:45
Organisation:	N-ECCO
Target audience:	IBD nurses – advanced level
Registration:	For registered participants only. No onsite registration.

Thursday, March 17, 2016

*Programme overview (as of February 15, 2016)
Elicium 1, Level 1, RAI Amsterdam*

09:00 - 09:15	1: Welcome & Introduction Janette Gaarenstroom, Utrecht, The Netherlands
09:15 - 10:30	Session 1: Patient involvement and patient participation Palle Bager, Aarhus, Denmark Karin Fienieg, Amsterdam, The Netherlands
09:15 - 09:45	2: Patient involvement and shared decision making Kirsten Lomborg, Aarhus, Denmark
09:45 - 10:15	3: Health literacy Kristine Sorensen, Maastricht, The Netherlands
10:15 - 10:30	4: Patient panels Helen Terry, St. Albans, United Kingdom
10:30 - 11:00	Coffee break
11:00 - 12:30	Session 2: e-health in IBD Kay Greveson, London, United Kingdom Maria de Jong, Amsterdam, The Netherlands
11:00 - 11:30	5: Status on e-health in IBD Pia Munkholm, Copenhagen, Denmark
11:30 - 12:00	6: Professional communication via electronic media Annemiek Linn, Amsterdam, The Netherlands
12:00 - 12:15	7: Experience from Canada: GI Bodyguard Usha Chauhan, Hamilton, Canada
12:15 - 12:30	8: Experience from Sweden: Swibreg Susanna Jäghult, Stockholm, Sweden
12:30 - 14:00	Lunch break

Thursday, March 17, 2016, cont.

*Programme overview (as of February 15, 2016)
Elicium 1, Level 1, RAI Amsterdam*

12:45 - 13:45	Industry sponsored satellite symposium Please refer to page 196
14:00 - 14:45	Session 3: IBD nursing Usha Chauhan, Hamilton, Canada Nienke Ipenburg, Leiden, The Netherlands
14:00 - 14:15	9: Abstract 1: The beneficial effects of mindfulness training on fatigue and psychosocial functioning in patients with IBD and IBS: A pilot study G. Drent ¹ , M. Kuijken ² , J. Mooibroek ¹ , G. Dijkstra ¹ , M. Schroevers ³ ¹ University Medical Center Groningen, Department of Gastroenterology and Hepatology, Groningen, Netherlands, ² University Medical Center Groningen, Paramedical support, Groningen, Netherlands, ³ University Medical Center Groningen, Health Sciences, Groningen, Netherlands
14:15 - 14:30	10: Abstract 2: Introduction of an Inflammatory Bowel Disease nurse flexible sigmoidoscopy clinic improves patient care by initiating earlier treatment and saves clinic slots H. Johnson , S. Weaver, S. McLaughlin Royal Bournemouth Hospital, Department of Gastroenterology, Bournemouth, United Kingdom
14:30 - 14:45	11: Abstract 3: Proving cost effectiveness through implementation of a nurse-led Inflammatory Bowel Disease (IBD) Patient Advice Line and Virtual Clinic (CHEAP) A. Sechi , E. Sawyer, W. Ng, S. Connor Liverpool Hospital, Department of Gastroenterology, Liverpool, Australia
14:45 - 15:15	Coffee break
15:15 - 16:40	Session 4: New drugs and drug monitoring Karen Kemp, Manchester, United Kingdom Angelie de Heer, Tilburg, The Netherlands
15:15 - 16:15	12: Is it time to welcome the new buddies? A debate on biosimilars Silvio Danese, Milan, Italy Pierre Michetti, Lausanne, Switzerland
16:15 - 16:40	13: Therapeutic drug monitoring in IBD Tariq Ahmad, Exeter, United Kingdom
16:40 - 17:00	14: N-ECCO in 2016 and beyond Janette Gaarenstroom, Utrecht, The Netherlands

3rd P-ECCO Educational Course

Date:	March 17, 2016
Time:	10:00-12:00
Organisation:	P-ECCO
Target audience:	Paediatricians, Physicians, Surgeons, Scientists, IBD nurses
Registration:	For registered participants only. No onsite registration.
CME accreditation:	2 CME credits, upon return of an evaluation form distributed during the workshop.

Thursday, March 17, 2016

Programme overview (as of February 15, 2016)

Room G106-107, Level 1, RAI Amsterdam

10:00 - 12:00	<i>New approaches to diagnosis and therapy</i> Arie Levine, Tel Aviv, Israel Patrick van Rheenen, Groningen, The Netherlands	
	10:00 - 10:05	<i>1: Welcome & Introduction</i> Arie Levine, Tel Aviv, Israel
	10:05 - 10:25	<i>2: Diagnosis, treatment and outcomes of Paediatric IBD Unclassified (IBD-U)</i> Dan Turner, Jerusalem, Israel
	10:25 - 10:50	<i>3: Personalising paediatric IBD: Identification of high and low-risk patients at diagnosis</i> Arie Levine, Tel Aviv, Israel
	10:50 - 11:15	<i>4: New treatments for UC: Do we have paediatric data?</i> Richard Russell, Glasgow, United Kingdom
	11:15 - 11:40	<i>5: Faecal transplantation in IBD - Who, when & how?</i> Salvatore Cucchiara, Rome, Italy
	11:40 - 12:00	<i>6: Managing the pouch in UC</i> Iris Dotan, Tel Aviv, Israel



BIOCYCLE: BIological therapy CYCLEs towards tailored, needs- driven, safer and cost-effective management of Crohn's Disease



BIOCYCLE Research Project selected for EU Horizon 2020 funding

- This project receives funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No 633168 — BIOCYCLE (PHC-13-2014).
- Focus on treatment de-escalation in patients with Crohn's Disease in sustained steroid-free remission under combination therapy with infliximab and immunosuppressant.
- Looking at cost and safety issues
- A three-arm controlled trial comparing combination maintenance with infliximab withdrawal or with immunosuppressant withdrawal.
- Beside clinical efficacy end-points, the project is aiming to assess biomarker prediction, cost-effectiveness, and the perceptions of patients/health care providers/health authorities.
- Project implementation within supporting networks of BSG, CED, SOIBD and ECCO.



UNIVERSITY OF GOTHENBURG



1st H-ECCO IBD Masterclass

Date:	March 17-18, 2016
Time:	March 17, 2016: 13:30-17:00 March 18, 2016: 08:00-12:15
Organisation:	H-ECCO Working Group, endorsed by ESP
Target audience:	Histopathologists
Registration:	For registered participants only. No onsite registration.
CME accreditation:	6 CME credits, upon return of an evaluation form distributed during the workshop.



Thursday, March 17, 2016

Programme overview (as of February 15, 2016)

Emerald Room, Level 1, RAI Amsterdam

13:30 - 13:35	1: Welcome & Introduction Cord Langner, Graz, Austria
13:35 - 15:00	Session 1: Basic aspects of IBD pathology Vincenzo Villanacci, Brescia, Italy James Lindsay, London, United Kingdom
13:35 - 13:45	2: Epidemiology of IBD Tine Jess, Copenhagen, Denmark
13:45 - 14:00	3: Clinical and endoscopic features of IBD Peter Irving, London, United Kingdom
14:00 - 14:15	4: What does the gastroenterologist want to know from the pathologist? James Lindsay, London, United Kingdom
14:15 - 14:40	5: Basic principles of histological IBD diagnosis Roger Feakins, London, United Kingdom
14:40 - 15:00	6: The classic histology of Ulcerative Colitis and Crohn's Disease Cord Langner, Graz, Austria
15:00 - 15:30	Coffee break
15:30 - 17:00	Session 2: Challenges and differential diagnosis Cord Langner, Graz, Austria Magali Svrcek, Paris, France
15:30 - 15:50	7: Ulcerative Colitis vs. Crohn's Disease in difficult cases Vincenzo Villanacci, Brescia, Italy
15:50 - 16:15	8: Paediatric and adolescent IBD Paula Borralho, Lisbon, Portugal
16:15 - 16:35	9: Superinfection Roger Feakins, London, United Kingdom
16:35 - 17:00	10: Non-IBD colitides Cord Langner, Graz, Austria

Friday, March 18, 2016

Programme overview (as of February 15, 2016)

Emerald Room, Level 1, RAI Amsterdam

08:00 - 10:00	Session 3: Dysplasia and cancer in IBD Paula Borralho, Lisbon, Portugal Rami Eliakim, Tel Hashomer, Israel	
	08:00 - 08:15	11: Cancer risk in IBD Vincenzo Villanacci, Brescia, Italy
	08:15 - 08:50	12: Molecular basis of dysplasia and cancer Magali Svrcek, Paris, France
	08:50 - 09:25	13: Diagnosis of dysplasia (Tandem talk) Rami Eliakim, Tel Hashomer, Israel Cord Langner, Graz, Austria
	09:25 - 10:00	14: Treatment of dysplasia (Tandem talk) Vito Annese, Florence, Italy Antonino Spinelli, Milan, Italy
10:00 - 10:30	Coffee break	
10:30 - 12:10	Session 4: Special situations Roger Feakins, London, United Kingdom Vincenzo Villanacci, Brescia, Italy	
	10:30 - 10:50	15: Activity in IBD Paula Borralho, Lisbon, Portugal
	10:50 - 11:10	16: The role of pathology in the evaluation of treatment Vincenzo Villanacci, Brescia, Italy
	11:10 - 11:30	17: Pouchitis Paula Borralho, Lisbon, Portugal
	11:30 - 12:00	18: What's hot in IBD pathology? Magali Svrcek, Paris, France
	12:00 - 12:10	19: The ideal pathology report Roger Feakins, London, United Kingdom
12:10 - 12:15	20: Closing remarks Cord Langner, Graz, Austria	

1st D-ECCO Workshop

Date: March 18, 2016
Time: 08:30-12:30
Organisation: D-ECCO Working Group
Target audience: Dietitians, IBD nurses
Registration: For registered participants only. No onsite registration.

Friday, March 18, 2016

Programme overview (as of February 15, 2016)

Room E102, Level 1, RAI Amsterdam

08:30 - 08:35	1: Welcome Rotem Sigall-Boneh, Tel Aviv, Israel
08:35 - 09:40	Session 1 Miranda Lomer, London, United Kingdom Rotem Sigall-Boneh, Tel Aviv, Israel
08:35 - 08:55	2: Diet, environment and genetics in IBD Arie Levine, Tel Aviv, Israel
08:55 - 09:15	3: Microbiota and IBD Philippe Seksik, Paris, France
09:15 - 09:35	4: Nutritional assessment in IBD patients Konstantinos Gerasimidis, Glasgow, United Kingdom
09:35 - 09:40	Panel Q&A
09:40 - 10:00	Coffee break
10:00 - 11:05	Session 2 Nicolette Wierdsma, Amsterdam, The Netherlands Philippe Seksik, Paris, France
10:00 - 10:20	5: Exclusive and partial enteral nutrition in IBD Richard Russell, Glasgow, United Kingdom
10:20 - 10:40	6: New dietary therapies in IBD Rotem Sigall-Boneh, Tel Aviv, Israel
10:40 - 11:00	7: Iron deficiency anaemia in IBD Charlie Lees, Edinburgh, United Kingdom
11:00 - 11:05	Panel Q&A
11:05 - 11:20	Coffee break

Friday, March 18, 2016, cont.

Programme overview (as of February 15, 2016)

Room E102, Level 1, RAI Amsterdam

11:20 - 12:25	Session 3 Konstantinos Gerasimidis, Glasgow, United Kingdom Petra Tap-Zandkuil, Woerden, The Netherlands	
	11:20 - 11:40	8: Dietary treatment of functional symptoms in IBD Miranda Lomer, London, United Kingdom
	11:40 - 12:00	9: Dietary treatment in short bowel syndrome/intestinal insufficiency Nicolette Wierdsma, Amsterdam, The Netherlands
	12:00 - 12:20	10: The evidence for fibre and prebiotics in IBD Kevin Whelan, London, United Kingdom
	12:20 - 12:25	Panel Q&A
12:25 - 12:30	11: Closing remarks Arie Levine, Tel Aviv, Israel	

2nd Y-ECCO Basic Science Workshop

Date:	March 18, 2016
Time:	15:00-18:00
Organisation:	Y-ECCO
Target audience:	Physicians, Surgeons, Paediatricians, IBD nurses
Registration:	For registered participants only. No onsite registration.
CME accreditation:	3 CME credits, upon return of an evaluation form distributed during the workshop.

Friday, March 18, 2016

Programme overview (as of February 15, 2016)

Room E103, Level 1, RAI Amsterdam

<i>Mouse models and microbiota in IBD</i>	
15:00 - 15:05	1: Introduction Isabelle Cleynen, Leuven, Belgium
15:05 - 16:20	Session 1: Mouse models in IBD Markus Neurath, Erlangen, Germany Pieter Hindryckx, Ghent, Belgium Nuha Yassin, London, United Kingdom
15:05 - 15:35	2: Animal models in IBD: Pros and cons Markus Neurath, Erlangen, Germany
15:35 - 15:50	3: Abstract 1: Improvement of experimental mouse models in Inflammatory Bowel Diseases using flexible video endoscopic colon evaluation Claire Gay, Besançon, France please refer to P071 on page 75
15:50 - 16:05	4: Abstract 2: Revised roles of matrix metalloproteinase/MMP-9 in Inflammatory Bowel Diseases/IBD: From target to biomarker Magali de Bruyn, Leuven, Belgium please refer to P038 on page 71
16:05 - 16:20	5: Abstract 3: Modulation of T cell glycosylation and the control of intestinal inflammation Ana Dias, Porto, Portugal please refer to P080 on page 75
16:20 - 16:40	Meet the speakers break

Friday, March 18, 2016, cont.*Programme overview (as of February 15, 2016)**Room E103, Level 1, RAI Amsterdam*

16:40 - 18:00	Session 2: Studying the microbiota in IBD Harry Sokol, Paris, France Timothy Raine, Cambridge, United Kingdom Sebastian Zeissig, Kiel, Germany	
16:40 - 17:10	6: Microbiota research in IBD: State-of-the-art	Harry Sokol, Paris, France
17:10 - 17:25	7: Abstract 4: Exploring MECHANISMS Of IBD traNsmission In Utero through the Microbiome: The MECONIUM Study Pilot	Joana Torres, New York, United States please refer to P735 on page 148
17:25 - 17:40	8: Abstract 5+6: Host-microbiome interactions in primary sclerosing cholangitis & genetic risk for Crohn's Disease has little impact on intestinal microbiota composition	João Sabino, Leuven, Belgium please refer to P737 & P742 on page 148
17:40 - 17:55	9: Abstract 7: IBD phenotypes differ in gut microbiota composition	Lukas Bajer, Prague, Czech Republic please refer to P754 on page 150
17:55 - 18:00	10: Closing remarks Isabelle Cleynen, Leuven, Belgium	

Tailoring mild-to-moderate IBD management

Symposium
sponsored by

FERRING
PHARMACEUTICALS

Friday 18 March 2016 | 12:30-13:10 | The Forum

FACULTY:

Silvio Danese (Chair)

Humanitas University, Humanitas Research Hospital,
Milan, Italy

Axel Dignass

Agaplesion Markus Hospital, Frankfurt, Germany

Edouard Louis

University Hospital CHU Liège, Liège, Belgium

EXPLORING EVIDENCE-BASED BEST PRACTICE FOR THE MAJORITY OF IBD PATIENTS: AN INTERACTIVE CASE STUDY SYMPOSIUM

Discussion points:

- What do patient-reported outcomes (PROs) mean for the future of IBD management?
- How do PROs correlate with clinical endpoints?
- How can PROs and guidelines for IBD be combined in clinical practice?



Industry sponsored satellite symposia

Industry sponsored satellite symposia are organised by pharmaceutical companies. These symposia are open to all congress participants. Please note that due to compliance reasons, non-prescribing delegates might not have access to industry sponsored satellite symposia. Responsibility for the programme content remains with the sponsor.

ECCO has scheduled parallel satellite symposia on Thursday, March 17, 2016 at 11:30-12:30 and at 17:15-18:15, on Friday, March 18, 2016 at 07:15-08:15 and at 18:05-19:05, and on Saturday, March 19, 2016 at 07:15-08:15. Furthermore, parallel educational lunchtime satellite symposia are scheduled for Friday, March 18, 2016 at 12:30-13:10.

Satellite symposia are held in the main Plenary hall (Hall 11) on Level 1 and in the Parallel hall (Elicium 2) on Level 1 of RAI Amsterdam, respectively.


Educational lunchtime satellite symposia are held in the main Plenary hall (Hall 11) on Level 1, in Elicium 1 (Level 1), Elicium 2 (Level 1) and Room Forum (Ground level) of RAI Amsterdam, respectively. The programmes of satellite symposia are not affiliated with ECCO.

Industry sponsored satellite symposia – Scientific programme Thursday, March 17, 2016

<i>Satellite symposium 1a – Organiser:</i>		AbbVie
<i>Meeting room:</i>		Plenary hall (Hall 11), Level 1, RAI Amsterdam
11:30 - 12:30	<i>Beyond the gut: The importance of controlling systemic inflammation in IBD</i> Chair: Geert D'Haens, Amsterdam, The Netherlands	
abbvie	11:30 - 11:35	<i>Welcome and introduction</i> Geert D'Haens, Amsterdam, The Netherlands
	11:35 - 11:50	<i>Examining the inflammatory burden of IBD</i> Yehuda Chowers, Haifa, Israel
	11:50 - 12:05	<i>Effective management of EIMs and fistulae</i> Remo Panaccione, Calgary, Canada
	12:05 - 12:20	<i>Targeting inflammation: Benefits of current and emerging IBD therapies</i> Geert D'Haens, Amsterdam, The Netherlands
	12:20 - 12:30	<i>Summary and Q&A</i> Geert D'Haens, Amsterdam, The Netherlands and panel

Industry sponsored satellite symposia – Scientific programme

Thursday, March 17, 2016, cont.

Satellite symposium 1b – Organiser:		Hospira, A Pfizer Company
Meeting room:		Elicium 2, Level 1, RAI Amsterdam
11:30 - 12:30	Are anti-TNFs still the cornerstone treatment in IBD in 2016? The case for biosimilars Chairs: Silvio Danese, Milan, Italy	
	11:30 - 11:40	Introduction and the place of anti-TNF in the therapy Silvio Danese, Milan, Italy
	11:40 - 11:55	Treat-to-target – which target? Stefan Schreiber, Kiel, Germany
	11:55 - 12:10	Therapeutic dose monitoring: Clinical benefit and remaining questions Walter Reinisch, Hamilton, Canada
	12:10 - 12:25	Biosimilars and the future of anti-TNFs Pierre Michetti, Lausanne, Switzerland
	12:25 - 12:30	Q&A and conclusions

Satellite symposium 2a – Organiser:		Pfizer
Meeting room:		Plenary hall (Hall 11), Level 1, RAI Amsterdam
17:15 - 18:15	Bridging the gap: Can new therapies address the unmet needs in Ulcerative Colitis? Chair: Geert D'Haens, Amsterdam, The Netherlands	
	17:15 - 17:20	Welcome and Introductions Geert D'Haens, Amsterdam, The Netherlands
	17:20 - 17:35	Understanding patient needs and treatment satisfaction in Ulcerative Colitis Gerhard Rogler, Zurich, Switzerland
	17:35 - 17:50	Tailoring treatment for optimal disease management Geert D'Haens, Amsterdam, The Netherlands
	17:50 - 18:05	New horizons in the treatment of Ulcerative Colitis Silvio Danese, Milan, Italy
	18:05 - 18:15	Questions and Answers

Industry sponsored satellite symposia – Scientific programme

Thursday, March 17, 2016, cont.

Satellite symposium 2b – Organiser:		Shire
Meeting room:		Elicium 2, Level 1, RAI Amsterdam
17:15 - 18:15	New trends in the management of Ulcerative Colitis and short bowel syndrome Chair: William Sandborn, San Diego, United States	
	17:15 - 17:20	Welcome and Introductions William Sandborn, San Diego, United States
	17:20 - 17:30	The IBD-ECCO Toolkit: A new resource for the management of patients with UC Janneke van der Woude, Amsterdam, The Netherlands
	17:30 - 17:45	Perspectives from Australia: Applying evidence-based UC management tools to clinical practice Jane Andrews, Adelaide, Australia
	17:45 - 18:10	Challenges of parenteral nutrition in short bowel syndrome and the potential of targeted therapy with teduglutide William Sandborn, San Diego, United States
	18:10 - 18:15	Summary, close and Q&A William Sandborn, San Diego, United States


Industry sponsored satellite symposia – Scientific programme

Friday, March 18, 2016

Satellite symposium 3a – Organiser:		Janssen
Meeting room:		Plenary hall (Hall 11), Level 1, RAI Amsterdam
07:15 - 08:15	Unmet needs and emerging therapies: A new era for Crohn's Disease management Chair: Silvio Danese, Milan Italy	
	07:15 - 07:25	Welcome and emerging aspects in Crohn's Disease pathogenesis: Moving towards the next generation of biologics Silvio Danese, Milan, Italy
	07:25 - 07:40	Key unmet medical needs in the management of Crohn's Disease Brian Feagan, London, Canada
	07:40 - 08:05	Focus on targeting IL-12/23 in Crohn's Disease therapy Matthieu Allez, Paris, France
	08:05 - 08:15	Questions and closing remarks Silvio Danese, Milan, Italy

Industry sponsored satellite symposia – Scientific programme

Friday, March 18, 2016, cont.


Satellite symposium 3b – Organiser: MSD	
Meeting room: Elicium 2, Level 1, RAI Amsterdam	
07:15 - 08:15	Targeting continuous clinical response in Ulcerative Colitis Chair: Walter Reinisch, Vienna, Austria / Hamilton, Canada
	07:15 - 07:20 Introduction Walter Reinisch, Vienna, Austria / Hamilton, Canada
	07:20 - 07:35 Unmet treatment needs in Ulcerative Colitis Charles Murray, London, United Kingdom
	07:35 - 07:50 CCR as a tool to enhance quality of care in Ulcerative Colitis Walter Reinisch, Vienna, Austria / Hamilton, Canada
	07:50 - 08:05 CCR from bench to bedside Bas Oldenburg, Utrecht, The Netherlands
	08:05 - 08:15 Q&A and Close


Lunch symposium LS1 – Organiser: AbbVie	
Meeting room: Plenary hall (Hall 11), Level 1, RAI Amsterdam	
12:30 - 13:10	The 3rd annual intimate lunchtime discussion: Practical application of therapeutic drug monitoring in IBD Chair: Michael Kamm, Melbourne, Australia
	12:30 - 13:10 The role of therapeutic drug monitoring in IBD Michael Kamm, Melbourne, Australia Discussants: Iris Dotan, Tel Aviv, Israel Peter Irving, London, United Kingdom

Lunch symposium LS2 – Organiser: Ferring	
Meeting room: Room Forum, Ground level, RAI Amsterdam	
12:30 - 13:10	Tailoring mild-to-moderate IBD management: An interactive case-based symposium Chair: Silvio Danese, Milan, Italy
	12:30 - 12:40 Patient-reported outcomes (PROs) – What does it mean? Silvio Danese, Milan, Italy
	12:40 - 13:00 How to combine PROs and guidelines in your clinical practice: Illustrated by two case studies Crohn's Disease: Edouard Louis, Liège, Belgium Ulcerative Colitis: Axel Dignass, Frankfurt, Germany
	13:00 - 13:10 Panel discussion & Closing remarks

Industry sponsored satellite symposia – Scientific programme

Friday, March 18, 2016, cont.

Lunch symposium LS3 – Organiser: Celltrion Healthcare	
Meeting room: Elicium 1, Level 1, RAI Amsterdam	
12:30 - 13:10	Leading the new generation of value-based medicines in IBD Chair: Joost Drenth, Nijmegen, The Netherlands
	12:30 - 12:35 Welcome & Opening Joost Drenth, Nijmegen, The Netherlands
	12:35 - 12:45 Efficacy and safety of switching from RMP to biosimilar infliximab: 102-week data from Extension Study Stefan Schreiber, Kiel, Germany
	12:45 - 12:55 Real-world experience with biosimilar infliximab Milan Lukáš, Prague, Czech Republic
	12:55 - 13:10 Closing

Lunch symposium LS4 – Organiser: TiGenix	
Meeting room: Elicium 2, Level 1, RAI Amsterdam	
12:30 - 13:10	Adipose-derived stem cells: Filling the gap in complex perianal fistulas in Crohn's Disease Chair: Gert Van Assche, Leuven, Belgium
	12:30 - 12:35 Welcome and introduction Gert Van Assche, Leuven, Belgium
	12:35 - 12:45 Facts and gaps in the management of complex perianal fistulas Krisztina Gecse, Budapest, Hungary
	12:45 - 12:55 Why using stem cells in the treatment of complex perianal fistulas? Gijs van den Brink, Amsterdam, The Netherlands
	12:55 - 13:05 ADMIRE CD Study: Efficacy and safety results of expanded allogeneic adipose derived stem cells in complex perianal fistulas Gert Van Assche, Leuven, Belgium
	13:05 - 13:10 Discussion and Conclusions

Industry sponsored satellite symposia – Scientific programme

Friday, March 18, 2016, cont.

Satellite symposium 4a – Organiser:		Takeda
Meeting room:		Plenary hall (Hall 11), Level 1, RAI Amsterdam
18:05 - 19:05	Management of Ulcerative Colitis: Putting patients at the centre Chair: Iris Dotan, Tel Aviv, Israel	
	18:05 - 18:10	Welcome and Introduction Iris Dotan, Tel Aviv, Israel
	18:10 - 18:30	Partnering with patients to optimise treatment outcomes in Ulcerative Colitis Peter Irving, London, United Kingdom
	18:30 - 18:50	Biologic therapy options for Ulcerative Colitis in a patient-centric treatment paradigm David Rubin, Chicago, United States
	18:50 - 19:05	Panel Discussion/Questions and answers Iris Dotan, Tel Aviv, Israel

Satellite symposium 4b – Organiser:		Tillotts
Meeting room:		Elicium 2, Level 1, RAI Amsterdam
18:05 - 19:05	How to improve your success in treating mild and moderate IBD Chair: Geert D'Haens, Amsterdam, The Netherlands	
	18:05 - 18:10	Chairman introduction Geert D'Haens, Amsterdam, The Netherlands
	18:10 - 18:35	Success factors in treatment of mild to moderate UC Ailsa Hart, London, United Kingdom
	18:35 - 19:00	Success factors in treatment of uncomplicated CD Pieter Hindryckx, Ghent, Belgium
	19:00 - 19:05	Chairman conclusion Geert D'Haens, Amsterdam, The Netherlands

Industry sponsored satellite symposia – Scientific programme
Saturday, March 19, 2016

Satellite symposium 5a – Organiser: Takeda	
Meeting room: Plenary hall (Hall 11), Level 1, RAI Amsterdam	
07:15 - 08:15	In it for the long haul: Managing the complexity of Crohn’s Disease Chair: Michael Kamm, Melbourne, Australia
	07:15 - 07:20 Welcome and Introduction Michael Kamm, Melbourne, Australia
	07:20 - 07:40 The complexity of Crohn’s Disease: Implications for biologic therapy Remo Pannacione, Calgary, Canada
	07:40 - 07:55 Gut-selective biologic therapy: Translating clinical trial data in real world clinical practice Stefan Schreiber, Kiel, Germany
	07:55 - 08:15 Panel Discussion/Questions and answers Michael Kamm, Melbourne, Australia

Satellite symposium 5b – Organiser: MSD	
Meeting room: Elicium 2, Level 1, RAI Amsterdam	
07:15 - 08:15	Crohn’s Disease in the current environment Chair: Brian Feagan, London, Canada
	07:15 - 07:20 Introduction Brain Feagan, London, Canada
	07:20 - 07:35 What do we know and what do we not know Brian Feagan, London, Canada
	07:35 - 07:50 Confident use of biologics; Important traceability and PV Pierre Michetti, Lausanne, Switzerland
	07:50 - 08:05 Confident decision making in real world practice Daniel Baumgart, Berlin, Germany
	08:05 - 08:15 Q&A and Close

International Symposia and Workshops

*Scientific Dialogue
in the Interest of
Therapeutic Progress*



Workshop
**Communication and System
Relevance in Liver Damage
and Regeneration**
Düsseldorf, Germany
January 21 – 22, 2016



Symposium 201
**Gut-Liver Interactions:
From IBD to NASH**
Innsbruck, Austria
March 11 – 12, 2016



Symposium 202
**Evolving Therapies in
Clinical Practice in IBD**
Prague, Czech Republic
April 29 – 30, 2016



Symposium 203
**XXIV International Bile Acid Meeting:
Bile Acids in Health and Disease**
Düsseldorf, Germany
June 17 – 18, 2016



Symposium 204
**Clinical Hepatology Practice in 2016:
From Science to Therapy**
Birmingham, Great Britain
September 2 – 3, 2016



Symposium 205
**New Treatment Targets in Gut
and Liver Diseases**
Lucerne, Switzerland
October 21 – 22, 2016

FALK FOUNDATION e.V.




Leinenweberstr. 5
79108 Freiburg
Germany

Congress Department
Tel.: +49 (0)761/1514-125
Fax: +49 (0)761/1514-359
E-Mail: symposia@falk-foundation-symposia.org
www.falk-foundation-symposia.org


2016

Industry sponsored satellite symposia – Educational programme

Wednesday, March 16, 2016 – ECCO Endoscopy Workshop

Satellite symposium organiser:		Medtronic
Meeting room:		Room G103, Level 1, RAI Amsterdam
11:45 - 12:45	Impact of capsule endoscopy (CE) on IBD management Chairs: Vito Annese, Florence, Italy Rami Eliakim, Tel Hashomer, Israel, Torsten Kucharzik, Lüneburg, Germany	
	11:45 - 12:00	Status of CE in IBD – guidelines and evidence Vito Annese, Florence, Italy
	12:00 - 12:15	How can CE positively influence IBD Management? – A case study Rami Eliakim, Tel Hashomer, Israel
	12:15 - 12:30	CE in paediatric IBD patients Salvatore Oliva, Rome, Italy
	12:30 - 12:45	The future of PAN-intestinal CE in IBD Bruno Rosa, Guimarães, Portugal

Thursday, March 17, 2016 – N-ECCO Network Meeting

Satellite symposium organiser:		Takeda
Meeting room:		Elicium 1, Level 1, RAI Amsterdam
12:45 - 13:45	The future is now – importance of the IBD nurse in patient care Chair: Marian O'Connor, London, United Kingdom	
	12:45 - 13:00	Introduction: Evolution of the nurse role in IBD Marian O'Connor, London, United Kingdom
	13:00 - 13:20	The gastroenterologist's perspective Silvio Danese, Milan, Italy
	13:20 - 13:40	What does the future hold for IBD specialists? Palle Bager, Aarhus, Denmark
	13:40 - 13:45	Panel Discussion/Q&A

JOIN US FOR A SCIENTIFIC SYMPOSIUM AT
THE 11TH CONGRESS OF ECCO

**Bridging the Gap: Can New Therapies Address
the Unmet Needs in Ulcerative Colitis?**



**TAILORING TREATMENT FOR
OPTIMAL DISEASE MANAGEMENT**

Geert D'Haens, MD, PhD—Chair
Academic Medical Centre
Amsterdam, The Netherlands



**UNDERSTANDING PATIENT NEEDS
AND TREATMENT SATISFACTION
IN ULCERATIVE COLITIS**

Gerhard Rogler, MD, PhD
University of Zurich
Zurich, Switzerland



**NEW HORIZONS IN THE TREATMENT
OF ULCERATIVE COLITIS**

Silvio Danese, MD, PhD
Humanitas Research Hospital
Milan, Italy



**THURSDAY
17 MARCH 2016
17:15–18:15**

RAI AMSTERDAM • PLENARY HALL



Congress information

Badges

Badges must be worn at all times throughout the entire congress and during social events. The coloured stripes on the name badges have the following significance:

- Congress delegates, Faculty members, Press
- Exhibitors, Participants of educational activities only
- Congress day ticket holders
- Congress Organiser, Staff

Banks and ATM

Banks are usually open from 09:00-16:00 (Monday-Friday), with a few big city banks also open Thursday evening until 21:00 or on Saturday morning. Offices are usually open from 09:00-18:00 (Monday-Friday) and closed during the weekends.

There will be ATMs (Automatic Teller Machine) all over the city of Amsterdam. At the airport and main station and along the main streets you find currency exchange offices as well.

Business centre

A business centre with copy and fax services (at a charge) is located at RAI Elicium's passageway, Level-1.

Certificate of attendance

All registered delegates can download and print their certificate of attendance in their individual user area in the online registration system after the congress.

Cloakroom

The cloakroom can be found in the exhibition hall (Hall 10) on Level 1 of RAI Amsterdam. Neither RAI Amsterdam nor the congress organisers may be held liable for any loss of belongings dropped off at the cloakroom.

Coffee breaks

Coffee breaks are always served in the exhibition halls (Halls 9 and 10) on Level 1. This year ECCO offers coffee and pastries free of charge, snacks and lunch are served at cash catering stations. Attendees of the educational lunchtime symposia on Friday will be offered lunch prior to or after the symposium.

Congress documentation

Abstract USB drives

The congress bags include a voucher for the abstract USB drive with all abstracts. You can pick up your USB drive at the following spots:

Option 1: This USB drive in a special design (bicycle) is available in a limited number at the Otsuka booth (no. 024) in the exhibition hall (Hall 9).

Option 2: To obtain abstracts on an ECCO USB drive, please visit the ECCO Booth in the foyer on Level 1.



Abstracts – Online access

All abstracts can be found online (www.ecco-ibd.eu) as well as on your smart phones (mobile version of the ECCO Website) and the digital & website edition of JCC – Journal of Crohn's and Colitis. Further, computer access points will be available in the exhibition hall (Hall 9, Level 1) for looking up abstracts online.

Online streaming (post-event)

Members of ECCO can access the presentations of the 11th Congress of ECCO after the event - online at www.ecco-ibd.eu in the e-Library of the e-CCO Learning platform. Presentation availability is subject to speaker authorisation.

Congress organiser

OCEAiN – Organsation, Congress, Emotion, Association, iNnovation GmbH*

ECCO Office

Ungargasse 6/13

1030 Vienna, Austria

Phone: +43-(0) 1-710 22 42

Fax: +43-(0) 1-710 22 42-001

E-mail: ecco-congress@ecco-ibd.eu

Web: www.ecco-ibd.eu/ecco16



European
Crohn's and Colitis
Organisation

*service provider fully owned by European Crohn's and Colitis Organisation

Congress venue

RAI Amsterdam

Europaplein

NL 1078 GZ Amsterdam

The Netherlands

www.rai.nl



Credit cards

All major cards are widely accepted, though in some small shops or hotels, there might an extra charge (2-6%). When paying by credit card for your shopping, you will be asked to show identification.

Please have your ID card or passport with you all the time, otherwise they may refuse to accept your credit card as payment.

Currency

The Dutch currency is the Euro (EUR). Major credit cards are accepted at most large businesses. When you are exchanging your currency, you need your passport or official ID card. If you don't have it with you, the bank may refuse to exchange your currency.

Disclaimer

Please note that in the event of a cancellation of the congress by the organisers in case of force majeure, the registration fee, hotel deposit and any other service ordered through the registration will be partially refunded or forfeited, subject to the commitments of the congress organiser at that time. You may wish to insure yourself directly against such a risk.

ECCOlogical

At ECCO, we believe that our commitment to more eco-friendly & sustainable meetings will benefit our host destinations by leaving a minimum ecological footprint and will elevate the delegate experience.

Traditionally, congresses and exhibitions are renowned for producing lots of unnecessary waste. At the 11th Congress of ECCO, we actively demonstrate our commitment to greener meetings as best as we can with a number of measures. For details please refer to the ECCO Congress website (www.ecco-ibd.eu/ecco16).



Face-to-face with ECCO

Following the great success of the “Face-to-face with ECCO” in the previous years, this year’s “Face-to-face with ECCO” will again be held at the ECCO Booth (foyer on Level 1) during the coffee breaks. Please stop by the ECCO Booth to have a chat with ECCO Officers in an informal atmosphere and to engage in lively discussions about IBD and ECCO’s initiatives!

Floor plans

Please refer to page 214-216.

General regulations

Visitors of the 11th Congress of ECCO are kindly asked to adhere to the following rules and regulations:

- Entrance to the 11th Congress of ECCO and affiliated events is granted only with the congress badge. Entrance to the “ECCO Interaction: Hearts and Minds” is only granted with an entrance ticket.
- The congress organiser may not be held liable for any theft and/or loss of visitors’ individual property. It is the visitors’ sole responsibility to safekeep their belongings.

Industry exhibition

Please refer to page 209.

Information on Amsterdam

For information on Amsterdam, such as tours, restaurants, museums, churches/synagogues please refer to the desk “Amsterdam information” in the entrance hall.

Insurance and liability

Neither the congress organiser nor the RAI Amsterdam will assume any responsibility whatsoever for damage or injury to persons or property during the congress. Participants are recommended to arrange their personal travel and health insurance.

Internet access

Internet access is provided in the Internet Lounge supported by Pfizer located in the exhibition hall (Hall 9). Please limit the viewing time to max. 5 minutes per person. Free WiFi is provided throughout the congress venue from March 17-19, 2016. Please use the network ECCO 16 with the password amsterdam.

Language

The official language of the congress is English. No simultaneous translation will be provided.

11th Congress of ECCO

RAI Amsterdam

A Shire organized and sponsored symposium

New trends in the management of ulcerative colitis and short bowel syndrome

Thursday 17th March at 17:15–18:15
Elicium 2 Hall

17:15

Welcome and introductions

Chair: Prof. Dr William Sandborn, University of California, San Diego, USA

17:20

The IBD–ECCO toolkit*: a new resource for the management of patients with UC

Prof. Dr C. Janneke van der Woude, Erasmus MC, Rotterdam, Netherlands

17:30

Perspectives from Australia: applying evidence-based UC management tools to clinical practice

Prof. Dr Jane Andrews, Royal Adelaide Hospital, Adelaide, Australia

17:45

Challenges of parenteral nutrition in short bowel syndrome and the potential of targeted therapy with teduglutide

Prof. Dr William Sandborn, University of California, San Diego, USA

18:10

Q&A and closing remarks

Prof. Dr William Sandborn, University of California, San Diego, USA

This programme is not affiliated with ECCO

*Shire provided support for the ECCO IBD toolkit in the form of a grant, but had no influence on the content. The toolkit was an ECCO-led initiative and was developed by an ECCO-appointed task force.

Shire International GmbH, Zählerweg 10, 6300 Zug, Switzerland

©2016 Shire INTSP/C-APROM/GBU/15/0020r(1). Date of preparation: Feb. 2016



Lost and found

For lost and found service in the RAI Amsterdam, please stop by the ECCO Booth (foyer on Level 1). For help in locating property lost outside the RAI Amsterdam, please contact the registration desk.

Medical facilities

Medical assistance can be provided by qualified onsite staff in a first aid room located at Level 1 in the corridor between Halls 9 and 11.

Photos, Filming and Recording

It is forbidden to film, take photos or record any presentation during the ECCO'16 scientific or educational programme and any poster presentation without the consent of the organiser (including smart phones, mobile devices, etc.).

Please note that the entire scientific programme as well as several educational activities will be recorded and published on ECCO's e-Learning platform after the congress and will be available for viewing for all ECCO Members free of charge. Further, all abstracts and presentations (subject to speaker authorisation) are included in the e-Library.

Poster exhibition


Please refer to page 38.

Programme changes

ECCO cannot assume liability for any changes in the ECCO'16 Congress programme and programmes of the educational activities due to external or unforeseen circumstances.

Public transportation

The RAI Amsterdam is well served by Amsterdam's public transportation system. The Amsterdam RAI railway station is 300 metres from the RAI and delegates can follow the signs RAI Amsterdam when they leave the station. Furthermore, Tram route 4 runs between the centre of Amsterdam, Amsterdam Centraal and the RAI (stop at Europaplein). The congress centre can also be reached via metro 51 or bus route 65.



Registration and accommodation

All registration procedures for the 11th Congress of ECCO have been conducted online. In case you wish to register onsite please refer to the registration desk in the entrance hall on the ground level where you will be assisted with your queries.

Registration desk and ECCO Congress Office

Opening hours of the ECCO Congress Office and the registration desk at the RAI Amsterdam:

Wednesday, March 16, 2016	07:00 – 19:00
Thursday, March 17, 2016	07:00 – 19:00
Friday, March 18, 2016	07:30 – 18:00
Saturday, March 19, 2016	07:30 – 13:00

The registration desk can be found in the entrance hall of the RAI Amsterdam. The ECCO Congress Office is located on Level 1, Room E108.

Registration fees

Fee in EUR (including 21% Dutch VAT)	Early registration until December 1, 2015	Late registration until March 1, 2016	Onsite registration after March 1, 2016
ECCO Member Congress registration fees:			
<i>Regular/Regular (Y-ECCO) Member Congress fee</i>	250.-	320.-	400.-
<i>Nurse Member Congress fee</i>	55.-	95.-	145.-
<i>Affiliate Member Congress fee¹</i>	55.-	95.-	145.-
Non-Member Congress registration fees:			
<i>Non-Member Congress fee</i>	605.-	685.-	770.-
<i>Nurse Non-Member Congress fee²</i>	355.-	395.-	545.-
<i>Affiliate Non-Member Congress fee³</i>	355.-	395.-	545.-
<i>Patient Advocate Congress fee⁴</i>	55.-	55.-	55.-

¹Students/PhD Students registering at the Affiliate Member Congress fee must upload a certificate of their Student/PhD Student status during the registration process. If no certificate is being uploaded, the registration process cannot be completed.

²Nurses registering at the Nurse Non-Member Congress fee must upload a certificate of their current nurse status and registration number during the registration process. If no certificate is being uploaded, the registration process cannot be completed.

³Students/PhD Students and delegates with the following professions may register for the Affiliate Non-Member Congress fee: Dietitian, Pharmacist, Psychologist. All delegates registering at this fee must upload a certificate of their professional status/Student or PhD Student status during the registration process. If no certificate is being uploaded, the registration process cannot be completed.

⁴Patient Advocates registering at this fee must upload a proof of their membership of a Patient Advocate Association during the registration process. If no certificate is being uploaded, the registration process cannot be completed. Please note that you might not have access to industry sponsored satellite symposia.

Registration fee for delegates includes:

- Access to all scientific sessions
- Access to poster exhibition
- Access to industry exhibition
- Free copy of all congress documentation
- Certificate of attendance
- Access to congress abstracts
- Congress bag
- Coffee breaks

Please note that in order to pick-up a pre-paid ticket, the passport/ID of the delegate must be shown.

Speakers' centre

The speakers' centre is located in the Holland Lounge on Level 1 (accessible via the entrance hall). Speakers are asked to hand in their power point presentation preferably three hours prior to the presentation. The presentation will be transferred to the central congress server and will be available on a special congress notebook in the hall of the presentation. Due to time and technical reasons we kindly ask the speakers not to use their own notebook. Technical staff will be happy to assist.

In order to facilitate the process and reinforce the 2nd slide policy, faculty speakers are reminded to disclose their potential conflicts of interest in their ppt in line with UEMS regulations. Based on the submitted Col form of each speaker, a draft Col slide has been prepared and is made available in the Speakers' centre with a reminder that if the respective presentation does not yet include a disclosure form, the slide draft should be checked/ amended and included in the ppt.

Opening hours of the speakers' centre at the RAI Amsterdam:

Wednesday, March 16, 2016	07:00 – 18:00
Thursday, March 17, 2016	07:00 – 18:00
Friday, March 18, 2016	06:45 – 18:30
Saturday, March 19, 2016	06:45 – 13:00



European
Crohn's and Colitis
Organisation

Amsterdam
The Netherlands

Toolkits

Find further
details in your
Congress bag!



Launch at Congress 2016: Toolkits for therapies in IBD

- Thankfully acknowledging the unrestricted educational grant by Shire
- Meant to serve as a checklist for daily use by clinicians at a local level to improve patient care with IBD
- Acts as a framework and explains mechanisms for translation into practice
- Due to the lack of data for many points of practice, a Consensus procedure (including two online voting rounds) was used to quantify expert opinion
- Available as a download in exchange for registering the email address in order to allow a follow-up survey later on

Immunomodulators

- Mercaptopurine
- Azathioprine
- Methotrexate

Biologics

- Infliximab
- Adalimumab
- Golimumab
- Vedolizumab

Steroids

- Budesonide
- Prednisolone

Calcineurin inhibitors

- Cyclosporin
- Tacrolimus

5 ASA-Derivatives

- Oral 5-ASA
- Sulfasalazine

Antibiotics

- Metronidazole
- Ciprofloxacin

Scan and contact the ECCO Office

www.ecco-ibd.eu



ECCO Business meetings

Upon invitation only.

Tuesday, March 15, 2016

<i>Y-ECCO Meeting</i>	14:00 - 16:00	Room D404, Level 4, RAI Amsterdam
<i>N-ECCO Meeting</i>	14:00 - 16:00	Room D406, Level 4, RAI Amsterdam
<i>ClinCom Meeting</i>	14:00 - 16:00	Room D402, Level 4, RAI Amsterdam
<i>EduCom Meeting</i>	16:30 - 18:30	Room D404, Level 4, RAI Amsterdam
<i>GuiCom Meeting</i>	16:30 - 18:30	Room D402, Level 4, RAI Amsterdam
<i>D-ECCO Working Group Meeting</i>	16:30 - 18:30	Room D406, Level 4, RAI Amsterdam
<i>SciCom Meeting</i>	19:00 - 21:00	Room D404, Level 4, RAI Amsterdam
<i>EpiCom Meeting</i>	19:00 - 21:00	Room D402, Level 4, RAI Amsterdam

Wednesday, March 16, 2016

<i>P-ECCO Meeting</i>	15:45 - 17:45	Room D402, Level 4, RAI Amsterdam
<i>S-ECCO Meeting</i>	16:15 - 18:15	Room D406, Level 4, RAI Amsterdam
<i>JCC Associate Editors Meeting</i>	19:30 - 21:30	Room D402, Level 4, RAI Amsterdam

Thursday, March 17, 2016

<i>ECCO-EBMT Meeting</i>	07:00 - 08:00	Room G106-107, Level 1, RAI Amsterdam
<i>Operational Board Meeting</i>	07:30 - 09:30	Room E107, Level 1, RAI Amsterdam
<i>Governing Board Meeting</i>	09:45 - 12:15	Room E107, Level 1, RAI Amsterdam
<i>C&M Investigators' Meeting</i>	16:00 - 17:30	Room E107, Level 1, RAI Amsterdam
<i>ECCO General Assembly</i>	18:30 - 19:30	Elicium 1, Level 1, RAI Amsterdam
<i>ECCO Strategic Council</i>	19:30 - 20:00	Elicium 1, Level 1, RAI Amsterdam

Friday, March 18, 2016

<i>JCC Editorial Board Meeting</i>	07:15 - 08:15	Room E104-105, Level 1, RAI Amsterdam
<i>ICARE Meeting</i>	10:30 - 11:30	Room E104-106, Level 1, RAI Amsterdam



ECCO Interaction: Hearts and Minds

ECCO Interaction: Hearts and Minds is THE event at ECCO to see and be seen, to network and engage. Anyone who has been to a previous ECCO Congress knows that it is a must and everyone is welcome, but places are limited.

This year's edition of the ECCO Interaction: Hearts and Minds will be held at the historic Beurs van Berlage, Amsterdam's former commodities exchange.

Date: Friday, March 18, 2016

Start time: 20:00

Venue: Beurs van Berlage, Damrak 243, 1012 ZJ Amsterdam

Highlights of the evening:

- Y-ECCO Networking Reception at Effectenbeurszaal from 20:00-20:45
- 3 course buffet dinner
- Live band
- DJ Walter

How to get to the Beurs van Berlage from the RAI Amsterdam by using public transportation:

Take the **Tram Line 4** from **"Europaplein"** in direction to **"Centraal Station"** and get off at the station **"Dam"**.

Beurs van Berlage is located on the main road (Damarak), opposite the tram stop.

Tickets need to be picked up at the registration desk "ECCO Interaction: Hearts and Minds" which is located in the entrance hall of the RAI Amsterdam.

Access to the event is strictly granted with ECCO Interaction tickets only. Please make sure to bring your ticket with you. **No ticket sale onsite at the Beurs van Berlage!**

Y-ECCO Networking Corner

- Unique opportunity to meet key opinion leaders from the Governing Board and Operational Board of ECCO and to network with fellow Y-ECCO Members
- Where/When
 - At the ECCO Interaction: Hearts and Minds 2016
 - Effectenbeurszaal- Beurs van Berlage
 - 20:00-20:45
- Welcome drinks served
- Join the main interaction following this great event
- Make sure you are registered and have your ticket with you!

ECCO EFCCA PATIENT GUIDELINES



Global press conference
Wednesday, March 16, 2016
15:00-16:00
RAI Amsterdam
Open access to everyone

Programme Overview:
15:00-15:15: Welcome
15:15-15:30: Presentation of UC Patient Guideline
15:30-15:45: Presentation of CD Patient Guideline
15:45-16:00: Panel Discussion



United We Stand



European
Crohn's and Colitis
Organisation

Industry exhibition

Opening hours


Thursday, March 17, 2016	12:00 – 18:00
Friday, March 18, 2016	09:30 – 18:00
Saturday, March 19, 2016	09:30 – 13:00

List of exhibitors & sponsors


Company	Booth number
<i>AbbVie Inc.</i>	011
<i>AbbVie Inc.</i>	027
<i>Biogen</i>	014
<i>Böhringer Ingelheim Pharma GmbH & Co. KG</i>	010
<i>Bühlmann Laboratories AG</i>	032
<i>Calpro AS</i>	002
<i>Celgene Corporation</i>	031
<i>Celltrion Healthcare Co. Ltd.</i>	026
<i>Cisbio Bioassays</i>	004
<i>DiaSorin S.p.A.</i>	018
<i>Dr. Falk Pharma GmbH</i>	025
<i>La lettre de l' Hépatogastroenterologie</i>	007
<i>EFCCA - European Federation of Crohn's and Colitis Associations</i>	005
<i>Eurospital S.p.A.</i>	006
<i>Ferring Pharmaceuticals SA</i>	035
<i>GE Healthcare</i>	020
<i>Grifols International SA</i>	003
<i>Hospira, A Pfizer Company</i>	037

Company	Booth number
<i>Immundiagnostik AG</i>	021
<i>Janssen Pharmaceutica NV</i>	012
<i>Medtronic</i>	033
<i>Mendes SA</i>	019
<i>MSD</i>	029
<i>Nikkiso Europe GmbH</i>	017
<i>Orgentec Diagnostika GmbH</i>	008
<i>Origin Sciences Limited</i>	009
<i>Otsuka Pharmaceutical Europe Ltd</i>	024
<i>Pharmacosmos A/S</i>	036
<i>Robarts Clinical Trials B.V.</i>	039
<i>R-Biopharm AG</i>	038
<i>Roche</i>	015
<i>Sanquin Reagents</i>	022
<i>Shield Therapeutics</i>	028
<i>Shire International GmbH</i>	030
<i>Takeda Pharmaceuticals International AG</i>	023
<i>TiGenix</i>	013
<i>Tillotts Pharma AG</i>	016
<i>Wisepress</i>	001


Exhibition hall 9



Exhibition hall 10



Scaffolds for Alternative DELivery



Nanofitin[®]-based drug in Inflammatory Bowel Disease (IBD)

- A project supported by the European Commission through the Seventh Framework Programme (FP7)
- Nanofitins, a new class of non-antibody affinity ligands extremely stable
- **Administered by oral route to prevent systemic-related side effects**
- Generated against TNF α , a target clinically validated in inflammatory bowel disorders
- Demonstrates a **strong preventive and curative anti-inflammatory action in mice** models of Crohn and Ulcerative Colitis

Want to learn more? Come to see us at the
EU Project Forum

Wednesday, March 16, 2016 from 15:00 to 18:15 @ G102 (First Floor), Amsterdam RAI



Corporate sponsors


ECCO gratefully acknowledges the support of the following ECCO Corporate Members:



Floor plans


RAI Amsterdam, Ground level

- Registration area
- Congress bag distribution
- 2nd Advanced ECCO: EduCational COurse for Industry, 5th S-ECCO IBD Masterclass, Satellite symposium (Room Forum)




RAI Amsterdam, Level 1

- Plenary hall (Hall 11): Scientific sessions, satellite symposia
- Exhibition halls (Hall 9+10): Industry and poster exhibition, catering, Internet lounge
- ECCO Booth
- ECCO Members' Lounge
- Cloakroom



RAI Amsterdam, Level 1, cont.

- Speakers' centre (Holland Lounge)
- Press room (G111)
- 14th IBD Intensive Advanced Course, 9th Y-ECCO Career Workshop (Room E104-105)
- 1st School for Clinical Trialists, 3rd N-ECCO Research Forum, 5th ClinCom Workshop, 1st D-ECCO Workshop (Room E102)
- 7th N-ECCO School (Room G104)
- Seminar/Breakout sessions (Room E103, Room E106, Room G105)
- 3rd Basic ECCO: EduCational Course for Industry, 3rd P-ECCO Educational Course (Room G106-107)
- 1st ECCO Endoscopy Workshop, 3rd ECCO-ESGAR Ultrasound Workshop (Room G103)
- EU Project Forum (Room G102)
- Press conference, 10th N-ECCO Network Meeting (Elicium 1)
- 3rd EpiComWorkshop, 2nd Y-ECCO Basic Science Workshop (Room E103)
- Molecular aetiology of IBD (Room G104-105)
- 1st H-ECCO IBD Masterclass (Emerald Room)
- Digital oral presentations (Room E102, Room E104-106, Room G102-103, Room G104-105, Room G106-107)
- Satellite symposia (Elicium 1, Elicium 2)
- ECCO Congress Office (Room E107-108)



Index of authors

(bold = first author)

- A**bbasi, A.M. DOP073
 Abbassi, A. P253
 Abdulganieva, D. P081
 Abdulkhakov, S. P081
 Abdullah, M. P118
 Abe, T. P567
 Aberg, J.A. P455
 Abhyankar, B. DOP050, P603
 Abitbol, V. DOP018, P256, P338, P554
 Abitbol, Y. **P554**
 Achim, A. P121
 Acton, N. P331, P390
 Adams, A. 20
 Adar, T. P135
 Adedokun, O.J. **32, DOP056**, P307, P522
 Adegbola, S. DOP074, P661
 Aden, K. P401
 Adigopula, B. P716
 Admyre, C. 18, DOP026
 Afferri, M.T. P447
 Affronti, M. P358, P454, P461
 Afif, W. DOP072, P529
 Afik, R. P037
 Agboton, C. P484
 Aguilar-Melero, P. P211
 Aguilera, M. P007
 Aguirre, U. P473
 Aguirre de Cárcer, D. P058
 Ahmed, I. DOP029
 Ahuja, V. P103, P154
 Ainsworth, M.A. P375
 Ajioka, Y. 30
 Ajmi, S. P194
 Akbar, A. P615
 Akin, F.E. P359
 Akin, H. P429
 Akinci, H. **P045**, P216
 Akriv, A. 26, DOP055
 Akriviadis, E. P689
 Aksit, H. P077
 Akyuz, F. P541
 Al Bakir, I. 24
 Al-Massad, N. P342
 Al-Taweel, T. **P529**
 Alam, N. P239, P288
 Alba, C. P404, P551, P681
 Alberts, R. **21**, P719, P732
 Alborzi, F. **P074**
 Alcaín, G. P246, N022, N023
 Alcaín Martínez, G. P160
 Aldahlawi, A.M. P085
 Aldaz, C.M. P719
 Aletaha, N. P074
 Alexakis, C. **P111**
 Alexander, G. 21
 Alexander, J.S. P087
 Alexopoulou, G. P689
 Alfaro, I. **P251**
 Algaba, A. P228, P404, **P412**
 Alibrandi, A. P630
 Alisik, M. P045
 Alizadeh, B. P196
 Alizadeh, N. P639
 Allegratta, L. P562
 Allez, M. 32, DOP018, DOP020, DOP041, P554, P688
 Alliet, P. DOP057, P153
 Allocca, M. **P477**
 Almamany, M. P529
 Almeida, C.R. P080
 Almeida, N. P222, P222, P250
 Almela, P. P653
 Almer, S. P419, P691
 Almerigogna, V. P494, N019
 Aloí, M. DOP062, P125, P181, **P213**, P516
 Alonso, A. P018
 Alonso, I. P133
 Alperovich, G. P609, P638
 Alrubaiy, L. P467
 Altorjay, I. P123
 Altwegg, R. DOP018, DOP041, P231, P306, P427, P554
 Alvaro, D. 21
 Alvisi, P. P544
 Amano, R. P328
 Amarante, H. **P683**
 Amato, A. P143, P544
 Ambrosio, L. P108, P416
 Amcoff, K. P430
 Amendola, A. P035
 Amil Dias, J. DOP055
 Amininejad, L. P405
 Amiot, A. DOP018, P256, **P306**, P338, **P427**, P554
 Amitai, M.M. P174
 Amo, V. P246
 An, V. P413
 Ananthkrishnan, A. P196, P335
 Anapaz, V. P327
 Anastasiadis, S. P234
 Anastasiou, J. P385
 Anbarasan, T. **P030**
 Andersen, V. P691
 Anderson, C.A. 21
 Anderson, S.H. DOP001, DOP014
 Andersson, D. N014
 Andersson, E. **DOP088**
 Andoh, A. P377, P468
 Andorsdóttir, G. P665
 Andrade, P. P141
 Andreozzi, M. P321
 Andrews, J. P226, P517, P523, P627, N018
 Andrews, R.K. P054
 Andriulli, A. P363
 Angelin, C. P360
 Angelucci, E. P284
 Anglin, R. P648
 Aniwani, S. P118
 Anjali, J. P347, P607
 Annaloro, C. DOP021
 Annunziata, M.L. P544
 Ansaloni, L. P553
 Antolin, B. P566
 Antolin-Melero, B. P653
 Antoniadis, S. P523
 Antunes, A. P417
 Antunes, O. P548
 Anwar, S. P484
 Anyfanti, P. P394
 Aoko, O. P539
 Aparici, A. P245
 Arai, K. P589
 Arai, M. P329, P658
 Arai, M. **P295**
 Arai, T. **P198**
 Arajol, C. P731
 Araki, M. **P679**
 Arancibia, C. P011
 Aranda, R. DOP052
 Aranzamendi, M. P753
 Arasaradnam, R. P614
 Arasawa, S. P542
 Araújo, R. P155, P209, P297
 Ardesia, M. **P630**
 Ardizzone, S. DOP021, P287, P544
 Arebi, N. 31, P685, P691, N016
 Arenas-Hernandez, M. P349
 Arévalo, J.A. P472
 Arguedas, Y. P478
 Argüelles Arias, F. P190, P228, P404, P452, P570, P595, P600, P653, P709, P710
 Ariadna, P. P731
 Arlukowicz, T. P513
 Arias, L. P138, P404
 Arihiro, S. P159
 Arijis, I. P004, P038, P065, P101

- Arimitsu, S. P679
 Arkir, Z. DOP067
 Arkkila, P. P594
 Arlt, A. P401
 Armengol-Debeir, L. P664, P700
 Armes, J. N006
 Armstrong, D. P130, N001, N011
 Armuzzi, A. DOP036, P117, **P365**,
 P395, P544, P558, P713
 Arnold, B. P038
 Arnold, J. DOP007
 Arnott, I. **31**
 Aronico, N. P094
 Arora, S. P195
 Arranz Hernández, L. P449
 Arreba, P. P472, P698
 Arribas, J. P404
 Arribas-López, M.R. P228, P653
 Arrigo, S. P232
 Arslan, G. N024
 Arts, W. DOP057, P153
 Asairinachan, A. **P413**
 Ascolani, M. **P269**
 Ashizuka, S. P185
 Ashruf, Y.K. DOP068
 Askari, A. DOP074, P661
 Assa, A. P445
 Astegiano, M. P279
 Atanasovska, E. P533
 Atay, K. P165, **P261**, P298,
 P334, P389, P527
 Aterido, A. P018
 Atreya, I. P001
 Atreya, R. **18**, **DOP026**, P001, P114,
 P386, P420
 Attar, A. P231
 Attara, G. **P433**
 Atug, O. P429
 Aubourg, A. 32, DOP041, P231,
 P427, P554
 Audhya, P. P484
 Augustin, M. P626
 Aumais, G. P433
 Aust, G. P401
 Avallone, E.V. P411
 Avedano, L. P432
 Avidan, B. P174
 Avila, A.D. P228
 Avni-Biron, I. **P445**
 Aw, H.Y. P415
 Awasthi, A. P614
 Ayan, G. P298
 Ayrizono, M.L.S. P003, P409, P642
 Ayvaz, S. P077
 Azevedo, M. P674
 Azizi, Z. P074, **P217**
 Azmude Ardan, F. P074
- B**ach, M. P059
 Bachmann, O. P272
 Baer, F. P579, **P586**
 Baert, F. 32, DOP057, P153
 Bager, P. **P538**, P657
 Bahbah, F. P336
 Bailey, R. P433
 Bailey, Y. P691
 Baima, J. N003
 Bajer, L. **P703**, P754
 Bajeux, E. P171, P199, P705
 Bal, J. P108, P416
 Baldaia, C. P300, P410, P483, P620
 Baldassano, R. DOP078
 Baldissarro, I. P536, P607
 Bálint, A. 19, **DOP010**, DOP031,
 P126, P127, **P266**,
 P357, P507, P717
 Ballabeni, V. P002
 Ballet, V. DOP040, P006, P737,
 P742, N007
 Balzarini, L. P477
 Bamba, S. DOP046, P377, P468
 Bamias, G. P163, P385, P564
 Bampton, P. P226, P517
 Banai, J. 19, DOP010, DOP028,
 DOP033, P126
 Banales, J.M. P211, P228, P653
 Banaszkiwicz, A. P530
 Banerjee, A. 25
 Banerjee, R. **P716**
 Banic, M. P577
 Banskota, S. P050, P099
 Bantleon, F. P242
 Banzragch, M. P429
 Bao, X. P735, P741
 Bar Lev Schlieder, L. P543
 Bar Yoseph, H. P506
 Bar-Gil Shitrit, A. P319, P621
 Barabino, A. P232
 Baranovsky, A. 27
 Barastegui, R. DOP019, P251
 Barba, P. P047
 Barberio, B. P117
 Barbosa, M. P164, **P237**, **P302**
 Barnich, N. DOP086, P177
 Barnicle, A. **P728**
 Barocelli, E. P002
 Barone, M. P252
 Barosa, R. **P299**, P545
 Barrachina-Sancho, M.D. P031, P079
 Barragán, A. P228
 Barreiro-de Acosta, M. P073, P116,
 P211, **P218**, P228, P319, P340,
 P404, P521, P610, P624, P651, P653
 Barreto, R. P734
 Barrett, K. P471
 Barrio, J. P138, P228
 Barros, J. **N003**
- Barthel, C. DOP038
 Bartolo, O. P621, P636, N005
 Bas, J. P731
 Basaran, M. P359
 Basavaraju, U. P716
 Basirat, V. P217
 Baskett, A. P425
 Basseri, S. **DOP058**
 Bassett, P. P294
 Bassi, A. DOP037
 Baston, I. P610
 Batanero, R. P228
 Battat, R. **DOP072**
 Baudry, C. DOP041, P554
 Baumann, C. P361
 Baumgart, D.C. 18
 Bay-Jensen, A.-C. DOP085, DOP087
 Bayart, P. **DOP016**
 Beattie, D. P036, **P069**
 Beaugier, L. DOP079, P172,
 P460, P582
 Becheanu, G. P240
 Bechi, P. P274, P581, P631
 Becker, F. **P087**
 Becx, M. P210
 Bednarz-Misa, I. P042
 Beebe, J. 25
 Begun, J. P058
 Beiderwellen, K. **P148**, P176
 Bejaoui, M. **P460**, **P582**
 Bell, S. P226, P668
 Bellaiche, G. P256
 Bellavance, D. P196
 Bellia, S. N005
 Bellicoso, M. P175
 Bellini, M. DOP012
 Belo, T. P417
 Belousova, E. P691
 Beltrán, B. P102, P211, P459, P624
 Bemelman, W. P169, P201,
 P376, P434, P555
 Ben Amor, S. P469
 Ben Khelifa, M. P166
 Ben Mabrouk, M. P194
 Ben Mansour, I. P194
 Ben Mustapha, N. P469
 Ben Rejeb, M. P194
 Ben Slama, A. P194
 Ben-Bassat, O. P445
 Ben-Haim, G. P498
 Ben-Horin, S. DOP036, DOP064,
P174, P204, P319, P498,
 P506, P526, P616, P726
 Benchimol, E. DOP063
 Bendtsen, F. P699
 Bene, L. 19, DOP010,
 DOP028, DOP033
 Benitez, J.M. P710
 Benítez García, B. P211
 Benítez Leiva, O. N008

- Benítez Roldán, A. P452, P600, P710
 Benítez-Rodríguez, B. P316
 Benjaminov, F. P543
 Benkov, K. **P350**
 Benninga, M. P343, P457, P488, P695
 Benoist, S. 31, P219
 Bequet, E. **P700**
 Berding, A. **P547**
 Berends, S. **P637**
 Bereswill, M. DOP083, P398, P462, P574
 Berg, S. P496
 Berga, K.-A. P416
 Bergemalm, D. DOP082, DOP088
 Bergin, F.G. P440
 Bergquist, A. 21
 Berliner, S. P531
 Bermejo, F. P211, P228, P624, P653
 Bernabini, C. P673
 Bernal, A. P472
 Bernal, P. P412
 Bernardo, D. **P027**, P033, P073, P104
 Bernardo, S. P300
 Bernardo De Almeida, V.F. P598
 Bernstein, C. DOP075
 Berrnago, F. P412
 Berroa, E. P566
 Bertani, A. P212
 Bertani, L. **DOP012**, P544
 Bertoletti, F. P404
 Bertoni, S. P002
 Besisik, F. P541
 Bessho, R. P295
 Bessissow, T. DOP072, P112, P529
 Beswick, L. P486
 Bethge, J. P342, P401
 Bettenworth, D. **P325**
 Bettey, M. **DOP029**
 Beuers, U. 21
 Beyer-Berjot, L. 31
 Bez, Y. P429
 Bezzio, C. P565
 Bhagat, S. DOP002
 Bhala, N. P200
 Bhandari, B. DOP025
 Bhandari, B.R. P611, **P721**
 Biagini, S. P494, **N019**
 Bialecki, M. **P277**
 Biancheri, P. P094, P100, P105
 Bianchini, M. P212
 Biancone, L. P269, P279, P280, P284, P544
 Bicakci, E. P429
 Biedermann, L. P400, P676, P688, P708, P729
 Biemans, V. 24
 Bierman, K. P706
 Bigard, M.A. P554
 Billiet, T. **20**, P259
 Bindesboell, A. N015
 Biondi, R. N003
 Bipat, S. P178
 Birimberg Schwartz, L. **26**
 Biro, E. 19, DOP033
 Bisschops, R. 30, P112
 Bissonnette, R. P626
 Biswas, A. DOP005
 Bitton, A. DOP072, P529
 Bizzarri, B. P540
 Bizzocchi, A. P232
 Bjarnason, I. P470
 Björnsson, E. 21
 Black, C. P585, P608
 Blaker, P. P349
 Blank, M. 25
 Blazquez, I. P211
 Blazquez, T. P459
 Bloemendaal, A. P563
 Bloemendaal, F. DOP027, **P010**
 Blokzijl, T. P048, P746
 Blomster, T. DOP035
 Bloom, S. 31, DOP026, P392, P575
 Blumenstein, I. **P114**
 Boal, C. P299
 Boal Carvalho, P. P131, **P164**, **P292**
 Boberg, K.M. 21
 Boccia, S. P713
 Bockisch, A. P148
 Bocus, P. P214
 Bodini, G. DOP012, **P232**, P347, P536, **P607**
 Body-Malapel, M. P063, P697
 Boeckxstaens, G.E. P015, P066
 Boirivant, M. P035
 Bokemeyer, B. P114, **P370**, **P386**, P579
 Boland, K. **P301**
 Bollen, L. DOP038
 Bommelaer, G. DOP015, DOP086, P121, P145, P177, P353, P554
 Bonanomi, A. P280
 Bonaz, B. DOP024, P231, P427, P615
 Bonder, M.J. 22, P744
 Bonifacio, C. P477
 Bonillo, D. P412
 Bonnaud, G. P121, P336
 Bontems, P. DOP057, P153
 Boone, J. P176
 Bopanna, S. P154
 Bor, R. DOP010, DOP031, P126, P127, P266, P357, **P507**, P717
 Borderon, C. P353
 Borghede, M. P375
 Borody, T. 26
 Borruel, N. P245, P480, P510, P701
 Bortlik, M. DOP010, DOP031, P311, P421, **P495**
 Boruchowicz, A. DOP016
 Borup, C. **P182**
 Borzan, V. P577
 Bos, W. **P144**
 Bosca Watts, M.M. DOP036, P459
 Bosch, R. N023
 Bossa, F. DOP036, P280, P320, P363, P448, P544
 Bossuyt, P. 32, OP29, DOP057, P153, **P259**, P319
 Botezzelli, J.D. P003
 Bots, S. **P584**, P695
 Boualit, M. DOP016, P436, P649
 Boubaker, J. P469
 Boube, M. P145
 Boubougianni, A. P689
 Boucher, A.-L. DOP015, **P353**
 Bouguen, G. P121, P171, P199, P256, P456, P554, P705
 Bouhnik, Y. 32, P296, P306, P427, P554
 Boulanger, E. P063
 Bouma, G. P696, P738
 Bourke, B. P235, P680
 Bournet, B. P256
 Bourreille, A. P121, **P231**
 Bourrier, A. DOP079, P172, P427, P460, P554, P582
 Bours, P. **P736**
 Bousvaros, A. DOP005
 Bouvier, D. DOP086, P177
 Bouvy, M. P550
 Bouza, M.J. P218
 Bowlus, C.L. 21
 Boysen, T. P319
 Bozcan, S. P261, **P298**, P334, P527
 Braegger, C. DOP062
 Brahem, A. P194
 Brakenhoff, L. P134
 Branche, J. DOP016, P436, P649
 Branco, J. P327
 Brandimarte, G. P411
 Brandse, H. P637
 Brandse, J.F. **DOP068**
 Brandt, B. **P342**, P401
 Branquinho, D. **P572**
 Brassil, P. P036, P069
 Bredin, F. P531
 Bremner, R. P382
 Bressler, B. P227, P433, **P583**
 Bretagne, J.-F. P171, P199, P456, P705
 Breukink, S. P663
 Breynaert, C. P038
 Brezina, J. P754
 Bridoux, V. 31
 Brinar, M. P577
 Brint, E.K. P007
 Brito, B. P222, P250
 Brixi-Benmansour, H. 32, P306
 Broderick, A.M. P235, P680
 Brodmerkel, C. DOP002
 DOP003, DOP090

- Broekman, M. **P305, P550, P725**
 Broide, E. P623
 Bronsky, J. DOP062
 Brooks, A.J. **P124**
 Brooks, J. P260
 Brotlik, M. DOP032
 Brouquet, A. **31, DOP018, P219**
 Brouwers, E. P005
 Brown, S. P226
 Bruckner, R. **P076**
 Bruining, D. P168
 Brynskov, J. P375
 Bucci, C. P587
 Bucci, L. P587
 Buchanan, E. P650
 Buchs, N. **P563**
 Buckley, M. P049
 Budding, A.E. P738
 Buderus, S. 26
 Bueno-de-Mesquita, B. P704
 Bugajski, M. P289
 Buhl, S. **P375**
 Buisson, A. 32, DOP015, DOP018,
DOP086, P121, P145, P177,
 P306, P353, P427
 Bujanda, L. P073, P183, P211,
 P228, P653
 Büning, J. P370, P386, P579, P586
 Burgess, L. P170
 Burisch, J. P665, P668, P685,
P691, P699
 Burke, A. P627
 Burnand, B. P619, P690, P707
 Burrelli Scotti, G. P447
 Buskens, C. P201, P376, P434
 Busó, E. P102
 Busquets, D. P404, P478, P624
 Butcher, R.O. DOP073, P253
 Butera, A. **P035**
 Buyukasik, N.S. P359
 Bwirire, D. P465
 Bye, W. **P523**
 Byeon, J.-S. P262, P273, P453,
 P499, P670
- C**aballero-Marcos, A. P593
 Cabalzar, A.L. P481
 Cabanne, A. P175
 Cabré, E. P018, P146, P263, P493
 Cabriada, J.L. P073, P183, P211, P472,
 P473, P698, P753
 Caccaro, R. P636
 Cachia, M. P672
 Cadiot, G. P256
 Caenepeel, P. 32
 Cahill, A. 31
 Calabrese, E. **P168, P269, P284**
 Calabro, S. P626
 Calafat, M. **P146**
- Calatayud, S. P031, P079
 Caldeira, P. P417
 Callaghan, J. DOP029
 Calvet, X. P228, **P709**
 Calvo, M. P228, P404
 Camacho, F. P583
 Camacho, L. **P246**
 Camacho Martel, L. P160
 Camargo, R. P246, N022, N023
 Camargo Camero, R. P160
 Cameron, F. 26
 Campanati, L. **P553**
 Campbell, S. P021
 Campderá, M. P228
 Campos, S. DOP084
 Can, G. **P077**
 Can, H. P077
 Canavan, J. DOP003
 Canbakan, B. **P165, P389**
 Cancela, E. P155, P209, P297
 Canner, J. P255, P282
 Cannizzaro, R. P279
 Cannon, A. P613
 Cano Sanz, N. **N009**
 Cantoro, L. P544
 Cao, Q. P354
 Cao, W. DOP077
 Cao, Y. P430
 Capannolo, A. P606
 Cappello, M. **P320, P358, P363, P544**
 Caprioli, F. P439
 Carbery, I. **P671**
 Carbonnel, F. P219, P306, P427
 Cardoso, H. P141, P292
 Cardoso, M. P327
 Carey, A. P007, P680
 Carey, N. P348
 Carlsen, K. **DOP044, DOP045,**
P588, P633, P668
 Carlson, M. P039, P430
 Carmagnola, S. P287
 Carman, N. **DOP063**
 Carmona, A. P521
 Carpio, D. P521, P709
 Carrascosa, J. P698
 Carreira, C. P299
 Carreño, R. N022, N023
 Carreras, E. DOP019
 Carrie, M. P535
 Carrillo Palau, M. P133
 Carroll, M. DOP063, P132
 Carter, L.L. **DOP022, P068**
 Carvalho Lourenço, L. **P327**
 Casadei, A. **P647**
 Casanova, M.J. **P228, P478,**
 P653, P621
 Casciani, E. P125, P213, P516
 Casellas, F. **P245, P480, P510,**
 P653, **P701**
 Casen, C. DOP089
- Caserta, L. P544
 Cassese, M. P484
 Cassieri, C. **P411**
 Cassinotti, A. **DOP021, P280, P287**
 Castanheira, A. P155, P209, P297
 Castaño-García, A. P228
 Castiglione, F. P122, P223, P225, P544
 Castro, B. P653
 Castro, E. P228
 Castro, E. P521
 Castro, J. P251
 Castro Laria, L. P190, P228, P452, P570,
 P595, P600, P653, P710
 Cataldi, F. 25, P465, P471
 Cattan, S. P649
 Caunedo Álvarez, A. P190, P452,
 P570, P595, P600, P710
 Cavallin, F. P636
 Cavargini, E. P647
 Cavus, B. P541
 Cea-Calvo, L. P340, P651, P709
 Ceccarelli, L. DOP012
 Cecil, E. P111
 Celeste, A.J. P068
 Celik, A.F. P261, P298, P334, P527
 Cenic, M.C. P744
 Cenni, S. P047, P321
 Centeno, A. P487
 Ceredig, R. P337
 Ceroni, A. DOP027
 Cerrillo, E. **P102**
 Cervino, A. P743
 Ceuppens, J. P038
 Cha, J.M. P667
 Chaara, D. P190, **P710**
 Chadokufa, S. **P331, P390**
 Chalisova, N. P755
 Chan, A. P142, P152
 Chan, D. 20, DOP003, DOP056, P522
 Chan, F.K. P142, P152
 Chan, G. 28, 28, DOP053, P428
 Chan, H. **P118, P142**
 Chan, J. P142
 Chan, J. P291
 Chan, P.W. P415
 Chan, S. P704, P740
 Chang, D.K. P197
 Chang, H.W. P050
 Chang, J.Y. P025
 Chang, K. P499, P670
 Chantias, M. P234
 Chanteloup, E. P554
 Chao, C.-Y. **P247, P500**
 Chao, J. DOP083, P398, P462, P574
 Chao, K. P723
 Chaparro, M. P027, P073, P104, **P183,**
P211, P228, P319, P404,
 P621, **P624, P653**
 Chapell, K.E. P501, P518
 Chapman, L. DOP013



Chapman, R.W.	21, P011	Chur-Hansen, A.	P627	Connors, J.	DOP058
Charbit-Henrion, F.	P582	Church, P.	DOP063, P345 , P435	Contaldo, A.	P366
Charpentier, C.	P664	Cibor, D.	P180	Cook, P.	DOP004, P021
Charro, M.	P228	Cid, J.	P521	Coope, A.	P003
Chater, C.	P057	Cid, J.	DOP019	Cooray, M.	P648
Chatzinakos, G.	P394	Ciemniewajska, E.	DOP089	Coppola, L.	P279
Chau, A.	P057	Cifticbasi Ormeci, A.	P257	Corazza, G.R.	P094, P279
Chauhan, A.	P054	Cilla, C.G.	P753	Corazziari, E.S.	P411
Chauhan, U.	P130, N001, N011	Cindoruk, M.	P639	Corfe, B.M.	P124
Chaussade, S.	P338	Cioni, L.	P598	Corrado, C.	P411
Chavannes, M.	P590	Cioplea, M.	P053	Correale, C.	P089
Chavarría-Herbozo, C.	P653	Civitelli, F.	P125, P181 , P213, P516	Correia, A.	P080, P086
Chavero, P.	P175	Clair Willi, C.	P688	Correia, L.	P300, P410, P483, P620
Chayut, D.	P351	Clapp, L.	P067	Corsetto, P.	P089
Chazouillères, O.	21	Clarençon, D.	DOP024	Corstjens, P.	DOP039
Che, X.	P016 , P044, P055, P072	Claridge, A.	P008	Cortelezzi, A.	DOP021
Chebli, J.M.F.	P481	Clark, C.M.	P083	Cortelezzi, C.C.	P143, P544
Chebli, L.A.	P481	Clark, M.	DOP020	Cortés, X.	P459, P502 , P653
Chen, A.	DOP077	Clark, S.K.	P115, P208	Cosín-Roger, J.	P031, P079
Chen, B.	P204, P635, P726, P730	Claus, S.	P019	Cosintino, R.	P280
Chen, C.-L.	P735	Clavelou, P.	P145	Coskun, Y.	P045, P216
Chen, G.	P611	Clemens, C.H.M.	P281, P344, P367	Cosnes, J.	DOP018, DOP079, P172, P460, P554, P582
Chen, H.	P745	Clemente, J.	P735	Costa, F.	DOP012, P544
Chen, H.	DOP059, P745	Cleynen, I.	20, P004, P006, P065, P101, P259, P737, P742	Costantino, G.	P320, P363, P565, P630
Chen, M.	P132	Clofent, J.	P502	Costanza, V.	P448
Chen, M.H.	P118	Clos, A.	P263 , P493	Coté-Daigneault, J.	P735
Chen, M.	P204, P635, P726, P730	Coban, S.	P216	Cotrina Lino, J.L.	P570, P595
Chen, N.	DOP083, P398, P462, P574	Coche, J.-C.	DOP057, P153	Cotruta, B.	P271
Chen, Y.	PP204	Cochran, S.	P030	Cotte, E.	31, DOP018
Cheon, J.H.	P016, P044, P055, P072, P497, P667	Coenen, M.	P305, P550, P725	Cotteau-Leroy, A.	P649
Chernin, E.	P285, P450, P592, P605	Coenen, S.	DOP040, N007	Cotter, J.	P131, P164, P237, P292, P302
Chetcuti Zammit, S.	P238, P672	Coevoet, H.	P664, P700	Cottone, M.	P358, P454, P461
Cheung, A.	21	Coffin, B.	DOP041, P256	Cox, B.F.	P030
Chevret, S.	32, DOP041	Cofiño, A.	P251	Cox, S.	P476
Chew, D.	P095	Cohen, A.	DOP072	Coy, C.S.R.	P409, P642
Chey, C.S.	P128	Cohen, B.	DOP017, P388	Cozzi, A.	P494, N019
Chhaya, V.	P111	Cohen, N.A.	P751	Cravets, M.	DOP052
Chiaramonte, C.	P168	Cohen, R.	P067	Cravo, M.	P741
Chiba, A.	P012	Cohen, R.	P368	Craxi, A.	P358
Ching, J.Y.	P118, P142, P152	Cohen, S.	P623	Cremer, A.	P405
Cho, J.	DOP077	Cohen, S.	P516	Crispino, P.	P411
Cho, K.B.	P136, P644	Colletti, R.B.	DOP078, P350	Crnecvic Urek, M.	P577
Cho, S.J.	P644	Collins, J.	P097	Crocchiolo, D.	P320
Cho, Y.-S.	P532	Collins, J.	P307	Croft, N.	P465
Choe, J.W.	P670	Collins, K.	P627	Croituru, K.	P371, P426
Choi, C.H.R.	24 , 31	Colman, R.	P640	Cronin, L.	P627, N018
Choi, C.H.	P422, P667	Colom, H.	P731	Cruz, C.	P299
Choi, Y.S.	P188, P332	Colombel, J.-F.	18, 23, 25, 28, DOP048 , DOP050, DOP051, DOP054 , DOP075, DOP077, DOP083, P192, P307, P335, P455, P573, P735	Cruzille, E.	P121
Chowbay, B.	P415	Comas, D.	DOP019	Csóká, C.	P220
Chowers, Y.	DOP064, P174, P351, P506, P526, P616	Comberlato, M.	P280, P439	Csontos, A.A.	P220
Choy, M.	P313 , P355	Comer, G.M.	25	Cucchiara, S.	DOP062, DOP078, P117, P125, P181, P213, P516
Christ, C.	P552	Con, D.	P317, P490, P712	Cuiv, PÓ	P058
Christiansen, L.	P699	Connell, W.R.	P226, P313, P355	Čuković-Čavka, S.	P577, P691
Christodoulou, D.K.	DOP036, P319, P668, P715	Connor, S.	26, 178	Cullen, G.	P376, P509
Christopher, B.	P539	Connor, S.J.	P523	Cummings, J.F.	DOP029, P008, P097
Chuah, S.W.	P415			Cupedo, T.	P026
Chung-Faye, G.	P187, P470			Curciarello, R.	P094

- Cúrdia Gonçalves, T. P131, P164
 Curtis, L. P650
 Cygankiewicz, A. P090
 Cytter, K.R. P161
 Cytter-Kuint, R. P113
 Czkwaniec, E. P629
 Czuber-Dochan, W. P294,
 P531, **N006**
 Czubkowski, P. **P418**
- D**
 Alessio, S. P089
 D'Amato, M. DOP088
 D'Arcangelo, G. P213
 D'Haens, G. 20, 27, **28, 32**, DOP025,
DOP047, DOP050, DOP052,
 DOP066, DOP068, DOP075, P010,
 P014, P020, P201, P376,
 P488, P555, P584, P601, P637,
 P695, P696, P727
 D'Hoore, A. P201, P259, P578
 D'Incà, R. P117, P279, P280, P475,
 P544, P636, P668, P691, N005
 da Silva, B.C. P222, P250, P267
 Dabbech, R. P166
 Daboussi, O. P166
 Dabrowska, M. P110
 Dabrowski, A. P110
 Dadalski, M. P374, P380, P396, P489,
P612, P617
 Dahl, F. DOP082
 Dahlerup, J.F. **P444**, P538, P657, P691
 Daikos, G.L. P564
 Dajnowiec, D. P580
 Dalekos, G. 21
 Dalle, R. P145
 Damaraju, L. P522
 Damen, G. DOP065, P457
 Damgaard, M. P182
 Danese, S. 18, **25, 27**, DOP036,
 DOP075, P089, P227,
P312, P398, P432, P462,
 P477, P544, P574
 Daniel, E. P413
 Daniluk, J. **P110**
 Daniluk, U. P110
 Daoui, A. P071
 Daperno, M. DOP021, **P280**,
P395, P439
 Dapoigny, M. P145, P353
 Darakhshan, A.A. DOP014
 Dart, R.J. **P092**
 Darvell, M. P531
 Darwinkel, H. P095
 Das, I. P058
 Das, P. **P103**
 Das, Y. P112
 Dassopoulos, T. P227
 Davidov, Y. **P616**
- Davies, I. DOP062
 Davis, C. N021
 Davis, H. 32, DOP056
 Day, A. P170, P437
 Daza, J.J. N023
 De Angelis, N. DOP018
 De Boer, N.K.H. P557, P696, P719, P738
 De Bortoli, N. DOP012, P607
 De Bruyn, J. DOP063
 De Bruyn, J. **P555**
 De Bruyn, M. **P038**
 De Buck van Overstraeten, A.
 P201, P259, P578
 De Caro, G. **P540**
 De Castro, M.L. **P464, P571, P654**
 De Cruz, P. **P226**, P313, P317, P355,
 P490, P712
 De Dood, C. DOP039
 De Franchis, R. P287
 De Graaf, A.P.J. P622
 De Greef, E. DOP057, P153
 De Groof, J. **P434**
 De Hertogh, G. 30, DOP054,
 P038, P112
 De Jong, D.J. DOP030, P281, P305,
 P344, P367, P550,
 P696, P719, P725, P732
 De Jong, J. P457
 De Jong, M. P505
 De Jong, M. DOP042, **P210**,
P652, P659
 De Jonge, H.M. P722
 De Jonge, W. P014, P020, P095,
 P601, P727
 De la Fuente, H. P073
 De la Iglesia, D. P610
 De la Portilla, F. 18
 De la Santa Belda, E. P330
 De Lima, A. DOP060, DOP061, P236
 De Marchi, E. P475, P636
 De Maria, C. P536
 De Meij, T. P343, P457
 De Munter, P. DOP040
 De Nitto, D. P035
 De Padova, A. P673
 De Palma, G.D. P223, P225, P587
 De Ridder, L. DOP007, **DOP062**,
 P026, P345, P457
 De Ruiters, L. DOP007, P026
 De Salvo, C. P062
 De Silva, J. P118
 De Villiers, W. 25, P573
 De Voogd, F. **P170**
 De Vos, M. 32, DOP057, P153
 De Vries, A.C. P706
 De Vries, B. 21
 De Vries, E.M. 21
 De Vries, F. P692
 De Vries, L. **P014, P020, P601**
 De'Angelis, G.L. P540
- Debeuckelaere, C. P259
 Debinski, H. P226
 Debuyser, D. P296
 Dechelotte, P. DOP015, P353
 Decousus, S. **DOP015**, P353
 Deelen, P. P732
 Dejaco, C. P677
 Dekker, E. P140, P254
 Del Campo, V. P464, P571, P654
 Del Nero, L. **P347**, P607
 Del Pozzo, G. P047
 Del Tedesco, E. **23**, DOP064, P408,
 P604, P632
 Dell'Era, A. P287, **P598**
 Della Valle, N. P320, P562
 Delladetsima, I. P564
 Delord, P. P415
 Demengeot, J. P545
 Demir, K. P541
 Demir, N. P261, P298, P334, **P527**
 Demirezer Bolat, A. P359
 Demirtaş, S. P077
 Demock, K. P068
 Démoré, C.E.M. P030
 Demuth, D. P167
 Denet, C. 31
 Deng, C. DOP071, P428
 Dennedy, C. P337
 Denost, Q. 31
 Derijks, L. P305, P550, P725
 Derikx, L. DOP030
 Derova, J. P402
 Desfourneaux, V. 31, P456
 Deslandres, C. DOP063, P590
 Desmond, P. P226
 Desreumaux, P. 25, 25, P057, P063,
 P436, P649, P697
 Detka-Kowalska, I. P513
 Deviere, J. P405
 Dewit, O. DOP057, P153, P231
 Dewulf, J. P465
 Dhingra, R. P154
 Di Girolamo, M. P212, P544
 Di Leo, A. P252, P366
 Di Marco, M. P673
 Di Martino, C. P274, P581, P631
 Di Martino, L. P062
 Di Mitri, R. P075, P448
 Di Ruscio, M. P606
 Di Sabatino, A. P094, **P279**
 Dias, A.M. DOP084, **P080, P086**
 Dias de Castro, F. P164
 Diaz-Hernández, L. P228, **P449**
 Diaz-Redondo, A. P593
 Dib, N. P554
 Dibley, L. **P294**
 Diederens, K. 20, **P343, P457**
 Dieleman, L. P108, P416
 Dieli, F. P075
 Dietrich, N.-A. **P579**

- Diez, M.C. 18
 Digby-Bell, J. **DOP067**
 Dignass, A. P119, P339, P341, **P402**,
 P552, P579, **P615**
 Dijkstra, G. 22, DOP087, P048, P144,
 P281, P344, P367,
 P622, P696, P719, P732,
 P744, P746, 178
 Dik, V. P704
 Dilillo, A. P117, P125, P181
 Dimitri, R. P358
 Dimitrijevic, P. P096
 Dimitriu, A. **P271**
 Ding, N. DOP059, P745
 Ding, N.S. 24, **31**, **P009**, **P597**, N016
 Dingley, G. P097
 Dionne, S. P070
 Dirrenberger, B. P361
 Diz-Lois Palomares, M.T. P621
 Djouina, M. P057, P063
 Dobos, G. P176
 Dobrin, R. 20
 Doherty, G. P376, P509
 Dolin, P. P675, P682, P711
 Domagala-Rodacka, R. P180
 Domènech, E. P018, P146, P263,
 P340, P484, P493, **P651**
 Domínguez Sánchez, P. **P387**
 Dominguez-Munoz, J.E. P116,
 P218, P610
 Dominique, T. P700
 Donaldson, R. P167, P288
 Donday, M.G. P621, P624
 Dorna, M. N003
 Dorofeyev, A. P402
 Dosal Galguera, A. N008
 Dotan, I. P174, P258, P290,
 P646, P666, P751
 DOP029
 Downey, L. DOP029
 Drastich, P. P703, **P754**
 Dray, X. P231
 Dreesen, E. P005
 Drent, G. **178**
 Drenth, J. DOP030
 Driessen, G. DOP007
 Driscoll, K. P680
 Drobne, D. **P309**
 Drummond, H. OP07, DOP082
 Duarte, J. P601
 Dubinsky, M. DOP017, DOP050,
 DOP078, P388,
 P576, P609, P735
 DOP015, P353
 P187, P470
 Dubois, A. P057
 Dubois, P. P057
 Dubuquoy, C. P247
 Dubuquoy, L. **P346**, **P479**
 Duchatellier, C.-F. P228
 Dudkowiak, R. P228
 Dueñas-Sadornil, C. P228
 Duffas, J.-P. 31
 Duggal, A. P561
 Duijvis, N. **P043**, **P727**
 Duley, J.A. P058
 Dulleman, H.M. P622
 Duran, A.E. P257
 Dumbrava, M. P240
 Dunlop, M. 31
 Dupas, J.-L. DOP041, P664
 Duran, N. P441, P487
 Durant, L. P033
 Duricova, D. DOP010, DOP031,
 DOP032, P311, P421,
 P495, P668, P691
 P121
 Duruy, M. DOP016, **P436**, P649
 Duveau, N.
- E**astham-Anderson, J. P406
 Eaton, J. 21
 Eberhardson, M. P419, P520
 Eberl, M. DOP008
 Ebner, D. DOP027
 Ebrahimi Daryani, N. P074, P217
 Echarri, A. **P521**, P624
 Eck, A. P738
 Eckhard, G. P677
 Eddama, M. **P067**
 Edwards, C. P169
 Efferth, T. P059
 Efremskova, L. P533
 Efron, J. P255, P282
 Egan, L. P337, P728
 Egea Castillo, N. **P569**
 Eglinton, T. P438, P492
 Eichner, S. P350, P576, P609, P638
 Eisele, C. P735
 Ejarque, M. P034
 Ekk-Cierniakowski, P. P147
 Eksteen, B. 21
 El Jery, K. P166 El-Matery, W.
 DOP063
 P260
 Eliadou, E. DOP064, P174, P319,
 P498, P526, P616
 Eliakim, R. DOP019
 P523
 21, P732
 P226
 P401
 Ellrichmann, M. DOP036, P238, P672
 P588
 P085
 Elshal, M.F. P740
 Elumogo, N. DOP002
 Emrich, S. DOP046
 Endo, K. **P013**, P041, **P268**
 P498
 P013, P041, P268
 P033
 31
 Engel, P.J.H. **P013**, P041, **P268**
 P498
 Engel, T. P013, P041, P268
 P033
 31
 Engel, U.H. P013, P041, P268
 P033
 31
 English, N. P033
 Ennis, H. 31
- Erarслан, E. P216
 Ercaliskan, K. P334
 Erel, O. P045
 Ersoy, O. P359
 Erzin, Y. P261, P298, **P334**, P527
 Esaki, M. 23, 30, **P185**, P318
 Escher, H. P026
 Escher, J. 26, DOP007, DOP055,
 DOP065, DOP078,
 P576, P634, P638
 P261, P527
 P034
 P487
 P517
 P109, P497, P667, **P748**
 P417
 P067
 P541
 P653
 Eskazan, T. P261, P527
 Espin, E. P034
 Esrailian, E. P487
 Esterman, A. P517
 Eun, C.S. **P109**, P497, P667, **P748**
 Eusébio, M. P417
 Evans, I. P067
 Evirgen, S. P541
 Ezquiaga, E. P653
- F**aber, K.-N. P048, P719, P746
 Fábíán, A. P266, P507
 Factum, C. P267
 Fadeeva, N. P485, P525
 Fadgyas-Freyler, P. P443, P694
 Fagerberg, U. DOP062, P520
 Faiz, O. DOP074, P115, P169, P195,
 P208, P661, P685
 Falcini, F. P673
 Faller, H. P547
 Fallon, P.G. P007
 Falony, G. P737, P742
 Fantini, M. P439
 Farbod, Y. P217
 Farbod, Y. P130, N001, N011
 Farge, D. DOP020
 Farineli, E. N003
 Farkas, K. 19, DOP010, DOP028,
 DOP031, DOP033, P126,
 P127, P266, P308, P357,
 P507, **P717**
 21, DOP035, P594
 Färkkilä, M. 21, DOP035, P594
 Farmer, A. P379
 Farré, R. P006
 Farrell, D. P049
 Farrell, R. P539
 Farro, G. P015, P066
 Faubion, W.A. DOP054, DOP078,
 P406, P465, **P576**
 Faucheron, J.-L. 31
 Fausel, R. **P192**, P455
 Fazi, M. P581
 Feagan, B. 25, 27, 28, 32, DOP025,
 DOP048, DOP052, DOP075,
 P227, P307, P368, P398, P462,
 P574, P603, **P611**
 Fechner, K. P123
 Fedorak, R.N. P108, P416

- Feichtenschlager, T. P677
 Fekih, M. P469
 Felice, C. DOP036, P117, **P558**
 Fell, J.M. DOP078, P501, P518
 Fellermann, K. P579, P586
 Felwick, R. **P097**
 Feng, T. P726
 Fenton, T. P021
 Ferenci, T. P357
 Féres, O. P373
 Feres Filho, O. P373
 Ferguson, A. **P535**
 Ferkolj, I. P309
 Fernandes, S. P621
 Fernández, F. P246
 Fernandez, L. P551
 Fernández, L. P478
 Fernandez, N. P138
 Fernández, S. P502
 Fernández Bonilla, E.M. P624
 Fernandez de Castro, C. P624
 Fernández-Avilés, F. DOP019
 Fernández-Bañares, F. **P478**
 Fernández-Calderón, M. P698
 Fernández-Salazar, L. **P566**, **P621**
 Fernandez-Veledo, S. P034
 Ferrante, M. 18, 20, 30, DOP023, DOP038, DOP040, P004, P005, P006, P038, P065, P084, P101, P112, P201, P259, P737, P742, N007
 Ferraro, P.M. P558
 Ferreira, M. P572
 Ferreira, M. P572
 Ferreira, R. P048
 Ferreiro, R. **P116**, P211, P218, P521, P610, P653
 Ferrer Bradley, I. **P356**
 Festen, E.A.M. 21, 22, P696, P719
 Feu, F. DOP019
 Ficari, F. **P274**, P581, P631
 Fichera, M. DOP021
 Fichna, J. P090
 Fidler, H.H. DOP023, DOP043, P134, P144, P281, P344, P367, P696
 Figueira, M. P464, P571, P654
 Figuerola, A. P228
 Filali, A. P469
 Filipe, V. P548
 Filippi, J. 32, DOP041, P121, P231, P306, P427, P548
 Finkel, Y. P520
 Finney-Hayward, T. P614
 Fiocca, R. P279
 Fiorino, G. **DOP036**, P312, P477, **P544**, **P621**
 Fischer, A. P001
 Fishman, S. P646
 Fisseha, N. P365
 Fitz, P. P126
 Fitzgerald, D. P049
 Flamant, M. P121, P554
 Flejou, J.-F. DOP079
 Fliss-Isakov, N. P666
 Floreani, A. 21
 Flores Cucho, A. P570, P595
 Florholm, J. P588
 Florin, T.H.J. P058, P226
 Fluiter, K. P043
 Fociani, P. DOP021, P279, P287
 Fogden, E. DOP037
 Fogel, R. DOP025
 Folgering, J. P095
 Folseraas, T. 21
 Fong, S. **P019**, P349
 Fonseca-Camarillo, G. P051, **P107**, P137, P734
 Fontaine, F. DOP057, P153
 Fonteyne, P. P089
 Forbes, A. P531
 Forcelledo, J.F. P624
 Ford, A. P403
 Fornaroli, F. P540
 Forry, M. P301, **N021**
 Fort Gasia, M. DOP080, P278
 Fortes, F. P222, P250
 Fortuna, M. **P214**
 Foshaug, R. P108
 Foster, M.R. P023, P064, **P100**, **P105**, P561, P224, P688
 Fournier, N. **P715**
 Fousekis, F. P484
 Fowler, H. P034
 Fradera, R. P063
 Fradin, C. P167
 Fraeman, K. **P224**
 Fraga, M. P521
 Fraga, R. P139
 Francés, R. **P425**
 Franceschetti, A. DOP022
 Franchi, L. 32, DOP057, P153, P405
 Franchimont, D. 21, P732, 22, P744, 25, P445
 Franke, L. P039
 Fraser, G. P572
 Fredricsson, A. DOP006, P061
 Freire, P. P299, P545
 Freise, I. DOP025, P611, P721
 Freitas, J. DOP009, P729
 French, D. 27
 Fried, M. 20, 32, DOP002, DOP003
 Friedman, G. P702
 Friedman, J. **P606**
 Friedman, S. P363, P544, P565, P630
 Frieler, G. P285, P450, P592, P605
 Friger, M. P126
 Froehlich, F. P049
 Frohna, P. P121, P554
 Frost, G. DOP079
 Frost, K. P666
 Fu, J. 21
 Fuchssteiner, H. P570, P595
 Fudim, E. P588
 Fuentes, S. P058, P226
 Fugazza, A. P043
 Fuhler, G. DOP021, P279, P287
 Fujii, S. DOP037
 Fujii, T. DOP025
 Fujimoto, T. P095
 Fujiya, M. 21
 Fukuchi, T. **P019**, P349
 Fukuno, Y. P051, **P107**, P137, P734
 Fukushima, T. DOP057, P153
 Fumagalli, C. P089
 Fumery, M. P531
 Furfaro, F. P624
 Furuzawa Carballeda, J. P403
 Fusco, G. P540
 Futatsuki, R. P301, **N021**
 Fyfe, M.C. DOP080, P278
 Gabe, S.M. P597
 Gabriëls, R.Y. **P622**
 Gaburri, P.D. P481
 Gaetano, J. P265
 Gagnière, J. P353
 Gago, T. P417
 Gaiani, F. P540
 Galanopoulos, M. P234
 Galéano-Cassaz, C. P338
 Gallas, M. P218
 Gallego, J. P521
 Gallego Barrero, M. DOP019, P251, N008
 Galletti, B. P606
 Gambitta, P. P287
 Gamian, A. P042
 Gan-Schreier, H. P059
 Ganeshanathan, T. P597
 Gao, L.-L. 25, 32
 Gao, X. DOP059, P723, P745
 Garber, J. P196
 Garcés, S. P545
 García, M. P139
 García, V. P340, P651
 García Tercero, I. P624
 García-Albert, A.M. P228
 García-Alvarado, M. P138
 García-Alvarez, L. P585, P608
 García-Arenas, D. P569
 García-Herola, A. P228
 García-Jaraquemada, A. P018
 García-López, S. P653

García-Olmo, D.	18	Giallourakis, C.	P196	Gómez-Sánchez, M.B.	P228
García-Sánchez, V.	P073, P211, P624, P710	Gianfrani, C.	P047	Gomez-Ulloa, D.	P585, P608
Gardiner, E.E.	P054	Giannarelli, D.	P565	Gomollón, F.	DOP082, P211
Gardstein, B.	P239	Giannini, E.G.	P232, P347, P536, P607	Goncalves, S.	P175
Garrick, V.	P650	Giannotta, M.	P494, N019	Gonçalves, T.	P237, P302
Gartner, J.	P677	Gibson, P.	DOP048, P226, P307, P486	Gonciarz, M.	P513
Gasbarrini, A.	P062, P713	Giffin, N.	DOP058	Goncz, L.	P308, P443, P694
Gasche, C.	DOP075	Giglio, M.C.	P587	Gonsalves, A.	P265
Gasink, C.	25, 32, DOP002, P573	Gijsbers, A.	P706	Gonzalez, B.	P521
Gaspar, R.	P141	Gil, A.	P175	Gonzalez, F.	P121
Gasparini, M.	P280	Gil-Ortega, D.	P549	González, J.M.	P566
Gasperoni, S.	P673	Gillespie, G.	DOP049, P310	González-Navajas, J.M.	P139
Gastin, I.	P361	Gilpin, K.	P196	González-Palau, A.	P133
Gasztonyi, B.	19, DOP010, DOP028, DOP033	Gils, A.	20, 32, DOP038, P005	Goode, E.	21
Gauci, J.	P672	Gimesi-Orszagh, J.	P443, P694	Goodman, W.	P062
Gault, N.	DOP018	Ginard, D.	P624	Gophna, U.	P666, P751
Gauss, A.	P059	Giner, A.	P251	Gordillo, J.	P263
Gavalas, E.	P394	Ginsburg, P.	P227	Gordon, D.	P747, P750
Gavins, F.N.	P087	Gionchetti, P.	P395	Gordon, I.	DOP077
Gawronska, A.	P530	Giorgetti, S.	P673	Gorelik, A.	P226, P313, P317, P355, P712
Gay, C.	P071	Giouleme, O.	P394	Goren, I.	P258, P290
Gay, M.	P531	Girardin, G.	P636, N005	Gorgun, J.	P028
Gaya, D.R.	26, DOP049, P310	Girardin, M.	P500	Gornet, J.M.	DOP018, P256, P554
Gazouli, M.	P024, P052	Gisbert, J.P.	P027, P073, P104, P183, P211, P228, P404, P478, P621, P624, P653	Górka, S.	P042
Ge, D.	P721	Gisbert-Ferrándiz, L.	P031, P079	Görtz, R.S.	P420
Gearry, R.	DOP075, P170, P226, P437, P438, P492	Gislason, E.	P665	Göttgens, K.	P663
Gebeyehu, B.	N010	Gitto, S.	P212	Gotthardt, D.N.	21
Geboes, K.	P038, P112	Giudici, F.	P274, P581, P631	Gottier, C.	DOP009
Geccherle, A.	P214	Giuffrida, P.	P094, P279	Götz, J.M.	P622
Gecse, K.	19, DOP028 , DOP031, DOP033, P308	Giugliano, F.P.	P321	Goukos, D.	P385
Geiger, T.	P037	Giuliani, O.	P673	Goutorbe, F.	DOP015, DOP086, P177, P353
Genes, J.	P121	Giunta, M.	P358	Goutte, M.	DOP015, DOP086, P145, P177, P353
Genin, M.	P697	Gizis, M.	P564	Goverse, G.	P015, P066
George, B.	P563	Glanville, T.	P348	Gower-Rousseau, C.	P649, P664, P697, P700
George, J.	P735	Glerup, H.	P149	Goya, L.	P133
George, R.	DOP073, P253	Glick, G.	DOP022	Goyal, K.	P626
Georgitseas, N.	P484	Glomsaker, T.	P693	Graça Rodrigues, C.	P327
Gerard, R.	DOP016, P436, P649	Glover, S.	DOP070	Graff, J.	P182
Gerardi, V.	DOP026, P713	Gluszek, S.	P244	Grafton, R.	P627, N018
Gerasimidis, K.	26, P083, P650	Godny, L.	P666	Graham, T.	24
Gerdes, U.	P691	Godwin, N.	P301	Grajkowska, W.	P380
Geremia, A.	P011	Goess, C.	P627	Grammatikos, N.	P394
Gerken, G.	P148	Goet, J.C.	P706	Grandi, A.	P002
Germain, A.	31, P578	Gogas, H.	P564	Granja, A.	P412
Gerritsen, C.	P736	Goh, K.L.	P118	Granovsky- Grisar, S.	P135
Gervais, F.	P590	Gold, B.	DOP078	Grant, A.	DOP058, P113, P638
Gervetti, P.	P223	Golden, A.	P728	Grasman, M.E.	P738
Geukens, N.	DOP038	Goldin, E.	18, P135, P161	Grassano, L.	P280
Gevers, D.	22	Goldis, A.	P668, P691	Gravito-Soares, E.	P621
Gheorghe, L.	P240, P271	Goldis, E.	27	Greally, J.	P728
Ghione, S.	P544	Goll, R.	P588	Greco, M.	P432
Ghiselli, A.	P540	Golovics, P.A.	19, DOP028, DOP031, P308, P443, P694	Greenberg, D.	P285, P450, P592, P605
Ghorayeb, J.	P678	Gombotz, E.	P739	Greger, G.	P114
Ghosh, S.	25, DOP052, DOP080, P168, P278	Gomez, B.	P148	Gregor, J.	P580
Giakoumis, M.	P385	Gómez, J.R.	P493	Gregorini, A.	DOP021
		Gómez, L.	P472	Greinwald, R.	P402
		Gomez-Pinilla, P.J.	P015, P066		

- Greuter, T. **P400**
 Greveson, K. P399
 Grgic, D. P577
 Griebbe, M. P060
 Griffin, M. P337
 Griffith, A. DOP005
 Griffiths, A. DOP063, DOP075,
 DOP078, P113, P345, P435, P522
 Grillo, F. P279
 Grimaud, J.C. 18, DOP041, P256,
 P306, P427
 Grimble, G. P531
 Gröchenig, H.P. **P677**
 Gröne, J. DOP006, P061
 Groome, M. P326
 Grooteman, K. P230
 Gross, A. **P088**
 Grossi, L. P320
 Gruber, E. P535
 Grueber, M. **P688**
 Grung, P. P050, P099
 Guagnozzi, D. P478
 Guardiola, J. P263, **P731**
 Guasch, M. **P493**
 Gubatan, J.M. **P641**
 Gubelaar, H.-J. P305, P550, P725
 Gueant, J.-L. P361
 Guerbau, L. **P649**
 Guerra, I. P073, P183, P211, P412, P621
 Guerra Veloz, M.F. P190, **P452**,
P570, **P595**, **P600**
 Guerreiro, H. P417
 Gui X, S. DOP080, P278
 Guidi, L. P544, P558
 Guijarro, L. P211
 Guillon, F. 31
 Gujrathi, S. DOP052
 Gulotta, G. P150, P151
 Gundin, M.J.F. N009
 Gundogdu, T. P298
 Guo, J. DOP059
 Guo, X. P721
 Guo, Z. DOP027
 Gupta, A. P195
 Gut, I. 20
 Gutiérrez, A. P139, P340, P404,
 P569, P621, P624, P651
 Gutierrez, G. DOP019
 Guttman, A. P145
 Guy, R. P563
 Gwela, A. **P011**
- H**aaas, T. P677
 Hackney, J. P406
 Hadad, Y. P562
 Haga, A. P414
 Haga, K. **P012**, P463, P491
 Hagymási, K. P220
- Hahm, K.B. **P040**, **P046**,
P091, **P556**
 Haj Natour, O. P616
 Halder, S.L. P130, N001, N011
 Halfvarson, J. DOP075, DOP082,
 DOP088, P430, P691
 Hall, B. **DOP013**
 Haller, W. P382
 Halling, M. **DOP076**, **P660**
 Halloran, B. P108, P416
 Hamamci, M. P045, P216
 Hamanaka, S. **P329**, P658
 Hameeteman, W. 24, DOP011,
 DOP034, P210
 Hamilton, A. P226
 Hamlin, J. P403
 Hamlin, P.J. DOP049, P310
 Hammami, A. **P194**
 Hammoudi, N. **P296**
 Hamzawi, M. P680, N021
 Han, C. P229
 Han, D.S. P109, P173, P748
 Han, S. P136
 Han, Y.M. **P304**, **P714**
 Hanauer, S. 25, 32, DOP052,
 DOP075, P168
 Hansen, B.E. P474, P706
 Hansen, L.F. DOP044, DOP045, P633
 Hansen, R. 26, P083, P650
 Hanzawa, A. P414, P431
 Hao, K. DOP077
 Hao, M. P015
 Har-Noy, O. P319
 Hara, T. P233, P393
 Harada, T. P442
 Harewood, G.C. P301
 Harmsen, H.J.M. P744, P746
 Harpaz, N. DOP077
 Harrison, E. P128
 Harrison, P. 27
 Harrow, P. **DOP069**
 Hart, A. 24, 31, DOP074, P009,
 P033, P115, P169, P195,
 P208, P597, P628, P661
 Hart, A. P704
 Hart, C. P575
 Hartmann, F. P119, P341, P552
 Hartmann, H. P599
 Hartmann, P. P386
 Hartono, J.L. P415
 Hassan, C. P516
 Hatemi, I. P261, P298, P334, P527
 Hauer, A. DOP062
 Hauser, B. DOP057, P153
 Hawkey, C. 18, DOP020, DOP026
 Hay, J. P650
 Hayashi, E. **P159**
 Hayday, A.C. P092
 Hayden, K. DOP002, DOP090
 Hayee, B.H. DOP037, P187, P470
- He, H. P745
 He, Y. P204, P635, P726, P730
 Healey, P. 27, 28, 28, DOP053, P369
 Heath, S. 20
 Hébuterne, X. 27, P548, P554
 Hebzda, Z. DOP048
 Hedberg, P. P184
 Hegde, S. P036, P069
 Heinrich, M. DOP047
 Heinsbroek, S. P095
 Hellstern, P. 25
 Helwig, U. **P314**, P386, P586
 Hendriks, N. P084
 Hendriks, R. P026
 Hendy, P. P009, **P033**, **P628**
 Henneman, P. P727
 Heo, J. P158
 Hergueta Delgado, P. P190
 Hernández, C. P031, P079
 Hernández, M. P412
 Hernández, V. P464, P571,
 P654, P668, P691
 Hernandez Alvarez-Buylla, N. P133
 Hernandez Camba, A. P133
 Hernández-Breijo, B. P211
 Hernández-Gallego, A. P146
 Hernández-Villalba, L. P138
 Herrera de Guise, C. P245, P480,
P510, P701
 Herreras, J. P459
 Herszényi, L. P220
 Hervás, D. P228
 Herzogova, J. P421
 Hetzel, D. P517
 Heusch, P. P148
 Hibi, T. 23, 33, DOP046, P120,
 P446, **P656**
 Hicks, K. P601
 Hida, N. 30, P333, P451, P508, P514
 Higashimori, A. P142, P152
 Higgins, P. DOP022
 Higgins, P.D.R. 28, P068, P264
 Higuera, R. P472, P698
 Hilhorst, V. DOP042
 Hilmi, I. P118
 Hinojosa, J. P356
 Hinojosa del Val, J. P211, N025
 Hinojosa del Valle, E. P356, N025
 Hirai, F. 30, 33, P328, **P560**
 Hirai, K. P414, P431
 Hirano, A. P318
 Hirjak, D. P060
 Hirohata, S. P656
 Hirsch, J. P543
 Hirschfield, G.M. 21
 Hisamatsu, T. 23
 Hiyama, S. P679
 Hjortswang, H. DOP082, N017
 Hlavaty, T. **P466**, **P655**
 Ho, T.H. **P455**

- Hodes, D. P504
 Hoeben, P. P504
 Hoekman, D. P343, **P488**, **P695**
 Hoentjen, F. DOP030, P696
 Hoffman, I. DOP057, P153
 Hoffmann, D. DOP024
 Högenauer, C. P739
 Hogg, J. P486
 Hohenester, S. 21
 Hoivik, M.L. P691, **P693**
 Hojsak, I. DOP062
 Holck, S. P013, P041, P268
 Holdam, A.S. **P657**
 Holleran, G. DOP013, P230, P613
 Hollman Frisman, G. N017
 Holm, K. 21
 Holmes, E. P009
 Holt, D. **P537**
 Hommes, D.W. P032, P134, P378, P441, P487, P687, P696
 Hommes, T. P378
 Honda, H. P528
 Hong, S.N. P197, P667
 Honrubia, R. P653
 Höög, C. **P419**
 Hoogenboezem, R. P026
 Hook, L. N012
 Hooymans, P. P305, P550, P725
 Hopkins, C. **P669**
 Hoque, T. DOP069
 Horan, R.M. P007
 Horgan, G. P509
 Hori, K. P451, P514
 Horta, D. P327
 Horwitz, B. DOP005
 Hotopf, M. P187
 Hotta, Y. P179, P362, P468
 Hotte, N. P108
 Houen, G. DOP045
 Houissa, F. P166
 Houwen, R. DOP065
 Hov, J.R. 21
 Hovgaard, V.P. P149
 Hozumi, K. P098
 Hrubá, V. DOP010, DOP031, DOP032, P311, P495
 Hu, J. P038
 Hu, J. P735, P741
 Hu, J. P745
 Hu, P. DOP059, P723, P745
 Hu, S. DOP059
 Huang, B. P496
 Huang, M. P723
 Huang, V.W. **P108**, P416
 Huang, W. P718
 Hudson, R. P069
 Huernos, S. P175
 Huggett, B. P331, **P390**
 Hughes, J. P627, N018
 Hughes, K. 26
 Hughes, P. P517
 Huguet, A. **P456**
 Huguet, J.M. P228, P621
 Huh, K.C. P173, P667
 Huls, G. P722
 Hume, G. **P352**, P523
 Hummel, T. P343
 Humphries, A. 31
 Huntzicker, E. DOP025, P611, P721
 Huo, D. P286
 Huorka, M. P466, P655
 Hüppe, A. P370
 Hussey, M. **P230**, **P613**
 Hussey, S. P007, P235, P680
 Hutchings, H. P467
 Huttenhower, C. 22
 Hutton, J. P187
 Huynh, H. DOP063, P132
 Hwang, S.W. **P262**, P273, P453, P499, P670
 Hyams, J. DOP056, DOP078, P345, P522, P576, P609, P638
 Iacucci, M. **DOP080**, P168, **P278**
 Iannone, A. **P252**, P366
 Ibañez, S. P472
 Ibarra, A. DOP069
 İbiş, M. P639
 Iborra, M. P102, P073, P211, **P459**
 Ichikawa, R. **P406**
 Icht, O. **P646**
 Ide, D. P159
 Ilerardi, E. P252, P366
 Ifergan, J. P219
 Iglesias-Flores, E. P404, P653, P710
 Iijima, H. P679
 Iimuro, M. P333, P451, P508, P514
 Iizuka, B. P233, P393
 Ijaz, U.Z. 26
 Ilangovan, R. P195
 Iliaz, R. **P541**
 Iliopoulos, D. P032
 Im, J.P. P304, P497, P667
 Imaeda, H. **P377**
 Imai, J. **P098**
 Imeryuz, N. P429
 Imhann, F. 21, **22**, P696, P719, **P744**
 Imperatore, N. P122, **P223**, P225
 Inaba, Y. **P534**
 Inagaki, Y. P098
 Inatomi, O. P377
 Indriolo, A. P553
 Ingham, M. P229
 Inman, R. P291
 Inoue, N. P295
 Inoue, S. P528
 Inoue, T. 30
 Invernizzi, P. 21
 Iqbal, T.H. P054, P200
 Irving, P. DOP001, DOP014, DOP049, DOP067, P092, **P310**, P476, P561
 Ishida, T. 23, **P528**
 Ishigatsubo, Y. P656
 Ishii, M. DOP046
 Ishikawa, D. P012, **P463**, P491
 Ishikawa, R. P198
 Ismail, H. P424
 Ito, A. P233, P393
 Ito, H. 33
 Itoh, Y. P179, P362
 Iturriaga-Goyon, E. P051, P107
 Itzkowitz, S. P741
 Iwamoto, F. P397
 Iwao, Y. P295
 Iwasaki, T. P159
 Izuta, M. P542
 Jabri, B. P265
 Jacenik, D. P090
 Jackson, B. **P317**, **P490**, **P712**
 Jacobs, R. P378
 Jacobson, K. DOP063
 Jacobstein, D. P573
 Jaghult, S. **N014**
 Jahnsen, J. DOP082, DOP089, P423
 Jakobsen, C. DOP044, DOP045, P588, P633
 Jakubanis, R. P568, P591
 James, A. DOP050, DOP070
 Janc, J. P069
 Jang, B.I. P136, P158, P249, **P512**, P667
 Jang, H.J. P173
 Jankipersadsing, S.A. P744
 Jankowska, I. P418
 Janousek, R. P703
 Jansen, E. P504
 Jansen, J.M. DOP043, P281, P344, P367
 Jantchou, P. P590
 Jarlot, C. 23, P408
 Jaroslaw, K. P380
 Jarzebicka, D. P530, P617
 Jatulis, D. P487
 Jauregui-Amezaga, A. DOP019, **P112**
 Javid, S. P217
 Jaziri, H. P194
 Jeon, Y.J. P193
 Jeon, Y.T. P667, **P752**
 Jenkins, J.T. P597
 Jennings, R. P535
 Jensen, M.D. DOP085
 Jeon, S.W. P158
 Jeong, B.-S. P050, **P099**
 Jeong, D.E. P249

- Jeong, J.S. P482
 Jessen, P. P370, P386
 Jeurung, S. **24, DOP011, DOP034, P662, P663**
- Jharap, B. P735
 Jiang, X. 21
 Jiang, Z. P721
 Jianzhong, H. DOP077
 Jiménez, M. P027
 Jin, H.A. P016
 Jin, M. P414, P431
 Jmaa, A. P194
 Jo, I.H. P025
- Jödicke, L.J. **DOP006**, P061
 Johanss, J. 25, 32, P307, P573
 Johnson, H. P128, P162, **178**
 Johnson, L.A. P068
 Johnston, E. DOP067, P349
 Johnston, M. P226, P413
 Jonaitis, L. P402
 Jonefjäll, B. **P546**
 Jones, G.-R. **DOP004, P021**
 Jonkers, D. 24, DOP011, DOP034, P207, P210, P662, P663, P692, P736, P744
- Joo, Y.H. P025
 Joosse, M. DOP062, **P026**
 Joossens, M. P737, P742
 Jordan, C. P187
 Jorissen, C. DOP040
 Joshi, A. P196
 Joubert, J. DOP015, P353
 Juan, A. P404
 Juanola, O. **P139**
 Jucha, B. P624
 Juga, A. DOP077
 Juhász, M. P126, P220
 Juillerat, P. P688
 Juliá, A. P018
 Juliá, B. P340, P651, P709
 Jung, H.-K. P025
 Jung, H.-J. P188, P332
 Jung, J.T. P136
 Jung, S.-A. P025, P173, P283, P497, P644, P667
- Jung, Y.H. P512
 Jung, Y.J. P078
 Jung, Y.J. P136
 Jung, Y.S. P129
 Jung, Y. P173
 Junker, R. P342
 Juran, B.D. 21
 Jurgos, L. P559
 Jussila, A. DOP035
 Juzlova, K. **P421**
- Kaakoush, N. 26
 Kaasalainen, S. P130, N001, N011
- Kabakchiev, B. P426
 Kachroo, S. P585, P608
 Kadenczki, O. P126
 Kadleckova, B. P275, P559
 Kagramanova, A. P485, P525
 Kaimakliotis, I. P668, P691
 Kajbaek Vester-Andersen, M. P699
 Kakkadasam Ramaswamy, P. P323
 Kalicinski, P. P424
 Kaliyaperumal, A. P515
 Kalla, R. 20, **DOP082**
 Kallajoki, M. P206
 Kallel, L. P469
 Kallemose, T. DOP045, P633
 Kaltz, B. P547
 Kamata, N. DOP046
 Kamath, B.M. P435
 Kamberovic, F. P018
 Kamikozuru, K. P333, P451, P508, P514
 Kamm, M. 26, P226
 Kammerlander, H. **P702**
 Kanai, T. 23, P295
 Kane, E. P441
 Kanemura, T. P414
 Kang, E. P453
 Kang, Y.H. P016
 Kang, Y.-H. DOP005
 Kangwan, N. P040
 Kani, H.T. P429
 Kaniewska, M. **P519, P645**
 Kanis, S. **DOP060, DOP061, P236**
 Kansen, H. **DOP065**
 Kanstrup-Fiehn, A.-M. P013, **P041**
 Kant, S. P088
 Kanwar, B. DOP025, P611, P721
 Kaplan, G. P293
 Kaplan, M. P351
 Kaptein, A.A. DOP043, P134
 Karaahmet, F. P045
 Karaboğa, I. P077
 Karaca, C. P541
 Karaca, T. P077
 Karagiannis, J. P689
 Karakan, T. **P639**
 Karamanolis, D. P234, P385
 Karamanolis, G. P024, P052
 Karasawa, H. P567
 Karatzas, P. DOP036, P234
 Karlen, P. P106
 Karlsen, T.H. 21
 Karlsson, A. 18, DOP026
 Karmiris, K. DOP036
 Karsdal, M.A. DOP085, DOP087
 Kasahara, K. P414, P431
 Kashida, H. 30
 Kashiwagi, H. P233, P393
 Kasper, S. DOP009
 Kaszubowski, M. P221
 Kato, S. 23
 Kato, T. P159
- Katopodi, K. P385
 Katsanos, K. DOP036, P319, P691, P715, P329, P658
 Katsuno, T. P468
 Kauhanen, S. P206
 Kaur, P. **P515**
 Kawagishi, K. **P157**
 Kawaguchi, T. DOP046
 Kawai, M. P333, P451, P508, P514
 Kawakami, A. **N002, N013**
 Kawamura, T. P468
 Kawk, M.S. P044
 Kaymakoglu, S. P541
 Kazemi-Shirazi, L. 18
 Keck, J. P413
 Kedra, S. P154
 Keerie, C. 31
 Keetarut, K. P392
 Keil, C. **P272**
 Keinan, A. P161
 Keir, M. DOP054, P406
 Keiran, N. P034
 Keller, E. P242
 Kellner, H. P484
 Kelly, A. P021
 Kelly, O. P270, **P291, P371**, P426
 Kempainen, H. DOP035
 Kempainen, J. P206
 Kennedy, N. 20, 31, DOP082
 Keogh, A. **N004**
 Kesztelyi, D. P692
 Keulen, E. P210
 Keum, B. P193, P752
 Khalid, J.M. P167, P239, P288
 Khalili, H. P196
 Khan, I.A. P103
 Khan, N. PP205, P248, P511
 Khomeriki, S. P525
 Kierkus, J. DOP055, P374, P396, P418, P424, P489, P513, P530, P612, P617, P629
 Kiernan, S. P680
 Kiesslich, R. **P360**
 Kikerkov, I. P533
 Kikuchi, H. P656
 Kilic, I. P429
 Kilincalp, S. P045
 Kim, B.G. P017, P078
 Kim, D.H. P044, P055, P072
 Kim, E.R. P197
 Kim, E.S. P136, **P158**, P482, P644, P667
 Kim, E.S. P193, P752
 Kim, E.Y. P136, P158
 Kim, G.-U. P499, P670
 Kim, H.J. P667, P684
 Kim, H.J. P158
 Kim, H.J. P156, P215
 Kim, H.M. P276

- Kim, H.S. P667
 Kim, H.S. P667
 Kim, H.-S. **P276**, P667
 Kim, J. **P497**
 Kim, J. P276
 Kim, J.H. P173
 Kim, J.H. P044, **P055**, P072
 Kim, J.H. P304
 Kim, J.K. P188, P332
 Kim, J.S. P017, P304, P667, P714
 Kim, J.W. P017, P078, P304, P667
 Kim, J.Y. P173
 Kim, J.-A. **P050**, P099
 Kim, J.-H. P262
 Kim, J.-S. **P532**
 Kim, K.O. P136, P158, **P249**, P482, P512
 Kim, K.-J. P262, P273, P453, P670
 Kim, M. **P407**
 Kim, M.-A. P215
 Kim, N.Y. P453
 Kim, N. P283, P714
 Kim, S.K. P136
 Kim, S.W. P016, P044, P055, P072
 Kim, S.W. P022
 Kim, S.-E. P025, P644
 Kim, S.-L. P022
 Kim, T.I. P016, P044, P072
 Kim, T.J. **P197**
 Kim, T.O. P667
 Kim, W.H. P016, P044, P072
 Kim, W.J. P188, P332
 Kim, W.J. P136
 Kim, W.S. P262
 Kim, Y. P667
 Kim, Y.G. P136
 Kim, Y.J. P040, P091, P556, P667
 Kim, Y.S. P173, P667
 Kim, Y.-H. P197
 Kimura, H. P414, P431, P589
 Kimura, M. P397
 Kindermann, A. DOP065, P343, P457
 King, E.C. P350
 Kinjo, K. P185
 Kinjo, T. P185
 Kinoshita, K. P679
 Kinova, S. P559
 Kiparissi, F. P331, P390
 Kirby, J. P406
 Kirchgatterer, A. P677
 Kirchgessner, J. **DOP079**, P172, P460
 Kita, Y. P333, P508, P514
 Kitamura, S. P679
 Kitazono, T. P318
 Kiudelis, G. P668
 Kiyohara, H. P295
 Kjeldsen, J. DOP076, DOP085, P660, P702
 Kjær Mikkelsen, E. **N015**
 Klang, E. P174
- Klett, D. **P420**
 Klimesova, K. P754
 Klopocka, M. 27, P277, P513
 Kluender, B. P524
 Klunder, L.J. **P048**
 Klungel, O. P305, P550, P725
 Kluthe, C. P132
 Knight, S. P033
 Knittel, T. 18, DOP026
 Knudsen, T. DOP076, P660, P702
 Knyazev, O. **P485**, **P525**
 Kobayashi, K. P157
 Kobayashi, T. **33**, DOP046, **P120**, P446
 Koblova, K. P421
 Kobunai, T. P720
 Koch, R. P677
 Koch, S. P071
 Koch Hansen, L. DOP076, P660
 Kodani, T. P012, P463
 Koelink, P. 20, P010
 Koffert, J. **P206**, **P206**
 Kofod Vinding, K. P691
 Koganei, K. P589
 Kogawa, T. P468
 Kogure, Y. P414, P431
 Koh, S.-J. **P017**, **P078**, P304
 Kohn, A. 25, P544, P565
 Kok, K.S. **P740**
 Kok, K. P094
 Kolacek, S. 26
 Kolar, M. DOP010, DOP031, **DOP032**, P311, P495
 Koletzko, S. DOP062, DOP078
 Kolho, K.-L. DOP062, P623
 Koliarakis, V. **P029**
 Koller, T. P466, P655
 Kollias, G. P029
 Kölmel, Y. DOP038
 Komori, M. P679
 Kondou, K. P656
 Kong, S.C. P415
 Konnikoff, F. P543
 Konoplyannikov, A. P485, P525
 Koo, J.I. P482
 Koo, J.S. P193, P667, P752
 Koot, B. P343
 Koppka, N. P314
 Kopylov, U. DOP036, DOP064, DOP072, P174, **P319**, P500, P526, P529, P616
 Korczowski, B. P374
 Kori, M. DOP055, P623
 Koriiche, D. P057
 Korkmaz, U. P077
 Korlatowicz- Bilar, A. P374
 Kornbluth, A. P735
 Kornschöber, C. P739
 Koroglu, E. P165, P389
 Korponai, G.B. P443, P694
- Koseki, H. P329, P658
 Koseoglu, H. P359
 Koshkin, S. P081
 Koslowsky, B. P161
 Kosmidis, C. P163
 Kostovcik, M. P754
 Kotze, L.M.S. P409, P642
 Kotze, P.G. **P409**, **P642**
 Koukouratos, T. P385
 Kouloumenta, A. P689
 Kountouri, A. P083
 Koutroubakis, I. DOP075
 Koutsounas, I. P163
 Kovács, A. P126
 Kovacs, G. **P123**
 Kowalewski, G. P424
 Kowalski, A. P424
 Kowalski, J. 18, DOP026
 Kowalski, M. P513
 Kowarzanow, J. P221
 Kozelj, M. P309
 Koziel, D. P244
 Krag, A. DOP085
 Krajcovicova, A. P466, P655
 Krajewska, W. P090
 Kräuchi, S. P242
 Krause, R. P739
 Krause, T. P586
 Krawczak, M. P342
 Kredel, L.I. DOP006, **P061**
 Kreijne, J. P391, P474, **P724**
 Krieger, A.P. P741
 Krishnan, E. P515
 Kristensson, M. P013, P041
 Kristof, T. 19, DOP028, DOP010, DOP033
 Kroeker, K.I. P108, P416
 Krogh, K. P149
 Kronborg, I. P226
 Krueger, G. P626
 Krugliak Cleveland, N. DOP081, **P265**, **P286**
 Kruis, W. DOP075, P372
 Krummenerl, T. P386
 Krusche, C. P088
 Kruse, R. DOP088
 Krznanic, Z. P577
 Krzystek-Korpacka, M. P042
 Ksiaz, M. P194
 Kuball, J. P722
 Kubo, A. P542
 Kubota, R. P414
 Kucharzik, T. P168
 Kuehbachner, T. 27
 Kuehl, A.A. DOP006, P061
 Kugathasan, S. DOP078
 Kuiken, M. 178
 Kuin, S. DOP068, P584
 Kuiper, J.G. P692
 Kumar, D. P103

Kumar, S.	P154	Langhorst, J.	P148, P176	Leon, G.	P007
Kumar, T.	P103	Langrish, C.	P069	Leonard, W.	DOP007
Kump, P.	P739	Lara, N.	P585, P608	Leoncini, E.	P713
Kunisaki, R.	P414, P431, N002	Lasch, K.	DOP050, DOP070	Leone, S.	P439
Kunne, C.	P043	Lasson, A.	P546	Leong, R.	25, 26, P226, P438
Kunovic, A.	P577	Latella, G.	P279, P606	Leong, W.F.	P415
Kupcinskias, J. L.	P691	Laterza, L.	P713	Leppa, V.	21
Kurachi, K.	P442	Lauenstein, T.	P148, P176	Lesch, C.	DOP022
Kurent, T.	P309	Lauria, A.	P320	Leselbaum, A.	18
Kuriyama, T.	P233, P393	Lavagna, A.	P395	Letkovsky, J.	P466, P655
Kuroki, H.	P589	Laveda, R.	P139	Leube, R.	P088
Kuronuma, S.	P120, P446	Lawendy, N.	27	Leung, Y.	P293
Kurrey, L.	P154	Lawrance, I.	P226	Levesque, B.	DOP025, DOP052,
Kurt, M.	P077	Lay, H.	P030		P611, P721
Kurti, Z.	19, DOP010, DOP028, DOP033, P308, P443, P694	Lazar, A.	P398, P462, P524, P574, P576, P609, P638	Levhar, N.	P174, P498
Kusaka, T.	P468	Lázár, G.	P127	Levi, G.	DOP077
Kuscu, K.	P429	Lazaridis, K.N.	21	Levin, A.	DOP027, P010
Kverka, M.	P754	Lazaris, A.	P024	Levine, A.	DOP055 , DOP062, P623
Kwak, M.S.	P262	Lazowska, I.	26	Levison, S.	P260
Kwak, S.G.	P136	Lazure, T.	P219	Lewis, A.	N012
Kwon, J.G.	P136	Le Roy, C.	P019	Lewis, C.M.	DOP001
		Leal, R.F.	P003	Lewis, J.	P335
		Lecca, G.	P411	Lewis, J.D.	P227
		Ledder, O.	P623	Lewis, S.	31
		Lee, A.R.	P109, P748	Ley, D.	P700
		Lee, C.	P304	Li, C.	25
		Lee, C.K.	P173, P497, P667, P684	Li, J.	P186
		Lee, D.H.	P283, P714	Li, K.	OP04, DOP000,
		Lee, D.-W.	P193		DOP003 , DOP090,
		Lee, H.J.	P273, P670	Li, L.	P726
		Lee, H.J.	P055, P156	Li, M.	P730
		Lee, H.S.	P136, P158, P482	Li, N.	P291
		Lee, H.Y.	P260	Li, P.	DOP007
		Lee, H.-S.	P262, P273 , P453, P499, P670	Li, Y.	P576
			P197	Li, Y.	P186
			P667	Li, Y.	P186, P202
			P422	Li Yim, A.	P727
			P262	Liang, H.	P675, P682, P711
			P025, P283, P644	Libier, L.	P649
			P017, P078	Lichtenstein, G.	P368, P471
			P497, P667	Lichtenstein, L.	P445
			25, DOP025, P721	Lie, M.	P096, P391, P474, P504
			P136	Liebert, A.	P277
			P535	Liefferinckx, C.	P405
			P438, P492	Liew, D.	P226, P317, P712
			P136 , P158, P482	Liew, I.Y.	P187
			P109, P748	Lightner, A.	P378
			P704	Lim, K.	P241
			31	Lim, S.	P714
			P024	Lim, W.C.	P415
			P735	Lim, W.-M.	P684
			P184	Lima, C.	P267
			P557	Lima, M.	P080
			P674	Limdi, J.	DOP037, DOP073,
			P739		P253, P614
			P112	Limsrivilai, J.	P264
			P357	Limsrivilai, J.	P118
			P606	Lin, E.	26
				Linares, P.M.	P027, P073 , P104,
					P183, P211
L'hopital, F.	P121				
Labeeuw, E.	P015				
Laberenne, J.-E.	DOP016				
Labidi, A.	P469				
Labopin, M.	DOP020				
Lacey, P.	P032, P487				
Ladas, S.	P689				
Ladas, S.	P385				
Ladefoged, K.	P691				
Lago, P.	DOP084, P080, P086				
Laharie, D.	32, DOP018, P121, P256, P306, P335, P554				
Lahat, A.	P174				
Lahmek, P.	P256, P338				
Laino, G.	DOP012				
Lakatos, L.	19, DOP010, DOP028, DOP033, P126, P668				
Lakatos, P.	19, DOP010, DOP028, DOP031, DOP033, DOP036, DOP075, P123, P308, P365, P443, P484 , P668, P691, P694				
Lakner, L.	DOP028				
Lam, K.	P142				
Lamb, C.	P406				
Lambrecht, G.	32				
Lamers, E.H.	P144				
Lampinen, M.	P039				
Landman, C.	DOP079, P172, P460, P582				
Landowski, P.	P629				
Lang, S.	DOP009				
Lang, Y.	25, 32, P573				
Langbrandtner, J.	P370				
Langhoff, W.	P368, P626				
Langholz, E.	P668, P691				

- Lindahl, R. **N020**
 Lindahl, T. DOP089
 Lindberg, A. **P106**
 Lindenbergh-Kortleve, D. DOP007
 Lindgren, S. P106, P444
 Lindsay, J. 31, DOP008, **DOP020**,
 DOP069, P476
 Lindström, J. DOP082
 Ling, K.L. P118, P415
 Ling, S.C. P435
 Linn, A. P505, **N010**
 Lionetti, P. DOP062, P544
 Lipman, M. P399
 Lippai, D. P220
 Lish, I. P543
 Lissner, D. P621
 Liu, J.Z. 21
 Liu, L. 24
 Liu, X. P068
 Liao, J. P653
 Llaó, J. P263
 Llerena, E. P549
 Lloyd-Ford, G. **N012**
 Lo Presti, E. **P075**
 Lobatón, T. P112, P146, P263, P493
 Lobb, M. P058
 Lobo, A.J. P124
 Löfberg, J. 21
 Löfberg, R. DOP026, P496
 Loftus Jr, E.V. 25, DOP047, **DOP051**,
 DOP075, **P626**
 Loizidou, M. P067
 Lolli, E. P168, P284
 Lombardi, G. P280
 Lomer, M.C. DOP014, P476
 Lönnfors, S. P432, P437
 Loos, W. P504
 Lopes, M. **P267**
 Lopes, S. P141
 Lopetuso, L.R. **P062, P713**
 López, A. P251
 López, B. P356
 Lopez, R. P437
 Lopez, R. P325
 López, S. P246
 López de Goicoechea, M.J. P753
 López García, A. **DOP019**
 Lopez Megias, J. P160
 López Viedma, B. P330
 López-Sanromán, A. P602, P709
 López-Serrano, P. P228, P621
 Lördal, M. P106
 Loren, V. **P018**
 Lorente Poyatos, R.H. P330
 Lorentsen, R. **P322**
 Lorenzo, A. P116, P218, P610
 Lorenzo, D. **P256**
 Lorenzon, G. P475, P544, **P636**, N005
 Lores, T. **P627**
 Loriau, J. 31
- Losurdo, G. P252, **P366**
 Louis, E. 32, DOP057, DOP083, P153,
 P315, **P496**, P548
 Lovasz, B. 19, DOP031, **DOP033**,
 P443, P694
 Lovén Wickman, U. **N017**
 Löwenberg, M. DOP066, P201, P376,
 P584, P637,
 P695, P696, P732
 Lozano, M. DOP019
 Lozano Lanagan, M. **P160**
 Lozinsky Rolnik, A. P331
 Lu, T. DOP054
 Lucas, B. N021
 Lucca, F.A. **P481**
 Lucendo, A.J. P478, P624
 Ludbrook, V. P014, P020, P601
 Ludlow, H. DOP037
 Ludwiczek, O. P677
 Lügering, A. P386
 Luglio, G. P223, **P587**
 Luinetti, O. P279
 Lukas, M. DOP010, DOP031,
 DOP032, P495
 Lukas, M. DOP010, DOP026, DOP031,
 DOP032, P311, P421, P495
 Lukas Jr, M. P311
 Luneau, F. P121
 Lung, P.F. P597
 Luo, X. **P635**
 Lutter, F. P314
 Luypaerts, A. P006
 Lv, H. P186, P191
 Łykowska-Szuber, L. P513
 Lyra, A. P267
- M**a, H.W. P044, P055, **P072**
 Ma, L. P745
 Ma, R. P317
 Maa, J.-F. P496, P609, P638
 Maagaard, L. P588
 Maaser, C. P168, P386, P586
 Maccioni, F. P125, P516
 MacDonald, A. DOP004, P021
 Macdonald, K. P132
 MacDonald, T.T. P094, P100, P105
 Macedo, G. P141, P292
 Mach, P. P180
 Machado, F. P292
 Machiels, K. P737, P742
 Machkova, N. DOP031, DOP032,
 P311, P495
 Macias-Ceja, D.C. P031, P079
 Macinga, P. P703
 MacIntyre, B. DOP058
 Mack, D. DOP063, P113
 MacKinder, M. P083
- Maconi, G. DOP021, DOP036, P168,
 P287, P319, P544, P565
 Macpherson, A.J. P688
 Macrae, F. P226, P313, P355
 Macri, G. P494, N019
 Madanchi, M. P676
 Maddipati, K.R. P089
 Madia, C. P540
 Madill, A. P678
 Madsen, K. P108
 Maeda, S. N002
 Maeda, Y. P115, P208
 Maehata, Y. 30, P318
 Magarotto, A. P621
 Magdziak, A. P289
 Mager, D. **P132**
 Maggiori, L. 31
 Magro, D.O. P409, P642
 Magro, F. DOP036, P319, P621,
 P668, P691
- Maguire, M.K. 25
 Maharshak, N. P666, **P751**
 Mahdi, G. DOP058
 Mahmmod, N. P210, P281, P344, P367
 Mahmud, N. DOP013
 Maia, L. DOP084
 Maillard, M.H. P619, P690, P707
 Mainenti, P. P122, P223, P225
 Maina, E. P195
 Maione, F. P225
 Maire, F. P256
 Maisano, S. P630
 Maiz, A. P698
 Maj, D. P513
 Majano, P.L. P073
 Makharia, G. P154
 Malaguti, C. P481
 Maldonado Pérez, M.B. P190, P452,
 P570, P595, P600, P710
- Malesci, A. P477
 Malickova, K. DOP010, DOP031,
 DOP032, **P311**, P495
 Malietzis, G. P597
 Maljaars, J. **DOP039**, P210
 Maljaars, P. P505
 Maller, E. 28, 28, DOP053, P428
 Mallet, A.-L. P171, P456
 Maltais, S. P270
 Mamtani, R. P335
 Man A Hing, W. P360
 Mana, F. 32
 Manceau, H. P296
 Manceño, N. P404
 Mandalia, S. P501, P518
 Manetti, N. P544
 Mangen, M.-J. P281, P344, P367
 Mangiarotti, R. P280
 Manne, S. P675, P682, P711
 Manninen, P. P691
 Manns, M.P. 21, P272

Manolache, O.	DOP016	Martino, G.	P448	McNamara, D.	DOP013, P230, P613
Mañosa, M.	P018, P146	Martino, M.	P279	McNelly, A.	P531
Mansfield, J.	P406	Martins, A.	P327	Mearadj, B.	P178
Mantzaris, G.	DOP036, DOP075,	Martins, D.	P155, P209, P297	Mearin, L.	P457
	P319, P621	Martos Plasencia, M.d.C.	P330	Meckel, K.	P265
Manyé, J.	P018	Maruoka, D.	P329, P658	Medcalf, L.	P187
Manyosa, M.	P263, P493	Mary, J.-Y.	P231	Meder, A.	P513
Manzi, I.	P647, P673	Marzioni, M.	21	Medvedev, P.	P132
Mao, R.	P204 , P635, P726	Marzo, M.	P558	Megias-Rangil, I.	P228
Marano, C.	DOP048, P307	Masamunt, M.C.	DOP019, P251	Meglicka, M.	P489 , P617, P629
Marchand, V.	P590	Masclee, A.	24, DOP011, DOP034,	Mehandru, S.	P455
Marchi, S.	DOP012		P207, P210, P652, P659, P662,	P557	
Marcon, T.	P475		P663, P692, P736	Meijer, B.	P043, P555
Marcos-Pinto, R.	DOP084, P080, P086	Masel, N.	DOP078	Meijssen, M.A.C.	P622
Maréchal, C.	P361	Maser, E.	P735	Melenhorst, J.	P663
Marín, A.C.	P027, P104	Mason, A.L.	21	Melgar, S.	P007
Marin, P.	DOP019	Massari, A.	P287, P544, P598	Mello, L.	P267
Marín-Jiménez, I.	P073, P183, P211,	Massella, A.	P544	Melum, E.	21
	P356, P624, P404, P593, P653	Massimino, L.	P089	Menchén, L.	P211, P356, P593
Marinaki, A.	P349	Masuda, E.	P679	Menckeborg, C.	P026
Marinos, E.	P024	Masure, J.	P360	Mendes, S.	P572
Marion, J.	P735	Mateescu, B.	P053	Mendolaro, M.	P358
Marits, P.	P520	Mathai, S.	P323	Mendoza, J.L.	P551, P681
Markowitz, J.	DOP078	Mathew, C.G.	DOP001	Mennini, M.	P117
Marks, J.	P286	Mathieu, S.	P121	Mensa, J.	DOP019
Markus, T.	P210	Mathôt, R.	DOP066, P637	Mensink, P.B.	P622
Maroto, N.	P356, P624	Matsui, T.	23, 30	Meraviglia, S.	P075
Marotte, H.	23	Matsumoto, K.	P189, P503, P643	Merchante, A.	P228
Márques, A.	P133	Matsumoto, T.	23 , P185, P318	Merighi, A.	P212
Marques, M.	P141, P292	Matsumura, T.	P329, P658	Merino, O.	P228, P472, P473,
Marques da Costa, P.	P410	Matsunaka, T.	P542		P653, P698, P753
Marren, A.	28, 28, P369	Matsuoka, K.	P397	Merino, V.	P452, P600
Marsal, J.	P484	Matsuoka, M.	P159	Mescoli, C.	P269, P279
Marsal, S.	P018	Matsuura, M.	P468	Mesnard, B.	DOP041
Marschall, H.-U.	21	Matteoli, G.	P015, P066	Mesonero, F.	P211, P624
Marshall, J.K.	P130, P433, P648,	Matusiewicz, M.	P042	Metselaar, J.	DOP023
	N001, N011	Matuszczyk, M.	P629	Meucci, G.	P143, P544
Marteau, P.	P256, P306, P427, P554	Matuz, M.	P507	Meurette, G.	31
Martel, M.	DOP072, P529	Maul, J.	P586	Miao, Y.	32
Marthey, L.	DOP041	Maunoury, V.	DOP016, P231,	Michalet, V.	P121
Marti Romero, L.	P624		P436, P649	Michalopoulos, G.	P052
Marti-Bonmati, E.	P228	Maurizi, G.	P494	Michetti, P.	P312, P315 , P554,
Martín, A.	P464, P571, P654	Mayer, A.	P677		P619, P690, P707
Martin, J.	P093	Mazza, G.	P094	Michopoulos, S.	P689
Martin, S.	P376	Mazza, M.	P358	Micsik, T.	P220
Martin, S.W.	DOP071, P428	Mazzuoli, S.	P363, P544	Micu, G.	P053
Martin Rodríguez, O.	P071	McArdle, P.	N021	Miehsler, W.	P677
Martín-Arranz, M.D.	P211, P340, P624,	McBride, S.	P399	Miele, E.	P047, P321
	P651, P653	McCarthy, J.	P049	Mierzwa, G.	P374
Martín-de-Carpi, J.	DOP062, P113,	McCarthy, N.	DOP008	Migliora, P.	P279
	P387, P549 , P569, P621	McCartney, S.	P392, P575	Mihály, E.	P220
Martín-Rodríguez, D.	P624	McCombie, A.	P437 , P438, P492	Miheller, P.	19, DOP010, DOP028,
Martinelli, M.	P321	McCoy, J.P.	P085		DOP033, P126, P220
Martínez, A.	P139	McGinley, C.	P326	Mikocka-Walus, A.	P517 , P627
Martínez, C.	DOP019	McGovern, D.	DOP075	Milassin, A.	DOP010, DOP031, P126,
Martínez, C.A.R.	P409, P642	McHutchison, J.G.	DOP025, P721		P127 , P266, P357, P507, P717
Martínez, N.	P464, P571, P654	McKay, E.	P492	Milgrom, R.	P270
Martínez-Cadilla, J.	P464, P571, P654	McKenzie, H.	P425	Milkiewicz, P.	21
Martínez-Cerezo, F.J.	P228	McLaughlin, S.	DOP037, P128,	Milla, M.	P494, N019
Martínez-Montiel, M.P.	P404, P653		P162, 178	Milan, M.	P034

- Mine, T. P098
 Minet Quinard, R. DOP086, P177
 Ming, Z. P596
 Ming-Il, S. P596
 Mínguez, M. P624
 Ministro, P. P155, P209, P297
 Minoo, P. DOP080
 Minsart, C. P405
 Miranda-Bautista, J. **P593**
 Mishevskva, P. P533
 Mishreki, A.P. **P440**
 Misra, R. P009, **P685**
 Mitchell, H. 26
 Mitrova, K. DOP010, DOP031, DOP032, P311, P495
 Mitsuhashi, S. P641
 Mitsunaga, M. P159
 Miyagi, T. P679
 Miyakawa, M. P383, P618
 Miyake, S. P012
 Miyamura, M. P198
 Miyazaki, T. P333, **P451**, P508, P514
 Mizuno, S. P295
 Moayyedi, P. P130, N001, N011
 Mocchiari, F. P075, P358, P439, **P448**
 Mody, R. P603
 Moerland, P. P043
 Mohammadi, A. **P270**
 Moisset, X. **P145**
 Molander, P. **DOP035**
 Moles, J.R. P502
 Molina, B. P228
 Molnár, T. 19, DOP010, DOP028, DOP031, DOP033, **P126**, P127, P266, P308, P357, P507, P717
 Molteni, P. P287
 Monast, C. **DOP090**
 Moniuszko, A. **P244**
 Montague, S.J. **P054**
 Montalvo, I. P698
 Montanari, R. P214
 Montauban van Swijndregt, A. P178
 Monteiro, S. **P131**, P164, P302
 Monteleone, G. DOP022, P279
 Monteleone, I. DOP022
 Montero Delgado, J.A. P449
 Monterubbianesi, R. **P565**
 Monti, M. P531
 Montoro, M. P228
 Mooibroek, J. 178
 Mooiwer, E. P140, P254
 Moon, C.M. P025, P644
 Moore, G. P313, P355, P537
 Moorghen, M. 24
 Mora Escrig, M. P356, N025
 Moradpour, D. P224
 Moraleja-Yudego, I. P653, P698
 Moran, C. P509
 Moran, T. P007
 Morandeira, F. P731
 Morar, P. **P169**, **P195**, N016
 Moraru, I.G. **P240**
 Moreau, J. 32, **DOP041**, P231, P427
 Moreels, T. DOP057, P153
 Moreira, M.J. P131, P164, P237, P302
 Moreno, M. P502
 Moret-Tatay, I. P102
 Morgan, R. DOP022
 Mori, K. P295
 Morita, Y. P377
 Moriyma, T. P318
 Morris, A. 31
 Mortensen, J.H. **DOP085**, DOP087
 Mortensen, N. P563
 Mortier, K. P467
 Moscariello, M. 28, 28, DOP053, P428
 Moser, B. DOP008
 Moss, A. P641
 Mostafa, N. P524
 Mota, J. P222, P250
 Motomura, M. P528
 Motoya, S. 23, 33, **P383**, P618
 Motta, B. DOP021
 Mottet, C. P619
 Mouelhi, L. **P166**
 Mould, D.R. DOP068
 Mouli, V.P. P154
 Moulton, C. P669
 Moum, B. DOP075, P691, P693
 Mountzouris, K. P052
 Moura, C. P410
 Moura Santos, P. P300, P410, P483, P620, P741
 Movva, R. P058
 Mowat, T. 31, P326
 Mozer-Glassberg, Y. P623
 Mróz, A. P289
 Mucha, S. P732
 Mücke, M.M. P325
 Muhammed, R. **P382**
 Mujagic, Z. P744
 Mukai, A. P679
 Mukai, M. P683
 Mukhametova, D. **P081**
 Mukherjee, A. 27, **DOP071**, **P428**
 Mul, A. P727
 Mulcahy, H. P376, P509
 Mulder, C. P557
 Müller, T. 21
 Müller, K. P126, P220
 Muls, V. DOP057, P153
 Mumbo, G. DOP012
 Muñagorri, A. P472, P698, P753
 Munck, L.K. P013, P041, P182, P322
 Munkholm, P.S. DOP044, DOP045, P588, P633, P668, P685, P691
 Muñoz, J.F. P473
 Muñoz, J.F. **P138**
 Muñoz Vicente, M. P228
 Muñoz Villafrañca, C. **P472**, P624
 Muñoz-Bongrand, N. 31
 Muqtadir, Z. P648
 Murakami, K. P528
 Murakami, M. **P414**, P431
 Murayama, Y. P679
 Murciano Gonzalo, F. N008
 Murray, C. P399
 Murray, E. P381
 Murray, F.E. P301
 Murray, S. P458
 Muscat, M. DOP036
 Musha, H. P567
 Muskens, F. P026
 Musto, D. P122
 Mustonen, H. DOP035
 Mutaguchi, M. P295
 Muzio, F. P598
 Myers, C. P476
 Myung, S.-J. P262, P273, P453, P499, P670
- N**
 Nacak, T. P402
 Nachury, M. 18, 32, DOP016, DOP018, DOP041, P121, P436, P649
 Naessens, D. P229
 Naftali, T. **P543**
 Nagahori, M. 23, P397
 Naganuma, M. P295, N002
 Nagao, M. P567
 Nagata, Y. P159
 Nagata, Y. **P318**
 Nagy, F. 19, DOP010, DOP028, DOP031, P126, P266, P357, P507, P717
 Nahon, S. DOP041, P256, **P336**, P338, P554
 Naito, Y. 23, P179, P362, P468
 Naitoh, T. P567
 Najjar, T. P166
 Nakagawa, T. 23, P329, P658
 Nakajima, S. P679
 Nakamura, M. P185
 Nakamura, S. P333, P451, P508, P514
 Nakano, M. P120, P446
 Nakase, H. 23, P468
 Nakazato, Y. P295
 Nakutis, F.S. **P056**
 Nam, T.-G. P099
 Nancey, S. DOP018, P121, P554
 Nancey, S. DOP026, P306, P427
 Nangia, N. P735
 Nanki, K. P295
 Nante, O. P472
 Nantes, O. P473
 Nardone, O.M. P122, P223, P225
 Narita, R. P528

- Narula, A. P648
 Narula, N. **P648**
 Nasuno, M. P383, P618
 Nathan, I. P531
 Navalón-Rubio, M. P549
 Navaneethan, U. DOP070
 Navarro, B. P459
 Navarro Correal, E. P480, P510, **N008**
 Navarro Cortes, P. DOP036
 Navarro-Llavat, M. P653
 Navas-López, V.M. **P113**, P549
 Naymagon, S. DOP017, P388
 Nebuloni, M. DOP021, P287
 Necoziano, S. P606
 Neclua, S. P271
 Negreira, S. P175
 Németh, A.M. P220
 Nesi, G. P279
 Neubauer, K. **P042**, P346, P479
 Neufert, C. P001
 Neuman, S. P174
 Neurath, M.F. 18, DOP026, P001, P114, P420
 Neut, C. P057
 Ng, K.K. P118
 Ng, S.C. DOP075, P118, P142, P152
 Ng, W. 26, P523, 178
 Nguyen, D. P441
 Nguyen, G.C. P371, P426
 Nichita, L. P053
 Nielsen, A.H. P149
 Nielsen, J. DOP076, P660, P702
 Nielsen, K.R. **P665**, P668, P691
 Nieminen, U. **P594**
 Nieuwenhuijs, V.B. P719
 Niezychowski, W. 27, 28, 28, DOP071, P428
 Nijhuis, L. P095
 Nikolaus, S. P342, P401
 Nilsson, S. P106
 Nimmo, E.R. OP07, DOP082
 Nion-Larmurier, I. DOP079, P172, P231, P460, P582
 Niriella, M. P118
 Nishida, A. P377
 Nishio, M. P414, P431
 Nishishita, M. 30
 Nishitokukado, I. P056
 Nishiyama, S. 30
 Nissinen, R. P368
 Nita, G.-E. P553
 Noben, M. **P084**
 Nobis, M. 20
 Noble, A. P033
 Noble, A. DOP058
 Nóbrega, V. **P222**, P250
 Noda, T. P542
 Nojima, M. 23, DOP046
 Noman, M. **30**, DOP023, DOP040, N007
 Nomura, O. P012, **P491**
 Nordberg, N. DOP082
 Nordine Bouchelouche, P. P182
 Nørgård, B. P702
 Norman, G.L. P123
 Norton, C. P294, P531, N006
 Nos, P. P102, P459, P602
 Nosegbe, U. **DOP073**, P253
 Noskova, K. P525
 Nouda, S. P185
 Nouraille, A. P427
 Novacek, G. P677
 Novak, G. P309
 Novák, J. P126
 Novak, K. P168, P293
 Nozaki, R. 30
 Nuevo-Sigüeiro, O. P228
 Nugteren, S. DOP007
 Nuij, V. 20
 Numata, K. P414, P431
 Nunes, A. P545
 Nunes, G. P299
 Nunes, V.S. P056
 Nurwakagari, P. P114, P315
 Nyári, T. DOP031, P717
 Nydegger, A. P224
 Nys, K. P101, P742
O'Brien, C. P747, P750
P403
 O'Connor, A. N013, N016
 O'Connor, M. DOP014
 O'Hanlon, D.V. P239
 O'Hara, D. P239
 O'Leary, K. 20
 O'Morain, C. DOP075
 O'Neill, E. **P235**, P680
 O'Sullivan, J. P613
 O'Toole, A. P301, P539
 Oancea, I. **P058**
 Obata, H. P468
 Occhipinti, P. P544
 Ocklind, A. DOP082
 Odes, S. P285, P450, P592, P605, P668, P691
 Odintsova, A. P081
 Offerhaus, J. P140
 Ogashiwa, T. P414, **P431**
 Ogata, H. 33, P295
 Ogawa, C. P542
 Ogawa, H. P679
 Ogawa, H. P159
 Ogawa, M. P472
 Oguetta, M.A. P684
 Oh, C.H. P684
 Oh, S.J. P546
 Öhman, L. 30
 Ohmiya, N. P295
 Ohno, K. P567
 Ohnuma, S. P397
 Oikonomopoulos, A. **P032**
 Ojanguren, I. P146, P263
 Oka, S. 30
 Okamoto, Y. 30
 Okimoto, K. P329, P658
 Olandoski, M. P409, P642
 Olbjørn, C. **P423**
 Oldenburg, B. 32, DOP023, DOP043, P140, P144, P254, P281, P344, P367, P696, P704, P719, P732, P743
 Olinga, P. DOP087
 Oliva, S. P125, P181, P213, **P516**
 Olivares, D. P211, P404, P551, P681
 Oliveira, A.M. P327, P741
 Olmedo, R. P246
 Olmedo Camacho, J. P330
 Olsen, J. P665
 Olson, A. DOP052
 Oltra Camps, L. N025
 Oluseyi, A. DOP080, P278
 Omori, T. **P233**, P393
 On, A. P623
 Onali, S. P269, P284
 Ong, C. P415
 Ong, D. P118
 Ong, E.H. P415
 Ong, P.L. P415
 Onida, F. DOP021
 On behalf of EuroSurg Collaborative **P243**
 On behalf of IG-IBD P544
 On behalf of the IBD-BIOM Consortium 20
 On behalf of the IBD-CHARACTER Consortium 20, DOP082
 On behalf of the ImproveCareNow Network P350
 On behalf of the International Paediatric IBD Network (PIBDNet) P345
 On behalf of the Toppic Trial Study Group 31
 Onken, J. DOP025
 Oomen, M. P457
 Oostenbrug, L. 24, DOP011, DOP034, P662, P663
 Opdenakker, G. P038
 Opstelten, J. **P704, P743**
 Oracz, G. P617
 Ordás, I. DOP019, P251
 Ordemann, J. DOP006
 Orepuller, S. DOP041
 Oreshko, L. P749
 Orlandi, A. P279
 Orlando, A. P280, P358, P454, P461, P544
 Orlando, E. P358, P454, P461
 Orozco, L. P406



- Ortiz de Zárate, J. P472, P753
Ortiz-Agostinho, C. P056
Ortiz-Masiá, D. P031, P079
Osada, T. P012, P463, P491
Oshita, M. P679
Osiecki, M. **P396**
Osredkar, J. P309
Öst, A. 18
Ostaniin, D.V. P087
Osterman, M.T. DOP070
Otley, A. DOP058, DOP063, P113, P638
Otottova, K. P559
Otte, A. P272
Ouahed, J. DOP003
Oubaya, N. DOP018
Ouchchane, L. P145
Overbeeke, A.N.J. P746
Owczarek, D. P180
Ozaki, K. 33, P656
Ozgursoy Uran, B.N. **N024**
- P**ack, L. P088
Padgett, L. DOP056, P307
Padhan, R.K. **P154**
Padullés, A. P731
Padullés, N. P731
Pærregaard, A. 26, DOP044, DOP045, P633
Paese, P. P363
Pagana, G. P280
Pai, R. DOP025, DOP052
Paiano, P. P363, P562
Pajares, R. P624
Palatka, K. 19, DOP010, DOP028, DOP031, DOP033, P123
Pallarés-Manrique, H. P316
Pallone, F. DOP075, P168, P269, P284
Palmela, C. P741
Palmieri, G. P269
Palone, F. **P117**
Panaccione, R. 25, 28, DOP047, DOP075, DOP080, DOP083, P168, P278, P293, P398, P433, P462, P574
Panackel, C. P323
Panchal, H. P735
Panés, J. **18, 27, 28**, DOP019, **DOP053**, DOP075, P251, P365, **P369**
Pang, J. P293
Panis, Y. 31, DOP018
Paoluzi, P. P411
Papa, A. P280, P558
Papamichael, K. P319
Papamichail, K. DOP038
Papatheodoridis, G. P052
Papay, P. P677
- Papi, C. P279
Papoff, P. P516
Papp, M. DOP028, P123
Pappalardo, B. P315, P365, P496
Paquot, I. DOP057, P153
Paradis-Suprenant, L. P529
Paramsothy, R. 26
Paramsothy, S. **26**
Pardi, D. DOP077
Pares, A. 21
Parfenov, A. P485, P525
Pariante, B. DOP016, P057, P121, P306, P427, P436, P649, P664, P700
Parikh, A. P227
Parisi, I. **P575**
Park, D.I. P129, P173, P497, P667
Park, J.J. P156, **P215**, P667
Park, J.M. P556
Park, J.Y. P453
Park, K.C. P016
Park, S.H. P262, P273, P283, P453, P499, P644, P670
Park, S.H. P046
Park, S.J. P016
Park, S.-K. **P129, P173**
Park, Y.S. P283, P714
Park, Y.S. P667
Park, Y.S. P667
Parkes, G.C. DOP037
Parra, R.S. P373
Parrilla Galdon, N. **N025**
Pasini, A. P094
Pasparakis, M. P029
Paspatis, G. **P689**
Patai, A. 19, DOP010, DOP028, DOP033, P220
Patai, A.V. P301, P539
Patchett, S. P205, **P248**, **P511**
Patel, D. P601
Patel, J. **DOP014**
Patel, K.V. DOP037
Patel, P. P299
Patita, M. P611
Patterson, S.D. P153
Paul, J. 23, DOP064, P408, P632
Paul, S. P263
Paúles, M.J. 31
Pautrat, K. P256
Pauwels, A. P402
Pavlenko, V. P747, P750
Pavli, P. **P470**
Pavlidis, P. **P533**
Pavlovska, K. P418
Pawlowska, J. P124
Peach, E.J. P075
Pecoraro, G. P448
Pecoraro, G.M. P691
Pedersen, N. DOP084
Pedroto, I. **P505**
Peek-Kuijt, N.
- Peeters, H. DOP057, P153
Peeters, M. P005
Peixoto, A. DOP036, P319
Pekow, J. P150, P151, P265
Peláez, A.C. P228
Peleg, S. P623
Pellegatta, G. **P536**
Pelletier, A.L. DOP018, P256, P427
Pellicer Bautista, F.J. P190
Pellissier, S. DOP024
Peltrini, R. P587
Peña Gómez, M. P330
Penez, L. P009, P597
Penna, A. P562
Penna, C. P219
Peoc'h, K. P296
Peppelenbosch, M. 20, P096, P724
Perdiki, M. P564
Perea Amarillo, R. P452, P600, P710
Pereira, B. DOP015, DOP086, P121, P177, P353
Pereira, M.S. **DOP084**, P080, P086
Pereira, S. P464, P521, P571, P654
Pereira da Silva, J. P741
Peretti, M. P683
Perevoschikov, P. P028
Perez, I. **P551**
Pérez, M.J. P245
Pérez, T. P251
Perez de Arenaza, A. P472
Pérez Hernández, F. P449
Perez-Calle, J.L. P404
Perez-Valderas, M.D. P593
Perruche, S. P071
Peter, I. DOP077, P735, P741
Péter, Z. P220
Peters, A. DOP042, P652, P659
Peters, D.A. P149
Peters, P.-G. P677
Petersson, J. DOP047, P315, P398, P462, P574
Petras, R. DOP077
Petren, C. DOP082
Petritsch, W. P739
Petrushev, B. P082
Petrushevyska, M. P533
Petruzzellis, C. P544
Petruzzello, C. P269, P284
Petryka, R. 27, DOP026
Petryszyn, P. **P147**
Petterson, E. DOP082
Peyrin-Biroulet, L. 23, 32, DOP075, P121, P306, P315, P361, P398, P427, **P432**, P462, **P548**, P574, P585, P604, **P608**, P664, P697, P700
Pezet, D. P353
Philip, J.M. 23, P408, P604, P632
Phillips, R. DOP074, P661
Pica, R. P035, P280, P411

- Picard, O. DOP064, P526
 Picchio, M. P562
 Piechota-Polanczyk, A. P090
 Piercy, J. P568, P591
 Pierik, M. 24, 32, DOP011, DOP034, DOP042, DOP043, DOP082, P144, P207, P210, P281, P344, P367, P652, P659, P662, P663, P692, P696, P719, P732, P736
 Pietrzak, A. P289, P513
 Pili, S. P103
 Pimentel, A. P222, P250
 Pinarbasi, B. P541
 Pineda, J.R. P464, P521, P571, P624, P653, P654
 Piñero, P. P139
 Pineton de Chambrun, G. DOP016, P256
 Pinheiro, L.V. P409, P642
 Pinho, J. **P155**, P209, P297
 Pinho, S.S. DOP084, P080, P086
 Pinillos Pison, S. P387, P569
 Pinó Donnay, S. DOP019
 Piñol, M. P493
 Pinto Sanchez, M.I. N001
 Pinzani, M. P094
 Piotrowicz, G. **P221**
 Piotrowski, P. P147
 Piqueras, M. P478, P624
 Piroli, S. P035
 Pisapia, L. P047
 Piscaglia, A. P713
 Pisespongsa, P. P118
 Pittet, V. P224, P619, **P690**, **P707**, P708
 Pizarro, T.T. P062
 Plassais, J. P743
 Platt, A. **P378**, P687
 Platzer, R. P677
 Plaz Torres, M.C. DOP012
 Plaza, R. P653
 Plocek, A. P530
 Plut, S. P309
 Podestà, A. P037
 Poiasina, E. P553
 Pollok, R. P111
 Poltarjonok, R. P030
 Pombo, M.d.C. P218
 Poniewierka, E. P346, P479
 Ponsioen, C.Y. 21, DOP066, P140, P178, P254, P281, P344, P367, P376, P584, P696, P719
 Pontas, C. P234
 Pop, C.S. P271
 Pop, G. P053
 Popa, M.A. DOP070
 Popov, J. P130, N001, N011
 Popp, C. **P053**
 Popp, J. P368, P626
 Portela, F. P319, P572
 Portillo, I. P698
 Portyanko, A. **P028**
 Potamianos, S. P689
 Potočník, U. P733
 Poturoglu, S. P257
 Poullenot, F. P121
 Power, V. N021
 Powrie, F. P011
 Pozzati, L. P228
 Pranzo, G. P562
 Pratt, J. P350
 Preda, C. P697
 Prescott, N.J. DOP001
 Previtali, A. DOP051, P603
 Prioux-Klotz, C. **P338**
 Prijic, R. P577
 Primo, J. P502
 Prince, A. P476
 Principi, M.B. P252, P320, P363, P366, P544
 Privitera, A.C. P320, P363
 Probert, C. **DOP049**, P310
 Proctor, M. P058
 Profeta, G. P448
 Profita, M.A. P448
 Pronicki, M. P380
 Pronio, A. P035
 Protheroe, A. P467
 Protheroe, S. P382
 Prudham, R.C. DOP073, P253
 Prüb, M.S. **P379**
 Pruvot, F.R. P057
 Prymak, O. **P364**
 Pugliese, D. P117, P395, P558, P621
 Pujol, G. P569
 Pujol Muncunill, G. P387, P549
 Puljiz, Z. P577
 Puricelli, L. P037
 Püschel, L. P272
 Puy, H. P296
 Pytko-Polończyk, J. P180
 Qian, J. P186, P191, P202
 Qin, O. P118
 Quadros, G. P683
 Queirós, P. P417
 Quercia, V. P439
 Quertinmont, E. P405
 Quince, C. 26
 Quinn, S. P680
 Quintero Carrion, E. P133
 Quraishi, M.N. **P200**
 Raatgeep, H. DOP007, P026
 Rabagliati, M. P280
 Rabilloud, M.-L. **P171, P199, P705**
 Racine, A. P256
 Radeke, H.H. **P372**
 Radford-Smith, G. P226
 Raes, J. P737, P742
 Rafferty, T. P680
 Raftery, T. P235
 Rahier, J.-F. DOP057, P153, P319
 Rahili, A. 31
 Raimundo Fernandes, S. **P300**, **P410**, **P483**, **P620**
 Raine, T. **DOP037**
 Rainteau, D. P182
 Rajagopal, S. **P399**
 Rajar, P. P309
 Raluy, M. **P167**, P239, **P288**
 Ramas, M. P104, P183, P211, P621, P624
 Rameil, S. DOP038
 Ramirez, G. P452, P600
 Ramirez de la Piscina, P. P228, P472
 Ramirez Morros, A. DOP019, P251
 Ramos, D. P102
 Ramos, L. **P133**
 Ramos-Lora, M. P316
 Rampal, R. P103
 Rangheard, A.-S. P219
 Rans, K. 30
 Rapaccini, G.L. P558
 Rashid, M. DOP058
 Raskin, J. P471
 Rasmussen, M. P375
 Raspe, H. P370
 Rath, N. 25
 Raveh, A. P135
 Ravelli, P. P553
 Raymond, K. P360
 Rea, M. P122, P223, P225
 Read, H. DOP047
 Ream, E. N006
 Reardon, S. P378
 Recio, D. N022
 Reddi, D. P033
 Reddy, N. P716
 Reenaers, C. P231, P256, P548
 Regalado, A. P545
 Regmi, S. P050
 Reicht, G. P677
 Reilly, N. P576
 Reimund, J.-M. P231
 Reindl, W. P060
 Reinisch, W. 18, 27, DOP047, DOP048, DOP075, P227, **P307**, P496
 Reis, C.A. DOP084, P080, P086
 Reis, G. P683
 Reis, J. P327
 Reisz, Z. P127
 Ren, Z. P069
 Renna, S. **P358**, **P454**, P461
 Renosto, F. N003
 Repakova, B. P275, P559

- Repici, A. P477
 Repnik, K. P733
 Repsilber, D. DOP088
 Reshef, L. P751
 Reszec, J. P110
 Reusch, A. P547
 Rey, E. P551, P681
 Reynolds, J. P486
 Reynolds, M. P167, **P239**
 Reynolds, N. P326
 Rhee, S.Y. P684
 Ribas Andrade, A. **P674**
 Ribeiro, A. P337
 Ribeiro, T.C.R. P481
 Ribeiro da Rocha, J.J. P373
 Ribeiro Feitosa, M. **P373**
 Ribot, R.R. P104
 Ricaneq, P. DOP082, **DOP089**
 Ricart, E. DOP019, DOP020, P251
 Ricchiuti, A. DOP012
 Ricci, E. P647, P673
 Ricciardelli, C. P562
 Ricciuto, A. **P435**
 Riddell, R. DOP075
 Rieder, F. DOP077, P325
 Riegel, B. N017
 Rigo, A. P475, P636, N005
 Riis, L.B. DOP044, DOP045, P588, P633
 Rijcken, E. P087
 Rimola, J. DOP019, P251
 Rinaldi, L. **P408**
 Rincón, M.L. P228
 Rio, P. P218
 Rispo, A. P122, P223, P225, P587
 Rita Carvalho, J. P410
 Rita Gonçalves, A. P300, P410, P483, P620
 Ritchie, K. P226
 Rivas, C. N023
 Rivas, M.A. P732
 Rivero, M. P404, P653
 Rizzello, F. P280, P395
 Rizzo, A. P089
 Rizzo, A. P279
 Rizzuto, G. P454, P544
 Roales, V. **P681**
 Robaszekiewicz, M. P171, P705
 Roberts, J. P535
 Robinson, A.M. DOP047, DOP083, P398, P462, P496, P524, P574, P576, P609, P638
 Robitaille, R. P590
 Robledo-Andrés, P. P228, P653
 Robles, V.P. P245, P478, P480, P510, P701
 Roblin, X. 23, 27, DOP041, DOP064, **DOP070**, P231, P306, P319, P408, P427, P432, P548, P604, P632
 Robson, S. P641
 Rocha, R. P267
 Roche, K. P034
 Roda, G. **DOP077**
 Rodacki, T. P180
 Rodansky, E. **P068**
 Rodriguez, C. P404, P472, P621
 Rodríguez, G.E. P228
 Rodríguez, I. P472
 Rodríguez, J. P502
 Rodríguez, P. P245
 Rodríguez, S. DOP019, P251
 Rodríguez Díaz, C.Y. P449
 Rodríguez González, G.E. P449
 Rodríguez Zarco, E. P190
 Rodriguez-Alonso, L. P731
 Rodríguez-Justo, M. P067
 Rodríguez-Lago, I. P211, **P473**, P621, **P698**, **P753**
 Rodríguez-Martínez, P. P263
 Rodriguez-Moranta, F. P731
 Rodríguez-Prada, J.-I. P464, P571, P654
 Rodriguez, D. DOP081
 Roelofs, H. P725
 Roemers, M. DOP042
 Rogge, C. P535
 Rogler, G. 25, DOP009, DOP020, DOP075, P076, P400, P676, P729
 Rolandsdotter, H. **P520**
 Roma-Giannikou, E. DOP062
 Romano, C. 26
 Romatowski, J. P402
 Romberg-Camps, M. 24, DOP011, DOP034, P210, P662, P663
 Romberg- Camps, M.J.L. P281, P344, P367
 Romero, C. P340, P651, P709
 Romero Gómez, M. P570, P595
 Ron, Y. P646
 Ronchetti, A. P544
 Roosen, D. P652
 Roque Ramos, L. P192, **P545**
 Rorsman, F. P039
 Rosa, B. P164, P292, P302
 Rosales, K. P569
 Rosario, M. DOP070, P227
 Rosella, G. P486
 Rosenbach, Y. P445
 Rosenberg, L. P641
 Rosenstiel, P. P342
 Roseth, A. P227
 Rosh, J. P576
 Roshan, N. P074
 Rosiñol, L. DOP019
 Rosman, M. P504
 Rosner, G. P646
 Rossel, J.-B. P708, P729
 Rossi, A. P284
 Roubelakis, M. P024
 Rove, J.B. P423
 Rovira, M. DOP019, DOP020
 Rowley, A. P064, P100, P105, **P561**
 Rowse, G. P124
 Rubertà, F. P553
 Rubin, D.T. **DOP081**, P150, P151, P265, P286, P640
 Rubio, S. P624
 Ruchkina, I. P485
 Ruczak, W. P513
 Rueffer, A. P176
 Ruemmele, F. DOP062, DOP078, P113, P345, P576, **P609**
 Ruenzi, M. P148
 Ruffa, A. P269, **P284**
 Ruffo, G. P214
 Ruggie, M. P269, P269, P279
 Ruiz, N. **N022**, **N023**
 Ruiz Belmonte, L. P624
 Ruiz-Castro, P. P676
 Ruiz-Cerulla, A. P263, P478, P731
 Ruksha, K. P028
 Rumessen, J.J. P182
 Rupp, C. 21
 Rusak, M. P110
 Rush, M. DOP029
 Rushbrook, S.M. 21
 Russel, M.G.V.M. P622
 Russell, G. P350
 Russell, R. 26, P083, P113, P650
 Russell, S.E. **P007**
 Russo, G. P075, P448
 Rust, C. 21
 Rustemovic, N. P577
 Rutgeerts, P. **25**, 30, DOP023, DOP048, P065, P307, P573
 Rutka, M. 19, DOP010, DOP028, DOP031, DOP033, P126, P127, P266, P308, **P357**, P507, P717
 Rutter, M. 24
 Ryan, B. DOP013
 Ryder, A. P124
 Ryzewska, G. P221, P244, P519, P645
 Ryoo, E. **P241**
 Ryu, H.H. **P453**
 Ryu, M.S. P025

S

Saab, B. P409, P642
 Saab, M.P. P409, P642
 Saad-Hossne, R. N003
 Saadah, O.I. P085
 Saas, P. P071
 Sabino, J. **P737**, **P742**
 Sabot, E. P580
 Sacchini, E. P713
 Sacco, M. P587
 Sack, J. P378
 Sadaghian Sadabad, M. P746
 Sadiq, F. P286

- Saeed, S. P113
 Sáez-González, E. P102
 Safar, B. P255, P282
 Safroneeva, E. P224, P400
 Sagar, D. P378
 Sagi, I. P037
 Sahami, S. P201, **P376**
 Sahnna, K. **DOP074, P661**
 Saibeni, S. P143, P544
 Said, Y. P166
 Saito, E. P120, P397, **P446**
 Saito, K. P329, P658
 Saito, S. 30
 Saito, Y. 30
 Saitoh, Y. P534
 Sakamaki, K. P414
 Sakamoto, N. P491
 Sakemi, R. **P618**
 Sako, M. **P203, P324**
 Sakurai, T. P658
 Sakurai, T. 30, P329
 Salama, P. P413
 Salamon, A. 19, DOP010, DOP028, DOP033, P126
 Salas, A. DOP019
 Salazar, E. P415
 Salazar-Salas, L. P137, P734
 Salem, M. P166
 Salemm, M. P279
 Sales, L. P267
 Salh, B. P580
 Salleron, J. P548
 Salmoral Luque, R. P330
 Salupere, R. P691
 Salvador, P. **P031, P079**
 Salvatore, C. 26
 Salzberg, B. P368
 Samanci, C. P257
 Sambuelli, A. **P175**
 Sampaziotis, F. 21
 Samperi, L. P647, P673
 Sampietro, G. DOP021, P279
 Samsom, J. DOP007, P026
 Samson, C. P350
 Samuel, D. 26
 San Juan Acosta, M. P449
 Sanchez, M. P035
 Sánchez Pastor, E. N008
 Sanchez-Elsner, T. P008, P097
 Sanchez-Morales, G. P303, P625
 Sanchez-Ramón, S. P551
 Sandall, A.M. DOP014
 Sandborn, W. 25, **27**, 28, 32, **DOP025**, DOP048, **DOP052**, DOP075, **DOP083**, P307, P368, P611, P721
 Sanderson, J.D. DOP001, DOP014, DOP067, P019, P349
 Sandford, R.N. 21
 Sands, B.E. 25, 27, 28, DOP017, DOP075, P227, P388
 Sanromán, L. P464, P571, P654
 Sansom, O. 20
 Santacana, E. P731
 Santana, G. P222, P250, P267
 Santos, F.M.D. P056
 Santos, L. P327
 Santos, P. P410
 Santos-Antunes, J. P141
 Sapiano, K. P672
 Saporiti, G. DOP021
 Sarafian, M. P009
 Sargin, Z.G. P639
 Sarid, O. P285, **P450**, P592, P605
 Saritas Yuksel, E. N024
 Sarter, H. P664, P697, P700
 Sartini, A. **P212**
 Sartor, B. DOP075
 Saruta, M. 30, P159
 Sasaki, M. P377
 Sassaki, L. N003
 Satman, A. P298
 Sato, N. 33, P656
 Sato, T. P333, P451, P508, **P514**
 Satsangi, J. 20, 31, DOP020, DOP047, DOP082
 Sattin, B. P580, P583
 Saunders, B. 24, 31
 Savarino, E.V. P232, P347, P475, P536, P607, P621, P636, N005
 Savarino, V. DOP012, P232, P347, P536, P607
 Savelkoul, P.H. P738
 Savoye, G. DOP041, P256, P306, P427, P664, P697, P700
 Sawada, R. P159
 Sawyer, E. 178
 Saxena, S. P111
 Scaldaferrì, F. 18, DOP026, P062
 Scaringi, S. P274, P581, **P631**
 Scharl, M. DOP009, P076, P139, P676, P729
 Scharl, S. P676
 Scharloo, M. P134
 Scheffer, H. P305, P550, P725
 Scheffer, R.C. DOP043
 Schembri, J. **P238**
 Scherl, A. DOP054, P406
 Schmidt, A.-M. P063
 Schnabel, R. DOP026, P402
 Schneider, M. P059
 Schneider, M. P242
 Schoepfer, A. P224, P400, P619, P688
 Schouten, W.R. P706
 Schramm, C. 21
 Schreiber, S. 21, 25, 27, 27, 28, DOP075, P314, P342, P370, P386, P401, P732
 Schreiber, V. P058
 Schreiner, P. **P708**
 Schroevers, M. 178
 Schrumpp, E. 21
 Schuit, F. P004, P065
 Schuldt, D. P342
 Schulz, J. P119
 Schuster, T. **P242**
 Schwartz, D. P496
 Schwartz, D. **P285**, P450, **P592**, **P605**
 Schweistein, H. **P135**
 Schwender, B. P415
 Scimeca, D. P448
 Scott, F. P335
 Scott, J. **P253**
 Scott, J.A. DOP073
 Scott, N. P403
 Seah, D. P313, **P355**
 Sebastian, B. P323
 Sebastian, S. DOP036, DOP049, P310, P691
 Sebko, L. P621
 Sechi, A. **178**
 Seidler, U. DOP026
 Seidman, E.G. DOP072, **P070**, P247, **P500**
 Seinen, M. P557
 Sejben, A. P127
 Seksik, P. DOP018, DOP041, P172, P256, P460, P554, P582
 Selby, W. P226
 Selinger, C. DOP037, **P348**, P403, P671, **P678**
 Sellge, G. P088
 Selvarajah, U. P685
 Selvi, E. P359
 Semper, L. P139, P211
 Sengul Samanci, N. **P257**
 Sengupta, S. P539
 Senkal, Z. P429
 Senturk, H. P165, P389
 Seo, D.H. P016, **P044**, P055, P072
 Seo, G.S. **P022**, P667
 Seo, H. P273, **P499**
 Seo, M. P273, P499
 Seo, W.S. P482
 Seoighe, C. P728
 Seong, J.H. P276
 Seow, C. P293
 Seppen, J. P095
 Serafin, Z. P277
 Serban, D. DOP062
 Serena, C. **P034**
 Serghini, M. P469
 Sergienko, R. P450
 Serin, I. P261
 Serizawa, H. P446
 Serrano, P. P228
 Sevdalis, N. P169
 Severs, M. **P281**, **P344**, **P367**
 Shackelton, L. DOP025

- Shah, N. P331, P390
 Shah, S. **DOP017, P388**
 Shaik, F. P348
 Shamaly, H. P623
 Shamir, R. P113, P445
 Shanahan, F. P007
 Shaoul, R. DOP062, P113, P623
 Shapiro, M. DOP083
 Sharma, A. P614
 Sharma, N. P200
 Shaul, R. DOP055
 Shcherbakov, P. P485
 Shelton, E. **P335**
 Shen, F. **P036, P069**
 Shen, L. P067
 Sheng, Y. P058
 Shenoy, A. P037
 Sherlock, M. P613
 Shi, H.Y. **P142, P152**
 Shibatoge, M. P542
 Shibukawa, N. P679
 Shibuya, T. P012, P463, P491
 Shick, J. P675, P682, P711
 Shim, H.H. P415
 Shim, K.-N. P025
 Shim, S.Y. P644
 Shimamoto, F. 30
 Shimoyama, T. P189, P503, P643
 Shimshoni, E. **P037**
 Shin, C.M. P283, P714
 Shin, J.E. P173, P497, P667
 Shin, S.J. P667
 Shinozaki, M. **P686**
 Shinzaki, S. DOP046, P679
 Shioya, M. P377
 Shitrit, A. P135, **P161**
 Shon, S.H. P249
 Shonova, O. P691
 Shouval, D. DOP003, **DOP005**
 Shreiner, A. P264
 Shrivastav, S. P154
 Shteingart, S. P135
 Shteyer, E. P623
 Shums, Z. P123
 Shuvo, M. P628
 Shwana, S. **P467**
 Siakavellas, S.I. P163, **P564**
 Siba, P. 26
 Sibia, C. N003
 Sica, G. P269, P284
 Sicilia, B. P138, P624
 Siddhanathi, P. P011
 Sider, S. P331, P390
 Sieczkowska, J. **P530, P617**
 Siegel, C. **DOP075**
 Siegmund, B. DOP006, P061, P379
 Sierra, M. P138, P404, P624, N009
 Sierra-Salinas, C. P549
 Siersema, P.D. DOP043, P281, P344, P367, P704
- Sigall Boneh, R. DOP055
 Sike, R. 27
 Silva, A. P155, P209, P297
 Silva, I. P222, P250
 Silva, J. P222, P250
 Silva, M. DOP036, P319, P621
 Silva, M.C. P222, **P250**
 Silva, R. N003
 Silverberg, M.S. 21, DOP075, P270, P291, P315, P371, P426
 Silverman, J. DOP025
 Simadibrata, M. P118
 Siminoski, K. P132
 Simon, M. DOP041, P231
 Simonetti, F. P475, P636, N005
 Simons-Oosterhuis, Y. DOP007
 Simpson, A. P187
 Simrén, M. P546
 Simsek, Z. P216
 Simunic, M. P577
 Sinayoko, L. P338
 Sincic Mijandrusic, B. P577
 Singh, A. P325
 Singh, A.K. P103
 Singh, R. **P524**
 Singh, S. **P293**
 Sinniger, V. **DOP024**
 Sipahi, A. P056, P674
 Sipeki, N. P123
 Sipos, F. P220
 Sipponen, T. DOP035, P594
 Siproudis, L. P171, P199, P456, P705
 Sirohi, S. **P023**, P064, P100, P105, P561
 Sitkin, S. **P749**, P755
 Siva, S.S. **P150, P151**
 Skinner, C. DOP069
 Skok, K. P733
 Skok, P. P733
 Skup, M. DOP083, P398, P462, P487, P568, P574, P591
 Sladek, M. DOP055, DOP062, P113
 Slak, M. P309
 Slamán, M. P043
 Slaninka Miceska, M. P533
 Stawińska, A. P277
 Slevin, S. **P337**
 Śliwczynski, A. P513
 Sloan, S. P626
 Slonim-Nevo, V. P285, P450, P592, P605
 Smeekes, O. DOP068
 Smeets, H. P695
 Smets, F. DOP057, P153
 Smid, A. P309
 Smidt, H. P736
 Smit, E. N010
 Smith, H. DOP052
 Smith, J. P069
 Smith, K. P108, P416
- Smith, M. DOP037
 Smith, S. P230
 Smith, V. P611
 Smits, L. **DOP030**
 Smrekar, N. P309
 Smyth, C. P539
 Smyth, M. DOP051, P167, P239, P288
 Snapper, S. DOP003, DOP005
 So, H. P283
 Sobolewska-Włodarczyk, A. P090
 Söderholm, J. DOP082
 Sofia, A. P286
 Sofia, C. P572
 Sokol, H. DOP079, P172, P460, P582
 Solanke, Y. P023, P064, P100, P105, P561
 Solcia, E. P279
 Solina, G. **P461**
 Sollazzo, V. P587
 Sollellis, E. P121
 Sollima, L. P606
 Solmi, L. P673
 Sommer, J. P315
 Son, H.M. P025
 Song, E.M. **P025**, P273, P499
 Song, G.A. P667
 Song, H.J. P173
 Song, K.-H. P188, P332
 Song, K.H. **P482**
 Song, S.U. P046
 Sordyl, B. P629
 Soto, S. P521
 Soto Villagran, S. N014
 Soufleris, K. P394
 Souguir, A. P194
 Sousa, P. P155, **P209, P297**
 Spadarella, E. P587
 Spahr, M. DOP022
 Spalinger, M. **DOP009**, P076, P729
 Sparrow, M. P226, P313, P355, P486, P523
 Spatoliatore, A. P213
 Speca, S. P057, **P063**
 Spekhorst, L.M. 22, **P696**, P719
 Spicak, J. P703, P754
 Spiegel, B. DOP075
 Spijkerboer, A. P178
 Spinelli, A. P477
 Spooen, C. **P207**
 Spray, C. DOP062
 Spyckerelle, C. P700
 Sreenivas, V. P154
 Sridhar, A. P095
 Srivastava, B. 21
 Srivastava, N. P505
 St.Clair Jones, A. **P458**
 Stabuc, B. P309
 Staffer, S. P059
 Stagg, A. DOP008
 Staiano, A. P047, P321

Stakenberg, M.	P015, P066	Sulz, M.C.	P729	Tanaka, S.	30
Stallmach, A.	P586	Sundin, U.	P520	Tanaka, T.	P720
Staniak, A.	P147	Sundström, J.	P206	Tang, J.	P745
Staniceanu, F.	P053	Sung, J.J.	P118, P142, P152	Tang, K.	DOP078
Stanley, R.	P680	Sung, M.-K.	P714	Tang, R.	P142
Starr, M.	P500	Sunoqrot, M.R.S.	P030	Tang, W.	P118
Stassen, L.	P663	Surlo, V.	P222, P250	Tanimukai, H.	P679
Statovci, D.	P007	Sutiman, N.	P415	Tanis, P.	P376, P434
Stec-Michalska, K.	P090, P513	Suvorova, M.	P749	Tanke, H.	DOP039
Steenholdt, C.	P375	Suzuki, Y.	23, 30, 33, P185, P198	Tantau, A.	P082
Steenkamer, J.	P555	Svensson, H.	P106	Tantau, M.	P082
Stefanelli, M.L.	P713	Svolos, V.	26, P650	Tarabar, D.	DOP048, P307
Stefanescu, C.	DOP041, P231, P256, P296, P306, P554	Svrcek, M.	DOP079	Taranto, M.L.	P122, P223, P225
Stefani, A.	P475	Swartz, T.H.	P455	Tardillo Marin, C.A.	P449
Stefani-Hunyady, D.	P465, P471	Swidzinski, A.	P059	Targan, S.	25
Stefanowicz, M.	P424	Szalay, B.	DOP028, P308	Taruishi, M.	P534
Stefanska, A.M.	P007	Szamosi, T.	19, DOP010, DOP028, DOP033, P126	Taslimi, R.	P074
Stein, J.	P093, P119, P339, P341, P372, P552, P599	Szapary, P.	32	Tasset, C.	27
Steiner, P.	P677	Szczeklik, K.	P180	Tate, H.	DOP049, P310
Steiner, S.	P350	Szczepanski, M.	P489	Tateishi, U.	P656
Steinhart, A.H.	P371, P426, P583	Szczypkowski, A.	P683	Tatro, E.	P301
Sterneck, M.	21	Székely, H.	P220	Tatsumi, K.	P589
Stewart, K.	P196	Szepes, A.	P126	Taxonera, C.	P183, P211, P365, P404 , P551, P602 , P681
Sticlaru, L.	P053	Szepes, Z.	19, DOP010, DOP028, DOP031, DOP033, P126, P127, P266, P357, P507, P717	Tayfur Yurekli, O.	P359
Sticova, E.	P703	Szigeti, N.	P126	Taylor, J.	P403
Stitt, L.	DOP025	Szilagyi, A.	P319	Taylor, K.M.	DOP001
Stojmirovic, A.	20	Szücs, M.	P266	Taylor, M.	P561
Stoker, J.	P178	Szurowska, E.	P221	Taylor, N.S.	DOP001
Stokkers, P.C.	P696	Szymanska, E.	P380 , P612	Tchah, H.	P241
Stoltenberg, M.	P360	Szymanska, S.	P380	Te Boome, L.	P722
Stone, J.	P735	Szymczak, S.	P342	Te Velde, A.	20, P043, P727
Strauss, B.	P537			Teich, N.	P586
Strauss, R.	20, DOP003, DOP048, DOP056, P307, P522			Teixeira, V.	P741
Stremmel, W.	P059			Telesco, S.	DOP003, DOP090
Strid, H.	P546	T abbers, M.	P343	Ten Hove, J.	P140, P254
Strik, A.	DOP066 , DOP068, P637	Tacconi, C.	P089	Ten Thije, J.J.	P144
Strisciuglio, C.	P047 , P321	Tadin Hadina, I.	P577	Ter Steege, R.W.F.	22, P622
Strnad, P.	P088	Tae, C.H.	P025	Terpin, M.M.	P544
Strobel, D.	P168, P420	Tagliaferri, E.	DOP021	Terracciano, F.	P587
Strohl, M.	P529	Tahtaci, M.	P359	Terry, H.	P531
Stronati, L.	P117, P181	Taida, T.	P329, P658	Testa, A.	P122 , P223, P225
Sturdik, I.	P466, P655	Tajiri, H.	30, P159	Teufel, A.	21
Sturkenboom, R.	P663	Takada, Y.	P328 , P560	Thakkar, R.	DOP083, P398, P462, P524, P574
Sturniolo, G.C.	P475, P636, N005	Takagawa, T.	P451, P514	Thangarajah, D.	P501, P518
Sturt, J.	P294	Takagi, T.	P179, P362, P468	Thayu, M.	DOP078
Su, C.	27, DOP071, P369	Takahashi, K.	P377	Theocharis, G.	P689
Su, M.	P745	Takatsu, N.	P328	Theodoropoulos, G.	P024
Suarez, P.	N009	Takazoe, M.	P203, P324	Thevenin, A.	P121
Suárez-Lledó, M.	DOP019	Takehara, T.	P679	Thieme, F.	P342
Subramanian, M.	DOP025, P611, P721	Takenaka, K.	P397	Thijs, G.	P038
Subramanian, S.	31	Takeuchi, K.	30, P198	Thomann, A.	P060
Suchá, V.	P559	Takeuchi, O.	P120, P446	Thomann, P.	P060
Sugaya, T.	DOP046	Talar-Wojnarowska, R.	P513	Thomas-Gibson, S.	24, 31
Sugimoto, M.	P377	Tamaki, H.	P542	Thomsen, O.Ø.	P375
Sugimoto, S.	P295	Tanaka, H.	DOP046 , P383, P508, P618	Thorkilgaard, T.	P588
Sugita, A.	P589	Tanaka, M.	P179, P362 , N002	Thwaites, P.	P486
Sugrue, K.	P049			Tierens, D.	P465
				Tigchelaar, E.F.	P744

- Timmer, M. **P619**
 Tirado, P. P175
 Tiszlavicz, L. P127, P266
 Tittmann, L. 21
 Tittoni, R. P606
 Tjon A Ten, W. DOP065
 Tkachenko, E. P749
 Todd, J. P326
 Togashi, K. P185
 Tognolini, M. P002
 Toke, N. **P323**
 Tokem, Y. N024
 Tokushige, K. P233, P393
 Tolone, S. P607
 Tomakili, T. P032
 Tonelli, F. P274, P279, P581, P631
 Tonic Ribarska, J. P533
 Toporowska-Kowalska, E. P530
 Torisu, T. P318
 Torra, S. P228
 Torres, J. DOP077, P192, P455, **P735, P741**
 Torres-Rodriguez, P. P146
 Tortosa, L. P102
 Toth, G.T. 19, DOP010, DOP028, DOP033
 Toth, J. P466, P655
 Toubeau, J.-F. P405
 Toya, Y. DOP046
 Toyokawa, Y. P179, P362
 Toyonaga, T. P120, P446
 Tozer, P. DOP074, P661
 Trajkovski, A. P371
 Tran, A. P265
 Trang, C. DOP041, P256, P306
 Trautwein, C. P088
 Travis, M. P021
 Travis, S. DOP075, P011, **P398, P462**, P561, **P574**, P614
 Trejo, G. P459
 Tremelling, M. P740
 Tretton, X. DOP018, P427
 Triantafyllou, K. P689
 Trindade, E. DOP062
 Triossi, O. P673
 Trocmé, C. DOP024
 Tron, I. P171, P199, P705
 Troncone, R. P047
 Troy, F. N021
 Troya, J. P493
 Trunecka, P. P703
 Truta, B. **P255, P282**
 Tse, F. P130, N001, N011
 Tseng, L. P457
 Tsianos, E. P715
 Tsigaridas, A. P234
 Tsimperidis, A. P394
 Tsiouli, E. P740
 Tsoukali, E. P234
 Tsuchiwata, S. DOP071
 Tsuda, S. P414, P431
 Tsujii, M. P679
 Tsujikawa, T. P377
 Tsunoda, I. P087
 Tsuruda, P. P069
 Tulassay, Z. P220
 Tulchinsky, H. P258, P290, P666, P751
 Tuncer, M. P165, P389
 Turcan, S. P668, P691
 Turk, N. **P577**
 Turner, D. 26, DOP055, DOP056, DOP062, P113, P345, **P522, P623**
 Turner, G.B. P381
 Turner, J. P132
 Tursi, A. P363, **P562**
 Turunen, U. P594
 Tutein Nolthenius, C. **P178**
 Tyler, C. **DOP008**
 Tyrrell, T. N013
 Tysk, C. DOP075, P430
 Tzathas, C. P052, P689
 Tziortziotis, I. P234
U
 Uchiyama, K. **P179**, P362, P468
 Ueo, T. P528
 Ulivi, G. P348
 Ullman, T. P735
 Ulrich-Rueckert, S. P093
 Umeda, S. P120
 Umegae, S. P189, P503, P643
 Umeno, J. DOP046, P318
 Underhill, C. DOP029
 Ungar, B. DOP036, **DOP064**, P506, **P526**, P616
 Ungaro, F. **P089**
 Ungaro, R. P192
 Unno, M. P567
 Unsworth, N. DOP067
 Urbano, A. DOP019
 Urbanski, S. DOP080
 Ustun, Y. P216
 Uzzan, M. **DOP018**
V
 Vadan, R. P240
 Vaiarello, V. P447
 Vakhitov, T. P749, **P755**
 Valcz, G. P220
 Valente, A. P300, P410, P483, P620
 Vallejo Benitez, A. P190
 Vallier, L. 21
 Valls, M. P653
 Valmary Degano, S. P071
 Valpiani, D. P647, **P673**
 Van Assche, G. 18, 20, 30, **DOP023**, DOP038, DOP040, P005, P038, P084, P101, P112, P259, **P585**, P608, P737, P742, N007
 Van Berkel, L. DOP007, P026
 Van Biervliet, S. DOP057, P153
 Van Bodegom-Vos, L. P505
 Van Bodegraven, A.A. P210, P557, P696, P732, P738, N010
 Van Buuren, H.R. P706
 Van Damme, J. P038
 Van de Meeberg, P.C. P281, P344, P367
 Van de Vijver, E. DOP057, P153
 Van Deen, W.K. P378, **P441, P487**, P687
 Van den Bogaerde, J. 26
 Van den Brink, G. 20, DOP027, DOP066, DOP068, P010, P376, P555, P584
 Van den Broeck, K. 30
 Van den Heuvel, T. 24, DOP011, DOP034, P207, **P662**
 Van der Aa, A. 27
 Van der Aalst, A.M. P144
 Van der Aalst, K. P144
 Van der Borden, R.J. P738
 Van der Burg, S. DOP039
 Van der Ent, C. DOP060
 Van der Goten, J. P065
 Van der Have, M. **DOP043**, P144, P281, P344, P367
 Van der Heijde, D. P134
 Van der Heijden, F. DOP042
 Van der Meer, R. P746
 Van der Merwe, S. P737, P742
 Van der Meulen-de Jong, A.E. DOP039, DOP043, P134, P140, P144, P210, P254, P281, P344, P367, P505, P696, P719, P732
 Van der Ploeg, V.A. **P115, P208**
 Van der Sloot, K. **P196**
 Van an der Valk, M.E. P281, P344, P367
 Van der Vliet, Q. P144
 Van der Woude, C.J. 20, 32, DOP060, DOP061, P096, P236, P281, P344, P367, P391, P474, P504, P634, P696, P706, P719, P724, P732
 Van Bodegraven, A.A. P281, P344, P367
 Van Diemen, C.C. P732
 Van Dijk, L. N010
 Van Domselaar, M. P228
 Van Dongen, D. P662
 Van Dooren, F. P043
 Van Dullemen, H. 22
 Van Egmond, P. P637

- Van Erp, S. **P134**
 Van Esch, A. DOP030
 Van Gennep, S. **P201**
 Van Gossum, A. P405
 Van Haaften, W.T. **DOP087**
 Van Hamersveld, P. P020
 Van Hoek, B. 21
 Van Hootegem, P. 32
 Van Ijendoorn, S.C.D. P048
 Van Langenberg, D. P313, P355, P486
 Van Leeuwen, M. DOP007
 Van Leeuwen-Hilbers, F. P020, P601
 Van Limbergen, J. DOP058, DOP063
 Van Loo, E.S. P719
 Van Marrewijk, C. P305, P550, P725
 Van Mil, S. P743
 Van Oijen, M.G. DOP043, P441, P487
 Van Oorschot, V. P236
 Van Rheenen, P. DOP065, P457
 Van Ruler, O. P434
 Van Schaik, F. P704
 Van Sommeren, S. P719, **P722**
 Van Stappen, T. **DOP038**
 Van Tubergen, A. DOP042, P652, P659
 Van Tuyl, S.A. DOP043
 Van Weert, J. N010
 Van Wering, H. P457
 Van Winge, M. P015
 Vanamala, R. P492
 Vancamelbeke, M. P004, **P006**, P065
 Vande Castele, N. DOP038
 Vanhove, W. **P101**
 Vanoli, A. P094, P279
 Vanuysel, T. P006
 Varbobitis, I. **P163**
 Vardi, H. P285, P450, P592, P605
 Varea, V. P549
 Variola, A. P214, P544
 Varitimidiadis, L. P234
 Varvara, D. **P363**, P448, P544
 Vaskivuo, T. P184
 Vasseur, F. P697
 Vatn, M. DOP082
 Vatn, M.H. DOP089
 Vatn, S. DOP082, DOP089
 Vaucher, C. P690, P707
 Vavricka, S. P224, P400, **P676**, P688, P729
 Vaz, A. **P417**
 Vazeille, E. DOP086, P177
 Vázquez, I. P228
 Vázquez-Morón, J.M. **P316**
 Vecchi, M. P544
 Veenbergen, S. **DOP007**, P026
 Veenendaal, R. P134, P505
 Veereman, G. DOP057, P153, P522
 Veereman-Wauters, G. DOP062
 Veerman, G. DOP078
 Vega, R. P575
 Vegh, Z. 19, DOP010, DOP028, DOP031, DOP033, P308, P443, **P668**, P694
 Vela González, M. P449
 Velayos, B. P138
 Velho, S. P741
 Vella, S. P238
 Vellenga, E. P722
 Velloso, L.A. P003
 Velosa, J. P300, P410, P483, P620
 Vendrell, J. P034
 Veneziano, M.A. P320
 Ventham, N. **20**, DOP082
 Venugopal, A. P484
 Vera, M.I. P211, P602
 Verbeek, A. P305, P550, P725
 Verbeke, K. P006
 Vercueil, L. DOP024
 Verdejo Gil, C. P330
 Veres, G. DOP062, P123
 Verfaillie, C. P084
 Verhaegh, B.P.M. **P692**
 Vermeijden, J.R. P281, P344, P367
 Vermeire, S. 20, 25, 25, 27, **27**, 28, 30, 32, DOP023, DOP038, DOP040, DOP052, DOP057, P004, P005, P006, P038, P065, P084, P101, P112, P153, P201, P259, **P603**, P737, P742, N007
 Vermeulen, S. P305, P550, P725
 Vernia, P. P411, **P447**
 Verot, C. **P604**
 Verseijden, C. P601
 Verspaget, H.W. P719
 Verstockt, B. P004, P065
 Verstockt, S. **P004**, **P065**
 Verstraeten, V. P652, P659
 Vessby, J. P039
 Vettorato, M.G. P475, P636, **N005**
 Viazis, N. **P234**, **P385**
 Vicaut, E. 31
 Vicente, R. P621
 Vich Vila, A. 22, P744
 Vieira, A.I. P299, P545
 Vieira, C. P741
 Vieira-Silva, S. P737, P742
 Viel, J.-F. P171, P199, P705
 Viennot, S. P256
 Viennot, S. P306, P554
 Viganò, C. **P143**
 Vignal, C. P063, P697
 Vila, A.V. 21
 Vila Miravet, V. P387, P569
 Vilanova, M. P080, P086
 Vilches Arenas, A. P452, P600
 Villa, E. P212
 Villagrana, J.R. P104
 Villanacci, V. P279
 Vincenzi, D. DOP021
 Vincenzi, F. P540
 Vincze, A. 19, DOP010, DOP028, DOP033, P126
 Viola, F. P125, P181, P213, P516
 Virtanen, J. P206
 Viscido, A. P606
 Visschedijk, M.C. 22, P696, **P719**, **P732**
 Vitale, A. P047
 Vitale, S. P047
 Vitali, R. P117
 Vlieger, A. P343
 Vogels, E. P043
 Vollmann, M. P134
 Von Känel, R. P708
 Von Martels, J.Z.H. **P746**
 Vong, C. DOP071
 Vork, L. P744
 Vos, A.C. P010
 Voutilainen, M. P206
 Vowinkel, T. P087
 Vrakas, S. **P052**
 Vuitton, L. P071
Wada, K. P528
 Wade, K. **P162**
 Wadman, E. DOP002
 Waetzig, G.H. P342
 Waga, M. N013
 Waite, A. P399
 Waizbard, A. P646
 Wakabayashi, Y. DOP007
 Waldhör, T. P677
 Walker, L. P348
 Wallace, K. DOP083
 Walper, A. **P339**, P599
 Walsh, A. 26, P523
 Walsh, P.T. P007
 Walshe, C.A. P023, **P064**, P100, P105, P561
 Walshe, M. **P509**
 Walters, T. DOP063, P113, P435
 Wanders, A. P039
 Wang, A.W. P496, P638
 Wang, H. P611
 Wang, H. P726, P730
 Wang, J. P737, P742
 Wang, R. P058
 Wang, S. DOP083, P398, P462, **P568**, P574, **P591**
 Wang, W. 28, 28, DOP053
 Wang, X. P723
 Wang, Y.F. P118
 Wannhoff, A. P059
 Wanten, G. P305, P550, P725
 Ward, M. **P486**
 Warner, B. DOP067, **P349**
 Warusavitarne, J. 24, P169, P195
 Watanabe, K. **P567**

- Watanabe, K. 23, **30**, P185
 Watanabe, M. 23, 33, P168, P397
 Watanabe, N. P120, P446
 Watanabe, S. P012, P463, P491
 Watanabe, T. P720
 Waterman, M. P319, P351, **P506**
 Watson, S.P. P054
 Watts, G. **P614**
 Wauters, L. **DOP057, P153**
 Weaver, S. P128, P162, 178
 Webber, S. P023, P064, P100, P105, P561
 Weber, J. P242
 Weersma, R.K. 21, 22, P622, P696, P719, P722, P732, P744
 Wegner, A. **P374**, P612
 Weiland, R. P547
 Weinman, J. P315
 Weismüller, T.J. 21
 Weiss, B. P174
 Weizman, A. P371
 Well, M. P147
 Welting, O. P095
 Wenzl, H. P677, P739
 Wergeland, S.S. P588
 Wesselius, A. DOP011
 Wewer, V. DOP044, DOP045, DOP062, P588, P633
 Weyts, E. DOP040, N007
 Wheeler, C. DOP049, P310
 Whelan, K. P476
 White, M. P229
 Whiteoak, S. **P008**
 Whitman, C. DOP075
 Whyte, L. P382
 Wickson-Griffiths, A. N011
 Widlak, M. P200
 Wiecek, S. P374
 Wierikx, M. P207
 Wierstra, K. **P416**
 Wiest, R. P139
 Wieszczy, P. P289
 Wijmenga, C. 21, 22, P732, P744
 Wikström, A.-C. P520
 Wilbrink, J. P210
 Wildenberg, M. **20, DOP027**, P010, P014, P555
 Wildner, D. P420
 Wildt, S. P182, P322
 Wilkens, R. **P149**
 Wilkins, H.J. DOP022
 Willemze, R. **P095**
 Williams, A.B. DOP014
 Williams, J. P467
 Williams, K. P265
 Williamson, M. P580, P583
 Williet, N. 23, P408, **P632**
 Williman, J. P438, P492
 Wilson, A. **P381**
 Wilson, D. OP07, DOP062, DOP082
 Wilson, S. P168
 Wine, E. DOP055, DOP063, P132
 Winter, D. P376
 Winter, D. DOP007, **P634**
 Winter, H. DOP078
 Wintgens, K.F. **P341**
 Wintjens, D. DOP011, DOP034
 Wisniewska-Jarosinska, M. 27, P090
 Wisniewski, A. **P172**
 Witherington, J. P095
 Witkiewicz, W. P042
 Witte, C. P547
 Wittig, B. P114
 Włodarczyk, M. **P090**, P513
 Wójcik, J. P513
 Wolburg, H. P059
 Wolf, C. P060
 Wolf, D. DOP052
 Wolters, A. P662
 Wolters, V. DOP065, P457
 Wolthuis, A. P259, P578
 Wong, D. P305, P550, P725
 Wong, T. P382
 Woo, J. P611
 Wood, C. P563
 Wood, E. P100, P105
 Woods, R. P226, P413
 Woodward, S. P294
 Woodworth, D. 27, DOP071, P369
 Woolf, R. P092
 Wozniak, M. P418
 Wroblewski, K. P150, P151
 Wu, J. P132
 Wu, J. **P128**
 Wu, J. **P1718**
 Wu, J.C. P142, P152
 Wu, K. P118
 Wulandari, A.A. **P119**, P341
 Wyant, T. DOP070, P227
Xanthis, D. **P394**
 Xavier, R. P196
 Xavier, R.J. 22, P744
 Xia, J. P354
 Xiang, G. P596
 Xiang, P. **P596**
 Xiao, Y. P611
 Xie, R. DOP071, P428
 Xie, X. P204
 Xie, X. P204
 Xie, X. DOP025
 Xin, Y. **P202**
 Xu, H. P227
 Xu, J. DOP048
 Xu, S. DOP056
 Xu, Y. 32, DOP056
 Xu, Z. 26
 Xuan, W. 26
Yablecovitch, D. P174
 Yaguchi, K. P414
 Yahav, L. P258, P290, P666
 Yajnik, V. P196
 Yamada, A. DOP046, P198
 Yamada, K. P589
 Yamada, S. P468
 Yamada, T. P679
 Yamamoto, M. **P442**
 Yamamoto, S. P185
 Yamamoto, T. **P189, P503, P643**
 Yamamoto-Furusho, J. **P051**, P107, **P137, P303, P625, P734**
 Yamamoto-Mitani, N. N002
 Yanai, H. P174, P646
 Yanai, Y. DOP046, P528
 Yanartas, O. **P429**
 Yang, C.H. P136, P249, P512
 Yang, D.-H. P262, P273, P453, P499, P670
 Yang, H. P186, **P191**
 Yang, H. P227
 Yang, J.J. P455
 Yang, Q. **DOP059**
 Yang, S.-K. P262, P273, P283, P453, P499, P644, P670
 Yang, Y. P058
 Yano, Y. P328, P560
 Yarlus, A. **P229**
 Yaron, A. P646
 Yarow, H. N013, **N016**
 Yasaka, M. P328
 Yasukawa, S. P328, P560
 Yasunaga, Y. P679
 Yavzori, M. DOP064, P526, P616
 Yazumi, S. P384
 Ye, B.D. P262, P273, P453, P499, P667, P670
 Yen, E. DOP025
 Yerushalmi, B. DOP055, P623
 Yianni, L. 26
 Yildirim, Y. N024
 Yilmaz, B. P077
 Yim, J.-J. P497
 Yip, W. 31, P597
 Yngman Uhlin, P. N017
 Yokosuka, O. P329, P658
 Yokoyama, K. P157
 Yokoyama, Y. DOP046, **P333**, P451, **P508**, P514
 Yonezawa, H. P414, P431
 Yonezawa, M. P233, P393
 Yoon, H. **P283**, P304, P714
 Yoon, Y.S. P262
 Yoshimura, N. 23, P203, **P324**
 Yoshino, T. DOP046, **P384**
 Youn, E.J. P453
 Yu, C.S. P262
 Yu, D. 27, DOP071, P369

Yu, H.H.	P118	Zawadzki, M.	P042	Zhao, X.	P721
Yu, I.	P680	Zeegers, M.	24, DOP011,	Zhernakova, A.	22, P744
Yu, Q.	P726 , P730		DOP034, P662	Zhi, M.	DOP059, P745
Yu, S.	P675, P682, P711	Zeevenhooven, J.	P488	Zhigalova, T.	P749
Yu, Y.S.	P025	Zeissig, S.	P401	Zhongyang, Z.	DOP077
Yuksel, I.	P045, P216	Zeitz, J.	P676, P729	Zhu, J.	DOP007
		Zelinkova, Z.	P725 , P559	Zhu, X.	P723
		Zeng, Z.	P118, P204, P635, P730	Zhulina, Y.	P430
Z aal, R.	P504	Zenlea, T.	P641	Zini, I.	P002
Zagorowicz, E.	P018, P621	Zerbib, P.	31, DOP016, P057	Zippi, M.	P411
Zacharopoulou-Otapasidou, S.		Zhang, H.	27, P369	Zittan, E.	P426
	P392	Zhang, H.	DOP048, P307	Zollner-Schwetz, I.	P739
Zachou, K.	21	Zhang, M.	P745	Zonetti de Arruda Leite, A.	P056, P674
Zagorowicz, E.	P289 , P513	Zhang, N.	P515		P168
Zaharie, F.	P082	Zhang, S.	P726, P730	Zorzi, F.	P753
Zaharie, R.	P082	Zhang, S.	P186	Zubiaurre, L.	26, DOP055
Zali, N.	DOP038	Zhang, Y.	P726	Zucker, D.	P281, P344, P367
Zambonin, D.	P274, P581, P631	Zhang, Y.	P354	Zuithoff, P.N.	
Zand, A.	P687	Zhang, Y.	P745	Zundler, S.	P001
Zapata, E.	P698	Zhao, J.	P727	Zupančič, K.	P733
Zapater, P.	P139	Zhao, R.	DOP054	Zurac, S.	P053

Imprint

Publisher

ECCO – European Crohn’s and Colitis Organisation

OCEAIN – Organisation, Congress, Emotion, Association, iNnovation GmbH

Ungargasse 6/13

1030 Vienna, Austria

Phone: +43-(0)1-710 22 42

Fax: +43-(0)1-710 22 42-001

E-Mail: ecco@ecco-ibd.eu

Web: www.ecco-ibd.eu



European
Crohn’s and Colitis
Organisation

To visit the ECCO website, please scan this code
or look at www.ecco-ibd.eu



Dieses Produkt entspricht dem Österreichischen Umweltzeichen für schadstoffarme Druckprodukte (UZ24).
This product conforms to the standards of the Austrian Environmental Seal of Approval for environmentally
friendly printing products (UZ 24). Grasl Druck & Neue Medien, Bad Vöslau, UW-Nr. 715, www.fairprint.at



PEARLS GI: the medical education programme for gastroenterology.

Supported by Janssen and developed with a Steering Committee of leading gastroenterologists, the PEARLS GI programme provides a forum for exchanging the latest information and expert insights in this developing field.

BOOTH: Visit the PEARLS GI medical education booth (Hall 10, Booth 012) to find out more about the PEARLS GI medical education programme.

MEET THE EXPERT: Visit us at the booth at 10:30–11:00 on Friday 18th March for an interactive 'Meet the Expert' session including Professor Silvio Danese.

The inflammatory cascade and potential therapeutic targets in Crohn's disease will be discussed.

This programme is not affiliated with ECCO.

With the support of Janssen Pharmaceutical Companies of Johnson & Johnson in EMEA.

Janssen Pharmaceutica NV

©2016_Janssen Pharmaceutica NV, Turnhoutseweg 30, B-2340, Beerse, Belgium. PHEM/MMM/1215/0003b.

Janssen PEARLS GI symposium

UNMET NEEDS

and emerging therapies:

a new era

for Crohn's disease management

Friday 18 th March	Session 3A 07.15–08.15	Plenary Hall RAI
----------------------------------	---------------------------	---------------------

Breakfast will be provided

07.15–07.25

Welcome and emerging aspects in Crohn's disease pathogenesis: moving towards the next generation of biologics
Professor Silvio Danese

07.25–07.40

Key unmet medical needs in the management of Crohn's disease
Professor Brian Feagan

07.40–08.05

Focus on targeting IL-12/23 in Crohn's disease therapy
Professor Matthieu Allez

08.05–08.15

Questions and closing remarks
Professor Silvio Danese

The background is a teal gradient with several translucent bubbles of varying sizes. Each bubble contains a smaller, solid purple sphere. The bubbles are scattered across the frame, with some appearing larger and more prominent than others. The overall aesthetic is clean and scientific.

Stem cells are **full of possibilities**
We make them a **reality**

Solutions

Innovation

Future

Hope

Well-being

Efficacy

Working hard to turn hope into reality

TIGENIX is an advanced biopharmaceutical company focused on developing and commercialising novel therapeutics from its proprietary platforms of allogeneic, or donor-derived, expanded stem cells.

TIGENIX
Living Medicines